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 Transmissible spongiform encephalopathies (TSEs), well known as prion 
diseases, are fatal neurodegenerative disorders in humans and animals, which a prion 
protein (PrP) mainly implicates with the TSE pathogenesis. The normal cellular PrP 
isoform, referred to as PrPC, predominantly forms an α-helical structure. A structural 
alteration of the PrPC isoform can misfold into the infectious and pathogenic PrP 
isoform, referred to as PrPSc (or PrPD as disease-associated PrP).  The PrPSc isoform 
consists of a β-sheet rich structure and accumulates in the central nervous system 
(CNS). The structural change and accumulation of this abnormal conformer alters 
physiochemical properties of the PrPC isoform. However, the conversional mechanism 
from PrPC to PrPSc isoforms is not clearly known. In general, the PrPC structure has two 
conserved Asparagine (N)-glycosylation sites that generate four various glycosidic 
forms (unglycosyl, two differing monoglycosyl and diglycosyl). In preliminary studies, 
TSE-disease mice exhibited the increased detection of under-glycosylated PrP forms, 
compared to controls. Although protein glycosylation plays various structural and 
functional roles, the importance of these glycans is not clarified in TSE pathogeneses. 
 Recently, novel monoclonal antibodies (mAbs) against PrP molecules were 
reported. Of these mAbs, PRC7 mAb can recognize an unglycosyl form and one 
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monoglycosyl form (mono-1) of PrP molecules specifically. In addition, PRC7 mAb has 
a unique feature to require denaturation and renaturation of PrP molecules to recognize 
PrPSc isoforms. Since PRC7 mAb cannot react with a diglycosyl PrP form that an 
abundance of normal PrPC isoforms express, PRC7 mAb preferentially detects PrPSc 
isoforms. Thus, these features of PRC7 mAb were applied to develop a sensitive 
enzyme-linked immunosorbent assay (ELISA) for the detection and quantification of 
under-glycosylated PrP forms in TSE-infected samples. My central hypothesis is that, 
the detection of under-glycosylated PrP forms is the hallmark of TSEs as diagnostic 
biomarkers for the disease progression.  
 Here, I propose that loss of full glycosylation is implicated in the pathological 
mechanisms of TSEs. For instance, glycosylation is involved in the maintenance of 
protein structure. Thus, its modulation can initiate unstable conditions for maintaining 
proper PrPC conformations, which induce pathologic alterations of the PrPC structure. 
These aberrant formations could lead functional impairments of normal PrPC isoforms. 
In another aspect, the PrPSc isoform may lose glycans during the disease development 
of TSEs. Therefore, I assume that under-glycosylated PrP forms can be preferentially 
generated during the disease progression. To accomplish the proposed studies, I have 
developed two sensitive ELISA methods for the detection and quantification of PrP 
molecules in TSE-infected samples. Using the PRC7 and PRC5 mAbs as capture and 
detecting antibodies respectively, the 7-5 ELISA method specifically recognizes the 
certain under-glycosylated PrP forms that are significantly detected in TSE-infected 
materials. In addition, the D-5 ELISA method uses D18 anti-prion antibody as a capture 
antibody and has an exceptional capability to determine levels of only PrPC or total PrP 
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molecules by different sample preparations. Using the D-5 ELISA method, I have 
detected the reduction of PrPC levels in TSE-infected materials at terminal stages, 
whereas total PrP levels were increased. These results were similar observations to a 
recent article using the conformation-dependent immunoassay. Since my protocols do 
not require a proteinase K (PK) reagent, these ELISA methods will be ultimately 
beneficial for TSE diagnoses, especially for detecting PK-sensitive PrPSc forms. 
Furthermore, the ELISA approaches would contribute to understand the TSE 
pathogenesis under the specific detections of PrPSc isoforms, based on glycosylated 
forms for distinguishing PrPC from PrPSc isoforms. This dissertation study will provide an 
innovative framework of the proposed projects that will achieve beneficial impacts into 
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Alanine    Ala         A            89.094 
 
Arginine    Arg         R          174.203 
 
Asparagine    Asn         N          132.119 
 
Aspartic acid    Asp         D          133.104 
 
Cysteine    Cys         C          121.154 
 
Glutamic acid   Glu         E          147.131 
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Phenylalanine   Phe         F          165.192 
 
Proline    Pro         P          115.132 
 
Serine     Ser         S          105.093 
 
Threonine    Thr         T          119.119 
 
Tryptophan    Trp        W          204.228 
 
Tyrosine    Tyr         Y          181.191 
 












Transmissible spongiform encephalopathies (TSE, TSEs), well known as prion 
diseases, are fatal neurodegenerative disorders in humans and animals, such as 
Creutzfeldt-Jacob disease (CJD) in humans, bovine spongiform encephalopathy (BSE) 
in cattle, chronic wasting disease (CWD) in elk, deer and moose, and scrapie in sheep 
and goat.1-3 In general, TSEs are classified into three types: sporadic, genetic or 
infectious/acquired form. The characteristic features of the TSE pathology are observed 
in the central nervous system (CNS), especially in the brain, such as neuronal loss, 
spongiform degeneration and gliosis. Although these diseases develop slowly, TSE-
affected individuals and animals suffer from impairments of CNS functions that 
propagated and accumulated pathogens induce behavioral and neurological 
abnormalities. Once onsets of clinical signs appear progressively, these mental and 
physical abnormalities deteriorate health conditions. The prevention of possible TSE 
transmissions between same and different species is critically important in public health 
and veterinary medicine. At present, no treatment is available to cure these diseases. 
The relevant history of TSE most easily described through accounts of BSE in 
cattle, widely known as mad cow disease.4-6 Since the BSE epidemic between the 
middle 1980s and early 2000s in the United Kingdom, Europe, North America and 
Japan, this disease has had serious attentions in public health and veterinary medicine 
through the world, especially for zoonotic transmissions (communicable infectious 




influenced meat industry in economic and international trade. Through exposure to 
contaminated foods with BSE, its transmitted pathogens developed a new type of CJD 
in humans, described as Variant Creutzfeldt-Jacob disease (vCJD).7-9 After these 
emerging outbreaks, preventions of BSE have been organized. As a result, the 
incidences of BSE and vCJD in the United Kingdom have decreased after these 
epidemic peaks in 1992 and 2000, respectively. However, the risks of BSE re-
emergence and transmission to human and other animals still remain because of some 
limitations for detecting its pathogen by current TSE diagnoses.  
While BSE outbreaks have been under surveillance in affected countries for the 
last decade, CWD has continuously expanded its outbreaks as a current progressive 
TSE problem through the world.10,11 CWD is an emerging infectious disease in wild and 
captive cervid family (i.e. deer, elk and moose). In 1967, the first case of CWD was 
identified in captive deer in Northern Colorado. Since then, this infectious disease has 
been detected in 24 states of the United States and 3 provinces of Canada through 
North America. Until 2000, CWD was an endemic disease in these two countries. In late 
December 2000, however, the first CWD case outside the North America was detected 
in South Korea. This is also the first CWD detection in Asia. In the 1990s, several live 
elk were exported from CWD-contaminated farms in Canada to South Korea. 
Unfortunately, these CWD-exposed elk presumably became the infectious sources to 
spread its pathogens through a new country in a different continent. Alarmingly, the first 
European case of CWD was diagnosed in Norway in March 2016, which was also the 
first detection of natural CWD infection in a free-ranging reindeer through the world. The 




moose in May, another moose in June, and one reindeer in August. These affected 
animals in Norway were found in wild natures. Since it is still unknown how CWD 
appears in Europe, the spread and outbreak of CWD internationally indicates a serious 
situation of TSE-related epidemics. The propagating factors of these CWD outbreaks 
have not been definitively investigated nor has the communicability of CWD pathogen to 
humans or the incidence of human TSE development caused by the infectious disease 
been confirmed.12 The risk of CWD as zoonosis still remains under surveillance of 
public health and veterinary medicine. Given the spread of TSE etiology and 
propagation, investigations of its pathogenic mechanism would provide clear strategies 
for disease prevention and eradication.   
The common molecular mechanism of TSE pathogeneses in multiple species 
(i.e. human, cattle, deer, sheep) is defined as the conformational conversion of prion 
protein (PrP) from normal cellular PrP isoform (PrPC) to abnormally-misfolded infectious 
PrP isoform (PrPSc).13-16 PrPC is a monomer with predominantly α-helical structure, 
whereas PrPSc forms prone to oligomerization and aggregation with a β-sheet rich 
structure. At present, the mechanism of conversions from normal PrPC to pathologic 
PrPSc isoforms is not clearly understood. However, the structural change to this 
abnormal conformer alters the physiochemical properties of PrP molecules as its 
cellular and molecular pathogenesis, and also accumulations of aggregated PrPSc 
agents in the CNS lead to the development of TSEs as like other neurodegenerative 
diseases. During the disease progression, the pathogenicity protein and its propagation 
disrupt normal functions of the brain and nervous systems in TSE-affected individuals 




structure is a key element to trigger the TSE development. The conformational 
alteration of PrP is an essential target to identify further TSE pathogeneses and analyze 
the pathogens in diagnoses. The basic processes of protein conformational 
development are necessary to demonstrate what is normal protein structure and 
abnormal change. Therefore, this introductory chapter is comprised of four sections with 
general and specific background information: 1) Protein structures, synthesis, 
glycosylations, and related pathologies; 2) Prion Protein and TSE pathogeneses 
(including aberrant PrP glycosylations; 3) Traditional TSE diagnoses and limitations; 4) 
Introduction to work in this dissertation research (novel anti-PrP monoclonal antibodies 
in house; research overview and specific aims). The order of these sections will make it 




Section 1: Protein structure, synthesis, glycosylation, and related pathologies   
 
Fundamental Protein Structures 
Proteins are macromolecules formed in three-dimensional structures, referred to 
as polypeptides, which consist of large assembled chains of amino acid residues.17-19 
The amino acid residue is synthesized with series of 20 different L-amino acids, which 
are encoded in a gene (genetic code). A covalent chemical bond, called peptide bonds, 
links two consecutive amino acid residues. During protein synthesis, the amino acid 
residues in protein are chemically modified for its property, folding, stability, and activity. 
This process is critical for developing a proper structure and preforming biological 




A protein structure is typically classified in four levels: primary, secondary, 
tertiary, quaternary structures.17-19 The primary structure of a protein is specified as its 
unfolded liner sequence of amino acids in a polypeptide chain, which does not form the 
functional three-dimensional structure of a protein yet.  Two consecutive amino acid 
monomers in a polypeptide chain are linked by peptide bonds, which are known as 
covalent chemical bonds (molecular bonds) for sharing electronic interactions between 
atoms. After this synthesis, these primary structures of polypeptide chains fold into 
different shapes at the second level.   
The secondary structure is the general three-dimensional form of a local sub-
structure of the polypeptide chains stabilized by hydrogen bonds, electrostatic 
attractions between atoms.17-19 The definition of hydrogen bonds helps to explain a 
structural formation of a protein: “the hydrogen bond is an attractive interaction between 
a hydrogen atom from a molecule or a molecular fragment X-H in which X is more 
electronegative than H, and an atom or a group of atoms in the same or a different 
molecule, in which there is evidence of bond formation”.20  Such secondary structures 
are defined by patterns of hydrogen bonds: α-helix and β-sheet are the two common 
types that have important roles in protein conformation. The α-helix forms a right-hand 
coiled or spiral conformation, the most prevalent element in local structures of proteins. 
Among the 20 L-amino acids, methionine, alanine, leucine, glutamine and lysine have 
high propensities to form α-helical structures, whereas proline, glycine, tyrosine, and 
serine have low propensities to adopt this spiral conformation. Proline and glycine have 
features to disrupt or interfere the conformational regularity of α-helix. Another common 




hydrogen bonded β-stands. The β-stand is a single section of a polypeptide chain with 
amino acid residues in the β-sheet structure. Hydrogen-bonding interactions of adjacent 
β-stands in either parallel or antiparallel orientation form the β-sheet conformation. The 
β-strands in the truncal site of the β-sheet consist of large aromatic residues (i.e. 
tryptophan, tyrosine and phenylalanine) and β-branched amino acids (i.e. isoleucine, 
valine, and threonine): whereas proline is detected in the β-strands at the edge site of 
the β-sheet and introduces right-angle bends in the polypeptide.21  
These secondary structures of α-helix and β-sheet fold together to create tertiary 
structure—a global three-dimensional conformation of a single and monomeric protein 
molecule.17-19 Through this protein folding process, each protein achieves its specific 
native tertiary structure in order to function properly. A covalent bond, called disulfide 
bond (S-S bond, or disulfide bridge), links the thiol groups of two cysteine amino acids 
in this globular structure. The cysteine connection of disulfide bond has an important 
role to stabilize tertiary structure of a protein, and fold its proper conformation.  
Quaternary structure is the protein complex that multimeric protein molecules 
with tertiary structures assemble.17-19 In most proteins, proper assemblies of protein-
protein interaction and protein complex formation provide conformational stability and 
perform biological functions. Thus, properly folded (tertiary) and assembled (quaternary) 
structures are essential conditions for functionalities to promote normal ability of a 
certain protein. Obviously, protein folding is a critical process in which each protein 
acquires its specific native global three-dimensional shape, referred to as a native state 




Environmental or other external/internal factors such as temperature, pH, 
voltage, ion concentration, or chemical reagents influence this native state of the folded 
and/or assembled protein conformation.17-19 These factors disrupt three-dimensional 
protein conformations (secondary, tertiary and quaternary structures) and lead to an 
unfolded liner protein structure (primary structure). This unfolding process is called 
denaturation. After denaturation, a protein loses its functional activity because its native 
state conformation is already unfolded or disrupted, referred to as a denatured state. 
Although this denatured state is generally irreversible, an unfolding process could be 
reversible for some proteins in certain conditions when the denaturing factors are 
eliminated. Since denaturation does not alter peptide bonds of amino acid residues in a 
polypeptide chain, the primary structure of a protein remains intact and is capable of 
regaining its three-dimensional native conformation and function. This refolding process 
is called renaturation. Based on these folding and refolding mechanisms, proteins can 
maintain their proper native conformations and physiological functions. In other words, 
incorrect processes of these conformational mechanisms interfere protein homeostasis 
and initiate pathologic alterations of proteins in cellular and molecular environments. 
 
Structural Abnormalities of Proteins as Pathological Features 
The conformational change of the PrP molecule is the hallmark of TSE 
pathogeneses, which the natively folded isoform with a monomeric and α-helix rich 
structure alters to the abnormally misfolded isoform with an oligomeric/aggregable and 
β-sheet rich structure.22 This pathological modification of the PrP structure induces 




conditions dysregulate normal PrP functions and also generate toxic abilities of the 
abnormal PrP isoforms, causing damages and/or death to affected cells in the brain and 
nervous systems of TSE-affected individuals and animals.  
Similar protein conformational abnormalities in TSEs have recently been 
identified in several major human diseases, such as Alzheimer’s disease (AD), 
Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Type II diabetes mellitus 
(Type II DM) and cataracts.23-29 In these diseases, pathologies with disrupted native 
states and misfolded conformations of certain proteins have been identified. The TSE-
like pathological mechanisms of these major diseases have gained serious awareness 
leading to innovations in advanced diagnoses and treatments, as well as 
understandings in protein physiology and pathology. Including TSEs, these types of 
protein conformation-associated diseases are referred to as protein misfolding diseases 
(PMD, PMDs: proteopathy, proteinopathy, or protein conformational disorder).  
In PMD pathogeneses, several proteins have been identified their associations 
with certain diseases. 23-29 A specific protein is abnormally altered to misfolded structure 
that failures of its proper folding process induce. In this misfolded states, normal 
functions of the specific proteins are impaired because misfolded proteins can interfere 
with its protein physiology and proper protein assemblies to form protein-protein 
interactions and protein complexes. In fact, the misfolded proteins can induce 
disordered assemblies that lead to form massive aggregations and accumulations of the 
abnormal proteins. This pathological feature of a disordered proteinaceous assembly, 
called amyloid (amyloid fold or amyloid fibrils), is generally deposited extracellularly in 




physiological functions of organs in the body. Subsequently, these pathological 
alterations trigger disease developments. Just like the characteristic feature of TSEs 
pathogeneses, amyloid formations in PMDs consist with aggregations of massive 
misfolded proteins. In most PMDs, secondary and/or tertiary structures (three-
dimensional structures) of underlying misfolded proteins are altered conformationally 
from α-helix rich native state to β-sheet rich misfolded state.23,27,34-38 Generations of 
aberrant isoforms of a certain protein progressively propagate its misfolded proteins. 
This propagation results in depositions of these aggregations in affected tissues and 
organs. Moreover, an abundance of misfolded proteins in PMD generates toxic abilities 
to affected tissues and organs, induced by cellular injuries and deaths. Thus, the 
misfolded conformation and deposition of disease-associated proteins are characterized 
as the hallmarks of PMD pathogeneses.23-29 To understand the PMD pathogeneses and 
develop advanced diagnoses and therapies, it is essential to target misfolded proteins 
and aggregated proteinaceous assemblies in these diseases. Innovations of effective 
treatments and analytical methods for studying misfolded proteins and proteinaceous 
aggregates are still in progress. Future discoveries in TSE research will contribute to 
medical innovations in other PMDs, such as major human neurodegenerative disorders 
(i.e. AD, PD, and ALS).39-41 To investigate new targeting approaches, distinguishing 
between normal and abnormal protein isoforms must be one of novel diagnostic and 
therapeutic applications in PMDs and TSEs. The fundamental mechanisms of normal 
protein syntheses are important to understand how new proteins is generated properly 





Protein Synthesis and Glycosylation 
Proper protein structures and conformations are essential for maintaining normal 
biology and physiology in cells, as well as functions of tissues and organs in the body.17-
19 During the protein synthesis, cells generate new proteins with accurate compositions, 
structures, and conformations, based on genetic information in deoxyribonucleic acid 
(DNA) that encodes a specific amino acid sequence of each certain protein. The 
processes of the protein synthesis are defined by the two steps of transcription and 
translation, which are initiated from the nuclei to cytoplasms in individual cells. Newly 
synthesized proteins are transported to appropriate locations for their functions, known 
as another step of translocation. Modifications regulate protein maturation 
conformationally and functionally, and also eliminate incorrectly synthesized proteins. 
Glycosylation is an essential modification for facilitating protein folding correctly and 
stabilizing protein structure functionally. The five-key stages of protein synthesis 
describe below to clarify its normal processes and some possible impairment.17-19   
1) Transcription: In this initial stage of protein synthesis, the genetic information 
of proteins in DNA is copied (transcribed) to molecules of ribonucleic acids (RNA) with 
one strand of the DNA double helix, used as a template. This process in the nucleus is 
known as transcription, and this transcribed RNA molecule is called messenger RNA 
(mRNA). 
2) Translation: The next stage of protein synthesis, called translation, takes 
place in the cytoplasm. mRNA enters from the nucleus to the cytoplasm where the 
mRNA interacts with a ribosome. This transcribed template of DNA is decoded by 




subunits of ribosomal RNA (rRNA) molecules with a variety of ribosomal proteins. A 
small subunit determines the correct sequence of amino acids encoded in each mRNA. 
Another subunit is a large subunit that selects and assembles necessary amino acids to 
generate a polypeptide, which peptide bonds link amino acid residues in a long liner 
chain. Initially, the mRNA binds to a ribosome for translating the encoded specific amino 
acid sequence. For this interaction, transfer RNA (tRNA) molecules play a key role to 
specify the encoded specific amino acid sequence from mRNA and transport the 
corresponding amino acids to a ribosome for synthesizing new proteins.  
Through transcription and translation, the correct sequence of amino acids is 
generated longer and assembled into a polypeptide—an unfolded liner structure known 
as the primary structure of a protein. In the following processes of protein synthesis, 
primary structures of newly synthesized proteins fold into three-dimensional 
conformations for holding their native state structures, described above as protein 
folding.  
3) Translocation: Only qualified proteins are transported intracellularly or 
extracellularly to functionally appropriate locations at the end stage of protein synthesis. 
This protein transport, known as translocation, occurs during or after the processes of 
translation, called co-translational and post-translational translocations, respectively. To 
fold proper structures, newly synthesized proteins proceed through the quality controls 
in cellular mechanisms. Most proteins in eukaryotic cells (i.e. mammal and plant cells) 
are transported from a ribosome to the endoplasmic reticulum (ER), the Golgi apparatus 
(Golgi or Golgi complex) or endosome-lysosomal system through the co-translational 




prokaryotic organisms (i.e. bacterium and archaea). After translation has been 
completed, proteins are exported from a ribosome to the transporting destinations such 
as the ER (eukaryotes), plasma membrane (prokaryotes) or other organelles including 
mitochondria, chloroplast, and peroxisome via the post-translational translocation 
pathway. Through these translocation pathways, newly synthesized proteins in 
eukaryotic cells are assembled with a certain protein in the ER, called chaperone, which 
supports processes of proper protein folding and assembly. Chaperone proteins bind to 
these unfolded or partially folded proteins and assist their protein folding. This 
interaction with chaperone protects the newly synthesized proteins from aggregations 
with other molecules that form non-functional or abnormal protein assembly. 
Subsequently, only properly folded proteins contained in vesicles are transported to the 
Golgi apparatus for further enzymatic processes. These proteins are modified and 
sorted for transport to subsequent destinations in intracellular or extracellular sites for 
their functions, packaged by one of three different types of vesicles: exocytotic, 
secretory, and lysosomal.  
4) Modification: During the protein synthesizing processes above, responsible 
cellular recourses facilitate new protein products to fold correctly and to stabilize their 
structures functionally. Concurrently, these end-stage products of protein synthesis are 
modified chemically before or after proteins are released from ribosomes, called co-
translational and post-translational modifications, respectively. Mostly, proteins in 
eukaryotic cells are regulated by post-translational modification, which is associated 
with the quality control of protein synthesis. This modifying process is important for 




functionally in cellular networks. Specific modifications occur to the amino acid chains or 
the peptide termini (C-terminal and N-terminal) of proteins. One type of modification 
determines specific amino acids of a protein and catalyzes its linked peptide bonds by 
enzymes, called proteases. This proteolytic process breaks down the primary structure 
of a protein into small amino acids irreversibly, known as protein degradation, which 
prevents accumulations of damaged or misfolded proteins by the proteolytic reactions. 
These reactions can occur at various steps in the intracellular protein synthesis through 
the ER, the Golgi apparatus and the endosome-lysosomal or ubiquitin-mediated 
pathways during or after translation. Thus, impairments of protein degradation are 
involved in many disorders such as pancreatitis, rheumatoid arthritis, and Alzheimer’s 
disease. Furthermore, another type of modification targets specific amino acid side 
chains of a protein chemically or spontaneously, with or without enzymes. The common 
processes of these modifications include glycosylation, phosphorylation, ubiquitination, 
methylation and acetylation. Generally, the post-translational modification in eukaryotic 
cells is incorporated in various cellular organelles and membranes such as the ER, the 
Golgi apparatus, and endosome-lysosomal system. Briefly, the ER, specifically the 
rough ER, is an important organelle for the quality control and modification of newly 
synthesized proteins. This organelle facilitates protein folding, enzymatic-proteolysis 
process, and protein glycosylation (called N-linked glycosylation) into the functional 
three-dimensional native structure of a protein. The Golgi apparatus plays key roles in 
enzymatic modifications for glycosylation (called O-linked glycosylation), degradation, 
and translocation of proteins. In the final stage of protein synthesis, the endosome-




other modifications for protein maturation conformationally and functionally. Under the 
regulations of enzymatic cleavages, proteins acquire their active states from inactive 
forms, prior to transporting to intracellular destinations or secreting to cellular surface or 
extracellular space. Overall, hundreds of different proteins are newly synthesized in 
cells every single second, whereas almost 30% of new products are rapidly degraded 
within minutes of their syntheses.42 These regulations indicate that the quality control of 
protein synthesis is a critically important mechanism for conformationally generating 
new normal proteins and expressing them to functionally appropriate locations for 
cellular biology and physiology. Also, this quality-control mechanism prevents 
aggressions and accumulations of damaged, misfolded or incompleted structural 
proteins. The balance of protein degradation and protein translocation maintains protein 
synthesis correctly in these intracellular systems through co- and post-translational 
modifications. Therefore, it is clear that the normal protein function is directly dependent 
on protein structure with proper folding and modifications. Seriously, failures of these 
processes can initiate impairments of normal functions in cells and eventually induce 
pathological developments.  
5) Glycosylation: In the processes of protein synthesis, protein glycosylation is 
a key modification for most proteins in eukaryotic cells, to facilitate protein folding and 
stabilize protein structure functionally. Protein glycosylation is an enzyme-directed 
chemical reaction in which carbohydrates (sugar moieties or residues, referred to 
glycans and saccharides) are covalently attached by glycosidic bonds to specific amino 
acid residues in unfolded proteins (primary structures) during co- and post-translational 




organisms of eukaryotes and prokaryotes. The majority of newly synthesized proteins 
that proceed through the ER and Golgi apparatus are glycosylated. Generally, 
glycosylation in the ER is essential for monitoring protein folding as a checkpoint, 
whereas glycosylation in the Golgi apparatus contributes to protein translocation. 
Among various forms of carbohydrate-protein glycosidic linkages, major types of protein 
glycosylation are characterized by the two linkages based on binding sites of 
carbohydrates to specific amino acid residues: N-linked glycosylation and O-linked 
glycosylation. Briefly, N-linked glycosylation is the most common type of glycosylation, 
typically processed in the rough ER and the Golgi apparatus. Glycans are covalently 
attached to nitrogen atoms in the side chains of asparagine (Asn or N) that are adjacent 
to cysteine (Cys or C), serine (Ser or S) or threonine (Thr or T) followed by any amino 
acid except proline (Pro or P). For instance, the amino acid sequence of a N-linked 
glycosylation site is denoted as Asn-X-Cys or Asn-X-Ser in which X is any amino acid 
except Pro. Also, N-linked glycosylation has three main types, defined by formations of 
sugar residues and structures: high mannose, hybrid, and complex. O-linked 
glycosylation generally occurs only in the Golgi apparatus in which glycans bind to 
hydroxyl-oxygen atoms in the side chains of Ser (S), Thr (T), hydroxylysine (hLys), or 
hydroxylprotein acceptor site.43 These amino acids are located in close proximity to Pro 
(P). O-linked glycosylation are categorized into seven major types listed below, based 
on the glycan-linked sites of amino acid residues and the types of carbohydrates. As the 
major structural components on cell membranes and secreted proteins, these N-linked 
and O-linked protein glycosylations have critical roles to facilitate proper structural 




glycosylation influence nascent liner proteins to fold into their secondary structures and 
stabilize conformations into their native states of tertiary and quaternary structures.44 In 
fact, many proteins are not correctly folded without glycosylation because the glycosidic 
attachments assist the conformational stability for protein structure. In other words, 
glycosylated states are involved in the prevention and elimination of incorrectly folded 
proteins, which are proceeded to degradation. Given this process, glycosylation 
emerges an important process in the maintenance of correct protein conformations. 
Glycoproteins also interact with other specific proteins to initiate or modulate various 
essential biological mechanisms. As a result, glycosylation is a critical influence on the 
functions of glycoproteins and their assembled complexes in these mechanisms. Below, 
physiobiological and pathological features of N-linked and O-linked protein 
glycosylations are described. 
N-linked glycosylation. During protein synthesis in the ER, the quality control of 
proteins occurs at any stage, such as translation, modification, assembly with chaperon, 
and transport. In the quality-controlling processes, N-linked glycosylation has essential 
endogenous functions as a checkpoint for the quality control in protein folding and 
selection through the ER. On attached proteins, this glycosylation provides stability as a 
structural component and modifies solubility against molecular environmental changes 
(i.e. temperature, and pH). In addition, a checkpoint function for protein degradation is 
closely linked to glycosylation states on attached proteins. As an exogenous function, 
the N-linked glycosylation directs transportation of glycoproteins and mediates cell-cell 
signaling, such as cell-cell and cell-matrix interaction. In the immune system, 




carbohydrate-binding proteins, which recognize specific carbohydrate residues on 
proteins in targeting cells.  Furthermore, viruses propagate in infected cells and produce 
viral proteins linked with N-linked glycosylation.45 This glycosidic structural component 
on viral proteins has a protective role to shield viruses from recognition by immune cells. 
For instance, human immunodeficiency virus (HIV) contains a high density of N-linked 
glycans on its envelope viral protein.46 Parasites (i.e. Trypanosoma cruzi) also have 
similar strategies of immune evasion in glycoproteins.47 In contrast, immune cells can 
determine dissimilar chemical compositions of glycosidic diversities between host 
proteins and viral/parasitic proteins. Thus, this immunological recognition by glycans 
operates as a functional barrier against cross-species transmissions of pathogens, such 
as zoonotic transmission.45 Interestingly, current research indicates that this 
glycosylation-based self-recognition might be associated with underlying 
pathophysiological mechanisms in autoimmune diseases and organ transplant rejection. 
It is clear that N-linked glycosylation has protective functions for proteins and cells from 
intrinsic and extrinsic impairments. This glycosylation is also an essential checkpoint 
factor for self and non-self recognitions from infectious particles in transmissions and 
foreign materials from transplantations. Failures of this checkpoint factor impact the 
immune systems and the normal physiology in the body, which induce pathological 
development. In fact, defects of N-linked glycosylation or mutations of associated genes 
in this glycosylation have been detected in various disorders (i.e. congenital disorders of 
glycosylation in infants, the most known inherited glycosylation diseases). N-linked 
glycosylation-associated disorders cause pathological conditions particularly in the 




neurological impairments. Therefore, it is enough to assume that N-linked glycosylation 
is a critically important factor to understand normal physiology and pathological 
developments in the nervous system.  
O-linked glycosylation. The forms of O-linked glycosylation are defined by the 
glycosidic sites of amino acid residues on a protein and the types of carbohydrate 
moieties: glucose (Glc), galactose (Gal), mannose (Man), fucose (Fuc), N-
acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc), and N-acetylneuraminic 
acid (NAHA, also known as sialic acid) (Lis H and Sharon N, 1993, European Journal of 
Biochemistry). The most common form of O-linked glycosylation is the attachment of 
GalNAc to Ser or Thr residues in a protein, known as the mucin-type or mucin 
glycoprotein, in which the abundance of mucus is secreted on cellular surfaces and in 
body fluids. This mucosal secretion is a highly concentrated carbohydrate. Proteoglycan 
is a characteristic glycoprotein that the GalNAc-attached form is involved in its protein 
synthesis. This protein has a critical role in the generation of components to form the 
extracellular matrix that is essential for cell-cell interactions. Genetic mutations in this 
glycosylation lead to cause some autosomal recessive disorders and autoimmune 
diseases.48 Another form of the O-linked glycosylation is the GlcNAc-attached form, 
which only occurs to non-phosphorylated Ser or Thr residues. This form of glycoproteins 
in the nucleus and cytoplasm has a role of the interaction between O-glycosylation and 
phosphorylation. In addition, the GlcNAc-attached form has functions in transcription, 
translation, degradation and translocation, as well as a signal transduction pathway.49 
Interestingly, overexpression of the GlcNAc-attached form is involved in pathological 




this glycosylation have been recognized as the etiologies of neurodegenerative 
diseases and cancer development.  This form has regulating roles for various oncogenic 
proteins and tumor suppressor proteins. An additional form, the attachment of Man to 
Ser or Thr, occurs specifically on certain proteins, called α-dystroglycans, in brain and 
muscle cells. It is known that impairments of this glycoprotein and its related enzymes 
are associated with the pathology of congenital muscular dystrophy, particularly in 
Duchene Muscular Dystrophy.50,51 Other O-linked glycosylations of Fuc and Glc, the 
fourth and fifth forms, occurs between certain cysteines with repeats of epidermal 
growth factor (EGF) motifs in Notch proteins. Fuc attaches to Ser or Thr in between the 
second and third conserved cysteines, whereas Glc bonds to Ser in between the first 
and second conserved cysteines. This glycoprotein is essential in the Notch signaling 
pathway, which has an important role in various developmental processes in mammals.  
Thus, impairments of these forms affect regulations of this signaling pathway and 
initiate pathological developments of cancer (i.e. leukemia) and neurological disorders 
(i.e. cerebral autosomal dominant arteriopathy with subcortical infracts and 
leukoencephalopathy: CADASIL, the most common type of hereditary cerebral 
angiopathy/stroke disorder). As the sixth form, collagen is only the protein attached with 
Gal to its hLys residue. This form of O-linked glycosylation is required for proper 
functions of collagens as the major structural proteinous component in connective 
tissues. The impairments of collagen-sugar linkages are related to underlying 
pathological mechanisms in diabetes and autoimmune diseases, such as rheumatoid 
arthritis.  The seventh form, O-linked glycosylation of NAHA, has an essential role to 




NAHA is involved in an important pathway of sugar metabolisms. Thus, impairments or 
genetic deficiencies of this form and/or associated enzymes affect these activities in the 
metabolic pathway, resulting in casing abnormalities in neurological and 
musculoskeletal disorders, such as congenital myastheniac syndrome, 
immunodeficiency syndrome, and adult-onset inclusion body myopathy (hereditary 
inclusion body myopathy).54 Based on the information above, O-linked glycosylations 
are associated with cell-cell interactions and signaling pathways. Also, the impairments 
of the O-linked glycosylations are involved in immune-mediated pathological conditions. 
It provides a clear understanding that dysfunctions of this glycosylation type might affect 
regulations of immune systems. In addition, a genetic background of each protein 
influences its protein synthesis including glycosylation. Therefore, a genetic deficiency 
or mutation is closely related to incorrect processes of glycosylations in pathological 
developments of certain disorders. 
Overall, proper protein structures and conformations are critically important for 
normal functions of proteins in cells, tissues, and organs in the body. Protein 
glycosylation is a key factor to maintain the quality control of protein synthesis and 
prevent abnormal protein generations. Physiologically, glycosylation states are involved 
in regulations of immune and nervous systems. In another aspect, the impairments of 
glycosylations are associated with pathological developments and disorders. It is now 
indispensable to recognize how much impaired glycosylations have been identified in 






Aberrant Glycosylation and Diseases 
Recent studies describe that impairments of glycosylation pathways are 
underlying conditions in more than one hundred disorders in humans.55-57 Since multiple 
genes are involved in glycosylation and associated enzymes (approximately 100 and 
200 genes respectively), the large numbers of disorders by impaired glycosylation 
pathways might be unsurprising.  These glycosylation-associated diseases are defined 
into congenital defects and acquired alterations of glycosylations.  
Congenial defects of protein glycosylations implicate with various disorders, 
such as congenital disorders of glycosylations (CDG), congenital muscular dystrophies 
(CMD), and limb-girdle muscular dystrophies (LGMD).58-60 Gene mutations that 
associate with glycosylations cause fatal neurological impairments, including cerebral, 
ocular, and muscular abnormalities.61-63 In fact, gene mutations impair N-linked 
glycosylations in inherited neurological disorders, such as congenital myasthenic 
syndrome and schizophrenia.64,65 Also, alterations of N-linked glycosylations have been 
identified in neurodevelopmental diseases, including autism spectrum disorder (ASD) 
and attention-deficit hyperactivity disorder (ADHD).66,67 These findings indicate that N-
linked glycosylations have essential roles in the regulation of the nervous and muscular 
systems.68 Hence, the deficiency or alteration of protein glycosylations is a critical 
modulation influencing health conditions and causing pathological impairments. Failures 
or dysfunctions of glycosylations and associated pathways initiate developments and 
progressions of severe to fatal medical conditions. 
Acquired alterations or abnormalities of glycosylations have also been 




Here, I do not intend to summarize all protein glycosylations related to pathogeneses of 
these medical conditions.  However, some key glycosylations will provide general 
perspective roles in the developments and progressions of these diseases.  
1) Diabetes mellitus: Diabetes mellitus (DM) is a major metabolic disorder that 
disrupts glucose homeostasis.69 The pancreas is the insulin-producing organ in which β 
cells in the islets of Langerhans release insulin upon physiological elevations of glucose 
levels in the blood. Hyperglycemia is a chronic condition with increased levels of 
glucose in the blood (high blood sugar), and eventually induces glucose toxicity that 
affects functions of the pancreas and other insulin-targeted peripheral tissues (i.e. 
muscle, liver and adipose tissue).70,71 The dysfunction of β cells is a major etiology of 
DM and its complications, such as diabetic cardiomyopathy, nephropathy, retinopathy, 
and cardiovascular diseases.72-80 To understand pathogeneses of the DM etiology, 
protein glycosylations are key molecular targets in β cells and other tissues, especially 
for insulin resistance in the Type II DM and .81-83 For instance, N-linked glycosylation is 
involved in the DM pathogeneses.84 An insulin receptor (N-linked glycoprotein on cell 
surfaces) has functions in the glucose uptake by insulin, as well as insulin-like growth 
factor (IGF) 1 and 2.85 Bindings of insulin and its receptor play a regulating role of 
glucose homeostasis. Conditions of insulin receptors influence insulin sensitivity and 
resistance in cells. Decreases or defects of insulin receptors disrupt insulin binding and 
processing, which lead hyperglycemia, DM, and its complications.86,87 Since N-linked 
glycosylations of insulin receptors have roles in intracellular processing and signal 
transduction, defects of the N-linked glycosylation affect on the receptor activity in 




on the receptor, especially in the kidneys.78,79 Impairments of protein N-linked 
glycosylations can induce the pathological progression of diabetic nephropathy. Hence, 
glycosidic alterations are associated with in DM pathogeneses and disease 
developments, including insulin resistance, hyperglycemia, and complications. Thus, 
proteomics approaches target protein glycosidic statuses in DM diagnostic 
innovations.90 Profiling glycosylations is now referred as to glycomics.91 Screening 
states of glycosylations on certain proteins is a useful application to determine pre-
diabetes and DM conditions in patients.92-94 Therefore, a glycosylation-targeting 
diagnosis is an important strategy to establish novel analytical methods.95,96 New 
investigations will provide further advances to understand roles of protein glycosylations 
in pathological etiology. 
2) Alzheimer’s disease: Current researches have proposed Alzheimer’s disease 
(AD) as a new “Type III” DM, based on similar pathogeneses to DM, such as impaired 
metabolisms of insulin and glucose in brains.97-99 Insulin and its signaling are involved in 
various functions of brains including cognition and memory, which AD patients 
decline.100 Hyperglycemia and glucose tolerance are significant conditions in patients 
with AD.101-103 Also, altered glucose metabolisms cause cognitive impairments in brains, 
which are associated with the underlying causes of neurodegenerative pathologies in 
the AD development.103-105 
In PMDs, AD is the major neurodegenerative disorder in humans that has serious 
global impacts internationally because it is the most common cause of dementia.97-99 
Both hyperglycemia and hypoglycemia are well known risk factors of cognitive 




amyloid-β (Aβ) peptide and tau protein) that link to the AD etiology misfold and 
aggregate in brains. Aβ is a proteolytic fragment of amyloid precursor protein (APP), an 
integral membrane protein expressed in various tissues and concentrated in synapses 
of neurons.106 Tau protein is a microtubule-associated protein that is abundantly 
accumulated in axons of neurons but less expressed in other cells and tissues.107 The 
misfolding and aggregations of these certain molecules are the major pathologic 
hallmarks of AD. Aberrant Aβ and tau protein compose amyloid plaques and 
neurofibrillary tangles, respectively. The abnormal accumulations of these aggregated 
proteins toxically impair the nervous system and eventually induce the AD development.  
As described above, the Type II DM is one of the PMDs that islet amyloid 
polypeptide (IAPP) misfolds and accumulates in the pancreas like abnormal PrP feature, 
and its aggregation affects the function of β cells toxically.108-110 Recent studies report 
the pathological link between Type II DM and AD in which DM is a risk factor of the AD 
development.111-116 Insulin and its signaling are key regulators to form amyloid plaques 
and neurofibrillary tangles. In fact, insulin-resistant conditions and impaired signaling 
progress the accumulation and deposition of Aβ in brains of AD patients.99,100 The 
disease-associated proteins in Type II DM and AD alter conformationally from α-helix to 
β-sheet rich structures, which are characteristic features of amyloid deposits.117 The 
aggregations and accumulations of the misfolded proteins are potentials of disease 
transmission and propagation.118 These pathologic features of protein abnormalities and 
deposits are the hallmarks of PMDs.  
Similar to DM, these AD pathogeneses are also associated with modifications of 




reported in AD.76, 119 APP is well known as a precursor molecule of Aβ.120 Even though 
APP is a single molecule, this protein derived from human cerebrospinal fluid (CSF) 
consists of both N-linked and O-linked glycosylations.121 N-linked glycans are 
functionally important to regulate transports and secretions of APP. Increases of N-
linked glycans enhance secretions of APP and its metabolites.122,123 Thus, inhibitions or 
defects in N-linked glycosylations reduce APP transports and secretions. In addition, 
mutations of APP alter N-linked glycosylations but increase O-linked GlcNAc 
glycosylations.124 In AD patients, this glycosidic increase on APP upregulates mRNA 
expressions of GlcNAc transferase III (GnT-III), which is the responsible enzyme for 
synthesizing GlcNAc residues in their brains.125 The enzymatic upregulation induces 
increases of soluble APPα, whereas Aβ generations are decreased. This mechanism 
indicates protective effects of APP glycosylations for brains against Aβ generations and 
accumulations. Normally, O-linked GlcNAc glycosylations are abundant in neurons.126 
However, decreases or impairments of O-linked GlcNAc glycosylations have been 
found in AD brains. The decreases are associated with impaired metabolisms of insulin 
and glucose, and increased expressions of the enzyme O-linked GlcNAc transferase 
(OGT) that catalyzes the addition of GlcNAc residues in O-linked glycosidic 
linkages.127,128 Eventually, these aberrant alterations disrupt functions of O-linked 
GlcNAc glycosylations and affect stability, activity, expression, and interactions of 
glycoproteins.129,130 In consequence, altered protein glycosylations could initiate 
abnormalities and AD development.  
Tau proteins in non-AD brains only express O-linked GlcNAc glycosylations, 




helical filament, and tangle formation.131-133 In contrast, the tau proteins in AD brains 
alter glycosylations of both N-linked and O-linked glycans.134 The glycosidic 
abnormalities in AD brains could be caused by reductions of the enzymes that remove 
N-linked glycans.119 To assemble neurofibrillary tangles, N-linked glycosylations 
promote formations of tau proteins with paired helical filament or hyperphosphorylation, 
which highly contain truncated glycans.135,136 Aberrant N-linked glycosylations of tau 
proteins induce more susceptibility to phosphorylation but are less prone to 
dephospohorylation.134 Thus, the N-linked glycosidic abnormality leads 
hyperphosphorylation of tau proteins.137 In addition to the abnormal N-linked 
glycosylation, modifications of O-linked GlcNAc glycosylations are detected on tau 
proteins in AD brains that have 4-fold decreased levels.138,139  Glucose metabolism 
regulates protein O-linked GlcNAc glycosylations that control phosphorylation of tau 
proteins.140 Therefore, an impaired-glucose uptake in the brain induces decreases and 
dysfunctions of O-linked GlcNAc glycosylations that reciprocally increase 
hyperphosphorylation of tau proteins and neurofibrillary tangles.141-143 These 
dysregulations result in the development of AD pathology.  
Overall, alterations of N-linked and O-linked glycosylations could trigger 
pathologic modifications and aggregations of tau proteins, called tauopathy, in 
neurofibrillary tangles initiating AD development. Impaired glucose metabolism is 
associated with aberrant protein aggregation and accumulation in AD. Interestingly, 
recent articles discuss an association between DM and amyotrophic lateral sclerosis 
(ALS) by a large population study in Sweden.144-146 This study suggests that impaired 




also identify similar glycosylation patterns of AD in ALS, such as reduced O-linked 
GlcNAc glycans, increased N-linked glycans, and hyperphosphorylated proteins.147,148 
Thus, the disease development of ALS could be related to dysregulations of protein 
glycosylations and phosphorylations. According to all of the information in this Section 1, 
it is obvious that an alteration or impairment of glycosylations is one of the hallmarks in 
PMDs and a characteristic feature in neurodegenerative diseases. Because of PMDs, 
pathologic modifications of glycosylations could be associated with structural 
aberrations and misfoldings of disease-associated proteins. Using concepts of 
glycomics and glycoproteomics, targeting glycosylation states on disease-associated 
proteins is a practical approach for diagnostic and therapeutic innovations and for 
elucidating undefined pathogeneses in PMDs including neurodegenerative diseases. 
The upcoming Section 2 describes background information of prion proteins and 
abnormalities in TSE pathogeneses including glycosylations of normal and pathologic 
PrP. Aberrant N-linked glycosylations are key modulators of disease development and 
progression in TSEs.149-152 Alterations of glycosidic states are essential targets of TSE 
diagnoses to distinguish normal and abnormal PrP, as well as to evaluate infected 
states, disease development and prognoses.  
 
 
Section 2: Prion Protein and TSE Pathogeneses 
 
Normal prion protein isoform 
 
Prion protein (PrP) is an N-linked glycoprotein on a cell membrane, and cellular 
prion protein isoform (PrPC) is a normal prion protein that is monomeric, detergent 




Prnp in mice) located on the short (p) arm of chromosome 20 in humans (at position 13: 
20p13), which corresponds to chromosome 2 in mice.153 PrPC consists of α-helix-rich 
structures mostly with two N-linked glycans (diglycosyl form). PrPC is abundantly 
expressed in tissues of the central nervous system (CNS), especially in several regions 
of the brain, such as olfactory bulb, striatum, hippocampus, and prefrontal cortex.154,155 
PrPC mainly localizes on the cellular membrane, and its expression has been detected 
in neurons, extraneural tissues, and glial cells in the CNS.156-159 Conversely, neocortical, 
hippocampal, and thalamic neurons show intracellular expressions of PrPC in these 
cytosols.160,161 Cerebellar neurons, however, do not express this protein in their 
cytosols. A recent study identified that mitochondria in healthy mouse brains expresses 
PrPC with diglycosyl N-linked glycans that is localized to inner mitochondrial 
membranes.162 This finding indicates, in a natural state, PrPC exists intracellularly in 
brain mitochondria. The intracellular PrPC might influence mitochondrial functions 
physiologically and pathologically. Since intracellular accumulations of altered PrP 
isoforms are strongly neurotoxic and cause neurodegeneration, the cytosolic PrPC 
expressions in these neurons might be associated with molecular pathogeneses of 
TSEs.163-165 Furthermore, PrPC expressions have been identified in the peripheral 
nervous system, and other non-CNS organs and tissues, such as the heart, muscles, 
spleen, lungs, gastrointestinal tract, skin, kidneys, and lymphoid tissues.157,159,167-169 
Recent dental research reports that the PrPC interacts with neurotransmitters, such as 
dopamine and serotonin, in tooth development, maintenance, and abnormality.170-174 
Therefore, systemic expressions of PrPC throughout the body indicate its functional 




PrP Structure and Glycosylation 
PrP with N-linked glycans consists of approximately 250 amino acids in a length 
of its primary sequence.14 On a 253 amino acid sequence in human (and hamster) 
numbering, residues 1 to 124 form (NH2)-terminal (N-terminal) region. Residues 1 to 22 
consist of the primary-amino signal peptide of N-terminal. Residues 23 to 124 are 
composed of the flexible N-terminal domain that consists of five or six repeats of eight 
glycine-rich residues (PHGGGWGQ) known as the octapeptide repeat region, acting as 
binding sites of divalent metal ions, such as copper, iron, zinc, nickel and 
manganese.72,175-177 Recent studies determine that metal imbalances in the brain 
influence physiological functions of PrP molecules. These functional disruptions are 
possibly related to TSE pathogenesis.177 Furthermore, residues 125 to 253 form the 
carboxylic acid (COOH)-terminal (C-terminal) region. Residues 125 to 228 constitute the 
globular-structure domain in the C-terminal. Through proper folding, the tertiary 
structure of PrP forms a globular domain with three α-helices (corresponding to residues 
144-154, 173-194, and 200-228) and two antiparallel β-strand sheets (residues 128-
131, and 161-164) in the C-terminal.178-180 In addition, a large rigid loop links the second 
β-strand sheet (β-sheet 2) to the second α-helix (α-helix 2), known as a β2-α2 loop 
(residues 165-175) that has intriguing structural properties for stabilizing tertiary 
structures of PrP and folding these proper conformations.179-182 Recent studies propose 
this well-structured loop as a pathologic key factor of PrP conformational abnormalities, 
species barriers, and transmission in TSEs.183-187 At last, residues 232 to 253 form the 




During protein syntheses, the following post-translational modifications occur to 
PrP molecules: 1) removals of both N- and C-terminal signal peptides, 2) additions of 
glycophosphatidylinositol (GPI) membrane anchors, 3) formations of disulfide bands, 
and 4) attachments of N-linked glycans.188,189 After the cleavage of the N-terminal signal 
peptide and C-terminal hydrophobic peptide, the residue 231 in the C-terminal of PrP 
links a GPI membrane anchor that tethers a PrP to a specific-membrane microdomain 
of a cellular membrane (a plasma membrane). This microdomain is known as a lipid raft 
that is a cholesterol- and glycosphinogolipid-rich region and associates with signal 
transduction mechanisms.190,191 The cysteine (Cys) connection of one disulfide bond 
exists between Cys 179 on the α-helix 2 and Cys 214 on the α-helix 3 in human and 
hamster PrP numbering (178 and 213 in mouse PrP numbering).192,193 This disulfide 
bond stabilizes a tertiary structure of PrP and folds its proper conformation. In the 
process of N-linked glycosylation, glycans attach to two asparagine (Asn or N) residues 
located on the α-helices 2 and 3 (i.e. respectively, 180 and 196 in mouse PrP 
numbering; 181 and 197 in human and hamster) in the amino acid sequence of the PrP 
structure.194 This N-linked glycosylation generates four various forms of glycosylated 
PrP: 1) unglycosyl, 2) monoglycosyl at 180 = mono1, 3) monoglycosyl at 196 = mono2, 
and 4) diglycosyl at 180 and 196.195 Typically, an abundance of normal PrPC has the 
diglycosyl form (2 glycans). During these post-translational modifications in the ER and 
Golgi, the PrP sequence is shortened to almost 200 amino acids in length (209 in 
human) for its maturation.14 Eventually, the mature PrP is transported from the Golgi to 




Although the mechanisms of these N-linked glycans on PrP are not completely 
understood, it is recognized that glycosylation plays various structural and functional 
roles in proteins.197 For example, N-linked glycosylation is involved in the maintenance 
of PrP structure, and thus modulations of the N-linked glycosylation may lead to change 
a protein conformation.197 In fact, mutation or truncation of N-linked glycans interferes 
with protein folding and structure.198,199 Also, intracellular accumulations of unglycosyl 
proteins cause cytotoxicity that associates with molecular pathogeneses of 
neurodegeneration.200 In TSEs, it is suggested that N-linked glycans on normal PrP 
isoforms contribute to disease phenotypes. For instance, transgenic mice lacking a 
glycan at either one of the two consensus sites for N-linked glycosylation of PrP show 
more sensitivity to the infections of TSEs.201 This infectious sensitivity indicates that the 
loss of N-linked glycans on PrP is involved in the pathological mechanisms of prion 
diseases. Moreover, the absence of a diglycosyl PrP form is reported in cell culture 
models, and in brain tissues derived from human patients with TSEs.150,202 In addition, 
abnormal patterns of PrP glycosylation are detected by in vivo models of scrapie, with 
an increased ratio of under-glycosylated forms (unglycosyl and/or monoglycosyl form = 
0 or 1 glycan), but a decrease in diglycosyl forms.203 Although a normal PrPC isoform 
mostly localizes on a cell membrane, both PrPC with aberrant N-linked glycans and 
abnormal PrPSc isoforms exhibit intracellularly.204 This intracellular proteinous 
accumulation causes cytotoxicity.165,166 
In spite of numerous studies about the expression profiles of the glycosylated 
forms of PrP, the importance of the glycosylation in TSEs is not fully clarified.205 As a 




development. A possible reason is that alterations in states of glycosylation could cause 
PrP abnormalities and provoke TSE developments. Another feasible reason is that N-
linked glycosylation may play a significant role in prion pathogenesis by selective 
glycosyl forms. Therefore, N-linked glycosylation and its states are innovative targets to 
clarify different properties of normal and abnormal PrP isoforms. This dissertation 
project focuses on analytical and diagnostic aspects for distinguishing abnormal PrP 
isoforms with certain states of aberrant glycosylations. To establish the aims of the 
project, in-house anti-PrP antibodies are utilized to identify and to measure PrP 
molecules in TSEs. 
 
PrP Functions 
PrP abnormalities in TSEs have been largely studied, and three Novel Prize 
winners were awarded in TSE and related research fields: Dr. Daniel Carleton Gajdusek 
(Physiology or Medicine) in 1976; Dr. Stanley B. Prusiner (Physiology or Medicine) in 
1997; and Dr. Kurt Wüthrich (Chemistry) in 2002.206,207 While abnormalities of PrP have 
been well-documented, in contrast, normal functions of PrPC have yet to be determined 
clearly, and their physiological importance has been controversial.208 PrP-knocked out 
(PrP-KO) transgenic (Tg) mice have been used to determine functional roles of PrPC in 
normal physiology.209-212 At the initial stage of these investigations, an availability of 
various breed lines of PrP-KO Tg mice was limited.209,210 These mice lacking PrP 
expressions were clinically normal and also did not show clear onsets or symptoms of 
disease development.209,210,213 In addition, PrP-KO Tg mice with inoculations of TSE-




been recognized as evidence that the Tg mice lacking PrP are prone to maintain non-
disease conditions and are also not susceptible to TSE infections. These observations 
have implied that PrPC and their functions are non-essential molecules and regulators in 
biology and physiology of CNS and other organ systems for the survival of the 
laboratory mice.209,210,216,217 Therefore, PrPC researches have paid less attention to 
determine deficiencies and modifications of normal PrP physiological functions, 
compared to dysfunctions by abnormal PrP pathogeneses in TSEs. 
Current studies have increasingly reported associations of PrPC with major 
human disorders, such as AD,218-225 cancers,226-231 and DM.232-234 These identifications 
have sparked exploratory investigations of undefined PrP functions in normal 
physiology, as well as pathophysiology. Furthermore, several studies have revealed 
clinical abnormalities in various available breed lines of PrP-KO Tg mice, such as 
dysregulations of circadian and sleep rhythms, deficiencies in cognition and olfaction, 
and alterations in the immunological system.235-241 Clinical abnormalities in these mice 
are observed as strain-phenotype dependences in PrP-deficient Tg mouse breed 
lines.242-245 As mentioned above, the PrP-KO Tg mouse breed lines that were initially 
utilized to determine PrP functions did not show physiological or developmental 
aberrations.209,210,213 These findings indicate that different gene-targeting strategies for 
generating Tg mouse lines with PrP deficits influence PrP functions in mouse 
physiology. However, recent studies have identified spontaneously impaired conditions 
and drug sensitivities in these breed lines.237,245-260 Therefore, pleiotropic regulators 




functions still remain open, several clinical and physiological phenotypes attributable to 
PrP deficits have been identified from PrP-KO Tg mouse studies. 
The most recognized PrPC function is known as a copper interaction and 
transporter.13, 219,261-268 Impairments of copper homeostasis in nervous systems cause 
some inherited disorders of copper metabolism, and neurodegenerative diseases.269-271 
In copper metabolism and homeostasis, PrPC isoforms are highly interacted with copper 
ion (Cu2+).219,261-263 On the PrPC structure, Cu2+-binding sites are localized in the 
octapeptide repeat region at the flexible unstructured N-terminal.175,176,264,265 Since PrPC 
can chelate Cu2+, this protein is considered as an antioxidant to protect cells from 
oxidative damages, and reduce cellular reactive oxygen species (ROS) that comprise of 
radical and non-radical oxygen species.272-275 In fact, PrP-KO mice and their cultured 
neural cells exhibited the increased sensitivity to oxidative stress.276-283 Also, brains of 
PrP-KO mice decreased copper levels and numbers of mitochondria per cell.276-278. The 
majority of mitochondria were morphologically abnormal.278 These reports indicate that 
PrPC may have protective function for cells from oxidative damage.  
 Here, I do not intend to summarize all PrP functions for focusing on the 
dissertation topics. However, some PrP functions could be implicated with the TSE 
disease developments and progressions, as listed in following areas: neurotransmission 
system159,284-295; cellular proliferation, differentiation, death, and survival296-299; myelin 
maintenance property245,300,301; neuroprotection297,302-304; phenotypes of sleep, behavior, 
and memory235,305-308; and non-nervous systems (i.e. the immune, muscular, 




 Overall, PrPC expressions and functions are essential factors and regulators for 
cellular biology and neurophysiology in the CNS and PNS.  The loss or alteration of 
PrPC isoforms would influence neurological functions, leading to aberrant impairments 
and disease developments, such as neurodegenerative disorders. To understand PrPC 
implications in pathogenic mechanisms of functional failures, the measurements of PrPC 
expressions and alterations would be beneficial to determine physical impairments, 
abnormalities, disease developments and prognoses in longitudinal terms. This 
dissertation study will provide the practical prospects for these analytical applications.  
 
PrP polymorphisms and aberrant variants 
 1) Normal variants with disease implications: In the human PrPC gene, some 
polymorphisms of normal variants are not pathogenic, but influential factors on the 
susceptibility to sporadic, inherited, and infectious forms of TSEs, and the phenotypic 
properties of these diseases.315,316 The polymorphism at the codon 129 is the common 
normal variant that codes either methionine (Met: M) or valine (Val: V), which this 
polymorphism is usually denoted as M129V. In the Caucasian population, 
approximately 50% of people have homozygous variations of either M (40%) or V (10%) 
at the codon 129. However, the codon 129 genotypes are significant factors for 
increasing the developmental risks of CJD and its phenotypic variations, including 
PRNP mutations and inheritances.317-323 Also, the codon 129 homozygosis strongly 
implicates with acquired forms of TSEs, such as kuru, variant CJD (vCJD), and 
iatrogenic CJD. 324-329 For instance, 70% of sporadic CJD (sCJD) patients exhibit 




vCJD patients express only M homozygotes (MM). In contrast, the heterozygosis (MV) 
at the codon 129 is a resistant factor to CJD developments. CJD patients with MV 
variant at the codon 129 tend to prolong onsets of the disease until late ages, compared 
with those with the homozygosis (MM or VV). This protective efficiency of the MV 
heterozygosity is considered as in relation to the protein-protein interactions in PrPSc 
transmissions between homologous species.317,330,331 In addition, the codon 129 
variants in PRNP implicate with other neurological disorders that are not associated with 
TSEs. The VV homozygosis at the codon 129 is a risk factor to elicit early onsets in AD 
patients.332,333 Conversely, another study indicated the protective efficiency of the V 
allele homozygosis (VV) and heterozygosis (MV) at the codon 129 that reduce 13% 
from the developmental risk of AD and extend prolonged-disease onsets, especially in 
elder patients over 65 years olds, compared to people with the MM variants.334 In Down 
syndrome patients, this VV variant progressively aggravates their cognitive 
impairments.335 Even in healthy individuals, the VV variant is involved in the age-related 
declines of cognitive and long-term memory functions during adulthood and 
senescence.336-338 Moreover, the MM homozygosis at the codon 129 is associated with 
exacerbations of neurological impairments in senior patients with Wilson disease, an 
autosomal recessive inherited disorder of copper metabolism and accumulation, 
whereas the patients with VV or MV variant exhibit the early disease onset.339,340 
Although the PRNP 129 polymorphism is causally related to neurological impairments, 
these underlying mechanisms are uncertain yet.  
 Another non-pathogenic polymorphism has been reported at the codon 219 in 




Japanese population, coding either glutamic acid (Glu: E) or lysine (Lys: K), denoted as 
E219K for this polymorphism.316,341 Since the 219 heterozygosis is not detected in sCJD 
patients, this variant should have a protective property against PrPSc transmissions and 
conversions.343 In fact, the E219K ability was confirmed in cell cultures and transgenic 
mice with this variant, which also inhibited conversions of co-expressed wild-type PrPC 
to PrPSc in mice.344,345 One study reported a similar protective effect of the E219K 
variant in mouse models with human PrP 219K or mouse PrP 218K (corresponding to 
human 219K in the murine numbering) against sCJD transmissions.346 Interestingly, 
PrPC isoforms with these KK variants converted into PrPSc isoforms in the mice under 
vCJD infections, whereas the PrPC expressions with E219K heterozygosis (EK) were 
protective to the PrPSc conversion in the infections. Additionally, PrPC isoforms with 
other 219 heterozygotes (E0, K0: 0 = null) in mice were susceptible to the PrPSc 
conversion. These outcomes suggest that the EK variant at the codon 219 in human 
PrP isoforms promotes the heterozygous inhibition and resistance to PrPSc transmission 
and conversion. 
 Furthermore, during the last decade, researchers have investigated a new 
protective polymorphism of human PRNP against a TSE disease in a certain community 
at the Okapa District of the Eastern Highlands Province, Papua New Guinea.347,348 In 
this region, the ritual cannibalism causes transmissions of the human TSE among 
people in the Fore tribe, called kuru. As like CJD, the people with the codon 129 
homozygosis (MM or VV) are susceptible to the epidemic of kuru, especially for the MM 
homozygotes.329,349 In contrast, those with the heterozygous variant (M129V) are 




acquired a new naturally occurring variant of PrP gene at the codon 127 against the 
disease, over 10 generations347,348 In the highly disease-exposed areas, people 
predominantly present the heterozygotes of glycine (Gly: G) and V at the codon 127 
(G127V). Although the codon 129 MM homozygote is a common PRNP allele in the 
Fore communities, people with this variant exclusively exhibit the V allele at the codon 
127. This alteration from G to V allele is considered as the result of a missense mutation, 
a point mutation at the codon 127. Since this 127 polymorphism is not detected in the 
kuru patients as well as people in the non kuru-epidemic regions, the G127V 
heterozygous variant must be a protective allele and resistant factor against kuru. In 
addition, this protective property of the variant has been confirmed in mouse studies, 
which the V allele at the codon 127 demonstrates complete resistances to PrPSc 
transmission, conversion and disease development against CJD and kuru infections.348 
These outcomes provide a new scope of treatment and prevention for TSEs, as well as 
other neurodegenerative diseases and protein-misfolding disorders. 
 Instead of PRNP in humans, mouse PrP gene is denoted as Prnp or Prn-p, which 
also exhibits polymorphisms.350 Mice expressing PrP-A allotype are common breeds 
such as FVB/n and C57BL6: mouse prion protein gene Prnpa is the s7 allele of the sinc 
locus and encodes leucine (abbreviated as Leu or L) at the codon 108 and threonine 
(abbreviated as Thr or T) at the codon 189 of the mouse PrP open reading frame (ORF). 
In contrast, VM/DK is a mouse breed expressing PrP-B allotype: mouse prion protein 
gene Prnpb is the p7 allele of the sinc locus and encodes phenylalanine (abbreviated as 
Phe or F) at the codon 108 and valine (abbreviated as Val or V) at the codon 189 of the 




in the PrP-A allotype mice, but longer incubation periods in the PrP-B allotype 
mice.351,352 The mouse polymorphisms also influence aggregation tendency, strain 
adaptability, and conformational variability in TSE disease developments.353 Moreover, 
another study identified a novel mouse Prnp polymorphism at the codon 108 with F and 
189 with T in the MAI/Pas breed, denoted as the PrP-C allotype that prolonged the TSE 
incubation times longer than the PrP-B allotype mice.354 These phenomena suggest that 
the two amino-acid residues in primary structures of the Prnp allotypes modulate the 
incubation-times differences and the disease developments of TSE infections. 
 Moreover, small ruminants (i.e. sheep and goats) also exhibit various non-
pathogenic polymorphisms of PrPC genes that also link to disease susceptibilities and 
implications of TSEs. In the sheep PrPC gene, polymorphisms at three codons are 
associated with the occurrence of classic scrapie: the codon 136 with either alanine 
(Ala: A) or V, denoted as A136V; the codon 154 with either arginine (Arg: R) or histidine 
(His: H), denoted as R154H; and the codon 171 with glutamine (Gln: Q), R, or H, 
denoted as Q171R/H.355,356 The ovine susceptibility to classic scrapie links to the 136V 
(codon/amino acid: codon 136 with V), 154R, 171Q and 171H, whereas the 136A, 154H, 
171R are resistant to scrapie infection.357-362 Among the 12 possible combinations of 
these polymorphisms, the following five alleles are common in the notation of the 
codons 136, 154, and 171: ARQ (=136A-154R-171Q), ARR, AHQ, ARH, and 
VRQ.360,363 The predominance of these five alleles is dependent on sheep breeds.364 
Although the incident factors of these variations are not well understood, ovine ARR and 
AHQ are resistant alleles to classic scrapie.364,365 In contrast, ARQ, ARH, and VRQ are 




commonly found in sheep. Among these 15 genotypes, the scrapie susceptibility varies 
from the complete resistance to the extreme susceptibility.366 The ovine ARR/ARR and 
AHQ/VRQ alleles are significant genotypes for resistances to classic scrapie. In contrast, 
the ARQ/ARQ, AHQ/AHQ and VRQ/VRQ homozygous genotypes in sheep are the 
greater risk factors for the etiology of classic scrapie, in addition to other VRQ 
heterozygous genotypes with ARQ or AHQ (i.e. ARQ/VRQ, ARH/VRQ). Sheep with 
these susceptible genotypes are prone to present the morbidity and mortality of classic 
scrapie at younger ages: the risk peaks at the 2-year ages in VRQ/VRQ and ARH/VRQ 
sheep, and at the 3-year ages in ARQ/VRQ sheep. Although these susceptible sheep 
decrease the scrapie risks during 4 and 5 years of ages, the second risk peak rises from 
6-year age. Furthermore, the genetic susceptibility to atypical scrapie in sheep is 
different from classic scrapie. Many cases of atypical scrapie are frequently diagnosed 
in sheep with the ARR/ARR homozygote that is a resistant genotype to classic 
scrapie.367,368 In addition to the polymorphisms at the codons 154 (R or H) and 171 (Q, 
R, or H), variants at the codon 141 (L or F) implicate with the disease risk and 
occurrence.369,370 Mostly, sheep carrying F at the codon 141 with ARQ (A141FRQ; 
AFRQ) have the highest incidence for atypical scrapie, as well as sheep with the 
AHQ/AHQ homozygote.368 Also, sheep carrying L at this codon with ARQ and/or ARR 
(i.e. A141LRQ; ALRQ, A141LRR; ALRR) are susceptible to atypical scrapie. Thus, 
polymorphisms in the ovine PrPC gene are critical aspects for the strategies in scrapie 





 Interestingly, goats have the excessive variability in PrPC genes that presents 
more than 50 polymorphisms.371 These allelic viabilities of the caprine PrPC gene are 
widely dependent on breeds, regions, and countries. Against scrapie infections, caprine 
resistances have been evaluated in several polymorphisms at certain PrP alleles, such 
as the codons 142, 143, 146, 151, 211, and 222.372-374 The codons 142 with M (142M), 
143 with R (143R), and 151 with H (151H) have moderate properties for scrapie 
protections. The codon 211 with Q (211Q) has a property to decrease conversion rates 
from PrPC to PrPSc isoforms. Moreover, the codons 146 with aspartic acid (Asp: D) 
(146D), 146 with serine (Ser: S) (146S), 222 with lysine (Lys: K) (222K) significantly 
reduce the PrP conversion rates. Potentially, these three variants are protective against 
scrapie infections. Under experimental infections in goats and transgenic mice, the 
222K variant is an essential resistant factor against classic ovine scrapie and 
bovine/caprine BSE isolates.375-377 In addition, the latest studies have revealed that the 
classic scrapie agent in goat milk could transmit to sheep via oral routes, especially 
carrying the codon 141 polymorphisms.370,378 Although the genetic diversity in the PrPC 
gene has been investigated numerously in goats, their breeding programs with genetic 
selections against scrapie infections have not been under development yet.379 Thus, 
outbreaks of scrapie will seriously affect to the goat industries (i.e. meat, milk, and 
mohair productions) and economic situations through the world, and possibly spreading 
and disturbing sheep industries. Under the surveillance and disease control, it is 





 In addition to the TSE susceptibility and resistance in homologous species, the 
variability of PrP alleles is a pivotal factor to influence the cross-species transmissions 
of TSEs.380,381 In small ruminants, for instance, PrPC genes of sheep and goats are 
highly polymorphic, which these species share amino acid polymorphisms at the certain 
codons, including Q101R, G127S, H143R, N146S, R151H, R154H, R211Q, T219I (I = 
isoleucine/Ile), and Q220H. The substitutions of identical amino acids at these codons 
could be associated with the mechanisms in transmissions and propagations of scrapie 
agents between sheep and goats. Moreover, the polymorphic variations of octapeptide 
repeats in PrPC structures are also risk factors for the TSE transmission in these small 
ruminants, as well as its susceptibility.380-383 Overall, the diversity of these genetic 
backgrounds could be related to the conformational changes from normal PrPC isoforms 
to abnormal or pathogenic agents in new hosts, which facilitate PrPSc transmissions and 
propagations passing through homogeneous and heterogeneous species.  
 2) Insoluble and PK-resistant variant of PrPSc isoform: Prion is the etiological 
agent of TSEs, termed from “proteinaceous infectious only.”.384 According to the protein-
only hypothesis, this infectious agent does not consist of nucleic acids for its self-
replications and propagations in which normal PrPC isoforms are the necessary 
molecules.214,385 An abnormal isoform of PrPC molecule is called scrapie prion protein 
(PrPSc) that is capable of converting normal PrPC structure to its altered conformation.384 
PrPC structure has been investigated at its atomic level, but the high-resolution structure 
and related modifications of post-translational chemical factors are not clearly found in 
this abnormal structure alteration.386,387 However, limited data from low-resolution 




conformations.388-390 According to studies using infrared spectroscopy and circular 
dichroism spectroscopy, an abundant composition of PrPC structure is α-helices (42%) 
with a fractional content of β-sheets (3%). In contrast, β-sheets (>43%) consist largely 
of an abnormal PrPSc structure, and the PrPSc structure with truncated N-terminals 
contains an increased fraction of β-sheets (>54%). However, the definitive structural 
differentiation between these normal and altered isoforms is not elucidated yet, although 
numerous studies have investigated the PrP conformational conversion.390,391 In fact, 
many in vivo studies have not succeeded experimentally to recapitulate the 
transformation of PrPC isoforms to its amyloidogenic PrPSc aggregations, under the 
protein-only hypothesis. Thus, large evidences propose implications of other 
macromolecules in the mechanism of the PrP conformational alteration.392,393 Since 
multiple factors, described above, interact with PrPC isoforms for various important 
functions in physiology, it is not questionable that these influential factors might facilitate 
the conversional process of normal PrPC to infectious PrPSc structures.394-397 
Nevertheless, inoculations of recombinant PrP aggregates can develop sicknesses in 
wild-type and transgenic mice, under deficient conditions of cofactors.398-400 Another 
experimental approach, protein misfolding cyclic amplification (PMCA) assay, has also 
provided in vitro proofs of the protein-only hypothesis.401-403 In this assay, seeds of 
PrPSc aggregates interact and template with PrPC substrates for converting and 
replicating to infectious PrPSc particles. In fact, the PMCA assay generated the formation 
of bacterially expressed recombinant PrP particles into PK-resistant conformations and 
aggregations.394,404 Intracerebral inoculations of these PrP particles induced 




supportive aspects for the protein-only hypothesis in the PrP structural transformation 
and TSE pathogenesis. 
 In TSE pathogenesis, the conformational conversion is the critical molecular 
process that α-helix rich PrPC structures alter to β-sheet rich PrPSc compositions and 
aggregations. This β-sheet rich PrPSc structure acquires greater conformational stability 
and aggregational ability. The PrPSc isoform holds unconventional properties that are 
insoluble and resistant to inactivation by high pressures and temperatures, as well as 
chemical agents (i.e. proteinase K: PK), ultraviolet exposures, and radiation 
irradiations.405,406 Moreover, aggregated PrPSc complexes are capable of forming 
amyloid fibrils that locate and accumulate in extracellular spaces and intracellular 
vesicular compartments.407 These proteinous aggregates and fibrils release small 
particles that potentially behave as templates for other PrPC molecules to recruit into the 
PrPSc complexes. PrPC molecules that consist of an identical sequence to PrPSc 
isoforms could be integrated into further formations of amyloid fibrils.  
 In addition to the PrPSc conformations and aggregations, inoculations of PrPSc 
isolates from different TSE sources present varieties of pathological behaviors in new 
hosts with unique phenotypes, even if they are genetically identical.39,408,409 
Interestingly, each TSE source transmits consistently its distinctive features of disease 
developments in infected syngeneic hosts histologically and clinically, such as prion 
infectivity, incubation times, lesional regions and distributions of PrPSc depositions in the 
CNS. Based on these phenomena, disease phenotypes of the infectious particles are 
defined as “prion strains” or “strains” of PrPSc isoforms. These strain-dependent features 




PrPC structures. Hence, the infectious particles can adopt different PrP conformations 
with a biochemical property of each strain, leading to capabilities for developing 
characteristic features of diseases.39,410,411 These mechanisms implicate with the 
interaction of each strain with host polymorphisms (i.e. the codon 129 in human PRNP) 
and provoke phenotypic plethora. Interestingly, the strain-base phenotypes are also 
observed in AD, clinically and histologically.412-414 
 Several researches have revealed evidence that glycosylation states and relative 
proportions of four glycosyl forms (unglycosyl, mono-1 glycosyl, mono-2 glycosyl, and 
diglycosyl) contribute to molecular identities and diversities of PrPSc strains.415 In fact, 
different PrPSc strains exhibit distinct proportions of PrP glycoforms by western blot 
analyses.409,417 For instance, glycoform-specific ratios and differences are beneficial to 
distinguish phenotypes between sCJD and sporadic fatal insomnia (sFI) in patients with 
the same polymorphism (MM) at the codon 129.418 Furthermore, the electrophoretic 
mobility of PK-resistance fraction is a specific classification for PrPSc strain 
differentiations.419 Upon PK digestion, distinct fragments of PK-resistant PrPSc fractions 
can elucidate various degrees of the mobility in gel electrophoresis. The strain 
distinguishment can denote different resistances and cleavage sites against PK 
digestion among various PrPSc conformations. Even in sCJD, its subtypes exhibit 
different mobility of PK-resistant PrPSc fragments.420-424 Also, distinctive molecular 
subtypes between iatrogenic CJD (iCJD) and sCJD patients are identified by the codon 
129 polymorphisms and biochemical properties of PrPSc strain differences.425,426 In 
addition to human TSEs including CJD, FFI and kuru, animal TSEs (i.e. BSE, CWD and 




Thus, the detection of these characteristic fragments is an essential approach for 
profiling the molecular types of PrPSc strains. Possibly, the uses of several anti-PrP 
antibodies would be accurate to determine the strain differences rather than a single 
antibody, because of targeting variegated conformations among PrPSc strains.436 
 3) PK-sensitive variant of PrPSc isoform: PK is a serine protease that 
enzymatically cleaves proteins, and as described above, PrPC isoforms are sensitive to 
this proteolytic enzyme.437 This protein degradation enables TSE detection to eliminate 
these normal proteins from testing samples, specifically for detecting abnormal PrPSc 
isoforms, because of its partial resistance to PK digestion through α-helix rich to β-sheet 
rich structural transition. In contrast, PK truncates PrPSc isoform aminoterminally into its 
small portion, termed as PrP27-30 or PrP27-30 that ranges in molecular weights (MW) 
between 27-30 kilodaltons (kDa). Thus, the standard methods in TSE diagnosis and 
PrPSc analysis have specified to detect this fragment. In general, this partial PK 
resistance has been considered as a characteristic feature of the conformational 
stabilities that PrPSc isoforms possess. During the last two decades, however, 
accumulating evidence suggests another variant of an infectious PrPSc isoform that is 
sensitive to PK exposures.410,438-441 In human TSE study, sCJD brains exhibit both PK-
sensitive and -resistant PrPSc variants.442 The PK-sensitive PrPSc (senPrPSc) variant 
accounts for approximately 90% factions of the entire PrP molecules in the gray and 
white matters of brains from sCJD patients.439 Interestingly, variant CJD (vCJD) brains 
also exhibit similar outcomes of this sensitive variant in the sCJD patients.443 These 
detections of the senPrPSc variant in these two subtypes of CJD cases seem to be 




patients with the V homozygotes or heterozygotes. In familial CJD (fCJD) patients with 
144-base pair (bp) insertion mutations, the senPrPSc variant predominantly exhibits in 
pathognomonic PrP patches of the cerebellum, in which the PK-resistant PrPSc 
(resPrPSc) variant is undetectable.445 Thus, the senPrPSc variant must possess 
equivalent properties to implicate infectivity and neurotoxicity in TSE pathogenesis, as 
comparable to the resPrPSc variant. Furthermore, GSS brains constitute abundant 
portions of the senPrPSc variant.442 Although the pathogenic role of the senPrPSc variant 
is not elucidated yet, this molecule is predominantly detected in the brains from variably 
protease-sensitive prionopathy (VPSPr: a sporadic human TSE) patients with the codon 
129 VV homozygotes, whereas the resPrPSc variant is deficit.446-448 Interestingly, PK 
treatment diminishes approximately 90% quantities of total PrPSc isoforms, detected in 
the brain tissues from scrapie-infected sheep with the VRQ or ARQ genotypes.449 This 
finding indicates the majority of PrPSc isoforms is the senPrPSc variant. Thus, it is a 
serious concern that the use of PK arises potential risks for false-negative outcomes in 
TSE diagnoses and PrPSc analyses, because the use of PK would digest the senPrPSc 
variant and overlook its detection. In addition, the concentration and stability of the 
senPrPSc variant is associated with incubation periods and progression rates of TSEs, 
which seem to be implicated with the codon 129 polymorphisms and glycoform 
states.410,450,451 In fact, the senPrPSc variant with the VV homozygous genotype and 
unglycosyl form (no glycan) is predisposed to have shorter survival times in sCJD 
patients, compared to the patients with MM homozygotes. These findings indicate that 




variant should be a valuable biomarker to determine disease developments and 
progressions.  
 To study about the senPrPSc variant, a thermostable neutral metalloproteinase 
enzyme, called thermolysin, is an applicable reagent to isolate its fractions from rodent 
and human brains, combined with applications of differential centrifugation.440,444,452 As 
differed from the PK ability, thermolysin hydrolytically cleaves peptide bonds of a protein 
that contain the hydrophobic amino acids, such as A, V, I, L, M, and F (in the MW 
ordering). Preferentially, this enzyme truncates the N-terminus of these hydrophobic 
residues on proteins. Although thermolysin degrades normal PrPC isoforms into little 
pieces, PrPSc isoforms are resistant to its proteolytic effect and can maintain these full-
length forms. These isolation studies contribute to determine the comparable properties 
of the senPrPSc variant to the resPrPSc variant, such as infectivity and incubation times. 
Moreover, PMCA technology can amplify the senPrPSc variant as a seed in this in vitro 
replication, which indicates its propagative ability under the protein-only hypothesis. 
Understandably, PK treatment eradicates these pathogenic properties of the isolated 
senPrPSc particles with the thermolysin applications above.    
 The results from the sedimentation velocity method and PMCA also indicate 
similar structural properties of senPrPSc and resPrPSc variants from amplified 
monomers.440,453 Ratios of senPrPSc and resPrPSc variants are dependent on TSE 
strains. The productions of variant differences are associated with sizes of the 
monomers in these strains, but not the biochemical structures of aggregates. In fact, 
small PrPSc aggregates are low MW and sensitive to proteolysis, but the increases of 




resPrPSc variant. Moreover, the aggregate sizes are correlated to the seeding potency 
and conformation-converting activity, which are highly exhibited in small 
aggregates/oligomers of the isolated fractions.454 In sCJD patients, the continuum of 
PrPSc aggregates varies from less than 20 to more than 600 PrPSc molecules. The most 
effective initiators of the PrPC conversions to abnormal conformations are small 
oligomers with masses equivalent to 20-78 molecules of PrPSc isoforms. In contrast, the 
increases of aggregate sizes reduce the seeding efficacy of sCJD PrPSc molecules. 
Thus, smaller aggregates possess higher seeding potency in the conformational 
conversion and replicative process. Since these efficient aggregates are PK sensitive, 
the senPrPSc variant must be possessive to form smaller oligomeric aggregations or 
complexes, whereas the resPrPSc variant consists of larger formations.453 Possibly, the 
generations of the senPrPSc variant are associated with the strain-dependent features, 
as influenced by sizes of monomer and aggregates that each strain retains 
characteristically. 
 Some researchers have proposed another model of PrPSc formation that 
promotes the existence of a hypothetical lethal PrP variant (PrPL), as opposed to the 
PrPC-as-receptor mediating model of PrPSc toxicity.39,454-458 The PrPL variant is explained 
as a toxic intermediate or byproduct of the PrP conversions from PrPC to PrPSc isoforms, 
as well as during the PrP replication, under a template-associated progression of the 
protein-only hypothesis. This toxic PrPL variant is a small oligomer that induces 
neurotoxicity and neurodegeneration.39 Conceivably, the small aggregate is a causal 
molecule of protein misfolding and disease initiation.454 In fact, the accumulated 




as well as states of subclinical infections.455,456,460-462 Rapid increases of PrPL levels 
implicate with shorter incubation periods and survival times in mouse models of TSEs. 
In addition, an alternative aspect postulates that the PrPL variant is not an intermediate 
product in the pathway to be a mature PrPSc isoform. Although the mature PrPSc isoform 
plays as a surface template of the PrP conversions from normal to abnormal 
conformation, the small PrPL oligomers could be formed from the mature PrPSc 
isoforms.463 Although the PrPL variant is not physically defined, this lethal variant could 
be identical to PrPSc isoforms and modulate signals to cause neurotoxicity arising from 
the mature abnormal molecules. In mouse studies, kinetic measurements of the PrPSc 
infectivity indicate its plateau phase in brains, prior to developing clinical onsets of 
diseases at the latent period. Possibly, hypothetical PrPL variants induce these 
accumulations that would be initiators for clinical onsets of diseases. This phenomenon 
could be switched from the phase 1 (a clinically silent exponential phase: autocatalytic 
production of infectivity, with reaching rapidly to a maximal prion titer) to the phase 2 (a 
clinically toxic phase: activated pathway for PrPL generations, without an increase of 
infectious PrPSc propagations). According to the model of PrP propagation and toxicity, 
two distinct phases occurs: 1) replications of nontoxic PrPSc molecules (infectious PrPSc 
particles) until these accumulations saturate to a plateau phase as depended on levels 
of PrPC expressions, and 2) a continuous plateau phase of PrPSc infectivity, but the 
initiation of PrPL generation and formation/accumulation as in proportional to the PrPC 
concentration. This new model of PrP pathology is based on the uncoupling of infectivity 
and toxicity in the two distinctive phases. A further study proposes the generations of 




when prion propagation saturates during the template-assisted progression from PrPC to 
PrPSc conversion.464 Conversely, there are arguments to the PrPL hypothesis because of 
extrapolated interpretations in these proposed models above.459,465 However, the 
concept of the PrPL variant overlaps with features of the senPrPSc variant.  If this 
pathogenic PrP particle could be one of the senPrPSc variant, the PrPC expression and 
dysfunction would influence controls against neurotoxic signals arising from PrPSc 
isoforms, especially these small toxic PrPSc oligomers. Hence, the decreases of PrPC 
expression and function impair or sensitize neurons against PrPSc toxicity.   
 In addition to TSEs and other neurodegeneration disorders, numerous studies 
have reported the implication of PrP expressions in cancer pathogenesis, including 
progression, drug resistance, and proteinous amyloidogenesis.230,231,466-471 An intriguing 
study revealed that cancer cells in TSE-infected mice highly express the senPrPSc 
variant, but not the resPrPSc variant.472 These malignant cells with the senPrPSc variant 
possess aggressive behaviors in proliferation and metastasis, leading to progressive 
exacerbation. Thus, I hypothesize that TSE-infected cells expressing the senPrPSc 
variant have these cancer-like behaviors through the disease course. These cells can 
propagate and migrate locally and systemically with aggressive behaviors in TSE 
pathogenesis, as like cancer stem cells. This pathogenic feature should be different 
from general properties of the PrPSc infectivity, in which the senPrPSc variant might have 
unique biochemical features. Overall, the existence of the senPrPSc variant directs the 
necessity and importance of non-PK-based methods for detecting and understanding 




further investigate the unknown mechanisms of disease developments and 
progressions. 
 4) Insoluble and aggregative variant of PrPC isoform: The PrPC isoform is 
known as soluble, monomeric and protease sensitive features, expressed abundantly in 
the CNS of humans and animals as normal.1 However, the existence of an insoluble 
aggregate of PrPC isoforms has been reported in humans and cultured neuronal 
cells.473,474 This new PrPC isoform is termed insoluble PrPC (iPrPC) variant that forms a 
monomeric, dimeric, oligomeric, or multimeric structure, and is resistant to PK digestion 
even under high concentrations. In human brains without TSE infections, the iPrPC 
variant accounts for approximately 25% of the total PrPC expression. The gene 5 protein 
(g5p) and sodium phosphotugstate (NaPTA) are reagents that specifically bind to 
structurally altered PrP molecules, but not to normal PrPC isoforms.442,475 These 
affinities of the reagents enable isolations of the iPrPC variant. The g5p is a single-
stranded DNA binding protein that has an avidity to interact with nucleic acids.476 This 
binding ability was also utilized to isolate PrPSc isoforms and iPrPC aggregates. 
However, this proteinaceous reagent might have a specificity to interact with aggregated 
oligomers and complexes.477-479 
 For detecting the iPrPC variant, two anti-PrP monoclonal antibodies (mAbs), 1E4 
and 3F4, were applied.473,480 1E4 mAb binds to its epitope on the residues 97 to 105 in 
the PrP sequence, whereas 3F4 mAb interacts to the residues 106 to 112. Although 
these epitopes were adjacent, the iPrPC variant showed a high affinity to 1E4 mAb, but a 
low affinity to 3F4 mAb.150,474 These different reactivities of the two mAbs might indicate 




to 120 in the PrP sequence are known as the region implicated in the PrPC-PrPSc 
conversion.481 Thus, I assume that iPrPC variant has structural changes in the 3F4 
epitopic residues, because 3F4 mAb declined its binding affinity. Under 
immunofluorescence microscopic detections with 1E4 mAbs, the PK-resistant iPrPC 
aggregates predominantly localized in the cytoplasm around the nucleus, although PrPC 
isoforms generally express on cell surfaces and sensitize to PK exposures.150,482 These 
results suggest that the iPrPC variant has a unique conformation and localization, 
compared to PrPC and PrPSc isoforms. In addition, the researchers in these iPrPC 
studies also isolated the oligomers of soluble and insoluble PrPC isoforms from healthy 
human brains.475 Thus, they intriguingly hypothesized the chameleon-like abilities of 
PrPC isoforms in conformations.482 Possibly, the iPrPC variant with the unique abilities 
might be involved in the TSE pathogenesis, especially in hosts for mechanisms of the 
PrPSc infection and the PrPC-PrPSc conversion. In fact, in addition to PrPSc isoforms, 1E4 
mAb detected the iPrPC variant in VPSPr patients with MM or MV polymorphisms at the 
codon 129 of PPRP gene, as well as fCJD patients with the mutation from V to I at the 
codon 180.150,446,483 
 Furthermore, the same group investigated the cleavage sites of the PK-resistant 
PrP fragment from brains of VPSPr patients.434 The cleavage site for the N-terminal 
localized within the residues 99 to 101, while the C-termial cleavage site was detected 
between the residues 152 and 157. In addition, 1E4 mAb detected the iPrPC variant in 
human brains without TSE infections, although the PrPSc isoforms in the VPSPr and 
fCJD brains above reacted with this anti-PrP antibody. Interestingly, the same research 




conformer for interacting with amyloid β42 (Aβ42) aggregates in brains from AD 
patients.484 Three years later, another group reported this iPrPC-Aβ42 assembly in the 
AD pathogenesis.485 Additionally, the cytosolic inclusions of PrPC aggregations were 
detected in the β-islet cells of pancreases in rat models of DM, classified as PMD 
including TSEs and AD.233 These findings suggest the pathogenic roles of the iPrPC 
variant and PrPC aggregate in neurodegenerative diseases and PMD. Thus, detections 
of the iPrPC variant would be valuable molecular targets to evaluate potential risks and 
disease developments of TSEs and other PMD.  
 According to the report from an ischemic stroke study, moreover, detected PrPC 
molecules were resistant to formic acids and heat.486 Possibly, these PrPC molecules 
altered conformational properties under hypoxic conditions. In ischemic brains, PrPC 
molecules at the infarct regions highly aggregated with resistance to protease 
treatments.304,487 These implicated factors could arise from low-pH environments that 
hypoxia and ischemia induced. In fact, acidic pH induced the conversion of the soluble 
PrPC isoform into the iPrPC variant in brain samples from humans.486 Therefore, it is a 
pivotal importance to investigate the in vivo roles of this insoluble protein, especially for 
the implication of pH with the PrP conformation in physiology and pathology. This 
mechanism could be related to the chameleon-like abilities of the PrPC isoform above.  
 At last, highly α-helical proteinous conformers are involved in the cytotoxicity in 
PMDs. These intermediate monomers have been detected in aggregations (amyloid 
plaques) of amyloidogenic proteins, such as Aβ in AD, α-synuclein in PD, and islet 
amyloid polypeptide (IAPP) in Type II DM.489-492 A formation of highly α-helical protein is 




intermolecularly.493 For instance, the progression of amyloid formation in DM is 
proportional to the amount of highly α-helical IAPP494.495 However, biological 
significances of the intermediates still remain to be determined. In a recombinant PrP 
study, a monomeric and highly α-helical intermediate form of PrP molecules is the most 
neurotoxic substance on various types of cultured neuronal cells, on cerebellar brain 
slices, and in mouse brains, although oligomers of recombinant PrP molecules are also 
neurotoxic.496 Similar to PrPSc isoforms, this intermediate PrP monomer exhibits 
insolubility and PK resistance, in spite of its higher α-helical structure as like normal 
PrPC isoforms. The intermediate monomer also causes autophagic and apoptotic cell 
death.  Interestingly, it induces cytotoxicity without endogenous PrP expressions in 
neuronal cells. In addition, the PrP-induced toxicity implicates into the 
autopgaolysosomal degradation pathway in neuronal cells and mouse brain with TSE 
infections. This recombinant PrP study suggests that the toxic monomer is an 
independent product of the PrPSc isoform during its infection and replication, or a 
generated molecule during the structural transitions of normal PrPC to aberrant PrPSc 
conformations. These findings of the monomeric highly α-helical intermediate PrP form 
are consistent with features of the iPrPC and PrPL variants. Consequently, the 
investigations of novel PrP mechanisms would continue as a fascinating field in biology, 
physiology and medicine. As a reminder, however, it is still a serious risk that the use of 
PK might result in non-accurate analyses for PrPSc detections and TSE diagnoses. 
 Overall, the PrP polymorphism is associated with the biochemical property of 
PrPSc strain differences and the underlying mechanism of PrP conformational changes 




described above, the codon 129 polymorphism implicates with the susceptibility and 
disease phenotype: note, the codon 132 in elk corresponds to the codon 129 in 
humans.317,324,497-501 In addition, the glycoforms of VPSPr brain samples displayed the 
lack of diglycosyl PrPSc forms, but the high expression of mono-1 glycosyl forms (a 
single glycan at the glycosidic residue 181).150 This glycoform pattern is similar to fCJD 
cases with the PRNP mutation at the codon 180 from valine/V to isoleucine/I (V180I). 
These physiochemical and biological properties of VPSPr agents might have possible 
associations with fCJD agents with the V180I allele.448 In addition to this fCJD form, 
biochemical and neuropathological features of VPSPr resembled GSS and some sCJD 
forms. Feasibly, glycosidic deficits at the 180 residues could be attributable to 
clinicopathologic manifestations as well as conformational changes from normal PrPC to 
abnormal PrPSc structures. These findings suggested that under-glycosylated PrPSc 
forms were implicated with TSE pathogeneses. Importantly, the lack of glycosylations 
could link to the PrP conformational instability that might induce sensitivities to PK 
digestions. Therefore, the uses of protease reagents would increase risks of false 
negative results in PrPSc analyses and TSE diagnoses. Incidentally, the existence of PK-
sensitive PrPSc agents would cause potential occurrences of the iatrogenic PrPSc 
transmission to other patients via surgical and medical interventions including blood 
transfusions, organ transplantations, and instruments contaminated with the pathogens. 
For this transmissive concern and risk, the screening of glycosylation states would be 
essential targets as biomarkers to identify PrPSc existences and contaminations in 




would provide practical approaches to detect PK-sensitive PrPSc pathogens selectively 
and specifically. 
 
PrP glycosylations in TSE diseases 
 Glycosylation is the most common post-translational modification, which 
processes the addition of a carbohydrate moiety to a protein, lipid, and other organic 
molecules in cells endogenously or exogenously.502,503 In the co-translational and/or 
post-translational mechanisms, enzymatic modifications intimately commit the 
regulation of glycosidic processes, specifically for sites and substrates.504 Certainly, 
glycans secreted from glycoproteins influence various properties of proteins, such as 
solubility. Glycans localized on cell surfaces are also involved in numerous fundamental 
biological processes, such as cell-cell adhesions, cell-matrix interaction, cellular 
metabolisms, and intra- and inter-cellular signalings.505,506 Thus, the loss or 
dysregulation of glycosylations affects normal functions in the cellular physiology. In fact, 
altered glycosylations induce pathological modifications and several diseases, such as 
cancers and neurodegenerative disorders.507 In neurodegenerative diseases, 
modifications of different glycoproteins influence neural activity.508,509 Some 
glycosyltransferases, responsible enzymes for the biosynthesis of glycans, are essential 
for neural development. These enzymatic dysfunctions implicate with neuropathological 
manifestations. Consequently, aberrant glycosylations modify the normal neural 
migration, leading to congenital neurological or neuromuscular disorders, such as 
muscular dystrophy.509 In TSEs, a research group reported a declined activity of a Golgi 




PrPSc isoforms.510-511 This enzymatic reduction induced different proportions of glycans 
between PrPC and PrPSc molecules: 11% smaller bisected glycans, 5% greater 
triantennary glycans, and 10% greater tetra-antennary glycans in the N-linked 
glycosylation of PrPSc molecules, compared to PrPC isoforms. Thus, the GnTIII-related 
enzymatic modulation might be attributable to cause the aberrant glycosylations and the 
TSE pathogeneses. 
 In addition, glycosylations promote the stability of proteins in that an increased 
amount of oligosaccharide delivers a higher free-energy barrier for preventing the 
pathologic conformational conversions from PrPC to PrPSc isoforms.197,512 The inhibition 
or attenuation of glycosylations induces the aberrant PrP conversions. On the 
electrophoretic gel, the intensity of a diglycosyl PrPSc fragment is the smallest band in 
the sCJD form.197 This result suggests that the majority of diglycosyl PrPC isoforms 
might not convert to PrPSc isoforms. Hence, under-glycosylated PrPC forms could be 
prone to modulate conformations.514 Tunicamycin, an antibiotic that can remove glycans, 
inhibited the N-linked glycosylation, resulting in the acceleration of PrPSc formations in 
scrapie-infected cells and the acquisition of PrPSc properties in transfected cells with 
PRNP mutations.514,515 In familial TSE forms, a deletion or alteration of the PrP 
glycosylation is a frequent phenomenon, because of naturally occurring mutations in 
PRNP.150,516-518 In fCJD forms with PRNP mutations of V180I or T183A, diglycosyl forms 
of PK-resistant PrPSc fragments are generally undetectable, because these mutations 
cause the loss of a glycosidic site.517,518 Hence, the amino acid substitutions at these 
codons abolish or alter a N-linked glycosylation at the codon 181 in the human PrP 




insoluble PrP isoforms.475,482 Other PRNP mutations (i.e. D178N, F198S, E200K) also 
modulate glycoform ratios that induce pathogenic changes in PrPC structures.323,519 
Therefore, the underlying substitutions of amino acids in PRNP mutations directly 
impact PrPSc transformations.511,520 Similar to the fCJD form with the V180I mutation, 
VPSPr pathogenesis has a glycoform-selective prion formation pathway even without 
PRNP mutations.150,447,483 These two diseases notably lose both diglycosyl and 
monoglycosyl (the codon 181) PrPSc forms. Moreover, altered PrP glycosylations 
influence the binding affinity or reactivity of anti-PrP mAbs to PrPSc agents in VPSPr 
materials because of conformational conversions to abnormal PrP structures.150 
Accordingly, VPSPr should be the first TSE disease where the alterations of 
glycosylations cause structural abnormalities of PrP molecules.521  
 In in vitro experiments, glycosylations present the property to maintain PrP 
conformations.515 On the exogenous PrPC molecules, mutations of the N-linked 
glycosidic sites (the codons 181 and 197 in humans; 180 and 196 in mice) on PrP 
structures interfere glycosylations, resulting in alterations of conformations and 
properties from PrPC to PrPSc molecules, such as PK resistance. These findings indicate 
that the loss of the N-linked glycosylation modulates the PrPC sequence and structure 
that intrinsically adopt a β-sheet conformation. In contrast, cells treated with tunicamycin 
did not exhibit abnormal modulations for properties of the endogenous PrPC 
molecules.514 Also, PrP overexpressions provoked protein aggregations intrinsically as 
property alterations522. To investigate the glycosidic implications in TSEs, the unglycosyl 
form of short PrP peptides was synthesized from the helix-2 domain (the residues 175-




that subsequently formed amyloid fibrils. In contrast, the same peptide sequence with 
N-linked glycans (glycosylated peptide) significantly declined fibril formations. In another 
study, PrP peptides that synthesized with O-linked glycans also ensured similar 
observations.524 Although the PrPC structure does not have O-linked glycans naturally, 
this study suggests that glycosylations alter the kinetic equilibrium between monomeric 
PrPC and aggregated PrPSc molecules. Moreover, the glycosylation does not link to 
properties of PrPSc agents in propagations and infections. In scrapie-infection studies, 
the large productions of unglycosyl PrPC forms via tunicamycin treatment did not 
prevent PrPSc formations in murine neuroblastoma N2a cells.514  However, 
unglycosylated mutations of PrPC molecules (substitutions of asparagine to glutamine at 
the codon 180 and 196 in mouse numbering) caused susceptibilities to TSE infections 
in uninfected N2a cells.525 In scrapie-infected N2a cells and transgenic mice, mutations 
of the glycosidic consensus sequences in the PrPC structure affected subcellular 
locations of PrPC molecules and enhanced susceptibility to infections526.  
 In the PrPSc conversion, the glycosylation state can significantly modulate the 
interaction of host PrPC isoforms with invasive PrPSc seeds. Especially in different 
species, the glycosylation is an influential factor at the initial binding occasion of the 
PrPC-PrPSc interaction. For crossing the species barrier between hamsters and mice, 
hamster PrPSc seeds can introduce a species-specific amino acid residue into host mice. 
Subsequently, these seeds can initiate the conversions of mouse PrPC molecules to 
abnormal conformations more readily when the host PrPC molecules are unglycosylated 
forms.514,527,528 Conversely, the glycosylations of host PrPC molecules block the 




state of PrPC molecules influence the conformation of the PrPSc agents.205,529 In the 
cross-species conversion reaction, an unglycosyl PrPC form enhances the efficiency of 
the PrPSc conversion. This reaction should be attributable to an increased capability of 
the unglycosyl PrPC forms binding to the PrPSc seeds. Thus, the presence of the full 
glycosylation can inhibit or modulate the interactions of PrPC to PrPSc agents. Hence, the 
glycosylation states of host PrPC molecules are determinant influencers for the 
compatibility of amino acid sequences in the PrPC-PrPSc interaction and conversion over 
glycosylation states.  
 In fact, the glycoform patterns of PK-resistant PrPSc fragments exhibit different 
patterns among the disease forms in the CJD classification.420 Among TSE strains or 
subtypes, the composition and proportion of the glycans exhibit different glycoform 
patterns.510,530,531 The vCJD cases have abundances of diglycosyl forms, which cattle 
with classic BSE also dominantly express. In contrast, atypical BSE cases exhibit 
different glycoform patterns of PrPSc fragments from the classical BSE cases, but more 
atypical BSE cases resemble the glycosidic patterns of sCJD cases in humans.420,532,533 
Both atypical BSE and sCJD cases predominately express monoglycosyl PrPSc forms. 
These differences arise from PrPSc conformation and glycosylation that implicate with 
the molecular basis of TSE strain diversities. The properties that each strain maintains 
are stably transmissible and reproducible in the new host.331 In inoculated mice, PK-
resistant PrPSc fragments maintain the TSE strain-specific sizes and glycosylation 
patterns upon transmissions.325 These specific glycoform patterns influence strain 
properties, such as incubation periods and neuropathology.410,534 Transmissions of 




to classic BSE.535 In the molecular basis of TSE pathogeneses, these strain properties 
are also associated with host-specific factors, such as the primary PrPC structure and 
host-specific glycosylation. 
 Attachments of N-glycosylation to proteins are initiated in the ER lumen. 
Intriguingly, a glycopohosphatidyl-inositol (GPI) attachment to the PrPC molecule occurs 
in the ER lumen.528 The GPI moiety for the C-terminal membrane anchorage could be a 
required factor for the initiation of N-glycosylation to of the PrPC molecule.536 The GPI 
anchor also facilitates translocations of glycosylated PrPC molecules through the 
secretory pathway to cell membranes. Thus, a deficiency or dysregulation of the GPI 
anchor synthesis is influential for N-glycan attachments to proteins. Indeed, these 
impaired processes are observed in some severe and lethal diseases, such as 
congenital disorders of glycosylation.537-540 Hence, the GPI anchor could be involved as 
an essential role for proper PrP glycosylations.  
 In glycoproteins, cell surfaces could be the pivotal sites for the initiation of 
neurodegeneration, because the PrPC isoform functions on the cell membrane as a 
single molecule.541,542 Since the GPI anchors are involved in aberrant PrPSc 
transformations, the conditions of the PrP glycosylation critically implicate with the TSE 
development, classification, and strain characterization. In transgenic mice, mutations of 
the glycosidic consensus sites altered the subcellular localization of PrPC isoforms and 
the susceptibly to TSE infections.526,543 Alerted subcellular localizations induced the 
TSE-strain dependence for infection and propagation. Intriguingly, monoglycosyl PrPSc 
isoforms could be attributable to the molecular mechanisms of host susceptibilities to 




provoked intracellular PrPSc accumulations into neuronal cell bodies.204,545 Since the two 
N-link glycosidic sites localize in the structured globular domain at the C-terminal of the 
PrP structure, the loss of glycans might alter the protein conformation.  
 Overall, the PrP glycosylation is a key regulatory mechanism to control several 
pathophysiological processes in TSEs. Because glycans maintain various biological 
efficiencies, the glycosidic deficiency links to the loss of PrPC functions, such as 
neuroprotection.546,547 The PrPC dysfunctions would alter cellular microenvironments, 
leading to neurodegeneration and disease development.548 These pathogenic changes 
might gain toxicities in cells.458,549-551 Thus, the recognition of certain glycosylated PrP 
forms would specifically discriminate PrPSc agents and determine unidentified TSE 
pathogeneses including strain differences. Consequently, glycobiology has been an 
increasing subject to discover the implication of glycosylations in various disease 
researches.552-558 For these clinicopathologic implications, investigations have 
challenged to meet the needs for high specificity, sensitivity and capacity of analytical 
approaches. In this dissertation, the established analytical methods have utilized 
characteristic features of the in-house anti-PrP mAbs that have conformation 
dependences for PrP recognition specifically. In fact, one mAb binds specifically to 
unglycosyl and monoglycosyl (mono-1) PrP forms.  
 
 
Section 3: Traditional TSE diagnoses and limitations 
 
PrPSc detections in TSE diseases 
 1) Current and traditional methods: Currently, the detection of abnormal PrPSc 




most common procedure to obtain brain tissue samples from TSE-affected patients and 
animals. While brain biopsy is an available procedure technically at ante mortem, World 
Health Organization (WHO) does not recommend this intervention for suspected TSE 
cases, because of the risk for pathogen contaminations to instruments and further 
iatrogenic transmissions.559 Upon autopsy, histological and immunehistochemical 
analyses of brain tissues are standard examinations for definitive diagnoses of TSEs.560 
In all TSEs, the general features of neuropathology commonly include reactive gliosis, 
neuronal loss, spongiform change, and PrPSc depositions. Some neuropathological 
features can distinguish subtypes of TSEs, especially between sCJD and vCJD cases. 
PrPSc depositions are detected in amyloid plaques, called Kure plaques.560 This plaque 
is found in Kuru patients, sCJD patients with the MV2 subtype, and GSS patients. In 
vCJD cases, a dense core of PrPSc immunopositive deposition forms a plaque, 
surrounded by vacuoles of spongiform changes, known as florid plaque.561 In addition, 
vCJD brains exhibit multiple small plaques, but not associated with spongiform changes. 
Thus, the existences of florid plaques are useful features to confirm the vCJD form, 
which allows distinguishing from the sCJD form.561 
 While several methods have been innovated to detect TSE pathogens at ante 
mortem, definitive diagnoses of TSE are still based on tissue examinations at post 
mortem. Since PrPSc agents are transmissible pathogens in the same species and 
between different species, proper precautions must be undertaken to minimize a 
potential risk of exposures to the pathogen, especially for handling brains or related 
samples.562 In general, brains from patients with CJD suspicions should be handled in a 




fCJD cases, and a Level III facility for vCJD cases. For vCJD cases, tonsils and 
lymphatic tissues are potential samples to detect PrPSc accumulations at ante 
mortem.327,563-565 However, sCJD and fCJD cases do not exhibit PrPSc expressions in 
tonsils. Thus, PrPSc detections in these tissues via biopsy could differentiate suspected 
patients affected with either vCJD or other forms of human TSE diseases at ante 
mortem. In tonsils derived from vCJD cases, PrPSc expressions might be detectable 
even before developing clinical onsets. The spleen is also another organ that expresses 
PrPSc agents in TSE patients even with asymptomatic phases of the vCJD form.566 
Nevertheless, pathogen contaminations to instruments during biopsy and surgical 
procedures are serious concerns for potential risks of iatrogenic transmissions. 
 After collecting tissue samples, the western blot analysis should be one of the 
most common methods for PrPSc detection.562 This method requires the use of PK 
reagent in preparations of testing brain or tissue homogenates. PK digestion enables to 
differentiate abnormal PrPSc agents from normal PrPC isoforms. Because the pathogenic 
proteins are partially PK resistant and the normal proteins are completely sensitive, 
PrPC isoform should not be measurable in non-TSE infected tissues.2 Hence, only PK-
resistant PrPSc agents would be detectable in TSE-affected or contaminated samples. 
This enzymatic digestion generates a C-terminal core fragment from the PrPSc isoform, 
called PrP27-30. Using anti-PrP mAbs, western blot analysis detects a PrP27-30 
fragment as a PrPSc agent. In addition to an advantage that does not need large 
amounts of testing samples, this analytical method can distinguish subtypes of PrPSc 
isoforms in different variants or strains of TSEs, especially for human CJDs combined 




and characteristic histopathological features.562 Although western blot analyses can 
provide detectable sensitivities of PK-resistant PrPSc agents for definitive diagnoses, 
immunohistochemistry can evaluate resolutions of anatomical lesions and PrPSc 
distributions throughout the whole brain structures. Compared to western blot analyses, 
a detection sensitivity of immunohistochemistry is lower, because a background 
reactivity of PrPC isoforms interferes with analytical resolutions. However, this issue 
could be overcome with paraffin-embedded and formalin-fixed tissue sections that are 
heated and pre-treated with formic acid and hydrolytic autoclaving.562 These processes 
can eliminate PrPC immunereactivities and expose PrPSc depositions. Therefore, 
western blot and immunohistochemistry are absolutely imperative as routine tools to 
detect PrPSc agents for definitive diagnosis. 
 For human TSE cases, diagnostic imaging and electrophysiological examinations 
may define TSE features, but each form of human diseases present differently.567 
Magnetic resonance imaging (MRI) and electroencephalogram (EEG) examinations can 
provide differential diagnoses between vCJD and sCJD forms at ante mortem568 MRI is 
a unique imaging tool for CJD differentiations. In MRI evaluations, vCJD patients mostly 
pronounce signal enhancements in the posterior thalamus, called the pulvinar sign.569 
Since approximately 80% of vCJD cases present this sign, it has been included in the 
diagnostic criteria for vCJD. However, sCJD patients do not have signaling 
enhancements in the posterior thalamus. Thus, the presence of the pulvinar sign is a 
significant distinction between vCJD and sCJD forms, which is an essential aspect from 
public health. In addition, 60-80% of sCJD cases exhibit the hyper signal intensity in the 




molecular subtypes of the sCJD form.571 Thus, advanced imaging would contribute to 
the earlier diagnosis for CJD patients. 
 Furthermore, EEG could be another tool to distinguish between vCJD and sCJD 
cases. Periodic sharp wave complexes (PSWCs) are characteristic patterns of EEG in 
the sCJD form, accounting for 60-70% of patients.572-576 PSWCs can be detectable as 
early as 3 weeks after their disease onsets. Between two types of the sCJD form in the 
codon 129 genotypes, most common subtypes of type 1 (MM1, MV1) show PSWCs, 
while other subtypes (VV1, VV2, MM2, MV2) do not show.577,578 Possibly, the codon 
129 polymorphism might be an influential factor of the characteristic EEG pattern in 
sCJD cases.579 In addition, fCJD patients with the codon 200 or 210 mutations exhibit 
this EEG pattern during the disease course.580,581 In FFI cases, the EEG 
polysomnography might determine changing patterns in association with clinical 
symptoms during the course of disease progression.582,583 No diagnostic EEG pattern 
is found in GSS, iCJD, and vCJD patients.567  
 2) Limitations of current diagnostic methods: Spongiform change is known as 
a histological feature of TSEs, but not all cases exhibit this pathogenic alteration. In fact, 
various other diseases also cause this alteration or vacuolar degeneration in affected 
brains, such as AD, some neurodegenerative lysosomal disorders with autophagic 
vacuoles (i.e. neuronal ceroid lipofuscinoses, Battern disease, Niemann-Pick disease, 
aspartylglucosaminuria), canine distemper, avian vacuolar myelinopathy, progressive 
multifocal leukoencephalopathy (John Cunningham virus infection), cerebral autosomal 
dominant arteriopathy with subcortical infracts and leukoencephalopathy (a hereditary 




globoid cell leukodystrophy or galactosylceramide lipidosis,), and toxic spongiform 
leukoencephalopathy.584-591 Thus, the detection of vacuoles is not a sole decisive 
evidence for the TSE definitive diagnosis. 
 The most significant limitation for the TSE identification could be the definitive 
diagnosis at post mortem after autopsy. Without autopsy, this limitation could be a 
possible source of the iatrogenic PrPSc transmission if suspicious individuals donated 
bloods, tissues, and organs before the definitive diagnosis. Even for animals, necropsy 
would a critical procedure to prevent the PrPSc contamination to food products and its 
oral transmissions to humans and other animals. Furthermore, MRI and EEG are great 
diagnostic applications for neurological disorders. However, the MRI and EEG 
observations differ from each CJD case at ante mortem. These diagnostic results might 
differ from histological confirmations as TSEs at post mortem.592 Even if observing 
clinical progressions of TSE-like features, the PrPSc existence in brains should be 
necessary to confirm for definitive diagnosis. For this purpose of the PrPSc detection, PK 
reagents have been used to isolate the pathogenic proteins from its normal form. 
Conversely, recent studies have accumulated evidences of PK-sensitive PrPSc isoforms 
that are mostly implicated with TSE pathogeneses, such as infection, neurotoxicity, 
disease progression and lethal outcomes. 440,434,445,448,449,59-596 Thus, the use of PK 
reagents would cause potential risks of missing the pathogens in PrPSc analyses or TSE 
diagnoses. In other words, novel innovations are pivotal for the PrPSc detection at ante 
mortem or the asymptomatic phase. 
 New technologies have provided capable tests of detecting subtle amounts of 




analyses have been examined for clinical TSE patients at ante mortem, leading to a 
probable diagnosis for TSEs and a differential diagnosis for clarifying other 
neurodegenerative diseases.602-605 In bioassays, long incubation periods are impractical 
for infectious studies until animals initiate disease onsets over months to years. This is 
the major barrier of the TSE research. In contrast, the cycles for the PrPSc amplification 
and conversion take from hours to days. Hence, these advanced methods can 
overcome the major issue in bioassays. Thus, these analytical tools can contribute to 
the early detections of PrPSc particles in testing materials from TSE-affected individuals 
and animals. However, several questions arise for these methodologies, such as 
processing cycles under higher temperatures.60-610 These temperatures are at 42°C or 
higher that are causative factors for thermal protein degradations and irreversible 
structural instabilities.611-613 Since these processing cycles continue hours to days, 
degraded proteins could be produced and might link to conformational changes of PrP 
particles. In addition, the new methods do not have a system as like the degradation 
pathway in cells during the protein synthesis.614-617 Hence, the protein quality control is 
not available for eliminating incompleted or misfolded PrP structures in these 
methodologies. Moreover, repeated cycles of the PrP amplification and conversion 
might be similar to overproductions of PrP molecules in cells. It is known that the PrP 
overexpression induces the high possibility of protein aggregations.522. In fact, 
substances for amplifications in these experimental approaches are recombinant PrP 
molecules that are usually unglycosyl forms. Thus, the structures of these substrates 
could be susceptible to conformational conversions via templates of PrPSc seeds. In the 




transgenic mice generating PrP overexpression that should contain numerous PrPC 
molecules. Because of high PrP productions, many immature forms should be 
generated in these brains, especially those in cells intracellularly for processing full 
glycosylations through the protein synthesis. In addition, the methods for PrP 
amplifications and conversions do not have any systems to evaluate and eliminate the 
error of synthesized proteins with incorrect structure or misfolded conformation. Thus, 
increased cycles of the protein amplification might raise chances to generate insoluble 
PrP forms. For this point, WB requires PK reagent to determine amplified molecules. 
However, the presence of insoluble PrPC forms and these aggregations might result in 
false negative observations as PrPSc isoforms. In a case when PrPSc seeds are PK 
sensitive, amplified molecules might maintain this feature. Hence, PK digestion for WB 
preparations would eliminate this pathogen potentially. 
 3) A proposing strategy to detect PrPSc isoforms effectively: To differentiate 
PrPSc agents from the abundance of PrPC isoforms, one strategy could be a 
methodology for these conformational differences. One method is known as the 
conformation dependent assay or immunoassay.410,439,449,619-622 Although developments 
of immunological reagents and methods have attempted the capability of selecting 
these soluble and insoluble PrP isoforms, anti-PrP mAbs specifically distinguishing the 
PrPSc conformation are not available. Thus, detergents (i.e. guanidine hydrochloride) 
have ben used to denature proteins.623-626 The conformation of PrPSc isoforms is 
resistant to denaturation at lower concentrations of detergents, whereas PrPC isoforms 
are sensitive and soluble for detergents. Hence, increased concentrations of detergents 




a result, only insoluble proteins would remain persistently in the samples and maintain 
these resistant conformations for detecting in assays using anti-PrP mAbs.453,630-633 In 
this dissertation, established methods for PrPSc analyses utilized the guanidine-
mediated differentiation for innovating an experimental strategy without the use of PK 
reagents. 
 4) Enzyme-linked immunosorbent assay (ELISA) for detecting PrPSc 
isoforms: ELISA methods have been widely used as diagnostic tools in medicine and 
research because of these high sensitivities and strong specificities. Compared to 
western blot (WB) and immuneprecipitation (IP), the advantages of ELISA methods are 
the ability to test greater numbers of samples at the same time, and detect very low or 
unknown concentrations of targeted antigens. In general, ELISA procedures are quick, 
convenient and safe (i.e. no radioactive substance). Several ELISA methods are 
routinely applied for PrP detections in tissue samples, followed by PK digestion of PrPC 
isoforms for specific detection of PrPSc isoforms that are generally resistant to the PK 
reagent.634,635 This enzyme is also used for sample preparations in WB and IP 
procedures. PK digestion has been widely used in PrPSc analysis and TSE detection, 
whereas non-PK protocols of these standard analyses are limited in TSEs. 
Nevertheless, the existence of PK-sensitive PrPSc agents has been reported, and some 
studies suggest that a significant amount of the PrPSc agent is PK sensitive.449,453 
Therefore, the use of PK reagents for PrPSc detections has potential risks to produce the 
false negative results in the traditional PK-based diagnostic methods. In the public 
health aspect, these risks are serious concerns for food safety and zoonotic 




limitation of PK-based tests, the development of novel assays to detect PrPSc agents is 




Section 4: Introduction to work in this dissertation research 
 
Research Overview 
 The overreaching goal of this dissertation is to establish novel analytical systems 
for TSE diagnoses. TSEs, well known as prion diseases, are fatal neurodegenerative 
disorders in humans and animals, caused by the accumulation of the misfolded PrP 
isoform, referred to as PrPSc.2,3,28,637 The normal cellular PrP isoform, called PrPC, 
comprises a monomeric and predominant α-helical structure. The abnormal 
conformational conversion of the normal PrPC isoform misfolds into the pathogenic 
PrPSc isoform that configures an aggregation-prone β-sheet rich structure. This 
structural change renders the PrPSc isoform to be protease resistant and detergent 
insoluble, whereas the PrPC isoform is sensitive to PK reagents and soluble to 
detergents. Through long incubation periods, accumulations of aggregated PrPSc 
isoforms in the CNS implicate with the TSE disease development. Because of the 
structural modification, this abnormal conformer also alters the physiochemical 
properties of PrPC isoforms. However, the transformational mechanism from PrPC to 
PrPSc isoforms is not clearly known.  
 In general, the N-linked glycosylation is a covalent attachment of glycans to the 
carboxamido nitrogen on asparagine (N) residues on proteins.640,641 The PrPC structure 




(181 and 197 in humans).642-645 Glycosidic variances generate four different forms of 
PrP glycosylations: unglycosyl, monoglycosyl at 180/181 (mice/humans), monoglycosyl 
at 196/197, and diglycosyl forms. While the expression profiles of the glycosylated PrP 
forms have been studied, the role of the glycosylation and its importance is not clarified 
in TSEs.205 Conversely, glycosylation plays various structural and functional roles in 
proteins.511 For example, mutation or truncation of N-linked glycans interferes with 
protein folding.119,512,646 Since glycosylation has a role in the maintenance of the PrPC 
structure, the modulation of the N-linked glycosylation may lead to protein 
conformational changes. In TSEs, N-linked glycans on the normal PrPc isoform link to 
the disease phenotype. In fact, transgenic mice lacking a glycan at either one of the two 
consensus sites for N-linked glycosylation on the PrPC isoforms present more 
susceptibilities to the TSE infection.201 Therefore, the loss of N-linked glycans from the 
PrP structure should be involved in the pathological mechanisms of TSEs. Moreover, 
the absence of a diglycosyl PrP form is reported in cell culture models and brain tissues 
from TSE-affected patients.150,202 Also, in vivo models of scrapie exhibited abnormal 
glycosylation patterns of PrP molecules. These observations showed an increased ratio 
of under-glycosylated forms, but a decrease of diglycosyl forms.203 In the preliminary 
studies, TSE-affected mice exhibited increased detections of under-glycosylated PrP 
forms in brains, compared to controls (unpublished data). However, it is not clear why 
glycans on PrP molecules are lost during the disease development. Possibly, the 
alteration of glycosylation states may play a significant role in the TSE pathogenesis by 




 This dissertation research proposes that the under-glycosylated forms of PrP 
molecules are preferentially generated during TSE disease development, resulting in 
the increased efficiency of the conformational conversion of PrPC to PrPSc isoforms. 
Conversely, the tools to specifically determine the glycosylation state of PrPSc isoforms 
have been limited. Therefore, it is important to develop new and sensitive methods for 
detecting specific glycosylated PrPSc forms. The targeting approach to the under-
glycosylated state of PrPSc isoforms will reveal the molecular mechanisms in the 
selection of certain glycosylated forms for the PrP conformational conversion. These 
studies will identify molecular mechanisms of the PrP transformation providing insight 
for the development of innovative diagnostic methods and effective treatments against 
TSEs. 
 Among the in-house productions of antibodies, two novel anti-PrP mAbs, PRC5 
and PRC7, react with discontinuous epitopes in the structured globular domain of a PrP 
molecule.195 Interestingly, PRC7 specifically recognizes an unglycosyl form and one 
monoglycosyl form of PrP molecules. As another unique feature, PRC7 requires 
denaturation and renaturation of PrP molecules to recognize PrPSc isoforms. In addition, 
PRC7 cannot recognize a diglycosyl form of PrP molecules that an abundance of 
normal PrPC isoforms expresses. Consequently, PRC7 preferentially detects PrPSc 
isoforms. To innovate new analytical systems specifically for PrPSc isoforms, 
developments of sensitive ELISA protocols utilized the PRC5 and PRC7 features of 
conformational-dependent reactivities. The use of PRC7 would enable the detection and 




 The central hypothesis is that, the detection of under-glycosylated forms of PrP 
molecules is a hallmark of TSEs as a diagnostic biomarker for prion disease 
progression. Here, I propose that the loss of full glycosylation implicates with the 
pathological mechanisms of TSEs. For instance, glycosylation is involved in the 
maintenance of protein structures. Thus, its modulation can initiate unstable conditions 
for maintaining proper PrP conformation, which induces pathologic alterations of PrP 
structures. These aberrant formations could impair functions of normal PrPC isoforms. 
Another aspect of glycosylation is that PrPSc isoforms may lose glycans during the TSE 
developments. Therefore, I assume that under-glycosylated PrP forms can be 
preferentially generated during the disease progression. To accomplish the proposed 
studies, two sensitive ELISA methods were developed for the detection and 
quantification of PrPSc isoforms in TSE-infected samples.  
 Using the PRC7 and PRC5 mAbs as capture and detecting antibodies 
respectively, 7-5 ELISA specifically recognizes the two certain under-glycosylated PrP 
forms, significantly detected in TSE-infected materials. In addition, D-5 ELISA uses D18 
anti-prion antibody as a capture antibody and has an exceptional capability to determine 
levels of only PrPC or total PrP molecules by different sample preparations. Using the D-
5 ELISA method, TSE-infected materials at terminal stages decreased PrPC levels, 
whereas total PrP levels were increased. These results correspond to a recent article 
using the conformation-dependent immunoassay (CDI).647 Since the established 
protocols do not require PK reagents, these ELISA methods will be ultimately beneficial 
for TSE diagnoses, especially for detecting PK-sensitive PrPSc agents. In addition, the 




by detecting PrPSc isoforms, specifically based on glycosylated forms and distinguishing 
PrPC isoforms from PrPSc agents. The following Specific Aims will provide an innovative 
framework of the dissertation research that will result in beneficial impacts for the fields 
of veterinary medicine, human medicine, and public health. 
 
Aims of Study 
 Specific Aim 1 (Chapter 2): Development and optimization of a new ELISA 
approach, based on novel properties of the PRC7 mAb. I determined the capabilities of 
PRC5 and PRC7 in ELISA approaches, using recombinant PrP particles and brain 
homogenate samples from mouse models of TSEs. These mAbs were capable of 
reacting with these samples in both Indirect and Sandwich ELISA methods. These 
experiments identified the specificity for the productions of under-glycosylated PrP 
forms during the TSE development. To develop an optimized ELISA protocol, I 
attempted various approaches: i.e. mAb coating concentrations, sample 
denaturation/non-denaturation, sample protein concentrations, temperature, etc. 
 
 Specific Aim 2 (Chapter 3): Determination of the 7-5 ELISA method to detect 
disease-associated PrP in mouse models of TSEs. I hypothesized that the 7-5 ELISA 
method could detect under-glycosylated PrP forms in TSE-infected samples from 
different species. For this aim, I examined PrPSc isoforms in tissue samples from various 
transgenic mouse models of TSEs at terminal stages. The D-5 ELISA method also 
could determine modulations of PrPC levels and total PrP levels in the testing murine 




PrPSc strains, TSE-infectious states, species differences, and generations of under-
glycosylated PrP forms in TSEs.   
 
 Specific Aim 3 (Chapter 4): Evaluation of the utility of 7-5 ELISA as a diagnostic 
tool for TSEs in cervids. I hypothesized that under-glycosylated PrP forms were 
preferentially generated during the disease progression of chronic wasting disease 
(CWD), a naturally occurring infectious prion disease in cervid animals. The sensitivity 
of the 7-5 ELISA method would determine under-glycosylated PrP forms in collected 
samples from CWD-infected and uninfected cervids. The D-5 ELISA method was also a 
sensitive analytical tool to measure PrPC levels and total PrP levels from the collected 
samples. These investigations determined the generation of under-glycosylated PrP 
forms in CWD and the modulation of PrPC and total PrP levels. These alterations should 
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CHAPTER 2  
 
 
DEVELOPMENT AND OPTIMIZATION OF A NEW ELISA APPROACH,  






 TSEs are fatal neurodegenerative disorders that transmit horizontally and 
environmentally in humans and animals. Various analytical methods have been 
developed for PrPSc analyses and TSE diagnoses. However, each method has both 
advantages and limitations.1,2 In fact, PK-sensitive PrPSc existences and these 
pathogenic influences have been reported in TSE disease developments.3-5 Thus, the 
traditional TSE diagnostic methods using PK reagents have potential risks for false 
negative results. To overcome some limitations of the current TSE diagnoses, this 
Chapter 2 attempts to establish new analytical methods for PrPSc detections. For these 
purposes, the in-house anti-PrP mAbs of PRC5 and PRC7 were evaluated for 
applications in Indirect and Sandwich ELISA methods. Both mAbs were capable of 
detecting recombinant prion protein (RecPrP) of elk and mouse species by the Indirect 
ELISA application. In addition, these mAbs proved significant capabilities of detecting 
these RecPrP molecules by the Sandwich ELISA application that composed of the 
capture PRC7 antibody and the detecting PRC5 antibody. Without PK reagents, this 
Sandwich ELISA application could detect higher PrP levels in brain homogenates (BH) 
from TSE-diseased mice, compared to non-infected controls. To improve detectable 
abilities for PrPSc isoforms, various preparations and conditions were determined with 




PRC5 mAbs. Furthermore, this Chapter study defines the characteristic feature of the 






  The early detections and preventions of TSEs are critically important to 
eradicate further epidemic incidences throughout the world. In this dissertation, the 
overreaching goal set aims to establish new analytical systems for TSE diagnoses 
without the use of PK reagents. For these aims, ELISA applications utilized features of 
two anti-PrP monoclonal antibodies (mAbs), PRC5 and PRC7. PRC7 mAb specifically 
recognizes an unglycosyl form and one monoglycosyl form (mono-1: amino acid residue 
180 on mouse) of PrP molecules.6 In contrast, PRC7 mAb cannot recognize a 
diglycosyl form of PrP molecules, which the abundance of PrPC isoforms normally 
express this glycosidic state during non-infected states. In preliminary studies of 
western blot (WB) assay, PRC7 mAb preferentially detected unglycosyl and mono-1 
glycosyl PrP expressions in BH samples from TSE-inoculated mice, while non-infected 
BH controls did not exhibit clearly (unpublished data). Hence, PRC7 mAb might react 
selectively with PrPSc isoforms, but not PrPC isoforms. 
 WB or immnoprecipitation (IP) assay has been applied to study the PrP 
glycosylation using some other anti-PrP antibodies.7-10 However, these methods have 
limitations, such as time consumption and sensitivity. Compared to WB and IP assays, 
the ELISA method has the advantaged ability to test greater numbers of samples at the 




Thus, the ELISA method has been widely used as a diagnostic tool in medicine and 
research because of its high sensitivity and strong specificity. In general, ELISA 
procedures are quick, convenient, and safe (i.e. no radioactive substance). Several 
ELISA applications are used routinely for PrP detections in tissue samples with the PK 
treatment. It is well known that PrPC isoforms are sensitive to this reagent, whereas 
PrPSc isoforms are partially resistant.1,2 Thus, the PK reagent has been a common 
material specifically for detecting PrPSc isoforms in TSE research and diagnosis, 
including WB and IP assays. For this reason, non-PK protocols of these standard 
methods are extremely limited in TSEs. However, the existence of PK-sensitive PrPSc 
agents have been reported, and some studies suggest that significant amounts of PrPSc 
isoforms are PK sensitive.3,4 Therefore, the uses of PK reagents have potential risks of 
the false negative results for PrPSc detections in the traditional TSE diagnostic methods. 
This is a serious concern for food safety and zoonotic transmission in public health. To 
overcome this critical potential of PK-based analyses, the development of novel assays 
is required to avoid the use of PK reagents, but to ultimately improve the sensitivity and 
specificity for PrPSc detections. 
 For innovations of more advanced methods in the PrPSc detection and 
quantification, anti-PrP mAbs PRC7 (IgG1 isotype) and PRC5 (IgG2a isotype) were 
applied to develop new sensitive ELISA protocols that can react with PrPSc isoforms 
specifically and distinguish glycosylated forms. The established Sandwich ELISA 
method utilizes the unique properties of PRC7 mAb, named the “7-5 ELISA” method 
that comprises PRC7 and PRC5 mAbs as the capture and detection antibodies, 




isoforms in BH samples from several different species. Thus, the 7-5 ELISA method will 
be ultimately beneficial for detecting PK-sensitive PrPSc pathogens in TSE diagnostic 
investigations as well as for understanding TSE pathogenesis in research. Moreover, 
the novel 7-5 ELISA method will be the first-reported Sandwich ELISA protocol as 
specifically capable of the PrPSc detection and its glycosidic distinguishment. An 
innovative framework of the dissertation projects is provided in the following.  
 
 
Materials and Methods 
 
Antibodies 
 In 2012, Kang HE, et.al, reported the generation and characterization of novel 
anti-PrP mAbs: PRC1, PRC5, PRC7, and PRC9.6 This dissertation study evaluates the 
utilities of PRC5 (IgG2a isotype) and PRC7 (IgG1 isotype) mAbs to develop new ELISA 
protocols for detecting abnormal misfolding PrP (PrPSc) agents in the diagnosis of 
transmissible spongiform encephalopathy (TSE). PRC5 and PRC7 mAbs bind to 
discontinuous epitopes in the structured globular domain of the PrP molecule. Thus, 
these mAbs have conformational dependences for the PrP recognition. PRC5 mAb can 
react with all four glycosylated states of the PrP primary structure: 1) unglycosyl= no 
glycan at the amino acid residues either 180 or 196; 2) mono-1 glycosyl= a single 
glycan at the amino acid residue 180; 3) mono-2 glycosyl= one glycan at the amino acid 
residue 196; and 4) diglycosyl= two glycans at both 180 and 196 amino acid residues, in 
mouse PrP numbering.11,12 In contrast, PRC7 mAb only recognizes unglycosyl and 
mono-1 glycosyl forms of PrP molecules. In general, an abundance of PrPC isoforms 




infected individuals tend to generate under-glycosylated (no or one glycan) PrP forms.13 
Thus, the use of PRC7 mAb would be specifically capable of determining TSE infectious 
states by under-glycosylated states. To address this feature, PRC5 and PRC7 mAbs 
were paired for a conformation- and glycosylation-dependent approach to detect PrPSc 
isoforms selectively in the Sandwich ELISA method. In addition, horseradish peroxidase 
(HRP) conjugated secondary antibodies were applied: Sheep anti-Mouse IgG 
conjugated with HRP (NXA931, GE Healthcare Life Sciences, Pittsburgh, Pennsylvania, 
USA) for Indirect ELISA applications, Goat anti-Mouse IgG1 conjugated HRP when 
PRC7 is a detecting antibody in the Sandwich ELISA application (Cat#40126, Alpha 
Diagnostic Intl. Inc., San Antonio, Texas, USA), and Goat anti-mouse IgG2a conjugated 
with HRP (Cat#40127, Alpha Diagnostic Intl. Inc., San Antonio, Texas, USA) for a 
detecting antibody PRC5 in the Sandwich ELISA method.  
 
Indirect ELISA approach 
 A protein concentration of each recombinant prion protein (RecPrP) sample was 
measured by the ultramicroplate reader (ELx808 Absorbance Reader, BioTek 
Instruments, Inc, Winooski, Vetmont, USA) using the Pierce™ BCA Protein Assay Kit 
(Thermo Fisher Scientific Inc. Massachusetts, USA). Based on the BCA results, 
recombinant mouse and elk PrP samples synthesized in house were diluted with a 
coating buffer (0.05 M Carbonate-Bicarbonate buffer in distilled water) to 400µg/ml 
protein concentration.6 For denaturation, the same volume of 8 molar (M) guanidine 
hydrochloride (GdnHCL; G3272, Sigma-Aldrich Co. LLC, St. Louis, Missouri, USA) in 




water, pH 7.6) was applied to each prepared RecPrP sample to be 4M concentration 
during denaturation (protein concentration 200µg/ml) for 15 minutes at room 
temperature (RT) or testing temperatures (ºC). Denatured samples were diluted ten fold 
with the coating buffer to be 100µg/ml. Subsequently, serial dilutions of these samples 
were prepared with the same buffer. For non-denatured samples, 400µg/ml protein 
concentration of each prepared RecPrP sample was diluted with the same volume of 1X 
TBST buffer to be 200µg/ml protein concentration. Followed by incubation for 15 
minutes at RT or testing temperature (ºC) as matching to a paired sample of the 
denaturing process, the sample was diluted with a coating buffer to be 100µg/ml and 
serial dilutions. 100µl of each prepared sample was coated into wells (n=2 for each 
dilution of a sample) on ELISA plates (Nunc MaxiSorp® flat-bottom 96-well plate, 
Thermo Fisher Scientific, Rochester, New York, USA). Coated total proteins per well 
were as follows: 0.48, 0.97, 1.95, 3.90, 7.81, 15.62, 31.25, 62.5, 125, 250, 500 and 
1000ng. Also, bovine serum albumin (BSA: Sigma-Aldrich Co. LLC, St. Louis, Missouri, 
USA) was examined as a control, at the same amounts of total proteins for each 
dilution. After incubating ELISA plates with these samples overnight at 4ºC, all solutions 
were removed from the plates. For a blocking process, 200µl of 1X phosphate buffered 
saline (PBS: no calcium and magnesium, HyClone Laboratories, Inc. GE Healthcare 
Life Sciences, Logan, Utah, USA) with 3% BSA was added into each well. Followed by 
1-hour incubation at 37ºC, each plate was washed three to five times with 1X TBST 
buffer by a plate washer (the FinstrumentsTM Microplate Washer, MTX Lab Systems, 
Inc. Vienna, Virginia, USA). After removing all solutions from plates, 100µl of each 




was added into certain wells on the plates. Followed by incubation at 37ºC for 1 hour, 
the secondary antibody was added to all the testing wells after removing solutions from 
the plates and washing three times with 1X TBST by the washer. The plates with the 
secondary antibody were incubated at 37ºC for 1 hour. Subsequently, all solutions were 
removed from the plates. After washing seven times with 1X TBST by the washer, 
ABTS® Peroxidase Substrate was applied under the manufacturer’s protocol for 
developing a color reaction. At 405nm, the ultramicroplate reader measured an O.D. 
value of each well on the plates. 
 
Sandwich ELISA approach 
 PRC7 and PRC5 mAbs were applied as capture and detecting antibodies, 
respectively, for establishing a new Sandwich ELISA protocol, called the 7-5 ELISA 
method. Prior to experiments, testing ELISA plates were prepared with coating a known 
quantity of each capture antibody. The stock solution of PRC7 mAb was diluted with a 
coating buffer to be 20µg/ml concentration. 100µl of the diluted PRC7 solution was 
added into each well on the ELISA plate, and incubated overnight at 4°C. For blocking 
non-specific binding sites on the well surface, all solutions were removed from the plate. 
Subsequently, 200µl of 3% BSA-containing PBS was added into each well on the ELISA 
plate. After 1-hour incubation at 37°C, all solutions were cleared from the plate. Next, 
the plate was washed three times with 1X TBST buffer using the washer. Each 
prepared sample coated the wells on the plate, then were incubated overnight at 4°C. 
The sample-coated plate was emptied and washed three times with 1X TBST. A 




buffer (1% BSA-containing PBS without calcium and magnesium). 100µl of the diluted 
detecting antibody was added per well on the ELISA plate, and then incubated for 1 
hour at 37°C. A secondary antibody (Goat Anti-Mouse IgG2 HRP conjugate, 1mg/ml) 
was prepared at 1:5,000 in a dilution buffer. After evacuating and washing the plate 
three times with 1X TBST, 100µl of the diluted secondary antibody was used to coat all 
testing wells. Followed by an incubation for 1 hour at 37°C, the plate was drained and 
washed seven times with 1X TBST. Under the manufacturer’s protocol, ABTS® 
Peroxidase Substrate was applied for an enzymatic color development. To determine 
the presence and quantity of antigen by the chemical reaction, the ultramicro plate 
reader measured the plate for the absorbency of each well at a wavelength of 405nm.      
 
Preparation of brain homogenates   
 Brain samples isolated from uninfected and TSE-infected mice were stored at -
80°C. These samples were repeatedly extruded by aspirations using 18-gauge and 
serial fine syringe needles in cold 1X PBS (lacking calcium and magnesium) to be a 
10% (or 20%) brain homogenate (BH), preparing and testing ELISA, WB assay, and 
other future experiments. Each TSE-inoculation study with mouse information was 
recorded in the laboratory database of the Prion Research Center at Colorado State 
University (CSU). The tested murine BH samples in this chapter are listed in the 
following table (Table 1). In addition, BH samples from uninfected mice were prepared 
as controls for comparison with each study mouse group: PrP-KO (no PrP), FVB/n 
(wild-type MousePrP), Tg5037 (ElkPrP E226), Tg1536 (DeerPrP), Tg3533 (OvinePrP 




samples collected from uninfected mice are available in the database (i.e. dates of birth 
and tissue collection). 
 
Table 1. TSE-inoculated mouse brain homogenate samples 
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*RML: Rocky Mountain Laboratory mouse-adapted scrapie strain 
**IC: intracerebral inoculation (30ul BH). 




Preparation of tissue samples for 7-5 ELISA method 
 Followed by the manufacturer’s protocol of the BCA Protein Assay Kit (Pierce™ 
BCA Protein Assay Kit), protein concentrations of BH samples were measured by the 
ultramicroplate reader. To prepare a final protein concentration 200µg/ml of each 
analyte, a BH sample was aliquoted into an eppendorf tube and diluted with 1X PBS to 
be 4mg/ml initially. For denaturation, the prepared BH sample and 8M GdnHCL in 
50mM Tris buffer were mixed as 1:1 ratio, and incubated at 37°C with agitation by 
Thermomixer (Eppendorf AG, Hamburg, Germany) for 15 minutes or testing times: 4M 
GdnHCL during the denaturation. For evaluating lower concentrations of GdnHCL, two 
times higher concentration of GdnHCL solution was prepared. The same volumes of the 
GdnHCL and BH samples were mixed to be half concentration of GdnHCL: i.e. 6M 
GdnHCL to be 3M. These applications were also tested with guanidine thiocyanate  
(GdnSCN: Fisher Scientific, Fair Lawn, New Jersey, USA). After the incubation, the 
denatured sample was immediately diluted ten times with 1% BSA-containing PBS. At 
the final step, a protein concentration of the sample was 200µg/ml: the residue of 
GdnHCL was 0.4M concentration in the sample. 100µl of the prepared sample 
(200µg/ml) was coated per well (total protein = 20µg per well) on the prepared ELISA 
plate with the capture antibody. The sample-coated ELISA plate was stored at 4°C 
overnight. Subsequent procedures were performed under the Sandwich ELISA 
approach described above. All these preparations also evaluated RecPrP (mouse and 
elk) analyte by the 7-5 ELISA method. Note: tested protein concentrations of these 





Enhancement of PrP detections by the Sandwich ELISA approach 
 To enhance PrP detections by the Sandwich ELISA method, a detergent, Triton 
XTM-100 Electrophoresis (TX100; Fisher Scientific, Fiar Lawn, New Jersey, USA), was 
applied at the pre-denaturation step in the sample preparation. For coating the final 
protein concentration 200µg/ml of a testing sample, a BH sample was prepared with 
10% increase of protein concentration, compared with the sample preparation described 
above: i.e. 4mg/ml to 4.4mg/ml. The prepared BH sample was mixed with its 10% 
volume of 10% TX100-containing PBS (no calcium and magnesium) to be 1% TX100 in 
the sample in an eppendorf tube. This sample mixture was incubated for 1 hour at 37°C 
with agitation (BH protein concentration 4mg/ml). During optimizing an application of 
TX100 or its testing conditions for the 7-5 ELISA protocol, several conditions were 
modified, such as reagent concentrations in PBS (i.e. 0% TX100 means only 1X PBS), 
incubation times, and temperatures. Followed by this TX100 incubation, subsequent 
processes after the denaturation step were performed as described above under the 
sample preparation procedures for the Sandwich ELISA method.  
 
Conformation-dependent reactivity of the 7-5 ELISA method for PrP detections 
 PRC7 and PRC5 mAbs have conformational-dependences for binding to PrP 
molecules. To evaluate these characteristic reactivities in the 7-5 ELISA method, β-
mercaptoethanol  (βME: 2-Mercaptoethanol, Bio-Rad Laboratories, Inc. Hercules, 
California, USA) was used to cleave disulfide bonds of structured globular domains in 
PrP molecules. This chemical application disrupts protein folding and stability, and 




preparations, 50mM βME in PBS was added into BH samples (βME-treated), whereas 
only PBS was used for βME-untreated BH samples. These BH samples were incubated 
for 30 minutes at 55°C and diluted to be 200µg/ml protein concentration (βME 2.56mM 
as final concentration). In addition, the positive sample controls for the 7-5 ELISA 
method were prepared without βME and incubation under the current protocol above. 
To analyze these samples by the 7-5 ELISA method, 100µl of each prepared analyte 
was coated on the ELISA plate with PRC7 capture antibody and incubated at 4°C 
overnight. Additional procedures were preformed from the blocking process under the 





Indirect ELISA approach with recombinant PrP 
 Using RecPrP samples, the utility of PRC7 and PRC5 mAbs was assessed in 
ELISA methods. As an initial approach, these mAbs were tested by the Indirect ELISA 
method using RecElkPrP and RecMousePrP. Bovine Serum Albumin (BSA) was used 
as a control. These samples were diluted for the following range of protein per well 
(duplicate for each amount): 0.48, 0.97, 1.95, 3.90, 7.81, 15.62, 31.25, 62.5, 125, 250, 
500 and 1000ng. All prepared samples were coated onto wells of an ELISA plate, 
followed by incubations with each primary antibody PRC7 or PRC5 mAb, secondary 
antibody (Rabbit anti-Mouse IgG conjugated with horseradish peroxidase HRP), and 
ABTS® Peroxidase Substrate for color development. Both PRC7 and PRC5 mAbs 




 Since these results indicated that PRC7 and PRC5 mAbs reacted with native elk 
and mouse PrPC structures, the next assessment was the effect of protein denaturants 
on detections by the Indirect ELISA method. The RecPrP samples denatured with 4M 
GdnHCL showed similar O.D. values as non-denatured RecPrP samples. Because both 
mAbs have binding features to discontinuous conformation-dependent epitopes in the 
structured globular domain of the PrP molecule, these results suggested that RecPrP 
particles, once denatured, renature to these native structures that reinstate the 
conformation of these epitopes.6 Subsequently, the influence of sample-coating times 
was evaluated between 30 minutes and 1 hour at RT. This experiment found that longer 
coating enhanced detections of lower amounts of PrP molecules by both PRC7 and 





















































































































































Figure 2-1. Indirect ELISA approaches of PRC7 and PRC5 mAbs.  
(A) PRC7 and (B) PRC5, testing with BSA, RecElkPrP, and RecMousePrP  
(C) PRC7 with denatured (De+) RecElkPrP for the sample-coating time  
30 minutes at RT. (D) PRC7 with De+ RecElkPrP, 1 hour. (E) PRC7 with 
De+ RecMousePrP, 30 minutes. (F) PRC7 with De+ RecMousePrP, 1 hour.  
(G) PRC5 with De+ RecElkPrP, 30 minutes.(H) PRC5 mAb with De+ RecElkPrP,  
1 hour. (I) PRC5 with De+ RecMousePrP, 30 minutes.(J) PRC5 with De+ 
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Initial Application of the 7-5 ELISA method with recombinant PrP 
 Based on the capabilities of PRC7 and PRC5 mAbs (IgG1 and IgG2a isotypes 
respectively) in the Indirect ELISA method, these anti-PrP mAbs were applied to 
establish a new Sandwich ELISA protocol, called as the 7-5 ELISA method under the 
order of PRC7 and PRC5 mAbs as capture and detecting antibodies, respectively. 
Three different conditions were examined using RecElkPrP: 1) non-denaturation, 2) 
denaturation with 4M GdnHCL at 85°C, or 3) denaturation with 4M GdHCL at RT. This 
7-5 ELISA method detected RecElkPrP for all of the three sample conditions. For the 
RecPrP analyte, denaturant and temperature did not show influence to detect PrP 
molecules by the 7-5 ELISA method (Figure 2-2). Since the tested RecPrP samples 
have non-glycosylated structures, there is no limitation for detecting PrP molecules by 






























Figure 2-2. Sandwich ELISA approach of PRC7 and PRC5 mAbs. RecElkPrP with 
non-denaturation (pink and circle), denaturation at 85°C (orange and square), and 




Qualification of PRC5 mAb as a capture antibody in the 5-7 ELISA approach 
 In opposed to the 7-5 ELISA method, PRC5 mAb was tested as a capture 
antibody for a Sandwich ELISA approach with PRC7 mAb as a detecting antibody. This 
alternative antibody order as the 5-7 ELISA approach could detect RecPrP compared to 
BSA control. However, its O.D. value is much lower than results from the 7-5 ELISA and 
Indirect ELISA methods of PRC5 mAb under the same amounts of the tested total 
protein (Figure 2-3.A). In addition, this alternative application showed a potential to 
cause higher detectable backgrounds, based on O.D values including the BSA control 
(Figure 2-3.B). Comparing to the 7-5 ELISA results, the 5-7 ELISA approach could not 
distinguish PrP molecules between RML (Rocky Mountain Laboratory mouse-adapted 
scrapie)-infected and uninfected materials (Figures 2-3.C and D). Therefore, the 
application of the 5-7 ELISA approach may not be useful to detect PrP molecules in 
TSE-infected materials under the protocol procedure for the 7-5 ELISA method at this 
experimental point. Therefore, the development and optimization of the 7-5 ELISA 
protocol were concentrated specifically and selectively for PrP detections in TSE-


































Figure 2-3. The 5-7 ELISA approach with different conditions. 
(A) RecElkPrP with non-denaturation, (B) RecElkPrP and RecMousePrP  
with non-denaturation, (C) mouse BH samples with denaturation at RT,  
and (D) mouse BH samples with denaturation at 85°C. (n=2 for each prepared 







































































































Denaturation and temperature optimization for the 7-5 ELISA method  
 Combinations of three different concentrations of GdnHCL (0, 2, or 4M) with two 
temperatures (RT or 85°C) were applied to denature BH samples from PrP-KO, 
uninfected and RML-infected FVB/n mice. These results showed that GdnHCL 
enhanced PrP detections in the infected samples with the denaturation using 4M 
GdnHCL at RT, which measured the highest O.D. value (Figures 2-4.A and B). 
Procedures of 85°C incubation and/or non-denaturation are less effective for PrP 
































     

























FVB Uninfected De+ 2M/RT
RML-infected FVB De+ 2M/RT
















FVB Uninfected De+ 4M/RT
RML-infected FVB De+ 4M/RT
















FVB Uninfected De+ 2M/85°C
RML-infected FVB De+ 2M/85°C
















FVB Uninfected De+ 4M/85°C
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Figure 2-4. GdnHCL concentration and temperature are influential factors for 
denaturation to detect PrP levels in TSE-infected murine BH samples.  
(A) 2M GdnHCL denaturation at RT, (B) 4M GdnHCL denaturation at RT,  
(C) 2M GdnHCL denaturation at 85°C, (D) 4M GdnHCL denaturation at 85°C, 









Optimized Concentration of Capture Antibody in the 7-5 ELISA method 
 To find an optimized concentration of the capture antibody, various 
concentrations of PRC7 mAb (1, 2.5, 5 and 10µg/ml) were accessed with different total 
protein levels (2.5, 5, 10, 20, and 40µg per well) of mouse BH samples from uninfected 
PrP-KO and RML-infected FVB/n mice. The 7-5 ELISA method only detected PrP 
molecules in the denatured sample from the infected mouse, whereas this method did 
not detect higher PrP levels in the samples from the knockout or non-denatured infected 
mouse (Figures 2-5.A to D). In fact, the 10µg/ml PRC7-coating concentration showed 
the highest O.D. values to detect PrP levels in the infected sample.  
 A subsequent experiment increased coating concentrations of PRC7 mAb (5, 10, 
20, and 30µg/ml) for testing the same brain samples at total protein levels, 10, 20, and 
40µg per well (Figures 2-5.E to H). The coating mAb concentrations 20 and 30µg/ml 
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Figure 5. Optimized Concentration of PRC7 mAb as Capture Antibody in the range  
 E. F. 
 G. H. 







RML/FVB 4M GdnHCL De+ RT 7-5 ELISA











Figure 2-5. Optimized Concentration of PRC7 mAb as Capture Antibody in  
the range for the 7-5 ELISA method. 1-10µg/ml concentrations: (A) PrP-KO  
mouse BH sample with non-denaturation, (B) PrP-KO with denaturation at RT,  
(C) RML-inoculated FVB mouse BH sample with non-denaturation, and  
(D) RML-inoculated FVB with denaturation at RT. 5-30µg/ml concentrations:  
(E) PrP-KO mouse BH sample with non-denaturation, (F) PrP-KO with denaturation 
at RT, (G) RML-inoculated FVB mouse BH sample with non-denaturation, and  





Addition of Triton X-100 to enhance PrP detections in the 7-5 ELISA method 
 Selecting the 20µg/ml as a coating concentration of PRC7 mAb, the 7-5 ELISA 
method allowed for detections of PrP levels only in the infected material with 
denaturation, whereas no detection in the controls of PrP-KO and uninfected FVB/n 
mice (Figure 2-6.A). However, the detected PrP level in the infected analyte was not           
a significant high value. To improve the PrP detection in TSE-infected materials,             
an additional detergent Triton X-100 (TX100) was evaluated for its possible effects in 
the 7-5 ELISA method, such as the cell lyses, the permeabilization of cell membranes, 
and the solubilization of membrane proteins.14 The 1% TX100 addition into testing 
samples was examined at two different time points before or after denaturation 
procedures (pre- or post-denaturation). For the pre-denaturation time point, samples 
with 1% TX100 were initially incubated for one hour at RT. Subsequently, 4M GdnHCL 
was added into these incubated samples for denaturation, and additionally incubated 15 
minutes at RT. For preparing non-denatured controls, the same volume of a diluent 
buffer (50mM Tris) was added into non-denaturing samples, instead of GdnHCL. The 
processes of post-denaturation were performed through the opposite direction of pre-
denaturation samples by the following: denaturation with 4M GdnHCL in samples for 15 
minutes, and then 1-hour incubation with the TX100 addition as 1% in the sample. In 
non-denatured samples, TX100 did not enhance PrP detections in the infected material 
at either adding points of this reagent (Figure 2-6.B). However, the TX100 addition at 
the pre-denaturation time point increased the PrP detection in the infected material, 
compared to the infected sample without this detergent. In contrast, the infected sample 




(Figure 2-6.B and C). Hence, the use of TX100 should be effective prior to denaturation 




























































1% TX100 Non-denaturation RT 7-5 ELISA
KO Non-/RT only
FVB Uninfected Non-/ RT only
RML-infected FVB Non-/RT only
KO Non-/RT Pre-TX100
FVB Uninfected Non-/ RT Pre-TX100
RML-infected FVB Non-/RT Pre-TX100
KO Non-/RT Post-TX100
FVB Uninfected Non-/ RT Post-TX100
RML-infected FVB Non-/RT Post-TX100
KO Non-/RT -BisTX100
FVB Uninfected Non-/ RT Bis-TX100












1% TX100 Denatured RT 7-5 ELISA
KO DE+/RT only
FVB U infected De+/ RT only
RML-infected FVB De+/RT only
KO De+/RT Pre-TX100
FVB Uninfected De+/ RT Pre-TX100
RML-infected FVB De+/RT Pre-TX100
KO De+/RT Post-TX100
FVB Uninfected De+/ RT Post-TX100
RML-infected FVB De+/RT Post-TX100
KO De+/RT -BisTX100
FVB Uninfected De+/ RT Bis-TX100
RML-infected FVB De+/RT Bis-TX100
Figure 2-6. Applications of TX100 for enhancing PrP detections in RML-infected  
murine analyte. (A) PRC7 20µg/ml with denatured BH samples from PrP-KO, 
uninfected FVB/n and RML-infected FVB/n mice, without TX100 (n=2, each  
total protein amount). Under the 7-5 ELISA protocol, (B) non-denaturation and  
(C) denaturation with 4M GdnHCL. Additions of TX100 were compared at  















1% TX100 Denatured RT 7-5 ELISA
KO DE+/RT only
FVB Uninfected De+/ RT only
RML-infected FVB De+/RT only
KO De+/RT Pre-TX100
FVB Uninfected De+/ RT Pre-TX100
RML-infected FVB De+/RT Pre-TX100
KO De+/RT Post-TX100
FVB Uninfected De+/ RT Post-TX100
RML-infected FVB De+/RT Post-TX100
KO De+/RT -BisTX100
FVB Uninfected De+/ RT Bis-TX100
RML-infected FVB De+/RT Bis-TX100














































Triton X-100 enhances PrP detections in brain homogenates from CWD-infected 
transgenic mice in the 7-5 ELISA method 
 Based on the results from the RML-infected mouse BH samples above (Figures 
2-4 to 2-6), the same procedure and sample preparation were applied to uninfected 
transgenic mice expressing elk PrP (referred as Tg5037) and CWD-infected Tg5037 
mice. However, the 7-5 ELISA method could not detect PrP levels in the BH samples 
from the CWD-infected mice and the uninfected mice. To overcome this issue, TX100 
was used to enhance the PrP detection in CWD-infected materials. For testing this 
detergent at three different percentages 0, 1, or 5% (0% = only PBS), the following 
conditions were also applied to sample preparations: 1) non-denaturation, 2) 
denaturation, and 3) incubation at RT or 85°C. As the same application in Sections 2 
and 3, two time points (pre- or post-denaturation) were tested for adding 1% TX100 into 
testing samples and incubating 1 hour at RT. Wells in these ELISA plates were 
duplicated for each category. In non-denatured sample preparations, the 7-5 ELISA 
method did not show clear differences for O.D. values between infected and uninfected 
materials under these two temperatures (Figure 2-7.A and B). In contrast, denatured 
samples at RT with 1% TX100 at pre-denaturation enhanced the PrP detection in the 
CWD-infected material, compared to uninfected and KO mouse samples (Figure 2-7.C). 
Moreover, denaturation at 85°C was ineffective, which may be due to the high 
temperature because of the cloud point of TX100, known to be 66°C (Figure 2-7.D). 
Compared to the condition of 0% TX100 with denaturation at RT, the PrP detection in 
the CWD-infected material was enhanced with 1% TX100 (Figure 2-7.E). Note: a cloud 




TX100) starts to solidify molecular agglomerates, resulting in cloudy precipitations.15 
Thus, a cloud point influences a phase separation, stability, and effect of a surfactant 















































Figure 2-7. TX100 enhances PrP detections in CWD-infected murine analyte.  
Under the 7-5 ELISA protocol testing with 0, 1, or 5% TX100 concentration,  
(A) non-denaturation at RT, (B) non-denaturation at 85°C, (C) denaturation at RT, 
(D) denaturation at 85°C, (E) comparison of 0% (left side) and 1%(right side)  


















CWD Non- RT 0-5% TX100 7-5ELISA KO Non-/RT only
Tg5037 Uninfected Non-/RT only
CWD-infected Tg5037 Non-/RT only
KO Non-/RT 1% TX100
Tg5037 Uninfected Non-/RT 1% TX100
CWD-infected Tg5037 Non-/RT 1% TX100
KO Non-/RT 5% TX100
Tg5037 Uninfected Non-/RT 5% TX100












CWD Non- 85C 0-5% TX100 KO Non-/85°C only
Tg5037 Uninfected Non-/85°C only
CWD-infected Tg5037 Non-/85°C only
KO Non-/85°C 1% TX100
Tg5037 Uninfected Non-/85°C 1% TX100
CWD-infected Tg5037 Non-/85°C 1% TX100
KO Non-/85°C 5% TX100
Tg5037 Uninfected Non-/ 85°C 5% TX100














Tg5037 Uninfected De+/ RT only
CWD-infected Tg5037 De+/RT only
KO De+//RT 1% TX100
Tg5037 Uninfected De+/ RT 1% TX100
CWD-infected Tg5037 De+/RT 1% TX100
KO De+/RT 5% TX100
Tg5037 Uninfected De+/RT 5% TX100














Tg5037 Uninfected De+/85°C only
CWD-infected Tg5037 De+/85°C only
KO De+/85°C 1% TX100
Tg5037 Uninfected De+/85°C 1% TX100
CWD-infected Tg5037 De+/85°C 1% TX100
KO De+/85°C 5% TX100
Tg5037 Uninfected De+/ 85°C 5% TX100












m KO De+/RT only
Tg5037 Uninfected De+/ RT only
CWD-infected Tg5037 De+/RT only
KO De+//RT 1% TX100
Tg5037 Uninfected De+/ RT 1% TX100




Optimizations of incubation times and temperatures with TX100 and GdnHCL  
 In order to evaluate the optimal conditions of TX100 in the 7-5 ELISA method, 
three concentrations (0, 0.5, and 1%) of this detergent were initially tested at different 
incubation times (1 hour vs. 16 hours) and temperatures (RT vs. 37°C). For each 
sample group, a same temperature was applied for incubations of TX100 treatment and 
GdnHCL denaturation: i.e. the A sample at RT for TX100 and GdnHCL, and the B 
sample at 37°C for TX100 and GdnHCL. Through the 1-hour incubation with 0.5 or 1% 
TX100 and a subsequent incubation with GdnHCL denaturation for 15 minutes, the 
37°C incubation temperature enhanced higher O.D. values for PrP detections in CWD-
infected materials, compared to the RT incubations (Figures 2-8.A and B).  In contrast, 
the 16-hour incubation with TX100 showed opposite results, whereas the 1-hour TX100 
incubation detected higher O.D. values in the infected material (Figures 2-8.C and D). 
Therefore, this shorter TX100 incubation with 37°C can be practical for further 
applications of the 7-5 ELISA method as laboratory procedures and diagnostic 
applications. Furthermore, several denaturation times of GdnHCL were compared to the 
15-minute incubation in the all experiments above. Prior to the denaturation, all samples 
were incubated with 0.5% TX100 at 37°C for 1 hour. Following this TX100 treatment, 
these samples were denatured with GdnHCL, testing for 10, 15, 30 or 60-minute 
incubation. Measured by the 7-5 ELISA method, the denatured samples for the 15-
minute incubation showed the peak of PrP detections in CWD-infected material, 
whereas longer incubations decreased O.D. values (Figure 2-8.E). In addition, the 7-5 
ELISA method showed higher O.D. values of PrP detections in CWD-infected material 




denatured samples with 0.5% TX100 at 37°C  (Figure 2-8.F). These results indicated 
















































Figure 2-8. Optimizations of sample-incubation times and temperatures with  
TX100 and GdnHCL for PrP detections in CWD-infected murine BH samples.  
Under the 7-5 ELISA protocol, (A) 1-hour TX100 incubation at RT,  
(B) 1-hour TX100 incubation at 37°C, (C) 16-hour TX100 incubation at RT,  
(D) 16-hour TX100 incubation at 37°C, (E) comparison of GdnHCL-incubation time 
(10, 15, 30, and 60 minutes) with 1-hour TX100 incubation at 37°C, and  
(F) Comparison of non-denatured and denatured-murine BH samples with 0.5% 














RT 1 hr Triton X-100
KO De+/RT/ 0% TX100
Uninfected Tg5037 (ElkPrP) De+/RT/ 0% TX100
CWD-infected Tg5037 De+/RT/ 0% TX100
KO De+/RT/ 0.5% TX100
Uninfected Tg5037 (ElkPrP) De+/RT/ 0.5% TX100
CWD-infected Tg5037 De+/RT/ 0.5% TX100
KO De+/RT/ 1% TX100
Uninfected Tg5037 (ElkPrP) De+/RT/ 1% TX100
















KO De+/37°C/ 0% TX100
Uninfected Tg5037 (ElkPrP) De+/37°C/ 0% TX100
CWD-infected Tg5037 De+/37°C/ 0% TX100
KO De+/37°C/ 0.5% TX100
Uninfected Tg5037 (ElkPrP) De+/37°C/ 0.5% TX100
CWD-infected Tg5037 De+/37°C/ 0.5% TX100
KO De+/37°C/ 1% TX100
Uninfected Tg5037 (ElkPrP) De+/37°C/ 1% TX100
















KO De+/RT/ 0% TX100
Uninfected Tg5037 (ElkPrP) De+/RT/ 0% TX100
CWD-infected Tg5037 De+/RT/ 0% TX100
KO De+/RT/ 0.5% TX100
Uninfected Tg5037 (ElkPrP) De+/RT/ 0.5% TX100
CWD-infected Tg5037 De+/RT/ 0.5% TX100
KO De+/RT/ 1% TX100
Uninfected Tg5037 (ElkPrP) De+/RT/ 1% TX100














37°C 16hr Triton X-100
KO De+/37°C/ 0% TX100
Uninfected Tg5037 (ElkPrP) De+/37°C/ 0% TX100
CWD-infected Tg5037 De+/37°C/ 0% TX100
KO De+/37°C/ 0.5% TX100
Uninfected Tg5037 (ElkPrP) De+/37°C/ 0.5% TX100
CWD-infected Tg5037 De+/37°C/ 0.5% TX100
KO De+/37°C/ 1% TX100
Uninfected Tg5037 (ElkPrP) De+/37°C/ 1% TX100














Denaturation Time for TX100
KO De+/37°C/0.5% TX100
Uninfected Tg5037 (ElkPrP0 De+/37°C/0.5% TX100
CWD-infected Tg5037 (ElkPrP0 De+/37°C/0.5% TX100
KO De+/37°C/0.5% TX100
Uninfected Tg5037 (ElkPrP0 De+/37°C/0.5% TX100
CWD-infected Tg5037 (ElkPrP0 De+/37°C/0.5% TX100
KO De+/37°C/0.5% TX100
Uninfected Tg5037 (ElkPrP0 De+/37°C/0.5% TX100
CWD-infected Tg5037 (ElkPrP0 De+/37°C/0.5% TX100
KO De+/37°C/0.5% TX100
Uninfected Tg5037 (ElkPrP0 De+/37°C/0.5% TX100











CWD-bala05 37°C 1hr-TX100 15min-GdnHCL
KO Non-/0.5% TX100/37°C
Unnfecred Tg5037 De+/0.5% TX100/37°C
CWD-nfecred Tg5037 De+/0.5% TX100/37°C
KO De+/0.5% TX100/37°C
Unnfecred Tg5037 Non-/0.5% TX100/37°C







Optimization of incubation temperatures and agitation for sample preparations 
 To compare the effective sample preparations from the 7-5 ELISA method using 
CWD-infected materials above, the identified procedures were applied to BH samples 
from RML-infected FVB/n, uninfected FVB/n, and PrP-KO mice. Briefly, prepared BH 
samples were incubated with TX100 for 1 hour and 4M GdnHCL denaturation for 15 
minutes, at either RT or 37°C. These testing samples were agitated at 800rpm in the 
Thermomixer (eppendorf) throughout these incubations. This approach attempted to 
obtain consistent protocol for minimizing influences from sample types, such as among 
species, TSE strains, and other experimental variables. Another notable modification 
was changing dilutions of the detecting antibody PRC5 mAb from 1:2,000 (Figures 2-
9.A and B) to 1:5,000 (Figures 2-9.C and D). Compared to controls in testing ELISA-
plate wells, the 1:2,000 dilution of the PRC5 concentration showed color developments 
in the infected materials faster than the 1:5,000 dilution (Figures 2-9.A to D). 
Conversely, the 1:5,000 dilution enhanced PrP detections in the PrPSc-contained 
materials. These results could be arisen from a higher binding probability of the 
secondary antibody to PRC5 mAb, which could induce quicker reactions for color 
development. In fact, color changes occurred in the controls because the secondary 
antibody can bind to murine IgG2a in the testing mouse samples. Based on these 
results, the 7-5 ELISA method was applied to protein-dose dependent responses for the 
samples with the 0.5% TX100 treatment (Figure 2-9.E). Clearly, these modifications 
above enhanced detectable levels of PrP molecules in TSE-infected materials by the 7-











































RT TX100% plus De+ 
KO De+/0% TX100/RT
Uninfected FVB De+/0% TX100/RT
RML De+/0% TX100/RT
KO De+/0.5% TX100/RT
Uninfected FVB De+/0.5% TX100/RT
RML-infected FVB De+/0.5% TX100/RT
KO De+/1% TX100/RT
Uninfected FVB De+/1% TX100/RT
















37°C TX100% plus De+
KO De+/0% TX100/37°C
Uninfected FVB De+/0% TX100/37°C
RML De+/0% TX100/37°C
KO De+/0.5% TX100/37°C
Uninfected FVB De+/0.5% TX100/37°C
RML-infected FVB De+/0.5% TX100/37°C
KO De+/1% TX100/37°C
Uninfected FVB De+/1% TX100/37°C
RML-infected FVB De+/1% TX100/37°C















FVB Uninfected De+/0.5% TX100/37°C













37°C TX100% plus De+
KO De+/0% TX100/37°C
Uninfected FVB De+/0% TX100/37°C
RML De+/0% TX100/37°C
KO De+/0.5% TX100/37°C
Uninfected FVB De+/0.5% TX100/37°C
RML-infected FVB De+/0.5% TX100/37°C
KO De+/1% TX100/37°C
Uninfected FVB De+/1% TX100/37°C













RT TX100% plus De+ 
KO De+/0% TX100/RT
Uninfected FVB De+/0% TX100/RT
RML De+/0% TX100/RT
KO De+/0.5% TX100/RT
Uninfected FVB De+/0.5% TX100/RT
RML-infected FVB De+/0.5% TX100/RT
KO De+/1% TX100/RT
Uninfected FVB De+/1% TX100/RT
































Figure 2-9. Optimizations of sample-incubation times and temperatures with  
TX100 and GdnHCL for PrP detections in RML-infected murine BH analyte.   
PRC5 mAb applications at (A) 1:2,000 dilution with TX100 and GdnHCL 
incubations at RT, (B) 1:2,000 dilution with TX100 and GdnHCL incubations  
at 37°C, (C) 1:5,000 dilution with TX100 and GdnHCL incubations at RT,  
(D) 1:5,000 dilution with TX100 and GdnHCL incubations at 37°C,  
(E) PRC5 mAb 1:5,000 application with 0.5% TX100 and denaturation with  
1-hour incubation at 37°C. (n=3, each analyte category or amount) 




Comparisons of sample incubation times for the 7-5 ELISA method 
 In the Figure 2-1, sample-coating times were compared using RecPrP with PRC7 
and PRC5 mAbs by the Indirect ELISA method. These results indicated that longer 
coating times enhanced detections of RecPrP by these mAbs, especially for lower 
amounts of the antigens (Figures 2-1.C to J). Under the developed protocol of the 7-5 
ELISA method above, incubations for samples-coating times were evaluated. Note: 
PRC7 capture antibody was already coated on each well of the testing ELISA plate as a 
preparation. This experiment included the following murine BH samples: RML-
inoculated FVB/n mice, controls (uninfected FVB/n and PrP-KO mice), and TSE-
inoculated transgenic mice with PrP expressions of deer (Tg1536), elk (Tg5037), or 
sheep (Tg3533 with alanine (Ala: A) at the amino acid residue 136). Compared to the 1-
hour sample incubation, the overnight (16 hours) sample incubation enhanced the PrP 
detection in all of the TSE-infected materials, while no significant increase of PrP 
detections in the control samples (Figures 2-10.A and B). In contrast, the 6-hour sample 
incubation exhibited an equivalent O.D. value of PrP detections in the RML-infected 
sample, compared to the overnight sample incubation (Figure 2-10.C).  Therefore, 6-
hour sample incubation could be applicable to save time consumption for urgent or 
emergency cases that would require rapid TSE diagnoses. However, the overnight 
































Figure 2-10. Comparisons of sample-incubation times for the 7-5 ELISA method.  
(A) 1-hour incubation at 4°C, (B) 16-hour incubation at 4°C, and (C) compared 
incubations of 6 hours and 16 hours at 4°C. (n=3, each sample category with  
20µg total protein amount) 















GdnHCL Dose Dependent 7-5 ELISA 
RML Group (400µg/ml for all wells)
KO De+/0.5% TX100/37°C






















































Conformation-dependent reactivity of the 7-5 ELISA method for the PrP detection 
 PRC7 and PRC5 mAbs are described as conformation-dependent antibodies 
against PrP molecules.6 In mouse PrP numbering, PRC5 mAb binds to the amino acid 
residues A132 and N158 constituting a discontinuous epitope. PRC7 mAb recognizes 
the residues Y154 and Q185 constituting a discontinuous epitope. These residues 
acquire the proximity that requires for antibody recognitions in tertiary structures of PrPC 
isoforms. Therefore, the reactivities of these two mAbs are dependent on the PrP 
conformation. These reactivities of conformation-dependent antibodies were evaluated 
by the WB assay with and without proteinase K, using BH samples from RML-infected 
wild-type mice in the presence or absence of β-mercaptoethanol (βME).6 βME is a 
reducing agent, commonly used to cleave disulfide bonds that consist of structured 
globular domains in proteins. Disulfide bonds play an important role for protein folding 
and stability. In fact, the WB assay reduced PrP detections in the presence of βME with 
the uses of PRC7 and PRC5 mAbs. These observations indicated the characteristic 
features of these mAbs, which recognized discontinues epitopes with conformational-
dependences reactivities. Based on the WB results, βME was applied to evaluate the 
conformation-dependent reactivity of the 7-5 ELISA method for PrP detections. Initially, 
BH samples from RML-infected and control mice were incubated for one-hour 
incubation with 0.5% TX100 and 15-minute with 4M GdnHCL. 50mM βME in PBS was 
added into a βME-treated (+) sample, whereas only PBS addition for a βME untreated  
(-) sample. Subsequently, these βME samples were incubated for 30 minutes at 55°C. 
The positive control was prepared without this βME addition and incubation, as under 




RML-infected samples with the βME treatment, as an equivalent O.D. value to the 
controls (Figure 2-11). Hence, PRC7 and PRC5 mAbs could not react with PrP 
molecules because βME disrupted disulfide bands and globular structures of PrP 
conformations. Therefore, it is obvious that the 7-5 ELISA method has the property of 
conformational dependence for PrP detections. Compared to the positive controls of the 
RML-infected sample, the infected sample with non-βME treatment (PBS only) 
decreased O.D. value for PrP detections. This outcome might link to the extra 
incubation time for the βME treatment with higher temperature. Possibly, this additional 
incubation could induce further denaturations to the sample. As mentioned in Section 2-
8, longer denaturation times decreased O.D. values of PrP detections in TSE-infected 






























Figure 2-11. The 7-5 ELISA method has a conformation-dependent reactivity for 
the PrP detection in RML-infected murine analyte. (n=3, each analyte with 20µg 




Comparisons of two denaturants in the 7-5 ELISA method 
 Guanidine hydrochloride (GdnHCL) and guanidine isothiocyanate  (GdnSCN) are 
common denaturants in the TSE research field for measuring PrPSc isoforms.16-18 The 
effectiveness of these denaturants was compared under sample preparations for the 7-
5 ELISA method. Testing samples were denatured with different concentrations of 
GdnHCL (0-4M) or GdnSCN (0-3M) for 15 minutes at 37°C incubation. In the GdnHCL 
study, the 4M concentration showed the highest O.D. value of PrP detections in the 
TSE-infected material (Figure 2-12.A). However, the 2M GdnHCL concentration showed 
the reduced O.D. value, compared to lower concentrations. This phenomenon was also 
observed in the repeated experiment (Figure 2-12.B). In the GdnSCN study, the 3M 
concentration showed the highest O.D. value of PrP detections in the infected material 
(Figure 2-12.C). However, GdnSCN was less effective to detect PrP levels by the 7-5 
ELISA method, compared to GdnHCL. To confirm a potential negative effect of TX100 
to GdnSCN, 0% (only PBS) and 0.5% TX100 treatments were compared for the same 
samples above. After the 1-hour incubation at 37°C, these samples were denatured with 
3M GdnSCN. These results found that 0.5% TX100 enhanced PrP detections in the 
infected material (Figure 2-12.D). Hence, TX100 did not interfere the effect of GdnSCN 
in the 7-5 ELISA method. Therefore, GdnHCL is a proper reagent for sample 
denaturation in the 7-5 ELISA protocol than GdnSCN. The use of TX100 also enhanced 






























Figure 2-12. Comparison of GdnHCL and GdnSCN for the sample denaturation in  
the 7-5 ELISA method. (A) GdnHCL-dose dependence, (B) Repeated evaluation of      
GdnHCL-dose dependence, (C) GdnSCN-dose dependence, (D) TX100 application 
with GdnSCN denaturation. (n=2, each analyte with 40µg total protein amount) 














GdnHCL Dose Dependent 7-5 ELISA 
RML Group (400µg/ml for all wells)
KO De+/0.5% TX100/37°C
Uninfected FVB De+/0.5% TX100/37°C
RML De+/0.5% TX100/37°C














GdnSCN Dose Dependent 7-5 ELISA 
RML Group (400µg/ml for all wells)
KO De+/0.5% TX100/37°C
Uninfected FVB De+/0.5% TX100/37°C
RML De+/0.5% TX100/37°C














GdnHCL Dose Dependent 7-5 ELISA 
RML Group (400µg/ml for all wells)
KO De+/0.5% TX100/37°C
Uninfected FVB De+/0.5% TX100/37°C
RML De+/0.5% TX100/37°C
 C. 
 B.  A. 














3M GdnSCN +/- TX100 7-5 ELISA
KO De+/0% TX100/37°C
Uninfected FVB De+/0% TX100/37°C
RML De+/0% TX100/37°C
KO De+/0.5% TX100/37°C
Uninfected FVB De+/0.5% TX100/37°C


















GdnHCL Dose Dependent 7-5 ELISA 
RML Group (400µg/ml for all wells)
KO De+/0.5% TX100/37°C





Higher temperature incubations with both denaturants using the 7-5 ELISA 
method 
 Previously, sample denaturations were evaluated at different temperatures: RT, 
37°C and 85°C. For the next step, samples for the 7-5 ELISA method were denatured 
with 4M GdnHCL or 3M GdnSCN at different temperatures between 37°C and 85°C. In 
GdnHCL, 67°C incubation showed slightly higher O.D. values in the CWD-infected 
materials, compared to lower temperatures (Figure 2-13.A). In contrast, GdnSCN 
decreased O.D. values in the infected samples along with increased temperatures 
(Figure 2-13.B). Potentially, a GdnSCN treatment might not require a heating process 
for samples, measured by the 7-5 ELISA method. For a further analysis, temperatures 
37, 65, 75, and 85°C were evaluated for sample denaturations with 4M GdnHCL. As a 
result, these temperatures did not show clear differences for PrP detections in the 
infected materials (Figure 2-13.C). Hence, 37°C should produce an equivalent effect to 


















































GdnHCL 4M-denaturing temperature dependet 7-5 ELISA 
(400µg/ml for all wells)
KO De+/0.5% TX100/37°C
Uninfected Tg5037 (ElkPrP) De+/0.5% TX100/37°C
CWDbala05-infected Tg5037 De+/0.5% TX100/37°C














GdnSCN 3M-denaturing temperature dependet 7-5 ELISA
 (400µg/ml for all wel
KO De+/0.5% TX100/37°C
Uninfected Tg5037 (ElkPrP) De+/0.5% TX100/37°C
CWDbala05-infected Tg5037 De+/0.5% TX100/37°C














GdnHCL 4M-denaturing temperature dependet 7-5 ELISA 
(400µg/ml for all wells)
KO De+/0.5% TX100/37°C
Uninfected Tg5037 (ElkPrP) De+/0.5% TX100/37°C
CWDbala05-infected Tg5037 De+/0.5% TX100/37°C
Figure 2-13. Influences of high denaturing temperatures for PrP detections.  
For the sample preparation under the 7-5 ELISA protocol, (A) 4M GdnHCL 
denaturation, (B) 3M GdnSCN denaturation, and (C) repeated evaluation  







Efficacy of TX100 when using recombinant PrP in the 7-5 ELISA method 
 To evaluate the TX100 effectiveness for PrP detections, this detergent was 
treated with recombinant PrP that is composed of a native PrP-globular structure. For 
the 7-5 ELISA method, the following four different conditions were applied to 
RecElkPrP, RecMousePrP, and a BSA control: A) no TX100 and GdnHCL reagent, B) 
only 0.5% TX100 treatment without GdnHCL, C) only 4M GdnHCL denaturation without 
TX100, and D) both 0.5% TX100 and 4M GdnHCL reagents (Figures 2-14.A to D). 
These procedures were performed by the following incubations: 1 hour for TX100 and 
15 minutes for GdnHCL at 1,000 rpm agitation and 37°C. The TX100-only treatment (B 
condition) enhanced detections of RecPrP even at lower amounts of total proteins, 
compared to no treatment (A condition) (Figures 2-14.A and B). In addition, both 
treatments (D condition) induced higher RecPrP detections than only GdnHCL 
denaturation (C condition) (Figures 2-14.C and D). Based on these results, the TX100 
treatment demonstrated the ability to enhance PrP detections. Also, this detergent has 
an effect to enhance or prolong GdnHCL denaturation for RecPrP structures. Therefore, 
the TX100 application could be useful as a selective approach to detect abnormal PrP 

































































m BSA Control -TX100/+De
RecElkPrP -TX100/+De
RecMousePrP -TX100/+De
































m BSA Control -TX100/-Non
RecElkPrP -TX100/-Non
RecMousePrP -TX100/-Non
Figure 2-14. Evaluation of TX100 efficacy for recombinant PrP in the 7-5 ELISA 
method. For the sample preparation of RecMouse PrP under the 7-5 ELISA 
protocol, applications of (A) no TX100 and GdnHCL reagent, (B) only 0.5% TX100 
treatment without GdnHCL, (C) only 4M GdnHCL denaturation without TX100, and  









Denaturant effects for recombinant PrP by the 7-5 ELISA method 
 In the GdnHCL-dose dependent evaluation, 0.5% TX100 was added to all testing 
samples for the 1-hour incubation process at 37°C prior to denaturations. After that, 
RecElkPrP and RecMousePrP were denatured with different concentrations of GdnHCL 
(0, 1, 2, 3, or 4M). Evaluated by the 7-5 ELISA method, both RecElkPrP and 
RecMousePrP samples showed the highest O.D. values with 0M GdnHCL denaturation 
(Figures 2-15.A and B). Among 1-4M GdnHCL denaturations, the 7-5 ELISA method 
measured subtle differences for PrP detections in these samples among the denaturant 
concentration, especially for RecElkPrP. According to the Section 2-2 result, GdnHCL 
denaturation and temperature were no influential in RecElkPrP, compared to non-
denatured condition (Figure 2-2). Hence, the denaturation was a minimal effect for 
detections of this RecPrP sample. However, 0M-denatured RecElkPrP with Triton-X 100 
showed a higher O.D. value than denatured analyte (Figure 2-15.A). Therefore, these 
results suggested that the pre-treatment with Triton-X 100 enhanced an efficiency of 
GdnHCL denaturation. In addition, the denatured RecMousePrP with 2M GdnHCL 
reduced the O.D. value, compared to this analyte with other GdnHCL concentrations 
(Figure 2-15.B). This phenomenon was also observed in the GdnHCL-dose dependent 
study with RML-infected mouse BH samples (Figures 2-12.A and B). Thus, the 







































































Figure 2-15. GdnHCL-dose dependent responses in RecPrP by the 7-5 ELISA 
method. (A) RecElkPrP and (B) RecMousePrP (n=2 for each prepared sample  
















































Effective GdnHCL concentrations for mouse brain homogenates in the 7-5 ELISA 
method 
 The 7-5 ELISA method analyzed dose-dependent responses of GdnHCL to four 
different protein amounts of BH samples from three TSE-infected mouse study groups. 
Including PrP-KO mice for each group, these study groups were 1) RML-infected and 
uninfected FVB mice, 2) CWD-infected and uninfected Tg5037 (ElkPrP) mice, and 3) 
CWD-infected and uninfected Tg1536 (DeerPrP) mice. Prior to denaturations, all 
prepared samples were treated with 0.5% TX100 for 1 hour at 37°C with 1,000 rpm 
agitation. For all TSE-infected samples in the three study groups, the highest protein 
amounts exhibited the peaks of O.D. values at 5M GdnHCL, whereas 6M GdnHCL 
decreased the values (Figures 2-16.A to C). These outcomes indicated that the range of 
4-5M GdnHCL concentrations could be adequate to detect PrP agents in TSE-infected 
materials. Notably, over 5M GdnHCL concentrations have potentials to decrease PrP 
detections. Therefore, the GdnHCL denaturation should maintain between 4-5M 



































Figure 2-16. GdnHCL-dose dependences to different protein amounts of  
TSE-infected murine BH materials in the 7-5 ELISA method. BH samples of  
PrP-KO mouse with (A) RML-infected and uninfected FVB mice, (B) CWD-
infected and uninfected Tg5037 (ElkPrP) mice, and (C) CWD-infected and 
uninfected Tg1536 (DeerPrP) mice. (n=3, each dose). 













0-6M GdnHCL CWD Tg1536 group De+/0.5% TX100/37°C
KO (19µg) 
Uninfected Tg1536(DeerPrP) (10µg) 







Uninfected Tg1536(DeerPrP) (2.5µg) 
CWDbala05-infected Tg1536(DeerPrP) (19µg)
CWDbala05-infected Tg1536(DeerPrP) (2.5µg)













0-6M GdnHCL CWD Tg5037 group De+/0.5% TX100/37°C
KO (19µg) 
Uninfected Tg5037(ElkPrP) (10µg) 







Uninfected Tg5037(ElkPrP) (2.5µg) 
CWDbala05-infected Tg5037(ElkPrP) (19µg)
CWDbala05-infected Tg5037(ElkPrP) (2.5µg)













0-6M GdnHCL RMLgroup De+/0.5% TX100/37°C
KO (20µg) 
FVB Uninfected (10µg) 
















Efficacy of TX100 for PrP detections in brain homogenates from CWD-inoculated 
transgenic mice by the 7-5 ELISA method 
 To enhance PrP detections in CWD-infected materials, four different 
concentrations of TX100 (0.5, 1, 2.5, and 5%) were tested with BH samples from 
transgenic mice with expressing cervid PrP. These samples with each TX100 
concentration were incubated for 1 hour or 2 hours. After these TX100 treatments, all 
testing samples were denatured with 4M GdnHCL for 15 minutes. The 7-5 ELISA 
method measured that the controls of PrP-KO mice, uninfected Tg5037 mice (elk PrP 
expression), and uninfected Tg1563 mice (deer PrP expression) did not have clear 
differences for O.D. values by the TX100 treatments and incubation times (Figures 2-
17.A to C). In contrast, the 1% TX100 treatment exhibited the peak of PrP detections in 
both CWD-infected Tg5037 and Tg1536 murine BH samples. However, higher TX100 
concentrations decreased PrP detections (Figures 2-17.D and E). Therefore, the 1% 
TX100 should be applicable for enhancing PrP detections in mouse BH samples by the 









































CWDbala05-Tg1536 TX100 1hr vs 2hr incubation plus De+ 4M GdnHCL






m CWD/bala05-Tg1536(DeerPrP) 0.5% TX100/37°CCWD/bala05-Tg1536(DeerPrP) 1% TX100/37°C
CWD/bala05-Tg1536(DeerPrP)  2.5% TX100/37°C
CWD/bala05-Tg1536(DeerPrP)  5% TX100/37°C




























Tg5037 7-5ELISA TX100 1hr vs 2hr incubation time plus De+ 4M GdnHCL







Uninfected Tg5037(ElkPrP) 0.5% TX100/37°C
Uninfected Tg5037(ElkPrP)  1% TX100/37°C
Uninfected Tg5037(ElkPrP)  2.5% TX100/37°C
Uninfected Tg5037(ElkPrP)  5% TX100/37°C








Tg1536 7-5ELISA TX100 1hr vs 2hr incubation time plus De+ 4M GdnHCL







Uninfected Tg1536(DeerPrP) 0.5% TX100/37°C
Uninfected Tg1536(DeerPrP)  1% TX100/37°C
Uninfected Tg1536(DeerPrP)  2.5% TX100/37°C
Uninfected Tg1536(DeerPrP)  5% TX100/37°C








CWDbala05-Tg5037 TX100 1hr vs 2hr incubation plus De+ 4M GdnHCL






m CWD/bala05-Tg5037(ElkPrP) 0.5% TX100/37°C
CWD/bala05-Tg5037(ElkPrP)  1% TX100/37°C
CWD/bala05-Tg5037(ElkPrP)  2.5% TX100/37°C
CWD/bala05-Tg5037(ElkPrP)  5% TX100/37°C
 A. 





























Figure 2-17. TX100 efficacy under different concentrations and incubation times  
in the 7-5 ELISA method. (A) PrP-KO mouse BH samples,  
(B) Uninfected Tg5037 mouse BH samples, (C) Uninfected Tg1536 mouse BH 
samples, (D) CWD(Bala05)-infected Tg5037 mouse BH samples,  
(E) CWD(Bala05)-infected Tg1536 mouse BH samples. (n=3, each sample 




1% TX100 application to RML-infected murine brain homogenate in the 7-5 ELISA 
method 
 Based on the experiments above, 1% TX100 was the most effective 
concentration for PrP detections in CWD-infected materials by the 7-5 ELISA method. 
However, RML-infected materials exhibited similar PrP levels with 0.5% and 1% TX100 
incubations at 37°C. To confirm the 1% TX100 concentration as the optimized 7-5 
ELISA protocol, this detergent was re-evaluated with BH samples from RML-infected 
mouse and its controls (uninfected FVB/n and PrP-KO mice). Initially, these BH samples 
were incubated with 1% TX100 for 1 hour at 37°C, and subsequently denatured with 5M 
GdnHCL for 15 minutes at 37°C. After ten-time dilutions, these prepared samples were 
further diluted in a range from 0.625µg to 160µg total proteins per well (each well 
number = duplicate), evaluating for protein-dose dependent responses in the 7-5 ELISA 
method. The efficacy of TX100 was obvious to detect PrP agents in the infected 
material, based on the previous results in this chapter. Between 0.625µg and 20µg total 
proteins, the dose responses showed a linear range on the curve (Figure 2-18.A). For 
the TX100 incubations, different times were previously tested at 1, 2, or 3 hours, or 
overnight. The 1-hour incubation was the most effective and convenient time for PrP 
detections. To determine minimal incubation times for enhancing the 1% TX100 
efficacy, its treatment was tested for shorter incubation times (5, 10, 20, 30, 40, 50, or 
60 minutes) using the same brain samples above. After these time-point incubations, all 
samples were denatured with 5M GdnHCL for 15 minutes at 37°C. Followed by the 10-
time dilutions, the 20µg total protein of each prepared sample was coated per well 




sample did not exhibit significant differences for O.D. values of PrP detections (Figure 
2-18.B). However, these results suggested that at least 40 minutes of the TX100 
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Figure 2-18. TX100 effects for PrP detections in RML-infected murine analyte  
in the 7-5 ELISA method. (A) protein-dose dependent responses, and  
(B) incubation-time dependent evaluation of TX100 with testing samples.  








Application of the optimized 7-5 ELISA protocol to scrapie-infected transgenic 
mice 
 For further analyses of the 7-5 ELISA method, its optimized protocol was tested 
with BH samples from scrapie-inoculated transgenic mice expressing ovine PrP. These 
murine samples were derived from the following past bioassay in KG study numbers: 
KG-49 (sheep scrapie 48x35), KG-50 (sheep scrapie SSBP/1), KG-51 (sheep scrapie 
CH1641/4), and KG-62 (US goat scrapie 76/12/22). The background information of 
these four scrapie strains are described below. The three strains (SSBP/1, 48x35, and 
CH1641/4) were originally isolated at the Neuropathogenesis Unit (NPU), Edinburgh in 
the United Kingdom. The SSBP/1 isolate originated from three sheep that naturally 
developed scrapie. Mixed homogenates of these brains were inoculated into other 
sheep for passages, mainly in the Cheviot breed (Dickinson et al., 1989). The sheep 
scrapie 48x35 was the isolate from a scrapie-developed Cheviot sheep expressing a 
heterozygous VRQ/ARQ genotype with Leucine (abbreviated as Leu/L) at the codon 
141 in the ARQ allele of the PrP gene. Another scrapie isolate CH1641 was derived 
from a Cheviot sheep with natural scrapie infection. The US goat scrapie 76/12/22 
isolate originated from a US goat with an experimental scrapie inoculation, provided by 
Dr. Jason Bartz at Creighton University (Omaha, Nebraska, USA). For the transmission 
analyses, the KG bioassay inoculated these scrapie isolates intracerebrally into Tg3533 
mice expressing ovine PrP (ARQ) that is composed of alanine (Ala: A) at amino acid 
residue 136. 
 For this scrapie experiment, one mouse brain from each KG experiment was 




the following: #5060 (48x35 in KG-49), #5064 (SSBP/1 in KG-50), #5075 (CH1641/4 in 
KG-51), and #5520 (US goat scrapie 76/12/22 in KG-62). Moreover, one mouse brain 
(animal number #6369) from the KG-98 study (the transmission of SSBP/1 sheep 
scrapie) was analyzed. This transgenic mouse Tg4166 (Ovine VRQ) expressed sheep 
PrP with valine (abbreviated as Val or V) at amino acid residue 136. Since PRC5 mAb 
does not bind sheep PrP with Valine at the amino acid residue 136, the VRQ sheep PrP 
sample was a negative control for the 7-5 ELISA method. Other controls included BH 
samples from PrP-KO, uninfected Tg3533 (Ovine ARQ) and Tg4166 (Ovine VRQ) mice. 
Briefly, all BH samples were treated with 1% TX100 for 1 hour at 37°C, and then 
denatured with 5M GdnHCL for 15 minutes at 37°C. Subsequently, these prepared 
samples were diluted 10 times to be 200µg/ml protein concentration. 100µl of each 
diluted sample was coated per well (total 20µg/well; duplicate for each mouse) for the   
7-5 ELISA analyses. All samples from the scrapie-infected Tg3533 mice showed higher 
O.D. values of PrP detections, compared to the controls (Figure 2-19).  
 However, these detections were lower values, compared to the previous 
experiment of another isolate Colorado Scrapie in Tg3533 mouse in Section 2-10 
(Figure 2-10.B). These different detections might indicate quantitative estimations or 
determinations of PrP levels by the 7-5 ELISA method, as depended on individual 
variances. To analyze this possibility, additional numbers of mice from scrapie bioassay 
would be necessary. Notably, the KG study samples have been stored over a decade, 
and also transferred from another institute to CSU. In contrast, the inoculum 
experiments with the Colorado Scrapie isolate were performed at CSU. Then, mouse 




(shorter storage times). Potentially, the sample storage time and condition might be a 
causal factor to decrease PrP detections. In addition, the 7-5 ELISA method could not 
measure PrP levels in the SSBP/1 scrapie-infected Tg4166 (Ovine VRQ) mouse 
because of the PRC5 property. Therefore, the 7-5 ELISA method can be utilized to 
detect scrapie infections in sheep with a non-Valine background at the amino acid 


















Figure 2-19. The 7-5 ELISA method is capable of detecting PrP levels in BH 
samples from scrapie-infected transgenic mice. (n=3, each sample with  
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 Several different analytical methods have been used to diagnose TSE infections. 
However, each method has both advantages and limitations for PrPSc detections, based 
on technical processes.1,2 This thesis established objectives to develop novel analytical 
methods that overcome some of the current limitations for TSE diagnoses. These 
investigations anticipated promoting the identification of underlying mechanisms in 
TSEs. For these fundamental aims, the ELISA approach was selected to develop an 
analytical and diagnostic tool with high sensitivity and strong specificity for PrPSc 
detections. Compared to western blot (WB) and immnoprecipitation (IP) assays, ELISA 
methods are capable of testing greater numbers of samples at the same time and also 
detecting very low or unknown amounts of targeted antigens. In general, the ELISA 
method is quick, convenient and safe (i.e. no radioactive substance). Thus, several 
ELISA approaches are used routinely for PrP detections in tissue samples, with PK 
treatment for PrPC digestions and for specific PrPSc detections.1,2 Since the PrPSc 
isoform is generally known as partially resistant to the PK reagent, this enzyme has 
been utilized in sample preparations for TSE diagnoses including WB and IP assays for 
identifying PK-resistant PrP or PrPSc agents. Thus, non-PK protocols of these common 
analytical methods are extremely limited in TSEs. However, some studies suggest that 
significant amounts of PrPSc isoforms are PK sensitive, which highly implicate 
neurotoxic mechanisms in the TSE pathogenesis.3-5 Therefore, the PK application for 
PrPSc detections has potential risks to produce false negative results in the traditional 
PK-based diagnostic methods. This is a serious concern for food safety and zoonotic 




the development of new PrPSc detectable assays is required to avoid the PK reagent 
and ultimately improve the sensitivity and specificity. 
 PRC7 and PRC5 mAbs are the in-house products of new anti-PrP mAbs.6 PRC7 
mAb specifically recognizes both unglycosyl and one monoglycosyl (mono-1: amino 
acid residue 180 for mouse) forms of PrP molecules. Conversely, PRC7 mAb cannot 
recognize a diglycosyl PrP form that is in abundance during non-infected states. 
Therefore, PRC7 mAb preferentially detects the under-glycosylated form of PrP 
molecules. According to the preliminary studies, PRC7 mAb detected under-
glycosylated PrP forms in infected samples from TSE-inoculated mice by WB assay 
(unpublished data). Since WB and IP assays have limitations such as time consumption 
and analytical sensitivity, the development of more advanced methods was aimed using 
PRC7 and PRC5 mAbs for the PrP detection and quantification in TSE-infected 
samples. Based on the characteristic feature of PRC7 mAb that react with two of the 
under-glycosylated PrP forms in TSE-infected materials, the establishment of a new 
ELISA method with more sensitivity was attempted for detecting certain glycosylated 
PrPSc forms. 
 In order to evaluate capabilities of PRC7 and PRC5 mAbs for ELISA 
applications, these antibodies were initially tested by the Indirect ELISA method using 
recombinant prion protein (RecPrP) samples (Figure 2-1). These two mAbs were 
capable of PrP detections in different species (elk and mouse) under the Indirect ELISA 
approach. In addition, denatured RecPrP samples must be renatured to these native 
conformations because these O.D. values were similar to non-denatured samples, in 




increase the specificity of PrP detections, these antibodies were examined by the 
Sandwich ELISA approach. However, the use of PRC7 mAb had a potential restriction 
to detect large amounts of PrP molecules in testing samples by the Sandwich ELISA 
method, because of its selective reactivity to unglycosyl and mono-1 glycosyl PrP forms. 
Thus, the combination of PRC7 and PRC5 mAbs for the Sandwich ELISA approach was 
determined using RecPrP with different sample preparations. In fact, the Sandwich 
ELISA approach with the capture PRC7 and detecting PRC5 antibodies (the 7-5 ELISA 
method) showed PrP detections under RecPrP-dose dependences for both elk and 
mouse species. Similar to the results from the Indirect ELISA method, denaturation did 
not influence PrP detections by the 7-5 ELISA method, compared to the non-denatured 
preparation. Since the incubation temperatures also did not show differences for the 
denaturation state, it is obvious that the 7-5 ELISA method can recognize renatured PrP 
structures after the sample denaturation (Figure 2-2).  
 In contrast, the 5-7 ELISA approach (the reverse order of PRC7 and PRC5 mAbs 
in Sandwich ELISA) did not detect PrP levels, specifically in TSE-infected murine 
materials (Figure 2-3). However, this ELISA approach reacted with RecElkPrP and 
RecMousePrP samples that were non-glycosylated forms. These results indicated that 
the capture antibody PRC5 mAb bound to all four glycosylated PrP forms in BH 
samples, whereas PrP molecules with unglycosyl and/or mono-1 glycosyl forms were 
possibly less captured by this mAb. Therefore, the detecting antibody PRC7 mAb could 
not have a greater chance to bind with these two glycosylated PrP forms. In the 7-5 
ELISA method, conversely, PRC7 mAb captured only unglycosyl and/or mono-1 




reported, TSE infections tend to increase generations of under-glycosylated PrP forms 
in affected animals.10 Thus, the selective capture by mAbs against under-glycosylated 
PrP forms must be an analytical tool, specifically for PrPSc detections in TSE-infected 
materials. Hence, under-glycosylated PrP forms are candidate biomarkers to diagnose 
the TSE infection state and disease progression. Consequently, the 7-5 ELISA method 
has a potential utility as a novel analytical system in TSE diagnosis. 
 Evaluated by the 7-5 ELISA method, higher concentrations of GdnHCL increased 
PrP detections in TSE-infected materials, while extremely higher temperatures (85°C) 
reduced O.D. values of PrP levels (Figure 2-4). These results reflected thermal 
influence and protein degradation. In general, thermal injury and protein denaturation 
are initiated around 42-45°C, and increased temperatures progress protein degradation 
faster.19 In fact, proteins are prone to lose stabilities at temperatures 40°C and above, 
which induce unfolding protein structures.20 For the PrP conformational stability, the 
midpoint of denaturation temperatures is different between PrPC and PrPSc isoforms in 
that the abnormal structure has a higher heat tolerance than the wild-type protein.21 At 
elevated temperatures, therefore, the denaturation procedure might cause irreversibility 
for the PrP renaturation and conformation, possibly resulting in degradation of the 
damaged protein. 
 Followed by optimizing steps for sample preparations, the 7-5 ELISA method 
could increase its capability to detect PrP levels in BH samples from TSE-infected mice. 
Higher amounts of the PRC7 capture antibody would increase chances for capturing 
many unglycosyl and mono-1 glycosyl PrP forms in the tested samples (Figure 2-5). In 




materials (Figure 2-6). The efficacy of TX100 was obvious for CWD-infected Tg5037 
(ElkPrP) mouse samples (Figure 2-7). In the TSE research, several different detergents 
(i.e. sodium dodecyl sulfate, sodium deoxycholate) have been applied to enhance PrPSc 
detections in TSE-infected materials and to analyze PrP phenotypes and glycosylation 
profiles.22,23 However, various experimental factors are influential for the PrP 
detectability, such as detergent types and concentrations, PK reagents, host species, 
TSE strains, and analytical methods. Thus, it is important to select effective detergents 
for enhancing PrP detections through the development and optimization of the 7-5 
ELISA method. In fact, the TX100 application at the pre-denaturation showed the 
increase of PrP detections (Figure 2-6). The 1% TX100 obviously enhanced O.D values 
of PrP levels in CWD-infected Tg5037 mouse BH samples, compared to the 0% and 5% 
TX100 concentrations (Figure 2-7). In contrast, the 7-5 ELISA method could not detect 
PrP levels in CWD-infected materials without the TX100 treatment. These outcomes 
reflected previous reports that efficacies of detergents were dependent on detergent 
concentrations, TSE strains, and host species.22,23 In addition, denaturation at higher 
temperatures diminished PrP detections (Figure 2-7). Possibly, elevated incubation 
temperatures caused irreversible conditions for protein structural renaturation as an 
excessive effect of the thermal denaturation. However, the 37°C temperature for TX100 
and GdnHCL treatments enhanced PrP detections in CWD-infected materials during 
certain incubation times: 1 hour with TX100, and 15 minutes with GdnHCL (Figure 2-8). 
However, longer incubation times reduced O.D. values of PrP detections in the infected 
samples. For the TX100 concentration, 1% concentration was less influential by 




1% concentrations showed similar O.D values (Figure 2-9). Therefore, 1% TX100 
concentration could be appropriate to prevent temperature-related declines of PrP 
detections in the 7-5 ELISA method. In addition to the incubation temperature and 
detergent, sample-coating times on ELISA plates were also an influencing factor to 
obtain accurate results for PrPSc detections. The 6-hour incubation could provide 
equivalent captures of PrP molecules by the PRC7 mAb, compared to the overnight 
incubation (Figure 2-10). Nevertheless, the 1-hour sample incubation was also 
detectable for the TSE-infection state. The application of shorter incubations would be 
applied when rapid TSE diagnosis is required.   
 In the 7-5 ELISA method for PrP detections, β-mercaptoethanol (βME) cleaved 
disulfide bonds in conformational globular domains of PrP structures, resulting in the 
loss of protein folding and stability (Figure 2-11). Since PRC7 and PRC5 mAbs in the       
7-5 ELISA method are conformation-dependent features for PrP detections, this 
analytical method could not recognize PrP levels in βME-treated BH samples from 
RML-infected mouse, whereas the samples with non-βME treatment showed higher 
O.D. values for PrP detections (Figure 2-11). These outcomes indicated that the 
conformational-dependent ELISA approach only detected PrP molecules with structural 
conditions, but not for unfolding states. In addition, PRC7 mAb and the 7-5 ELISA 
method only detect unglycosyl and mono-1 glycosyl PrP forms. Based on these 
findings, under-glycosylated PrP conformations might be less stable for maintaining 
protein structures because of no protection by glycans. During the developmental 
processes of the 7-5 ELISA protocol, it was obvious that this analytical method required 




have conformational-dependent reactivities to PrP molecules, detected targets by the  
7-5 ELISA method must be renatured after denaturation to their structural 
conformations. In the conformational experiment for PrP detections in Section 2-11, 
βME was applied to the BH samples after denaturation (Figure 2-11). This βME 
treatment disabled renaturing abilities of denatured PrP molecules and eventually 
induced unfolded conditions. In neurodegenerative diseases including TSEs, unfolded 
protein responses are the central role of pathological mechanisms for disturbing the 
protein folding.24,25 In fact, a recent study identified that partially unfolded PrP forms 
were in the process of conformational conversions to misfolded PrP structures.26 
According to these recent findings, I propose that under-glycosylated forms of PrP 
molecules are immature or intermediate conformations in an alteration from PrPC to 
PrPSc isoforms and/or during newly PrPSc replications and generations. Furthermore,         
I suspect that under-glycosylated PrPSc isoforms or immature/intermediate conformers 
are fully or partially unfolding conditions. Since PRC7 mAb and the 7-5 ELISA method 
could not detect under-glycosylated PrP forms without denaturants, the sample dilution 
after denaturation would reduce its efficiency, leading to a renaturation process for 
these unfolding PrPSc forms to PrPC or its equivalent structure. As a future direction           
I hypothesize, the PrP glycosylation state changes during different disease stages of 
TSE pathogeneses, especially for under-glycosylated PrP forms. To investigate the 
kinetics of under-glycosylated PrP formations during the PrPSc replication and 
generation, the 7-5 ELISA method would be capable of determining the modulation of 
glycosylated PrP forms in TSE-mouse models, through different time points in the TSE 




analytical tool to measure PrP glycosidic alterations and expressional modulations. In 
further experiments, a longitudinal approach will identify the kinetic changes of PrP 
glycosylations and implications in the TSE disease course. 
 In general, GdnSCN is a stronger protein denaturant than GdnHCL. Thus, it has 
been widely used in various biological samples for denaturation. However, the 
comparison studies of GdnSCN and GdnHCL indicated that the 7-5 ELISA method 
exhibited a higher efficacy of GdnHCL for PrP detections in TSE-infected materials. In 
the literature, GdnHCL has a unique feature that inhibits propagation, replication, and 
aggregation of PrPSc isoforms in cellular models.27-29 These studies indicated the 
GdnHCL treatment cured PrP-generating phenotypes of cells from abnormal PrPSc to 
normal PrPC isoforms. Although mechanisms of GdnHCl-mediated PrP conformational 
modifications are not confirmed yet, the 7-5 ELISA results suggest that denatured PrPSc 
conformers with GdnHCL would renature to PrPC or PrPC-like structures (Figure 2-12). 
GdnHCL might not interrupt this reversible effect of the PrP conformation higher than 
GdnSCN. Thus, the 7-5 ELISA method requires GdnHCL denaturation for under-
glycosylated PrPSc isoforms in TSE-infected materials for detecting PrPC or PrPC-like 
conformations after spontaneous renaturation. Moreover, the 85°C incubation for 
GdnHCL denaturation reduced PrP detections in TSE-infected BH samples in Section 
2-4 (Figure 2-4). However, this experiment was performed without a TX100 addition 
prior to this denaturation. In contrast, when TX100 was pre-incubated before the 
denaturation step, temperatures between 37 and 87°C with certain ranges for the 
denaturation (GdnHCL) did not show clear influences for PrP detections in the infected 




have a potential to assist the renaturation of denatured PrPSc structures to normal PrPC 
or PrPC-like conformations. 
 Compared to no detergent (PBS only) and denaturant (50mM Tris buffer only) in 
Section 2-14, TX100 treatment enhanced O.D. values of RecPrP detections without 
GdnHCL (Figure 2-14). All tested samples were incubated for certain times so that 
thermal denaturations were possibly induced to the proteins. Thus, TX100 might 
mediate the protein renaturation to native conformational structures. In contrast, 
denatured RecPrP samples with 4M GdnHCL decreased O.D. values, while the TX100 
addition still enhanced detections of denatured PrP samples (Figure 2-14). Since 
RecPrP is a native PrPC structure without glycans, it should be less stable for 
maintaining its α-helix rich conformation after suffering denaturants and/or other 
experimental and environmental influences. Therefore, some denatured RecPrP 
samples might lose the ability for protein folding, which the 7-5 ELISA method detected 
lower O.D. values in GdnHCL-denatured samples than the non-denatured condition. On 
the other hand, under-glycosylated PrPSc conformers in TSE-infected mammal tissue 
samples might show more stability to detergents and denaturants because of β-sheet 
rich structures as misfolding PrP conformers.  
 For verifying the influential concern of denaturation, GdnHCL-dose dependent 
responses were evaluated with RecPrP samples by the 7-5 ELISA method (Figure 2-
15). In fact, GdnHCL decreased O.D. values of PrP detections in denatured RecElkPrP 
and RecMousePrP samples, compared to the 0M treatment (only PBS with 0.5% TX100 
during incubations). Interestingly, the 2M GdnHCL reduced the O.D. value of 




indicated that some denatured RecPrP molecules could not renature to native folding 
structures. Since PRC7 and PRC5 mAbs are conformation-dependent antibodies, the 7-
5 ELISA method cannot bind to unfolded conditions of RecPrP molecules if denatured 
samples do not renature.  
 Furthermore, the 7-5 ELISA experiment in Section 2-16 evaluated GdnHCL-dose 
dependent responses for the proper range of denaturant concentrations to enhance PrP 
detections in TSE-infected materials, using different TSE strains and host species 
(Figure 2-16). Notably, the highest GdnHCL concentration showed decreases of O.D. 
values in TSE-infected samples, compared to the lower dose treatments. This 
observation indicated that the denaturant-dose dependent applications also revealed an 
additional approach of the 7-5 ELISA method for a conformational stability assay. This 
new application would be utilized to determine TSE strain differences. As future 
directions for the 7-5 ELISA method, the use of other denaturants (i.e. GdnSCN, Urea) 
and PK reagents could be applied to the conformational stability assay that would 
provide more opportunity to evaluate various observations among TSE strains and 
species origins. 
 For an effective application of a TX100 detergent, 0.5-1% concentrations 
promoted PrP detections in CWD-infected samples from both Tg5037 (ElkPrP) and 
Tg1536 (DeerPrP) mice. In contrast, higher TX100 concentrations needed longer 
incubation times, but declined PrP detections in the infected materials, compared to the 
0.5-1% concentrations (Figure 2-17). In fact, the 1% TX100 showed the highest PrP 
detections under shorter incubations in these two transgenic mouse lines with CWD 




transgenic mice with cervid PrP expressions in the 7-5 ELISA protocol. It was obvious 
that the 1% TX100 application enhanced PrP detections in BH samples from RML-
infected FVB/n mice, compared to previous results which the same samples were 
treated with different TX100 concentrations at the 5M GdnHCL during denaturation 
(Figures 2-16 and 2-18).  Therefore, it is practical to select and maintain the 1% 
concentration for sample preparations in the 7-5 ELISA protocol as a current optimized 
TX100 application. 
 Furthermore, the optimized condition of the 7-5 ELISA protocol was examined 
with BH samples from Scrapie-infected transgenic mice with sheep PrP expressions. 
This analytical method detected higher PrP levels of all four different scrapie strains in 
the tested mice with sheep ARQ PrP expressions. However, this experiment also 
confirmed the limitation of the 7-5 ELISA method that could not detect PrP levels in a 
transgenic mouse BH sample with ovine VRQ PrP expressions, because PRC5 mAb 
does not react to PrP molecules with VRQ alleles.6 Therefore, it would be necessary to 
check the background information of the amino acid residue at 136 in testing sheep 
samples, when the 7-5 ELISA method would be applied in future diagnostic situations.  
  Overall, the experiments in this chapter determined the condition of Sandwich 
ELISA protocol using the in-house anti-PrP mAbs. In the 7-5 ELISA method, PRC7 and 
PRC5 mAbs can be utilized to detect PrP agents in TSE-infected materials specifically. 
In fact, this Sandwich ELISA method is capable of detecting RecPrP samples and PrP 
levels in BH samples from TSE-mouse models. This result indicated that the detected 
PrP molecule was unglycosyl and/or mono-1 glycosyl forms, because PRC7 mAb only 




the specificity of under-glycosylated PrP productions in the TSE disease development. 
As hypothesized, the detection of an under-glycosylated PrP form can be a valuable 
diagnostic biomarker for the TSE infection state and disease progression. In the 
Chapter 3, thereafter, the 7-5 ELISA method was examined by multiple approaches to 
optimize its protocol. Using BH samples from various transgenic mouse models of TSEs 
at terminal stages, the 7-5 ELISA method was capable of detecting under-glycosylated 
PrP forms in TSE-infected samples among various influential factors, such as different 
species, TSE strains, and infectious states. 
 In another aspect, the 7-5 ELISA method exhibited analytical limitations for PrP 
detections.6 PRC7 mAb does not recognize human, hamster and bovine PrP molecules 
due to amino acid differences at the antibody-binding site (Y154 and Q185 constitute a 
discontinuous epitope). In addition, PRC5 mAb is not capable of detecting sheep PrP 
molecules with Valine at the residue 136. To overcome these limitations and develop 
specific antibodies distinguishing each glycosylation state, the productions of new anti-
PrP mAbs for multiple species are future directions for TSE diagnostic innovations. 
Newly generated antibodies will be applicable to develop more advanced diagnostic 
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DETERMINATION OF THE 7-5 ELISA METHOD TO DETECT  






 This Chapter 3 expanded the 7-5 ELISA method to test more BH samples from 
various transgenic-mouse models of different TSE diseases, including CWD, TME, 
GSS, and scrapie. The 7-5 ELISA method was exceptionally capable of detecting PrPSc 
isoforms in these murine BH samples. These results indicated the abundant existences 
of under-glycosylated PrPSc forms at the terminal stage of the disease course in mice. 
Hence, TSE-infected brains were prone to generate under-glycosylated PrPSc forms 
throughout different species and with various PrPSc isolates. Intriguingly, different TSE 
isolates exhibited variances for PrPSc detections in quantities and stabilities among 
inoculated hosts. Thus, the 7-5 ELISA method might distinguish diversities of strain 
differences, based on the detections of under-glycosylated PrPSc specificities. In 
addition, this analytical assay validated another capability to estimate PrPSc infectivity 
and titration, in comparison to results from the cervid prion cell assay (CPCA) with 
PRC7. Therefore, the glycosidic deficit on the PrP conformation should implicate with 
the TSE pathogenesis. The unstable structures of under-glycosylated PrP forms might 
link to conformational alterations of the normal PrPC structure to the pathologic isoform. 
Furthermore, the D-5 ELISA method, which used a D18 anti-PrP antibody as a capture 
antibody, demonstrated an exceptional capability to determine levels of only PrPC 




denaturation, the D-5 ELISA method detects the decrease of PrPC levels in BH samples 
from TSE-infected materials at terminal stages. In contrast, these samples with 
denaturation exhibited increases of total PrP levels by the D-5 ELISA method. These 
results proved that the D-5 ELISA approach was capable of analyzing the modulations 
of normal PrPC and abnormal PrPSc levels in a same animal with TSE diseases. The 
PrPC-PrPSc modulations should be implicated with the pathological dysfunction, 






 The typical TSE bioassay involves the intracerebral inoculation of PrPSc-
contained materials into rodents, such as wild-type mice or genetically modified mice 
(transgenic mice) with PrP expressions of the pathogen-donor or recipient species.1-9 
Through slow and imprecise incubation periods, inoculated PrPSc agents replicate and 
propagate in infected animals, resulting in developments of TSE disease onsets and 
progressions. Brains in affected hosts exhibit accumulations of pathogenic PrPSc 
agents. Using brain samples derived from past mouse bioassays in the CSU Prion 
Research Center, the 7-5 ELISA and the D-5 ELISA methods determined disease-
associated PrP agents in various mouse models of TSEs at terminal stages. As 
hypothesized, the 7-5 ELISA method would detect under-glycosylated PrP forms in 
TSE-infected murine BH samples from different species backgrounds. These detections 
can indicate prominent generations of under-glycosylated PrP forms during the disease 




various PrPSc isolates and trains, TSE-infectious states, species differences, and 
generations of under-glycosylated PrP forms. Furthermore, the D-5 ELISA method has 
the property to measure only PrPC levels or total PrP levels in the testing samples. This 
analytical feature would be capable of evaluating PrPC-PrPSc modulations and variances 
through the disease courses. In fact, the loss of PrPC isoforms might be a causative 
factor of the functional abnormality in TSE-infected animals. Ultimately, the 7-5 ELISA 
and the D-5 ELISA methods would indicate aspects of the TSE pathogenesis. Possibly, 
glycosidic deficits implicate with pathological alterations of PrP conformations. Because 
of the important role of glycosylation, its modulation would affect the stability of protein 
structures. Subsequently, this unstable condition can alter the PrP structure abnormally. 
These aberrant formations would impair PrPC functions in physiology, and eventually 
cause pathogenic alterations. Therefore, the evaluation of PrPC and PrPSc modulations 
is a valuable analysis to monitor disease stages and prognoses. The generation of 
under-glycosylated PrP forms must be the characteristic feature of TSEs as a diagnostic 
biomarker for disease infection and progression. In this dissertation, the 7-5 ELISA and 
D-5 ELISA methods will demonstrate the exceptional capabilities of analyzing PrP 
detections and modulations in the TSE disease development. 
 
 
Materials and Methods 
 
Preparation of Brain Homogenates  
 The TSE mouse models with certain PrPSc inocula are listed (Table 2). These 
TSE-infected murine brains have been stocked at -80°C after tissue collections. The 




the server database of the CSU Prion Research Center. Note: RML = Rockies Mountain 
Laboratory; CWD = chronic wasting disease; TME = transmissible mink 
encephalopathy; Dr. RB = Dr. Richard Bessen (Colorado State University); Dr. MZ = Dr. 
Mark Zabel (Colorado State University); RA150 = a passage of CWD Bala05 (elk brain) 
into Tg5037 mice (inoculated BH from the mouse B581); RA-154 = a passage of CWD 
Bala05 (elk brain) into Tg1536 mice (inoculated BH from the mouse B691); RA-86 = a 
passage of CWD 99W12389 (elk brain) into Tg5037 mice (inoculated BH from the 
mouse #7581); RA-78 = a passage of CWD 04-0306 (elk brain) into Tg5037 mice 
(inoculated BH rom the mouse #7455). 
 The testing mouse brains were homogenated by repeated extrusions using 
different sizes of syringe needles to 20% concentrations with cold 1X phosphate-
buffered saline (PBS: no calcium and magnesium, HyClone Laboratories, Inc. GE 
Healthcare Life Sciences, Logan, Utah, USA). Aliquots of these BH samples in 
eppendorf tubes were stored at -80°C after the preparation. In addition, BH samples 
from PrP-KO mice and uninfected wild-type or transgenic mice were used as controls to 
TSE-infected mice in each study: PrP-KO (no PrP), FVB/n (wild-type MousePrP), 
C57BL6 (wild-type MousePrP), Tg5037 (ElkPrP E226), Tg1536 (DeerPrP), Tg3533 















Table 2. List of tested murine brain samples and inocula 
 
Study/Provider Mice BH inocula of TSE 
SK-01 FVB/n (MousePrP) RML mouse-adapted scrapie 
CLC-04 Tg5037 (ElkPrP) RA-150/ CWD Bala05 (elk) 
CLC-05 Tg1536 (DeerPrP) RA-154/ CWD Bala05 (elk) 
JB-66 Tg3533 (OvineARQ PrP) Colorado Scrapie (sheep) 
VK-11 TgF431 (MinkPrP) TME #58 NBP 950825 (mink) 
VK-18 TgF431 (MinkPrP) TME 941031 (mink) 
VK-20 TgF431 (MinkPrP) TME 941201 (mink) 
Dr. RB C57BL6 (MousePrP) 22L mouse-adapted scrapie 
Dr. RB VM/Dk (MousPrP allotype B) 87V mouse-adapted scrapie 
Dr. MZ C57BL6 (MousePrP) D10 mouse-adapted CWD 
ES-02 Tg1536 (DeerPrP) CWD 08W-11,741 (moose) 
ES-03 Tg5037 (ElkPrP) CWD 08W-11,741 (moose) 
KG-18 Tg1536 (DeerPrP) CWD strain 99W12389 (elk) 
RA-26 Tg1536 (DeerPrP) CWD Bala04-0306 (elk) 
GT-142 Tg5037 (ElkPrP) RA-86/ CWD 99W12389 (elk) 









Applied 7-5 ELISA protocol to murine BH samples  
 Initially, PRC7 mAb was diluted to 20µg/ml concentration in a coating buffer 
(0.05M Carbonate-Bicarbonate in distilled water). 100µl of the prepared PRC7 solution 
was coated into each well on ELISA plates (Nunc MaxiSorp® flat-bottom 96-well plate, 
Thermo Fisher Scientific, Rochester, New York, USA), and subsequently incubated at 
4°C overnight. After emptying the plates gently, 200µl PBS with 3% bovine serum 
albumin (BSA: Sigma-Aldrich Co. LLC, St. Louis, Missouri, USA) was added into each 
well for blocking non-specific binding sites on well surfaces. Following an incubation at 
37°C for one hour and a removal of all solutions, the plate was washed three times with 
1X TBS-Tween (TBST) buffer (50mM Tris, 150mM NaCl, 0.05% Tween-20 in distilled 
water, pH 7.6) by a plate washer (the FinstrumentsTM Microplate Washer, MTX Lab 
Systems, Inc. Vienna, Virginia, USA). 100µl of each prepared BH sample was coated 
into designated wells on the plate. After incubating overnight at 4°C, the plate was 
evacuated and washed three times with 1X TBST by the washer. 1:5,000 dilution of 
PRC5 mAb was prepared using a dilution buffer (1% BSA-containing PBS without 
calcium and magnesium). 100µl of the prepared PRC5 solution was added into each 
emptied well on the ELISA plate as a detecting antibody. Following an incubation of one 
hour at 37°C, the plate was cleared, washed three times with 1X TBST by the plate 
washer, and gently emptied. Thereafter, a horseradish peroxidase (HRP)-conjugated 
secondary antibody (Goat Anti-Mouse IgG2a HRP conjugate, 1 mg/ml, Alpha Diagnostic 
Intl. Inc. Texas, USA) was diluted in a dilution buffer (1:5,000 ratio), and 100µl of the 
diluted secondary antibody was added into all testing wells. Following an incubation of 




1X TBST by the washer. To evaluate an enzymatic reaction and color development, 
ABTS® Peroxidase Substrate (KPL, Inc. Maryland, USA) was applied under the 
manufacturer’s protocol. Using an ultramicroplate reader (ELx808 Absorbance Reader, 
BioTek Instruments, Inc, Winooski, Vermont, USA), the absorbency of each well on the 
plate was analyzed at a wavelength of 405nm. 
                               
Sample preparations for the 7-5 ELISA method 
 In this Chapter 3, most materials of Sandwich ELISA experiments were analyzed 
with the final protein concentration of 200µg/ml mouse BH samples, proceeded by the 
following steps: 1) dilution of BH sample with 1X PBS to be 5.87mg/ml, 2) addition of 
10% volume of 10% Triton X-100 (TX100) solution to be 1% concentration, 3) 
denaturation using 5M GdnHCL, 4) 10-time dilution with 1% BSA-containing PBS, and 
5) sample coating on an ELISA plate. For planning to coat 100µl of the prepared BH 
sample (200µg/ml) per well (total protein 20µg each well) for triplicate, the final volume 
of each analyte was prepared to be 400µl. At the first step, 13.5µl of BH sample 
(5.87mg/ml) diluted by PBS (no calcium and magnesium) was mixed with 1.5µl of 10% 
TX100 in PBS (= total 15µl volume of 5.33mg/ml protein concentration with 1% TX100). 
This mixture was incubated for 1 hour at 37°C with 1,000 rpm agitation. Subsequently, 
25µl of 8M GdnHCL (G3272, Sigma-Aldrich Co. LLC, St. Louis, Missouri, USA) in 1X 
TBST buffer (50mM Tris, 150mM NaCl, 0.05% Tween-20 in distilled water, pH 7.6) was 
added into the incubated 15µl BH sample. The total sample volume was 40µl of BH 
sample (2mg/ml) with 5M GdnHCL, which were then incubated for 15 minutes at 37°C 




dilution buffer (1% BSA-containing PBS: no calcium and magnesium). The total sample 
volume was 400µl of the BH sample (200µg/ml) with 0.5M GdnHCL. Then, 100µl of 
each prepared BH sample (200µg/ml) was coated per well (total protein 20µg each well) 
on the ELISA plate with pre-coatings of a capture antibody. The sample-coated plate 
was incubated overnight at 4°C. From the next blocking step, all other procedures were 
performed under the Sandwich ELISA method described above.                                                   
                                                                              
Cervid prion-cell assay 
 In 2014, Bian et al. reported the methodology of cervid prion-cell assay 
(CPCA).10,11 This method can be performed conveniently for titration of TSE infections 
in various species backgrounds. CPCA has an equivalent sensitivity to mouse bioassay 
and scrapie cell assay (SCA or standard scrapie cell assay) for evaluating infectivity and 
its titration of TSE strains.10-12 In addition, CPCA is capable of overcoming limitations of 
bioassay, such as processing times. CPCA utilizes a multiscreen 96-well filtration plate 
with filter membranes (0.45µm) on the bottoms of wells (an enzyme-linked immunospot 
(ELISpot) assay plate, Millipore, Billerica, Massachusetts 01821). In the CPCA 
experiment, it is essential to prepare fresh solutions daily, prior to starting any 
procedures with an ELISpot plate. Also, these solutions must be ultracleaned and 
filtered with 0.22µm pore membrane of a vacuum filtration system (Corning 
Incorporated-Life Sciences, Tewksbury, Massachusetts).   
 1) Activation of an ELISpot plate: Filter membranes on an ELISpot plate need 
to be activated before use. 100µl of 70% ethanol in ultrapure water was added into each 




Immediately, ethanol was vacuumed from all filter membranes on the plate, washed 
twice with 150µl of 1X PBS and vacuumed each time. After adding 50µl of 1X PBS per 
well, the plate was gently tapped to cover the entire surface of each filter membrane for 
all wells. This is a critical point to maintain moisture on the membranes. Followed by 
vacuuming for one minute, the ELISpot plate was washed twice with 50µl of 1X PBS per 
well and vacuumed. After the second wash, it is important to vacuum the plate for one 
minute and re-vacuum to remove moisture from all wells. Subsequently, the well-
vacuumed plate was dried at 50°C for one hour or until all membranes completely dried 
(membranes would be white when dried completely). After placing a lid on the dried 
ELISpot plate, it was wrapped with Saran Wrap to store in a -20°C freezer. 
 2) Preparation of Analyte: Based on a sample type and experimental aim, 
CPCA has two applications for testing analyte using an ELISpot plate. This study 
analyzed the infection of TSE-inoculated mouse BH samples into cultured cells, and the 
chronically TSE-infected cell lines and control cell lines. These two sample preparations 
were performed prior to transferring cells onto activated ELISpot plates. 
 Infection to RK13 cells 
 Preparation of brain homogenates and testing plate: According to the CPCA 
protocol (modified CPCA Protocol June 2013 in the lab database), The BH sample of a 
TSE-infected animal was prepared to be 10% (w/v) in PBS, and subsequently, its serial 
dilutions were made. For CWD or mouse-adapted prion analyte, the starting 
concentration of the serial dilutions was 0.1%: for reference, the 1% concentration can 
be applied to other TSE-infected materials for improving and enhancing PrPSc 




(ElkPrP) mice were utilized as TSE-positive controls on CPCA. Both bioassay studies 
were applied with the same CWD prion inoculum (012-09442). 100µl of each diluted BH 
solution was coated per well of certain testing spots on a 96-well tissue culture (TC) 
plate (triplicate for each dilution). In a cell/tissue culture hood without ultraviolet light, 
this BH-coated TC plate with a lid cover was incubated for one hour at RT. Followed by 
aspirations of the coated BH solutions from all wells, the TC plate was washed twice 
with 1X PBS (no calcium and magnesium) and then emptied. Subsequently, the TC 
plate was placed in the hood for desiccating the membranes of all wells for two hours at 
RT or until completely dried.  After that, the BH-coated TC plate was completely 
wrapped with Saran Wrap and stored at 4°C.  
 Plate cells onto the BH-coated TC plate: In the CPCA protocol, RK13 cells 
with PrP expressions of mouse, deer, or elk were utilized for TSE infections. RK13 cell 
line is a rabbit kidney epithelial cell line (ATCC, Manassas, Virginia, USA), in which its 
PrP expression is primarily undetectable. For the TSE research, this original cell line 
was stably transfected with vectors for developing a new cell line with PrP 
expressions.10 In this CPCA study, RKM7 (mouse PrP), Deer5E9-S1 (deer PrP) and 
RKE (Elk21-#3: elk PrP) were applied. For a PrP-negative control, RKV (RK13 cells 
only transfected with a empty vector: no PrP expression) was included. These cell lines 
were grown with DMEM (10% fetal bovine serum: FBS, 1µg/ml penicillin, 100U/ml 
streptomycin, and 1µg/ml puromycin) in TC dishes or T75 flasks. Before transferring 
cells, the cold-storage plate should be placed at RT for 20-30 minutes. To test these cell 
lines by CPCA, 100µl of 20,000 cells was placed per well on the BH-coated TC plate. 




carbon dioxide (CO2) incubator (5%) at 37°C for four weeks. The cell culture medium 
was changed weekly. In order to include positive controls for CPCA in the TC plate, 
Deer 5E9-S1 cells were added into the BH-coated wells of the SB-63 Tg1536 (DeerPrP) 
sample; RKE (Elk21-#3) cells were placed into the prepared wells of the RA116 Tg5037 
(ElkPrP) sample. For the negative-control wells that were coated with these TSE-
positive BH materials, RKV cells were added because the wells would not develop PrP 
replication and generation.  
 Transfer cells onto an ELISpot plate: At the end of the four-week TSE 
infections, the TC plate with coated cells was washed with 100µl of trypsin per well, and 
then aspirated gently in a cell culture hood. After adding another 100µl trypsin per well, 
the TC plate was incubated for five minutes in the CO2 incubator, prior to collecting 
adhesion cells from wells. Six wells were randomly selected, and then cell numbers 
were counted twice for each well (total 12-time measurements). Based on the average 
cell numbers from the 12-time counts, 20,000 cells were transferred from each well on 
the TC plate to its matching site on an activated ELISpot plate (i.e. cells from the well 
“A1” on TC plate were transferred to the well “A1” on an ELISpot plate).  
 Chronically TSE-infected cells and control cells 
 
 SMB cells: After the inoculation of the mouse-adapted scrapie strain Chandler, 
the SMB cell line was originally isolated from the brain of the mouse when it showed 
clinical signs.13 PrPSc expressions were detected in SMB cells even after continuous 
passages. Thus, the SMB cell line has been used as chronically TSE-infected cells. The 
SMB-PS cell line was established as a control that SMB cells were treated with 




after 50 passages, it was considered as a cured cell line.14 These cell lines were 
maintained in culture with medium (10% FBS, and 1µg/ml penicillin, 100 U/ml 
streptomycin) in a 5% CO2 incubator at 37°C. 
 TSE-infected RK13 cells: Using the transfected RK13 cell lines with stable PrP 
expressions described above, chronically TSE-infected cell models were established.10 
These TSE-infected cells chronically generate detectable amounts of PrPSc isoforms. 
The RKM7 cell line with mouse PrP expressions is highly susceptible to TSE infection. 
RML-RKM7 cells were isolated from RKM cells infected with a mouse-adapted scrapie 
strain RML.11 Elk+ cells were isolated from infected RKE cells with CWD positive elk 
brain (012-09442) and this cell line expresses PrPSc isoforms chronically.10 The RKV 
cell line is RK13 cells stably transfected only with empty vectors. In addition to these 
uninfected/cured and infected cells, this non-PrP expressing cell line was included as a 
control of non-TSE infection and non-PrPSc generation. These cells were maintained 
with DMEM (10% FBS, 1µg/ml penicillin, 100U/ml streptomycin, and 1µg/ml puromycin) 
in TC dishes or T75 flasks in a CO2 incubator (5%) at 37°C.  
 Transfer cells onto an ELISpot plate: Confluent cell monolayer of a dish/flask 
was washed twice with cold 1X PBS and then trypsinized. After counting numbers of 
collected cells, 20,000 cells of each cell line were placed per well (wells = triplicate) into 
assigned sites on an activated ELISpot plate.  
 3) Enzymatic cell digestion: Proteinase K (PK) was utilized to detect PrPSc 
molecules in TSE-infected cells on the ELISpot plate. Cells in PK-positive wells were 
enzymatically digested with 5µg/ml of the PK reagent (Roche Diagnosis, Indianapolis, 




deoxycholate, 0.5% Igepal CA-630). 60µl of the PK reagent in CLB was added into each 
PK-positive well on the ELISpot plate. Subsequently, the plate was covered with a lid 
cover. A humidified chamber was prepared and filled with 1X PBS (no calcium and 
magnesium) up to its quarter-inch level. Two empty pipet tip racks was placed into the 
humidified chamber. After the ELISpot plate was put on the racks, the chamber was 
closed with a lid, and then placed on a shaker in an oven to incubate for 90 minutes at 
37°C. Next, the ELISpot plate was vacuumed to empty all wells. To terminate this 
enzymatic digestion, 150µl of 2mM phenylmethylsulfonyl fluoride (PMSF: AMRESCO 
LLC, Solon, Ohio, USA) was added into all PK-positive wells. The ELISpot plate was 
placed into the humidified chamber, incubated on an orbital shaker at RT for twenty 
minutes, and finally vacuumed.  For the protein denaturation, 120µl of 3M GdnSCN 
(Fisher Scientific, Fair Lawn, New Jersey, USA) in 10mM Tris-HCl (pH 8.0) was added 
into each well. The ELISPot plate was incubated on the shaker at RT for 10 minutes 
(note: this incubation time should not be exceeded). Immediately after the incubation, 
the plate was vacuumed. 160µl of 1X PBS was added into all wells to wash filter 
membranes. Additionally, this washing and vacuuming procedure was repeated four 
times.  
 4) Immunodetection: In a blocking procedure, 160µl of 5% SuperBlock (Pierce, 
Rockford, Illinois) in ultrapure water was added into each well on the ELISpot plate. 
After covering with a lid, the plate was placed in the humidified chamber and incubated 
for one hour at RT on an orbital shaker. After vacuuming the plate, 60µl of a diluted anti-
prion antibody (i.e. 6H4 = 1:20,000, PRC5 = 1:3,000, PRC7 = 1:2,000-3,000) in fresh 1X 




mAb was used for the CPCA experiments. The ELISpot plate was covered with a lid 
and placed into the humidified chamber. This incubation was performed overnight at 
4°C on a rotating shaker in a refrigerator as recommended, or for one hour at RT on a 
rotating shaker as an alternative way. By flicking the plate, coated antibody solutions 
were removed from wells. For washing all wells, 160µl of fresh 1X TBST was added and 
then removed by flicking the plate. This procedure was repeated three times. At the 
same time, a secondary antibody, alkaline phosphatase (AP)-conjugated Goat anti-
Mouse IgG antibody (Southern Biotechnology Associates, Birmingham, AL), was 
prepared as 1:5,000 dilution in fresh 1X TBST.  After the fourth wash with 1X TBST, the 
plate was completely vacuumed, and immediately, 60µl of the prepared secondary 
antibody solution was added into each well on the ELISpot plate. The plate was covered 
with a lid and placed on empty pipet racks in a chamber without liquids for maintaining 
moisture. After incubating the plate for one hour at RT on a shaker gently, the 
secondary antibody solutions were flicked out from the plate. 160µl of fresh 1X TBST 
was added into each well to wash the plate. For each wash, the plate was flicked to 
remove 1X TBST. After repeating this washing procedure four times, fresh 1X PBS (no 
calcium and magnesium) was added into all wells as a final wash (the fifth time). After 
vacuuming the plate completely, a plastic drain was removed from the bottom of the 
ELISpot plate, and then the bottom area was gently rinsed with 1X PBS one time for 
eliminating residual agents. To dry the plate completely, it was placed on a bench 
overnight, and covered loosely with a large kimwipe paper (Kimberly-Clark Professional, 
Roswell, GA). For color developments, a tablet of an AP-conjugate substrate kit 




ultrapure water. 60µl of the prepared AP-conjugate substrate solution was added into 
each well at RT. Subsequently, the ELISpot plate was hidden in the dark for color 
development. When color change was detected, the plate was flipped to stop the 
reaction, and then washed with 160µl of water twice. The plate was flipped to remove all 
solutions. To dry the plate completely, it was placed in a 4°C refrigerator overnight, 
without stacking plates when multiple plates were used. Imaging scans were performed 
using ImmunoSpot S6-V analyzer (Cellular Technology Ltd, Shaker Heights, Ohio).  
Spot numbers of color-developed cells were measured by ImmunoSpot5 software 
(Cellular Technology Ltd, Shaker Heights, Ohio). The titer of the PrPSc detection was 
based on calculated numbers of color spot-forming TSE-infected cells (or cervid prion 
cells: CPC) per gram of an applied BH sample. 
 5) Tested reagents for modifying the CPCA protocol to utilize PRC7 mAb: 
To improve the utility of PRC7 mAb in the CPCA protocol described above, the following 
reagents were applied for permeabilization, enzymatic digestion, or denaturation. 
Tested conditions of each reagent in the CPCA experiments are described in the Result 
section. 
 Permeabilization = Triton® X-100 (TX100, Fisher Scientific, Fair Lawn, New 
Jersey, USA), Tween® 20 (Fisher Scientific, Fair Lawn, New Jersey, USA), and 
Saponin (Sigma-Aldrich, Inc. St. Luis, MO, USA).  
 Enzymatic digestion = proteinase K (PK, Roche Diagnosis, Indianapolis, USA), 
PMSF (AMRESCO LLC, Solon, Ohio, USA), and cell lysis buffer (CLB, pH 8.0) that 
contains 50mM Tris (Tris Base, Fisher Scientific, Fair Lawn, New Jersey, USA), 150mM 




Jersey, USA), 0.5% IGEPAL® CA-630 (Sigma-Aldrich, Inc. St. Luis, MO, USA), and 
0.5% Sodium Deoxycholate (Sigma-Aldrich, Inc. St. Luis, MO, USA) in filtered distilled 
water.  
 Denaturation = guanidine thiocyanate (GdnSCN, Fisher Scientific, Fair Lawn, 
New Jersey, USA), and guanidine hydrochloride (GdnHCL, Sigma-Aldrich, Inc. St. Luis, 
MO, USA).  
  
New Sandwich ELISA protocol for detecting PrPC molecules 
 Based on the 7-5 ELISA protocol described above, other capture antibodies were 
evaluated to establish a new Sandwich ELISA method without the detergent and 
denaturant (TX100 and GdnHCL respectively), which can detect normal PrPC 
molecules, predominantly with a diglycosyl form. Tested anti-PrP antibodies were the 
following: 6H4 (Prionics, Schlieren, Switzerland), PRC5 mAb, and D18 Fab Ab (both in-
house productions). To prevent protein degradation during experiments, a protease 
inhibitor product (cOmplete, Roche Diagnostics, Indianapolis, IN, USA) was added into 
buffers under the manufacture’s direction: sample dilution buffer, blocking buffer, and 
dilutions of detecting and secondary antibodies. 10% BH samples from uninfected 
homozygous Tg4112 (MousePrP overexpression) and PrP-KO mice were applied for 
these Sandwich ELISA experiments. Technical applications in this study will be 






The D-5 ELISA method and its comparative evaluations with other capture 
antibodies 
 A pair of D18-PRC5 antibodies was capable of detecting PrPC agents sensitively 
by this Sandwich ELISA approach, now called the D-5 ELISA method. D18 Fab Ab 
requires denaturation to detect PrP27-30 rods by ELISA and IP experiments.15 This new 
D-5 ELISA method examined the following BH samples with denaturation (n=1 each 
mouse category): RML-inoculated FVB/n, RML-inoculated C57BL6, and 22L-inoculated 
C57BL6 mice, and their controls (PrP-KO, uninfected FVB/n, uninfected C57BL6). All 
processes were performed by the 7-5 ELISA protocol, except the capture antibody D18 
Fab Ab. The D-5 ELISA method was optimized by the same approaches for the 7-5 
ELISA development, described in Chapter 2 and 3 above.  
 In comparison with the D18 Fab Ab, the following anti-PrP antibodies were 
determined as capture antibodies under the D-5 ELISA protocol: PRC7 (in house), 6H4 
(Prionics, Schlieren, Switzerland), POM2 (Prionatis AG, Alpnach Dorf, Switzerland), 
SAF-32 (Cayman Chemical, Michigan, USA16), and mAb132 (kindly provided by Dr. 
Motohiro Horiuchi, Hokkaido University, Japan17,18). Tested applications of these 
antibodies will be described in the Results section. BH samples of RML-inoculated 
FVB/n, uninfected FVB/n, and PrP-KO mice (n=1) were applied to this experiment with 
and without detergent and denaturant for measuring PrPSc or only PrPC levels 
respectively. Furthermore, the D-5 ELISA approach with or without detergent and 
denaturant was examined with TSE-inoculated mouse models expressing different PrP 
species: RML-inoculated FVB/n, CWD-inoculated Tg1563 (ElkPrP), CWD-inoculated 




inoculated Tg3533 (SheepPrP), TME-inoculated TgF431 (MinkPrP) mice, and these 
control mice.  
 
Enhancement of PrP detections in TSE-infected materials by the novel Sandwich 
ELISA methods 
 To improve sensitivity and selectivity of PrP measurements by the new Sandwich 
ELISA applications, the 7-5 ELISA and D-5 ELISA methods, the following reagents were 
utilized: Proteinase K (PK: Roche Diagnosis, Indianapolis, USA), cell lysis buffer (CLB: 
50 mM Tris (pH 8.0), 150mM NaCl, 0.5% sodium deoxycholate, 0.5% Igepal CA-630), 
phenylmethylsulfonyl fluoride (PMSF: AMRESCO LLC, Solon, Ohio, USA), Triton® X-
100 (TX100: Fisher Scientific, Fair Lawn, New Jersey, USA), Sarkosyl (Fisher Scientific, 
Fair Lawn, New Jersey, USA), sodium hydroxide (NaOH: Fisher Scientific, Fair Lawn, 
New Jersey, USA), sodium chloride (NaCl: Acros Organics, Thermo Fisher Scientific, 
Fair Lawn, New Jersey, USA), monosodium phosphate (also named as monobasic 
sodium phosphate and sodium dihydrogen phosphate, NaH2PO4: Sigma-Aldrich, Inc. St. 
Luis, MO, USA), sodium bicarbonate (NaHCO3: Sigma-Aldrich, Inc. St. Luis, MO, USA), 
sodium carbonate (Na2CO3: Sigma-Aldrich, Inc. St. Luis, MO, USA), carbonate-
bicarbonate buffer-capsule (contains both Na2CO3 and NaHCO3 in equilibrium: Sigma-
Aldrich, Inc. St. Luis, MO, USA), sodium deoxycholate (deoxycholic acid sodium salt, 
DOC: Sigma-Aldrich, Inc. St. Luis, MO, USA), and sodium dodecyl sulfate (SDS: Fisher 
Scientific, Fair Lawn, New Jersey, USA). Applications of each reagent and tested 





Applications of the new Sandwich ELISA methods to detect PK-sensitive PrPSc 
agents 
 The Tg464 mouse breed line is a transgenic animal model of Gerstmann-
Sträussler-Scheinker (GSS) syndrome, an autosomal-dominant inherited prion disease 
in humans. Although this GSS mouse model spontaneously develops clinical and 
pathological features of GSS, these mice generate PK-sensitive PrP molecules.19 
Therefore, standard PrPSc analyses using PK reagents are not applicable to Tg464 
mice. Since the 7-5 ELISA and D-5 ELISA protocols do not use PK reagents, these 
approaches should be capable of detecting the enzyme-sensitive PrP molecule. Under 
the current optimized protocols of these Sandwich ELISA methods with or without 
detergent and denaturant, BH samples from Tg464 mice at different ages (pre-clinical 
sign: 61, 81, 142 days) and with clinical signs (KN-35 study: 1% BH sample from a 
spontaneously GSS-developed Tg464 mouse was inoculated into 40-day ages of young 
Tg464 mice that were at non-clinical condition) were examined to measure detectable 
levels of PrPSc and PrPC isoforms, as well as PrP modulations at each time-point base. 
WB also analyzed the BH samples using the protocol, previously reported.11,20,21 
According to the protocol and these references, 100µg/ml of the PK reagent in cold lysis 
buffer was applied to each BH sample for 1 hour at 37°C, and subsequently terminated 
with PMSF (2 µM at a final concentration in each digested sample) for PK digestions. 
After the 10-minute boiling of prepared samples, proteins were resolved by SDS-PAGE 
and then transferred to Immobilon-FL PVDF (Polyvinylidene Difluoride) membranes 
(Millipore, Billerica, USA). Primary mAbs were applied to probe these membranes, 




Chalfont, UK). Proteins were visualized by chemiluminescence using ECL Plus (GE 






Sensitivity of the 7-5 ELISA method for PrP detections in TSE-infected mouse 
models  
 Using the optimized 7-5 ELISA conditions that I described in the previous 
chapter, the sensitivity of this method was determined for PrP detections in brain 
samples from RML-infected FVB/n mice, uninfected FVB/n mice, and PrP-KO mice in 
which the PrP gene was disrupted by homologous recombination, also referred to as 
Prnp0/0 mice. Using the 7-5 ELISA method, total protein levels in each sample were 
determined, and these reactivities were compared over an equivalent range of 
concentrations ranging from 0.06µg to 20µg. Triplicate replicates of each sample were 
analyzed to assess technical reproducibility. The lowest amount still showed subtle 
differences between the infected and control samples (P<0.0001) (Figure 3-1.A). For 
the further analysis of the assay sensitivity, the 7-5 ELISA method was tested with the 
range from 0.01ng to 20ng total proteins (wells = triplicate as technical replicates for 
each sample) for PrP detections in the same sample group above. Even in picogram 
amounts, the 7-5 ELISA method detected subtle levels of PrP molecules in the infected 
sample (Figure 3-1.B). To confirm the specificity of the 7-5 ELISA method, PRC7 was 
replaced with a non-specific murine IgG1 antibody as a capture antibody. These 




per well. The Sandwich ELISA approach with the IgG1 Ab and PRC5 mAb did not show 
differences among these samples. (Figure 3-1.C). These results suggest that the 7-5 
ELISA method has the sensitivity for detecting subtle PrP amounts in TSE-infected BH 






























































Figure 3-1. Sensitivity of the 7-5 ELISA method for PrP detections.  
(A) Half-log dilutions of proteins from murine BH samples of PrP-KO, uninfected 
FVB/n, and RML-infected FVB/n (n=3, each total protein amount from 0.06µg to 
20µg), (B) Protein-dose dependent responses of lower half-log dilutions in range 
from 0.01ng to 20ng total proteins  (n=3, each total protein amount), and (C) 
Comparisons of PRC7 mAb (left) and IgG1 antibody (right) as capture antibodies in 
Sandwich ELISA approaches (n=3, each sample with 20µg total protein amount).  
Sandwich ELISA PRC7-PRC5 
Lower Half log Protein-Dose Dependent Responses
RML-inoculated FVB Group 
10-31-2013











































Biological replicates of TSE-mouse models for PrP detections by the 7-5 ELISA 
method 
 To evaluate PrP variances among mice, the 7-5 ELISA method was tested with 
three different groups of the following TSE-mouse models: 1) RML-inoculation in FVB/n 
mice, 2) CWD-inoculation in Tg5037 (ElkPrP) mice, and 3) CWD-inoculation in Tg1536 
(DeerPrP) mice. The mean ± SEM of sick dates for these three mice in each inoculated 
experiment was 1) 129.33 ±2.33 for RML-FVB/n, 2) 263.33±45.88 for CWD-Tg5037, 
and 3) 401.33±1.76 for CWD-Tg1536. Each testing group contained nine total animals 
from TSE-infected mice, uninfected mice, and PrP-KO mice: three mice were from each 
mouse category. Using these BH samples, the 7-5 ELISA method exhibited significantly 
higher O.D. values of PrP detections in all TSE-infected mice (Figures 3-2.A to C). 
Statistically, p values of Infected vs. KO or uninfected mice were following: RML-FVB/n 
vs. KO or Uninfected as p < 0.0001 for both; CWD-Tg5037 vs. KO or Uninfected as p = 
0.00024, and 0.0027 respectively; CWD-Tg1536 vs. KO or Uninfected as p = 0.0056, 
and 0.0059 respectively. These results indicated the specificity of the 7-5 ELISA method 
for PrP detections in TSE-infected brain materials. In addition, the 7-5 ELISA method 
measured high quantities of under-glycosylated PrP forms in these analyte. As 
hypothesized, hence, the loss or deficit of the PrP glycosylation occurred during the 


















































































Figure 3-2. PrP detections in TSE-inoculated murine brain analyte by  
the 7-5 ELISA method. Biological replicates (n= three mice, each category).  
(A) RML-inoculated FVB/n mouse, (B) CWD(Bala05)-inoculated Tg5037 mouse, 







Capability of the 7-5 ELISA method for PrP detections from multiple species in 
TSE-mouse models 
 PRC7 mAb is only capable of reacting to an unglycosyl form and one mono 
glycosyl form (mono-1: one glycan at 180 amino acid residue) of PrP molecules.20 
Because of this characteristic feature, the 7-5 ELISA method specifically recognizes 
these two under-glycosylated PrP forms that are significantly detected in TSE-infected 
materials (Figures 3-2.A to C). For further analyses, the 7-5 ELISA method was applied 
for testing BH samples from five different TSE mouse models: 1) RML-inoculation in 
FVB/n mice, 2) CWD-inoculation in Tg5037 (ElkPrP) mice, 3) CWD-inoculation in 
Tg1536 (DeerPrP) mice, 4) Sheep scrapie-inoculation in Tg3533 mice (OvineARQ PrP: 
alanine (Ala: A) at the residue 136), and 5) Transmissible mink encephalopathy (TME)-
inoculation in TgF431 (MinkPrP) mice. Each TSE model included BH samples from its 
uninfected wild-type or transgenic mice. The 5th Group of TME contained BH samples 
from uninfected mink. These 7-5 ELISA analyses evaluated higher quantities of under-
glycosylated PrP forms as a hallmark of TSEs and a diagnostic biomarker of the 
disease progression. This approach also determined the capability of this method for 
detecting PrP molecules in different species. Initially, testing BH samples were treated 
with 1% TX100 for one hour, and then denatured with 5M GdnHCL for 15 minutes at 
37°C, with 1,000 rpm agitation for both incubation times. After 10-time dilutions, the 
prepared samples contained 60µg total proteins. To determine protein-dose dependent 
responses of PrP detections, these final samples were additionally diluted to the range 
from 2.5 µg to 50µg total proteins. Thereafter, all prepared samples were coated on 




incubation on the ELISA plates at 4°C overnight, the wells with samples on ELISA 
plates were blocked with 3% BSA-containing PBS for one hour at 37°C. Then, the 
detecting antibody PRC5 and secondary antibody were applied to the wells, and 
incubated 1 hour at 37°C for each antibody. After color development with ABTS® 
Peroxidase Substrate (under the manufacture’s protocol), the ELISA plates were read 
by the plate reader for measuring O.D. values of PrP detections in each sample. Based 
on the results from the protein-dose dependent responses (total proteins from 2.5µg to 
60µg per well with triplicate), higher detections of the under-glycosylated PrP forms 
were significant in all tested TSE-infected materials by the 7-5 ELISA method (Figures         
3-3.A to E). These results indicated that these certain forms of PrP molecules were 
generated in animals with TSE infections. Thus, the 7-5 ELISA method should be a 
powerful application to detect PrP molecules in multiple species. Also, this method was 
applicable to the PrP detection in various TSEs. However, a TME-infected mouse 
exhibited lower O.D. values than other TSE-infected samples. This finding suggested 
that the mouse with TME inoculation might not generate much under-glycosylated PrP 
forms. In another prospect, the sick date of this TME-infected mouse was 93 days 
(mean sick date = 108.5 days in its study group), which were shorter than those of other 
tested samples with TSE inoculations. Therefore, this short incubation period for the 
disease development may have not generated or accumulated under-glycosylated PrP 
forms in mice with the TME inoculation. Moreover, the 7-5 ELISA method measured 
some PrP detections in uninfected TgF431 with mink PrP expressions, compared to a 
PrP-KO mouse. Because of PrP overexpressions, this transgenic mouse breed line may 




mice. Thus, transgenic mice with PrP overexpressions should normally express some 
























































































CWDdeer  7-5 ELISA Protein-Dose Depedence















ScrapieOvine 7-5 ELISA Protein-Dose Depedence


























































Figure 3-3. Protein-dose responses of PrP detections in BH samples from  
mouse models with five different TSE strains by the 7-5 ELISA method.  
(A) RML-inoculation in FVB/n, (B) CWD-inoculation in Tg5037 (ElkPrP),  
(C) CWD-inoculation in Tg1536 (DeerPrP), (D) Sheep scrapie-inoculation in 
Tg3533 (OvineARQ), and (E) TME-inoculation in TgF431 (MinkPrP) mice. 




PrP detections in various mouse-adapted TSE strains by the 7-5 ELISA method 
 The RML strain of mouse-adapted scrapie was used in processes of the 7-5 
ELISA development and optimization. For further analyses, the 7-5 ELISA method 
measured PrP detections in BH samples from other mouse-adapted TSE strains: 22L 
(mouse-adapted scrapie in C57BL6 mouse), 87V (mouse-adapted scrapie in VM/Dk 
expressing PrP allotype B) and D10 (mouse-adapted CWD in FVB/n mice primary and 
passaged into C57BL6 mice secondary). Firstly, these BH samples were treated with 
1% TX100, then denatured with 5M GdnHCL, and incubated for 1 hour and 15 minutes 
at 37°C respectively, with 1,000rpm agitation. At the final step of the sample 
preparations, the total protein 20µg of the prepared sample treated at each GdnHCL 
dose was coated on ELISA plate wells, in which PRC7 mAb was coated previously 
(triplicate for each individual). For controls, uninfected PrP-KO (FVB/Prnp0/0), FVB/n and 
C57BL6 mice were included. An RML-infected FVB/n mouse was also contained as a 
positive control of TSE-infected samples. The 7-5 ELISA results showed higher O.D. 
values in all tested TSE-infected mouse BH samples, compared to uninfected controls 
(Figure 3-4.A).  
 However, the PrP detection in the 87V-infected sample was almost twice less 
than other TSE samples. The same BH samples from these mouse-adapted prions 
were analyzed by Western blot that showed similar results to this 7-5 ELISA experiment 
above (data not shown). Therefore, the 7-5 ELISA protocol can be utilized to analyze 
detections and quantifications of PrP molecules in TSE-mouse models. For the 87V 
strain and VM/Dk mouse background, several possibilities can be considered for low 




strain showed the sensitivity or resistance to denaturation, and 5M GdnHCL was not 
effective for its PrP detections. To investigate this possibility, the 7-5 ELISA method was 
determined by GdnHCL-dose dependent responses for the PrP detection in various 
mouse-adapted TSE strains. Based on the 7-5 ELISA protocol, BH samples from the 
tested mice above were prepared with different concentrations of GdnHCL (0, 1, 2, 3, 4, 
5, 6, or 7M). After the final procedure of the sample preparations, 20µg total protein of 
each prepared sample was coated on wells for PRC7-coated ELISA plates (well 
numbers = triplicate for each individual at each GdnHCL dose). The 7-5 ELISA results 
detected that the 22L prion strain showed the highest O.D. values of PrP detections with 
2M GdnHCL, whereas other strains required 3-4M GdnHCL for reaching to the peak of 
the O.D. values (Figures 3-4.B to E). However, the 87V-infected BH analyte decreased 
the O.D. value of PrP detections when denatured with 5M GdnHCL and higher 
concentrations. This observation could be related to the conformational stability of the 
87V strain, indicated by its tolerance level to denaturation. As described above, both 
PRC7 and PRC5 mAbs bind to these epitopes in the structured globular domain at the 
C terminal of the PrP structure. Thus, these results might suggest conformational 
differences in or around the mAb-biding sites among TSE strains and PrP allotypes. For 
further studies, the 7-5 ELISA method would have potential applications for analyzing 
biochemical properties in TSE-strain differences, such as a conformational stability 



















































































































































Figure 3-4. Comparisons of PrP detections among four different mouse-adapted 
scrapie strains. The 7-5 ELISA method measured GdnHCL-dose dependent 
responses of PrP levels in BH samples from TSE-mouse models: 
(B) RML, (C) 22L, (D) 87V, and (E) D10. (n=3, each GdnHCL dose with 20µg  





Variances of detectable PrP levels in CWD mouse models by the 7-5 ELISA 
method 
 Primarily, the following six mouse model studies were evaluated for transmissible 
properties of inoculated CWD isolates: 1) ES-02, 2) ES-03, 3) KG-18, 4) RA-26, 5) GT-
142, and 6) GT-143. For the 7-5 ELISA studies, each study group included BH samples 
of three CWD-infected mice. Controls were PrP-KO, uninfected Tg1536 (DeerPrP) and 
Tg5037 (ElkPrP) mice. These hemizygous Tg1536+/– and Tg5037+/– mice generate 
approximately five-fold higher levels of PrP expressions in their brains than the wild-type 
mice (FVB/n). The PrP structure between deer and elk is one difference at the amino 
acid residue 226, which consists of glutamine (abbreviated as Gln or Q) in deer, but 
glutamic acid (abbreviated as Glu or E) in elk. A recent study indicated that the residue 
226 was localized in α-helix 3 and consisted of the β2-α2 loop in the globular domain of 
the PrP structure.22 This domain implicated with the PrPSc replication and CWD 
pathogenesis. Thus, conformational compatibility at this amino acid residue should be 
associated with rearrangements of PrP structures between deer and elk. 
 1) PrP detections of moose CWD isolates in transgenic mouse models: In 
wild nature, five diagnosed cases of moose with CWD infections have been reported: 
three cases in Jackson County, Colorado23; one case in Star Valley, Wyoming; another 
case in Hilda, Alberta, Canada (no peer-review article for the cases in Wyoming and 
Canada but these information are available by internet searches). These moose cases 
with natural transmissions were found in CWD-endemic areas for other cervids, such as 
deer and elk. It is known that primary PrP structures in deer (Odocoileus species) and 




these species could be a potential infectious route. Thus, one publication determined an 
experimental inoculum of the brain tissue sample from a CWD-infected captive mule 
deer into three moose (captive Shiria’s moose) via oral transmission.24 In the mouse-
model studies of ES-02 and ES-03, a brain tissue sample from the CWD-infected 
moose (08W-11,741: one of the three CWD-infected moose above) was inoculated into 
Tg1536 (DeerPrP) and Tg5037 (ElkPrP) mice, respectively. BH samples from these 
moose CWD-infected mice and controls (uninfected cervidized transgenic mice and 
PrP-KO mice) were tested with the 7-5 ELISA method. In addition, the inoculated brain 
sample of the moose CWD isolate was included for this analysis. The total protein 20µg 
of each prepared sample was coated on a well (triplicate for each individual) on a 7-5 
ELISA plate. These analyses measured higher O.D. values of PrP detections in all 
infected mice from the two studies, compared to the controls (Figure 3-5.A and B).  In 
fact, the infected Tg1536 (DeerPrP) mice exhibited higher levels of PrP detections than 
the infected Tg5037 (ElkPrP) mice and the CWD-infected moose brain sample (Figure 
3-5.C). These findings suggested the transmissible property of the moose CWD isolate 
to deer and elk through the species barrier. Also, this inoculum might behave like a deer 
CWD pathogen in the transgenic mice with deer PrP expressing because of the 
identical primary PrP structure in deer and moose. Thus, the PrPSc propagation of the 
moose CWD agents could be more prominent in Tg1536 mice than Tg5037 mice. 
However, the disease incubation time in Tg5037 mice was shorter than Tg1536 mice: 
mean incubation times ± SEM, 286.33±15.56 days (Tg5037 in ES-03 study), and 
322.00±10.03 days (Tg1536 in ES-02 study). Based on these 7-5 ELISA results, the 




susceptibility of elk to the moose CWD transmission and the early or progressive 
disease development. In this point, it is not clear if generations and accumulations of 
under-glycosylated PrPSc forms were limited in the infected Tg5037 mice during the 
disease development. In the previous article, transmissions of several different CWD 
isolates were evaluated in these transgenic mice.25 Compared to the Tg1536 (DeerPrP) 
mice with CWD inoculations, the infected Tg5037 (ElkPrP) mice exhibited faster 
incubation times for all tested CWD isolates derived from deer or elk. Depending on 
inocula, the infected group of Tg5037 mice was 24-148 day shorter for disease-
incubation periods than that of Tg1536 mice. Therefore, the Tg5037 mouse with elk PrP 
expressions is prone to exhibit faster disease development and progressions after CWD 
inoculations. In another aspect, Tg5037 mice with the moose CWD inocula might 
generate preferentially diglycosyl and/or mono-2 glycosyl PrP forms, which PRC7 mAb 
in the 7-5 ELISA method cannot recognize. To determine this possibility, WB is 
applicable with the same samples from the moose CWD-inoculation studies. 
 2) CWD inocula isolated from elk into Tg1536 (DeerPrP) mice: The two 
prevalent types of CWD strains exhibited different pathological, biological and 
biochemical features.26 The CWD type 1 is the strain, progressing the disease 
development in short incubation periods with bilaterally symmetric lesions of its 
histological distribution in brain. In contrast, the features of the CWD type 2 are long 
incubation periods with asymmetrical distribution of PrPSc agents in brains. However, 
these CWD strains have similar biochemical characteristics. According to WB results, 
the proportions of various glycosylated PrP forms were equivalent among mice infected 




GdnHCL were similar properties between transgenic mice with deer or elk PrP 
expressions inoculated with CWD type 1 and 2. In addition, inoculations of CWD strains 
from elk (Elk CWD) to Tg1536 (DeerPrP) mice showed unstable responses for 
maintaining the strain types of the CWD inocula, and caused mixtures of pathological 
features of CWD type 1 and type 2 in brains, referred as strain mixtures or CWD type 3. 
However, the inoculated Elk CWD developed the features of the inoculated strain types 
in Tg5037 (ElkPrP) mice. This observation indicated stable propagations of inoculated 
Elk CWD strains in the same species.26  These features of CWD transmissions can be 
arisen as different primary PrP structures in deer and elk at the amino acid residue 226, 
mentioned above.  
 The following inoculations of mouse models were previously performed to 
analyze pathologic characters of Elk CWD transmissions using Tg1536 (DeerPrP) 
mice.26 One of the CWD inocula was 99W12389, originally from CWD-infected elk in the 
Sybille Wildlife Research Unit at the Wyoming Game and Fish Department. This strain 
was evaluated as a CWD type 1. Bala04/04-0306 was another CWD inoculum, derived 
from elk naturally affected with CWD in Saskatchewan, Canada, and identified as a type 
2 strain. Briefly, the KG-18 study was an inoculation of the CWD strain 99W12389 
(Type 1) into Tg1536 (DeerPrP) mice; the RA-26 study was an inoculation of the CWD 
strain Bala04/04-0306 (Type 2) into Tg1536 (DeerPrP) mice; the GT-142 study was a 
passage of 99W12389 (Type-1)-inoculated Tg5037 (ElkPrP) mouse brain (RA-86 study) 
into Tg1536  (DeerPrP) mice; and the GT-143 study was a passage of Bala04/04-0306 
(Type 2)-inoculated Tg5037 (ElkPrP) mouse brain (RA-78 study) into Tg1536 (DeerPrP) 




143 study had four mice), the 7-5 ELISA method analyzed PrP detections in these CWD 
mouse models. The onsets of clinical signs and terminal-disease conditions were 
diagnosed in all infected mice. Controls included PrP-KO, uninfected Tg1536 (DeerPrP) 
and Tg5037 (ElkPrP) mice (n=3 for each as biological replications). This 7-5 ELISA 
experiment was performed under the same procedures in the moose CWD study above. 
As an outcome, the 7-5 ELISA method measured higher O.D. values of PrP detections 
in all infected materials, compared to the controls. However, PrP detectable levels 
varied among the three individuals in each study. To evaluate these ELISA results, 
other analyses (i.e. WB and dot blot) can be useful to compare variances of PrP levels 
in tested samples by each inoculation study.  In general, the PK reagent is utilized in 
these two blotting methods as a common reagent in TSE research. Potentially, the use 
of PK reagents may influence biochemical properties of tested samples, inducing 
different responses. In fact, the WB did not distinguish differences between CWD type 1 
and type 2 strains among large numbers of infected mice, when treated with PK 
reagents.26  Since the 7-5 ELISA method can analyze PrP detections under its PK-free 
protocol, this method may recognize subtle type-base differences and other possible 
observations.  
 In the KG-18 study, infected Tg1536 (DeerPrP) mice showed higher PrP 
detections, as indicating the replication and propagation of PrPSc molecules derived 
from the 99W12389 Elk CWD strain (Type 1) inocula (Figure 3-5.D). This phenomenon 
also occurred in the infected mice from the GT-142 study (Figure 3-5.E): a passage of 
the 99W12389-inoculated Tg5037 (ElkPrP) mouse brain (from the RA-86 study) into 




folds higher than those in the KG-18 study. These results indicated that the Tg5037 
mouse-passaged Elk CWD type 1 strain could increase propagations of its PrPSc agents 
in transgenic mice with deer PrP expressions. However, incubation periods in the GT-
142 study were approximately twice longer than those in the first passage of the CWD 
type 1 strain in the KG-18 study: mean incubation time ± SEM; 417.83±36.74 days in 
the GT-142 study; and 229.88±8.62 days in the KG-18 study. Possibly, the prolonged 
incubation period in the GT-142 study was implicated with unstable and delayed 
propagations of the Elk CWD type 1 strain by deer PrP. Also, the strain mixtures of 
pathology (CWD type 3 by a deer PrP) might cause different features of disease 
developments. 
 In comparison with the RA-26 study that was the inoculation of the CWD type 2 
strain Bala04/04-0306 into Tg1536 (DeerPrP) mice, higher O.D. values of PrP 
detections were measured in infected Tg1536 mice of the GT-143 study (a passage of 
Bala04/04-0306-inoculated Tg5037 (ElkPrP) mouse brain from the RA-78 study) (Figure 
3-5.F and G). These measurements suggested that the transmission of the CWD type 2 
strain into Tg5037 mice could enhance PrPSc propagations in transgenic mice with deer 
PrP expressions. Notably, the incubation times between these two studies were not 
very different: mean incubation time ± SEM; 280.71±5.25 days in the RA-26 study; and 
291.13±15.17 days in the GT-143 study. Hence, the CWD type 2 strain may have stable 
properties in PrPSc propagations with deer PrP molecules, compared to the CWD type 1 
strain. Overall, the 7-5 ELISA experiments in this section demonstrated influential 
consequences of structural differences at the residue 226 on the globular domain of the 

































































































































































































































































































Figure 3-5. PrP detections of moose-isolated CWD inocula in transgenic mouse 
models with cervid PrP expressions by the 7-5 ELISA method. Measured PrP 
levels in BH samples from (A) Tg1536 (deerPrP) mice and (B) Tg5037 (elkPrP) 
mice with inoculations of moose-isolated CWD brain materials. (C) comparisons 
of Moose-CWD inoculum, and infected mice. PrP detections in BH samples from 
Tg1536 (deerPrP) mice with Type-1 CWD inocula (elk-isolated CWD strain, 
99W12389): (D) KG-18 inoculation study, and (E) GT-142 inoculation study.  
PrP detections in Tg1536 (deerPrP) mice with Type-2 CWD inocula (elk-isolated 
CWD strain, Bala04): (F) RA-26 inoculation study, and (G) GT-143 inoculation 









PrP detections in TME-inoculated transgenic mice by the 7-5 ELISA method 
 Previously, three isolates of transmissible mink encephalopathy (TME) from 
minks were kindly provided by Dr. Jason Bartz, Creighton University, Omaha, 
Nebraska, USA. These three TME inocula were 1) #58 NBP 950825, 2) 10-5 cloned 
TME 941031, and 3) 10-5 cloned TME 941201. Note: the laboratory database recorded 
these brain samples as 8/25/95, 10/31/94, and 12/1/94. However,                  I confirmed 
with Dr. Bartz about the correct notation as the order of Year/Month/Day, by e-mail 
communications. These TME mink brain samples were the cloned isolates by a serial 
passage of the Stetsonville TME souse, derived from a mixture of several brains from 
TME-affected minks.3 Although the laboratory database does not have clear 
background information of the three TME clones in minks, such as clinical signs and 
neuropathology, passages of these TME isolates showed both clinical signs of hyper 
and drowsy strains in Syrian golden hamsters (e-mail communications with Dr. Jason 
Bartz). In this section study, the 7-5 ELISA method measured BH samples of the three 
TME clones under its optimized protocol, described above. Controls included PrP-KO 
mice, uninfected FVB/n mice, and uninfected TgF431 (MinkPrP) mice. On a prepared 
ELISA plate, a well contained total protein 20µg of each sample (triplicate). The 7-5 
ELISA method results indicated that all TME isolates exhibited higher O.D. values of 
PrP levels, compared to the control BH samples (Figure 3-6.A). However, the TME 
941031 and 941201 isolates had much higher PrP levels than the #58 NBP 950825. 
These observations suggested that these two TME isolates prominently generated 
unglycosyl and mono-1 glycosyl PrP forms during the disease developments. As noted 




pooled brain sample of different disease minks in the same affected ranch.3 Thus, it is 
possible that these cloned isolates exhibit different phenotypes or strain dependences 
(e-mail communications with Dr. Jason Bartz). To determine these possible differences 
in the three isolates, further studies analyzed BH samples from mouse models with 
TME inoculations. 
 In the past mouse bioassay, three TME isolates were inoculated into transgenic 
mice with mink PrP expressions, referred to as TgF431 expressing an equivalent PrP 
level to wild-type mouse FVB/n: 1) VK-11 study with #58 NBP 950825 inoculation 
(scrapie sick date: mean ± SEM = 262.14±16.9 days); 2) VK-18 study with TME 941031 
inoculation (108.5±3.24 days); 3) VK-20 study with TME 941101 inoculation 
(123.25±3.44 days). Intriguingly, these sick date records indicated that the #58 NBP 
950825 isolate had a prolonged incubation period at least twice longer than the TME 
941031 and 941201 isolates. Based on the 7-5 ELISA results from the three TME 
isolates, #58 NBP 950825 exhibited approximately twice lower O.D. value of unglycosyl 
and mono-1 glycosyl PrP forms than other isolates (Figure 3-6.A). As hypothesized, 
therefore, these outcomes indicated that generations of under-glycosylated PrP forms 
could implicate with the disease development and progression in TME.  
 In the 7-5 ELISA experiments, three mice of each TME-inoculated study were 
tested. Three uninfected TgF431 mice were used as a non-TME control; one PrP-KO 
mouse and one uninfected FVB/n mouse were also included as negative controls of the 
7-5 ELISA method. In addition, the three TME inocula were examined to compare with 
these TME-infected mouse models. Under the optimized 7-5 ELISA protocol, BH 




prepared samples were coated into ELISA plate wells (= triplicate for each sample: total 
protein 20µg per well). All TME-inoculated mouse BH samples showed higher O.D. 
values of PrP detections, compared to uninfected TgF431 mice and other negative 
controls: p-values by group means for Uninfected TgF431 vs. TME-study were p= 
0.0007 (VK-11 = #58 NBP 950825), p= 0.0002 (VK-18 = TME 941031), and p= 0.0016 
(VK-20 = TME 941201) (Figures 3-6.B to D). However, the TME mouse models 
exhibited lower O.D. values than each inoculum of a TME isolate from affected mink. 
This observation could be associated with the first transmission passage of these 
cloned TME isolates through the species barrier, even though the inoculated mice had 
mink PrP expressions. Instead of PrP molecules, other murine factors might interfere or 
interact with the inocula for these mink-PrPSc replication. Moreover, the O.D. values 
between 0.6 and 1.0 in TME-inoculated mice indicated threshold amounts or levels of 
PrPSc generations and/or accumulations that caused clinical signs of neurological 
impairments and disease progressions to terminal stages for the TgF431 (MinkPrP) 
mouse line. Since the inoculation studies with the TME 941031 and 941201 isolates had 
twice shorter incubation periods than the #58 NBP 950825 isolate, generating and 
accumulating times of under-glycosylated PrPSc forms could be proportional to TME-




























































VK-18 + 941031 by 7-5 ELISA



















20 VK-20 + 941201 by 7-5 ELISA



































































Figure 3-6. Mink PrP detections by the 7-5 ELISA method.  
(A) three TME inocula,  BH samples from TgF431(minkPrP) mice with  
three TME inocula: (B) VK-11 study with #58 NBP 950825 inoculation,  
(C) VK-18 study with TME 941031 inoculation, and (D) VK-20 study with  






Pilot application of the 7-5 ELISA method as comparison of CPCA 
 Bioassay has been utilized to assess infectivity and its titration of TSE prion 
strains. However, this in vivo approach has limitations, such as time consumption and 
cost. Dr. Charles Weissmann’s group established a cell assay, referred to as scrapie 
cell assay (SCA) or standard scrapie cell assay.12 SCA is equivalently sensitive to 
mouse bioassay for titrating prion infectivity using cell culture models, by ten-fold faster 
processing times. On the other hand, this cellular assay restricts applications only for 
mouse-adapted scrapie prion strains, because of the use of murine cell lines with 
mouse PrP expressions. To overcome this limitation, Dr. Jifeng Bian, an assistant 
professor at CSU, reported a new cell-base quantitative method, called cervid prion-cell 
assay (CPCA).10,11 The methodology of CPCA was described in the Materials and 
Method of this Chapter. Briefly, this method is performed conveniently for necessary 
processes to establish TSE infections in cell culture models, compared to the SCA 
procedure. Moreover, a rabbit kidney epithelial cell line RK13 (ATCC, Manassas, 
Virginia, USA) was utilized to generate stably transfected RK13 cells expressing PrP of 
elk, deer, sheep, mouse, mink or others. Primarily, the RK13 cells do not have 
detectable levels of PrP expressions. The establishment of these transfect RK13 cells 
has promoted the CPCA application, which is a capable method to develop susceptible 
cell culture models for infection and replication of a testing TSE strain in its 
corresponding species of PrP expressions.10 However, CPCA and SCA generally 
require a 4-week incubation period of a TSE infection in cell culture models to assess its 
proper infectivity and titer. For overcoming this time consuming issue, detectable PrPSc 




with the infectivity, titrated by CPCA from the cell culture models with TSE infection of 
the same sample. If this correlation appeared, the 7-5 ELISA method would have a 
potential utility for titrating prion infectivity. Since this ELISA procedure can be 
completed within 2-3 days, the time consumption for analyzing prion infectivity would be 
ten times less than CPCA and SCA methods. As noted above, SCA is ten-fold faster 
than bioassay. Therefore, this ELISA approach might be 100 times faster than bioassay 
for analyzing infectivity and titration of TSE prion strains. 
 Ms. Carla Calvi, a former research coordinator in the CSU Prion Research 
Center, examined CPCA with RK13 cells expressing cervid PrP using multiple brain 
homogenates from CWD-infected transgenic mouse models. According to her CPCA 
outcomes, two study groups (the inoculation studies RA-24 and SB-41) showed 
different titers between the tested samples from each inoculation study (Figure          3-
7.A). In the RA-24 study using a CWD inoculum Bala02-0306, derived from elk brain 
with subclinical signs but pathologically TSE positive, the hemizygous Tg1536 
(DeerPrP) mouse #5695 had a lower titer value than the mouse #5696. In the SB-41 
study using a CWD inoculum H92 derived from a deer brain, the hemizygous Tg1536 
(DeerPrP) mouse #3684 had a lower titer value than the mouse #3685. Thus, these 
results indicated that infectivity of the inoculum could be different among animals even 
in the same study group. However, it was unknown what factors could be involved in 
this observation. As an initial approach, the 7-5 ELISA method measured PrP levels in 
these four CWD-infected BH samples. Controls included PrP-KO and uninfected 
Tg1536 mice. Intriguingly, the low-titer animals showed lower O.D. values of PrP 




for each sample (Figure 3-7.B). In fact, these detectable differences between the 
samples in the same inoculation study were similar patterns to the CPCA data by Ms. 
Calvi. Therefore, the 7-5 ELISA method might have a potential application to estimate 
prion infectivity and titer of a TSE-infected material, in comparison with the bioassay 
and cell culture model. For a further pilot study, CPCA evaluated prion infectivity and 
titer of the CWD-infected materials from transgenic mice tested in the Figure 3-5 above: 
RA-26, KG-18, GT-142, and GT-143.    
 Under the guidance of Dr. Bian, CPCA was performed using RK13 cells 
expressing deer PrP and calculated titers for each tested sample. The anti-PrP antibody 
for this cellular assay was 6H4 mAb, commonly used in TSE research (Prionics, 
Schlieren, Switzerland). Interestingly, these two experimental methods suggested that 
the infected samples with higher O.D. values have higher titers by CPCA (Figures 3-7.C 
and D). Although these observations were still pilot data among the tested BH samples 
by the 7-5 ELISA and CPCA experiments, the 7-5 ELISA approach can be utilized as an 
alternatively rapid method to estimate infectivities and titers of testing TSE-infected 
materials. Therefore, it is an appropriate direction for continuing further experiments that 
evaluate prion infectivity and titer by the 7-5 ELISA method, and develop its additional 
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Figure 3-7. Comparisons of CPCA and the 7-5 ELISA method. 
(A) PrP titers from CPCA results, using RK13 cells with CWD infections.  
(B) PrP detections in selected murine BH samples with CWD infections that 
CPCA tested, (C) PrP titers in CPCA results using RK13 cells, infected with  
CWD inocula from four bioassays, and (D) PrP detections in murine BH samples 
from four CWD bioassays that CPCA tested. (n=3, each sample with 20µg total 





Potential utility of the 7-5 ELISA method for monitoring prion infectivity and 
titration 
 Furthermore, the CPCA method evaluated an infectivity and titration of the 
mouse-adapted scrapie prion strain RML with RK13 cells expressing mouse PrP, using 
the RML-infected mouse brain homogenate, which was the same sample in the Figure 
3-1 (Figure 3-1.A). For analyzing prion infectivity and titer of the RML-infected FVB/n BH 
sample, the CPCA experiment obtained titers 4.64 x 108 CPCA unit/g. The unit value for 
the nanogram (ng) protein amount was 0.464 CPCA unit/ng (i.e. 4.64 x 108 CPCA 
unit/g; 4.64 x 105 CPCA unit/mg; 4.64 x 102 CPCA unit/µg). This value was applied to 
calculate infectivity per total protein in the half log protein-dose study of the RML-
infected murine material in the study of the Figure 3-1 (Table 3). Combined with the half 
log data by the 7-5 ELISA method, the obtained titer was scaled at each protein 
concentration of the tested RML-inoculated FVB/n mouse BH sample, and these two 






























































Figure 3-8. Comparisons of CPCA and the 7-5 ELISA method. Evaluations of  
the PrP titration of RML infectivity with RK13 cells in CPCA, and PrP detections  
in RML-inoculated FVB/n murine BH samples by the 7-5 ELISA method. 
(n=3, each total protein amount). 
	  
F. 
4.64 x 108 CPCA unit/g = 4.64 x 105 SCA unit/mg = 4.64 x 102 SCA unit/µg  
= 0.464 SCA unit/ng 
 




Modified protocol for the PRC7 utility into CPCA testing with SMB cells 
 The 7-5 ELISA approach presented a potential utility to estimate prion infectivity 
and titer as an alternative method of in vitro and in vivo assays. However, the CPCA 
results above were based on PrP detections by another anti-PrP mAb 6H4. Since 6H4 
can react with all four glycosylated PrP forms, the utility of the 7-5 ELISA method might 
not be simply compared with outcomes from different experiments unless PRC7 and 
PRC5 were applied. In the Sandwich ELISA approach, PRC7 only captures unglycosyl 
and mono-1 glycosyl PrP forms. Thus, an evaluation of the PRC7 application in CPCA 
was necessary for proper comparisons of its data with the 7-5 ELISA results using the 
same analyte. According to Dr. Bian, the PRC7 application was not successful in his 
past CPCA experiments, compared to other common anti-PrP antibodies such as 6H4. 
Also, PRC5 was prone to cause higher color-background issues on membranes of 
ELISpot plates. In the CPCA procedures, however, cellular samples were denatured 
with 3M GdnSCN at RT for 10 minutes. As described above, the GdnSCN denaturation 
with lower temperature and/or shorter incubation times was less effective to detect PrP 
molecules in the 7-5 ELISA method. For the undefined utility of PRC7 in past CPCA 
results, a new working hypothesis also proposed that under-glycosylated PrP molecules 
were immature forms localized in intracellular domains rater than on cell surfaces, and 
that glycosylation states may be changed during the transportation of PrP molecules 
from intracellular domains to cell surfaces. Therefore, additional permeabilizations for 
cellular membranes would facilitate chances of PRC7 reacting with intracellular PrP 
molecules in testing cells. For these fundamental purposes, different cell lines and TSE 




different detergents; 2) PK digestions or non-PK digestions; and 3) denaturations with 
GdnSCN or GdnHCL.  
 1) Permeabilization: In the immunocytochemistry (ICC) protocol for TSE-
infected cells that Ms. Calvi obtained from Dr. Bessen and used, digitonin (a toxin 
derived from the poisonous foxglove plant Digitalis purpurea) was applied for cellular 
permeabilization. However, this detergent is a costly reagent and requires one-hour 
incubation time on the protocol. Since other detergents have been used for 
permeabilizing cell membranes for ICC, other effective chemicals were tested for PRC7 
in the CPCA application. In an initial approach, Triton X-100 (TX100), Tween 20, and 
saponin were tested under different concentrations and incubation times, but not 
including digitonin. PBS was used as a dilution buffer, and the control was the only PBS 
addition. Note: Sarkosyl was not included in this experiment, although this reagent is 
one of the common detergents in the TSE research. The following study with the Figure 
3-16 explains the negative efficacy of Sarkosyl for the 7-5 ELISA method.  
 2) PK digestion: the 7-5 ELISA protocol does not require the use of proteinase 
K (PK) for PrP detections in TSE-infected materials. Under-glycosylated PrPSc forms are 
commonly detected in the infected analyte, but not usually generated in uninfected 
individuals and animals. In addition, non-PK application allows recognizing PK-sensitive 
PrPSc forms. However, the PK treatment is one of the procedures in CPCA for detecting 
PK-resistant PrP agents in TSE-infected cells. To evaluate the PK efficacy for the PRC7 
application in CPCA, PK-treated (PK 1mg/ml in cell lysis buffer (CLB); final 
concentration 5µg/ml during incubation with samples) and non-treated (CLB only) 




150mM NaCl, 0.5% IGEPAL-CA630 and 0.5% Sodium Deoxycholate. Since IGEPAL-
CA630 is a similar detergent to TX100 and NP-40, it might induce permeabilization on 
cell membranes.      
 3) Denaturation: GdnSCN and GdnHCL were compared at different 
concentrations. Tris-HCL buffer was a dilution buffer for these denaturants: 10mM for 
GdnSCN in CPCA, but 50mM for GdnHCL in the 7-5 ELISA method. Potentially, 
different denaturants and buffer concentrations might have influenced the PRC7 
application in CPCA. To determine efficacies of PRC7 in CPCA, various conditions of 
denaturations were tested with the following two cell lines: 1) the scrapie-infected SMB 
cell line, derived from the brain of a disease mouse after an inoculation with the mouse-
adapted scrapie strain Chandler 13; 2) the SMB-PS cell line, which is the permanently 
cured SMB cell line by the pentosan sulphate (PS) treatment, and PrPSc expressions 
are no longer detectable over 50 passages.14  
 For permeabilizations of cell membranes on SMB and SMB-PS cell lines, four 
different conditions were applied: 1) PBS only, 2) 0.1% TX100, 3) 0.1% Tween 20, and 
4) 0.1% saponin. These detergents were diluted in PBS. On the ELISpot plates, cells 
were incubated with each detergent condition for 30 minutes at RT. Then, the cells were 
digested with final concentration 5µg/ml of the PK reagent for 1 hour at 37°C, whereas 
only CLB was added for non-PK treated cells. The PK digestion was terminated by 
additions of PMSF 2mM in PBS for each well, with incubations at RT for 20 minutes. 
Consequently, all cells on ELISpot plates were denatured with different doses of either 
GdnSCN (0, 1.5, 3M) or GdnHCL (0, 2, 4M). These denaturants were prepared with 




time for the denaturation was 10 minutes at RT. Subsequent procedures were 
completed under the CPCA protocol.  Based on all outcomes from these CPCA 
experiments, the GdnHCL denaturation with detergents enhanced PrP detections under 
PK-treated SMB cells, whereas the GdnSCN with detergents decreased (Figures 3-9.A 
to F). Intriguingly, saponin showed the highest spot numbers, compared to other 
detergent conditions. Also, low doses of these detergents without PK treatment did not 
show clear differences for spot numbers between SMB and SMB-PS cells. In contrast, 
the higher doses of GdnHCL and GdnSCN presented more differences for spot 
numbers between these cell lines. In fact, 0.1%-detergent permeabilization enhanced 
spot numbers in SMB cells, but decreased in SMB-PS cells. For 0M denaturant with 
additions of either 10mM or 50mM Tris-HCL buffer, the combination of saponin with the 
50mM Tris-HCL buffer did not influence spot numbers in SMB cells between PK-
digested and non-treated conditions. In contrast, other combinations of detergents and 
buffers decreased detections of spot numbers. These outcomes suggested that saponin 
with 4M GdnHCL denaturation can be useful for the PRC7 application in CPCA. 
Possibly, 50mM Tris-HCL buffer is a better concentration of a dilution buffer for GdnHCL 
in CPCA, as well as the 7-5 ELISA method. Furthermore, PRC7 detected stained spots 
of PrP expressions in SMB-PS cells without PK treatment, although these cells did not 
generate PK-resistant PrP molecules. This finding indicated that these detections were 
unglycosyl and/or mono-1 glycosyl PrP forms, frequently identified in TSE-infected 
materials. Hence, the SMB-PS cells still exhibited the under-glycosylated state even 
after cured for PrPSc generations. Thus the cured cells might not have had normal 




glycosylation state in SMB-PS cells should be one of the reasons that the cured cells 





































































































































































Figure 3-9. Efficacies of detergents for PrP detections in SMB cells with  
PRC7 mAb by CPCA. Comparisons of PBS, TX100, Tween20, and Saponin  
(0.1% concentration for each detergent), under different dinaturations with  
(A) 3M GdnSCN, (B) 4M GdnHCL, (C) 1.5M GdnSCN, (D) GdnHCL,  
(E) 0M (10mM Tris-HCL), and (F) 0M (50mM Tris-HCL). 





























Detergent efficacies for PrP detections in RML-infected RKM cells with PRC7 mAb 
by CPCA 
 For additional evaluations of the PRC7 application, the transfected mouse-PrP 
expressing RK13 cells (RKM7 cells) and its chronically infected cells with a mouse-
adapted scrapie strain RML (RML-RKM7 cells) were tested in CPCA.11 RKV cells were 
the RK13 cells stably transfected with empty vector, and were included in a control for 
non-PrP expression and non-TSE infection. As described above, a RK13 cell line 
(ATCC, Manassas, Virginia, USA) originated from rabbit kidney epithelial cells line and 
originally does not have PrP expressions. Transfecting this parent cell line, RKM7 cells 
with stable PrP expressions were generated previously. Using these cells, the four 
different detergent conditions (PBS only, 0.1% concentration of TX100, Tween20 or 
saponin) were compared with two different incubation times (10 minutes vs. 30 minutes 
at RT). Also, PK-treated and non-treated conditions were determined under the 
procedure (including PMSF) in the SMB cells. Denaturations of the cells were 
processed with 4M GdnHCL in 10mM Tris-HCL buffer for 10 minutes at RT. These 
results indicated that the 30-minute incubation with PBS, TX100, or Tween20 reduced 
spot numbers in RML-RKM7 cells with PK digestion, compared to the 10-minute 
incubations (Figures 3-10.A and B). Interestingly, saponin with these incubation times 
did not show clear differences for spot numbers in the infected cells with PK treatment. 
Thus, saponin with 10-minute incubation can be an applicable condition for PRC7 in 
CPCA. Instead of the 0.1% concentration, moreover, the 0.2% concentration of these 
four-detergent conditions were determined with the 10-minute incubation time, followed 




concentration of the detergents reduced detectable spot numbers in PK-treated RML-
RKM7 cells, especially with saponin, compared to the 0.1% concentration (Figures 3-
10.A and C). Therefore, the 0.1% detergent concentration with the 10-minute incubation 









































































RML-RKM 0.2% detergent 10 min incubation









































Figure 3-10. Efficacies of detergents for PrP detections in RML-RKM cells with  
PRC7 mAb by CPCA. Comparisons of PBS, TX100, Tween20, and Saponin 
(0.1% concentration of each), under different incubations for (A) 10 minutes  








Detergent efficacies for PrP detections in CWD-infected RK Elk cells  with PRC7 
mAb by CPCA 
 The efficacies of the tested detergents and conditions were evaluated with 
another TSE using PRC7 in CPCA. For this aim, the following cell lines were included: 
the transfected elk-PrP expressing RK13 cells (RKE cells), and its chronically infected 
cells (Elk+ cells) with brain homogenates derived from the CWD-positive elk brain 
(isolated sample: 012-09442).10 RKV cells were the negative control of the PrP 
expression and TSE infection. As the first approach, the same procedures in RML-RKM 
cells above were applied to RKE cells, Elk+ cells, and RKV cells: the four different 
detergent conditions (PBS only, 0.1% concentration of TX100, Tween20 or saponin) 
with incubation for either 10 minutes or 30 minutes at RT. Also, PK and PMSF 
procedures were same as the SMB cells and RML-RKM7 cells above. GdnHCL was 
prepared in 10mM Tris-HCL buffer and its final concentration was 4M.  Cells were 
denatured with 10 minutes at RT. In contrast to SMB cells and RML-RKM cells with TSE 
infections, the uninfected RKE cells showed higher spot numbers without the PK 
digestion than the CWD-infected Elk+ cells (Figures 3-11.A to C). This outcome 
suggested that the CPCA protocol required the PK reagent for PrPSc detections in 
transfected RK13 cells with PrP expressions. Although the 30-minute incubation with 
detergents decreased spot numbers in the uninfected cells without the PK digestion, 
this condition did not enhance increases of spot numbers in the CWD-infected cells both 
with and without PK treatments.  Therefore, an efficacy of Tris-HCL buffer was 
evaluated for GdnHCL. Instead of 10mM Tris-HCL buffer, 50mM concentration was 




spot numbers in cells with PK and saponin treatments, compared to 10mM (Figures 3-
9.E and F). Followed by the same procedures with 50mM Tris-HCL buffer for GdnHCL, 
RKV, RKE, and Elk+ cells were examined with PRC7 in CPCA. In fact, this buffer 
modification increased spot numbers in the CWD-infected cells with all detergents, 
especially for saponin (Figure 3-11.C).  
 Based on the optimization of the 7-5 ELISA protocol, the utility of PRC7 mAb was 
explored to CPCA. Importantly, the results from the all three cell groups above indicated 
existences of PK-sensitive PrP forms in TSE-infected cells, in comparison of PK-treated 
and non-treated conditions. Moreover, the PK-sensitive PrP forms must be unglycosyl 
and/or mono-1 glycosyl forms because of the PRC7 property. Thus, the CPCA 
approach with PRC7 mAb revealed the increased generation of under-glycosylated PrP 
forms in cell culture models of TSE-infection states. Although the final concentration of 
PK reagents was 5µg/ml, PK-sensitive PrPSc forms were still susceptible to this 
concentration. Therefore, the optimized PK concentration might be different for 
detecting maximum levels of PrPSc agents by PRC7 mAb in CPCA. As a future direction, 
a PK-dose dependent study would be required. The following study with the Figure 3-15 
describes PK-dose dependent responses in the 7-5 ELISA method, using mouse BH 
samples. This result would be useful for optimizing PK concentrations for PRC7 mAb in 
CPCA.  
 Furthermore, additional permeabilizations for cellular membranes enhanced 
detectable spot numbers of PrP expressions in TSE-infected cells with the tested 
detergents, especially saponin. These results could overcome the previous limitation of 




cells. Thus, this PrP detection endorsed the working hypothesis that the intracellular 
PrP molecules were under-glycosylated forms, which might be immature structures and 
will be fully glycosylated during its transportation from intracellular to cell surface.  
 In addition to all outcomes in the studies with the Figures 3-9, 3-10, and 3-11, 
further optimizations would be beneficial to develop a new utility of the 7-5 ELISA 
approach for infectivity and titration of TSE strains. For instance, the following 
experiments can be practical to initiate: 1) saponin and other reagents for the 
permeabilization under different concentrations, incubation times, temperatures, and 
buffers; 2) GdnHCL for denaturation to find optimized conditions by its dose-
dependence, incubation times, and temperatures; and 3) the PK digestion with different 
buffers because its dilution buffer CLB contains IGEPAL-CA630 and Sodium 
Deoxycholate. Since IGEPAL-CA630 is a similar detergent to TX100 and NP-40, an 
extra permeabilization might occur during the PK digestion. Potentially, IGEPAL-CA630 
and Sodium Deoxycholate might influence PrP detections by PRC7 mAb in CPCA. 
Therefore, the CLB without IGEPAL-CA630 and Sodium Deoxycholate should be 
compared with PBS only for PK preparations. These outcomes will more confirm the 









































































































Figure 3-11. Efficacies of detergents for PrP detections in CWD-infected Elk+ cells 
with PRC7 mAb by CPCA. Comparisons of PBS, TX100, Tween20, and Saponin 
(0.1% concentration of each), under different conditions with (A) 10-minute 
incubation with 10mM Tris-HCL buffer for GdnHCL, (B) 30-minute incubation with  
10mM Tris-HCL buffer for GdnHCL, and (C) 10-minute incubation with 50mM 








New ELISA approach for PrPC detections 
 Instead of targeting PrPSc agents in TSE-infected materials, an additional ELISA 
approach is capable of measuring only PrPC molecules. Initially, Dr. Richard Bessen, a 
former faculty in the Department of Microbiology, Immunology and Pathology at 
Colorado State University, talked with me about his finding. Briefly, Dr. Bessen’s 
laboratory detected lower mRNA expression levels of the Prnp gene in the tested TSE-
infected mouse tissue samples using a quantitative polymerase chain reaction (qPCR) 
method, compared to uninfected controls. Thus, we discussed capabilities of the 7-5 
ELISA method for testing these mouse samples for only PrPC expressions and for 
determining the correlation of Prnp gene expressions and PrPC levels in the same 
samples. Since a diglycosyl form is the most abundant PrPC conformation, PRC7 and 
the 7-5 ELISA method are inefficient approaches for targeting normal PrPC molecules. 
Thus, 6H4 mAb, a well-known anti-PrP antibody in TSE research that recognizes all 
four glycosylated PrP forms, was an alternate antibody for this Sandwich ELISA trial, as 
a replacement of PRC7. 
 In the pilot study, Sandwich ELISA approaches with 6H4 and PRC5 mAbs 
evaluated three infected and three uninfected mouse nasal tissue samples from Dr. 
Bessen’s laboratory as a blind study. Under sample procedures without Triton X-100 
and denaturation, both orders of these antibodies were examined as capture and 
detecting antibodies in the ELISA approaches: 6H4-PRC5 ELISA and PRC5-6H4 ELISA 
applications. Both ELISA measurements revealed lower O.D. values of PrP detections 
in all infected materials than the uninfected samples (data are not present here). This 




Sandwich ELISA methods with the two anti-prion mAbs found the decrease of  PrP 
levels in TSE-infected materials. However, it was not clear if these PrP detections were 
only PrPC or total PrP amounts in the mouse tissue samples. 
 For further approaches to develop new Sandwich ELISA applications for only 
PrPC detections, the following experiments included the D18 prion-specific recombinant 
antibody (fragment antigen-binding antibody = Fab Ab: Fab fragment is an antibody 
lacking the Fc, or constant region) as a candidate for establishing a new ELISA 
protocol, in addition to 6H4 and PRC5 mAbs. As previously reported, the D18 Fab Ab 
presented a unique feature applying to ELISA methods that required sample 
denaturation with guanidine thiocyanate  (GdnSCN) to detect PrP27-30 rods.15 PrP27-
30 was an isolate, purified from hamster-adapted scrapie prions and incorporated into 
liposomes. The PrP27-30 property in scrapie PrPSc agents has been identified as the 
protease-resistant core of infectious PrPSc isoforms that has an essential role in the TSE 
infectivity and pathogenesis.27,28 Intriguingly, the D18 Fab Ab could not react to the 
PrP27-30 rods without the denaturation step by ELISA methods.15 In addition, the same 
research group published a therapeutic potential of the D18 Fab Ab that bound to 
normal PrPC isoforms for preventing these interactions with abnormal PrPSc isoforms.29 
In this study, tested samples were not denatured with GdnSCN or other denaturants, 
such as guanidine hydrochloride (GdnHCL). Thus, I anticipated a potential that the D18 
Fab Ab would be capable of detecting only PrPC molecules, when testing samples are 
not denatured. 
 Combined with the anti-PrP antibodies 6H4, PRC5 and D18, three different 




capture and detecting antibodies: 6H4-PRC5, D18-PRC5, and PRC5-D18. Each 
capture antibody was coated into ELISA plate wells: 100µl of its 5µg/ml concentration 
per well (= 0.5µg/well). For PrPC detections, testing samples were not treated with any 
detergents or denaturants. To reduce possible degradations of PrPC molecules, sample 
handlings and preparations were carefully performed on ice or at 4°C. For the same 
purpose, a protease inhibitor product (cOmplete, Roche Diagnostics, Indianapolis, IN, 
USA) was added into buffers of sample dilution, blocking process, and detecting and 
secondary antibodies: one tablet of this protease inhibitor cocktail for 50 ml volume of 
an extraction solution at the manufacture’s direction. At first, these testing ELISA 
applications determined protein-dilution dependence using 10% BH samples of 
uninfected homozygous Tg4112 mice (MousePrP overexpression) and PrP-KO mice. 
According to the laboratory database, a hemizygous Tg4112 mouse line expresses 2-4 
times higher PrP levels, compared to a wild-type FVB/n mouse. The Tg4112 BH sample 
was diluted by the PrP-KO BH sample: the volume proportions were prepared from 30% 
to 100% Tg4112 BH (= from 70% to 0% PK-KO mouse BH) with each 10% increase. 
These prepared samples were added into wells on the ELISA plates, pre-coated with 
each capture antibody. Subsequent procedures were the same as the 7-5 ELISA 
protocol, except handling on ice. Consequently, the three Sandwich ELISA experiments 
detected high O.D. values of PrPC expressions in all tested samples, but no difference 
displayed from 30% to 100% Tg4112 sample proportion. These observations must be 
associated with PrP overexpressions in this mouse breed line (data not present). 
Therefore, the three ELISA candidates were re-evaluated using 1% BH of Tg4112 and 




samples was modified from 0% to 100% Tg4112 BH volume proportion (= 100% to 0% 
KO mouse BH volume) with each 10% increase. 50µl of each diluted Tg4112/PrP-KO 
BH sample was coated on ELISA plate wells (duplicate for each sample proportion). 
Since 1% BH was estimated as 1mg/ml (= 1µg/µl), 50µl of 100% Tg4112 BH sample 
proportion should be approximately 50µg total protein per well. All three ELISA 
applications measured PrPC detections of the lowest and highest O.D. values at 0% and 
100% Tg4112 BH volume proportion, respectively (Figure 3-12.A). At the 0% Tg4112 
BH volume proportion (= only PrP-KO mouse sample), the D18-PRC5 ELISA 
experiment showed the lowest background of O.D. value that was less than 0.1 (Figure 
3-12.B). In contrast, its opposite order PRC5-D18 ELISA application exhibited the 
highest background over 0.4 O.D. value. Compared to the 6H4-PRC5 ELISA approach, 
the D18-PRC5 ELISA method analyzed equivalent PrPC detections in all volume 
proportions (Figure            3-12.A). In addition, D18 and PRC5 antibodies are available 
to generate in house. Therefore, these in-house antibodies were selected to measure 
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Figure 3-12. PrPC detections by three anti-PrP antibody applications for  
Sandwich ELISA approaches. Tested samples were serial dilutions of  
the Tg4112 BH sample with the PrP-KO BH sample. (A) 0% to 100% Tg4112  
BH volume proportion (= 100% to 0% KO mouse BH volume) with each 10% 







Application of the D-5 ELISA method for PrP analyses in TSE-infected materials 
 The D18 Fab Ab is capable of detecting PrP27-30 rods in denatured samples by 
ELISA and IP experiments.15 Under the non-denatured condition, however, a Sandwich 
ELISA approach with this Ab measured high PrP levels in BH samples from an 
uninfected Tg4112 mouse with murine PrP overexpressions, but not from a PrP-KO 
mouse. Hence, these findings indicated that the D18 Fab Ab could detect PrPC 
expressions in the uninfected brain by an ELISA method without denaturation. To 
determine D18 features, two Sandwich ELISA approaches (D18-PRC5 and PRC5-D18) 
were applied for the following mouse BH samples: PrP-KO, uninfected FVB/n, RML-
inoculated FVB/n, uninfected C57BL6, RML-inoculated C57BL6, and 22L-inoculated 
C57BL6 mice (n=1 for each mouse). Followed by the optimized 7-5 ELISA protocol, two 
groups of these samples were prepared for denaturation with either 0M GdnHCL (only 
50mM Tris buffer as non-denaturant) or 5M GdnHCL, and then incubated for 15 minutes 
at 37°C. In this experiment, the concentration of coated capture antibodies was 5µg/ml 
(= 0.5µg in 100µl per well). Also, buffers containing protease inhibitor cocktail (one 
tablet in 50mL) were used for sample dilution, blocking step, and detecting and 
secondary antibodies. In the 5M GdnHCL denaturation group, both ELISA approaches 
detected high PrP levels in all infected materials (Figures 3-13.A and B). However, the 
PRC5-D18 Sandwich ELISA approach exhibited higher background, as predicted from 
CPCA studies. In contrast, the 0M GdnHCL condition showed lower O.D. values in 
these infected samples than uninfected controls by the two ELISA approaches (Figures 
3-13.C and D). Since the D18 Fab Ab requires denaturation to measure PrP27-30 rods, 




results indicated that the denaturation step in the D-5 ELISA method would be an 
influential factor to measure either only PrPC or total PrP (including PrPSc) levels. Also, 
TSE-infected mice had decreased PrPC levels in the disease course to the terminal 










































































































































































































Figure 3-13. PrP detections in TSE-infected murine BH materials using  
the D-5 ELISA method. Sandwich ELISA applications of D18-PRC5 mAbs for 
denatured samples with (A) 5M GdnHCL denaturation and (B) 0M GdnHCL;  
the application of PRC5-D18 mAbs for the samples with (C) 5M GdnHCL  















































Optimization of the D18 Fab Ab as the capture antibody in the D-5 ELISA method 
 To optimize a coating concentration of the D18 Fab Ab as the capture antibody, 
the same tested procedures in the study with the Figure 2-2 were applied for the D-5 
ELISA method under sample preparations with non-denaturation and denaturation. The 
96-well plates for the D-5 ELISA method were prepared for each denaturation state. 
Initially, the D18 Fab Ab was diluted to concentrations 0.5, 1, 2.5, and 5 µg/ml. 100 µl of 
each antibody concentration was coated into wells as triplicate: final total Ab amounts 
were 0.05, 0.1, 0.25, and 0.5µg per well. Testing mouse BH samples included a RML-
inoculated FVB/n mouse, an uninfected FVB/n mouse, and a PrP-KO mouse (n=1). For 
the non-denatured experiment, BH samples were only diluted with PBS containing a 
protease inhibitor to be a protein concentration 200µg/ml. Then, 100µl of each diluted 
sample were coated into wells (triplicate) on a prepared ELISA plate for each capture 
antibody concentration. Total protein of each sample was 20µg per well. For the 
denatured experiment, BH samples were treated with 5M GdnHCL under the optimized 
protocol of the 7-5 ELISA method. At the final step of the sample preparation, these 
denatured samples were diluted. 100µl of each diluted sample (200µg/ml protein 
concentration) was added into the wells for each capture antibody concentration. 
Subsequent procedures were followed by the 7-5 ELISA protocol.  In addition, further 
concentrations of the D18 Fab Ab at 5, 10, 20, and 30µg/ml were evaluated under the 
procedures above. In the denatured experiment, the 5µg/ml concentration of the D18 
Fab Ab showed the highest O.D value for PrP detections in the RML-infected material 
(Figure 3-14.A). At higher D18 concentrations, the O.D. values of both infected and 




concentrations (Figure 3-14.B). In the non-denatured experiment, an uninfected FVB/b 
mouse showed higher PrP detections than the infected samples at all concentrations of 
the D18 capture antibody. The signal plateaus of O.D. values were also observed 
between the 10 and 20µg/ml antibody concentrations (Figure 3-14.C and D). These 
results suggested that the 10µg/ml concentration of the D18 Fab Ab should be practical 
for the D-5 ELISA method, but the 20µg/ml concentration would be a proper application 
for both denatured and non-denatured sample conditions. In fact, the 7-5 ELISA method 
also contained the 20µg/ml concentration of a PRC7 capture antibody. To compare 
these two Sandwich ELISA approaches, therefore, the 20µg/ml concentration was also 
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Figure 3-14. Optimizations of coating amounts as the capture antibody  
D18 Fab Ab in the D-5 ELISA method. Testing with denatured samples and  
D18 concentration (per well) in the range of (A) 0.5-5µg/ml, and (B) 5-30µg/ml.  
Testing with non-denatured samples and D18 concentration (per well) in  
the range of (C) 0.5-5µg/ml, and (D) 5-30µg/ml. (n=3, each concentration with  
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Comparisons of two denaturants in the D-5 ELISA method 
 As described above, the study of the Figure 2-9 compared the effectiveness of 
GdnHCL and GdnSCN for the sample denaturations in the 7-5 ELISA protocol. For 
optimizing the D-5 ELISA method, these denaturants were again evaluated for sample 
denaturations using 5M GdnHCL and 3M GdnSCN. Testing mouse BH samples 
included a RML-inoculated FVB/n mouse, an uninfected FVB/n mouse, and a PrP-KO 
mouse (n=1 for each). After the treatment with 1% TX100 at 37°C incubation for one 
hour, these BH samples were denatured with either 5M GdnHCL or 3M GdnSCN for 15 
minutes at 37°C. Each denatured sample contained a protein concentration of 2mg/ml, 
which subsequently was 10 times diluted by PBS with 1% BSA and protease inhibitor to 
be 200µg/ml. 100µl of each diluted sample was added into wells of ELISA plates with 
pre-coating of the D18 Fab Ab 20µg/ml concentration. The total protein of each sample 
was 20µg per well at the final step. Similar to the 7-5 ELISA results in the study of the 
Fugire 2-9, the GdnHCL denaturation showed at least 1.5 times higher O.D. value of the 
PrP detection in the infected material, compared to the GdnSCN treatment (Figure 3-
15.A and B). In addition, the 7-5 ELISA experiment evaluated the same prepared BH 
samples as a comparative control (Figure 3-15.C and D). These outcomes indicated the 






































































































Figure 3-15. Comparisons of denaturant efficacies for PrP detections in  
RML-infected murine BH analyte by the D-5 ELISA method.  
Under the sample preparation protocol, the D-5 ELISA method with  
(A) 5M GdnHCL, and (B) 3M GdnSCN; the 7-5 ELISA method with  
(C) 5M GdnHCL, and (D) 3M GdnSCN. (n=3, each sample with  
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GdnHCL-dose dependent responses for PrP detections in the D-5 ELISA method  
 To optimize a GdnHCL concentration in the D-5 ELISA method, its different 
concentrations (0-6M) were determined with BH samples from a RML-inoculated FVB/n 
mouse, an uninfected FVB/n mouse, and a PrP-KO mouse (n=1 for each). All 
procedures were performed under the optimized 7-5 ELISA protocol. Controls for the 
denaturing procedures were non-denatured samples, which were only diluted by PBS 
with 1% BSA and protease inhibitor to be 200µg/ml protein concentration. The samples 
for 0M GdnHCL only contained 50mM Tris, whereas other GdnHCL concentrations 
were applied into the testing samples for each concentration. These prepared samples 
were then denatured for 15 minutes at 37°C incubation. At the final step of the sample 
preparations, all denatured samples were diluted 10 times by PBS with 1% BSA and 
protease inhibitor: the final protein concentration was 200µg/ml. 100µl of each prepared 
sample was coated into wells (triplicate: total protein 20µg per well) on the plate for the 
D-5 ELISA method. In this GdnHCL-dose dependent experiment, the infected material 
presented the plateaus of O.D. values from the 4M GdnHCL (Figure 3-16.A). 
 In comparison to the D18 Fab Ab, another anti-PrP mAb POM2 (Prionatis AG, 
Alpnach Dorf, Switzerland) was tested for this GdnHCL-dose dependence as a capture 
antibody (0.5µg/ml concentration; coated 0.05µg per well) in the Sandwich ELISA 
approach. POM2 mAb has four binding epitopes (four alternative non-competing 
epitopes: 58-64, 66-72, 74-80, 82-88) in the octarepeat peptide region at the 
unstructured flexible N-terminal domain of the PrP structure. In contrast, the D18 Fab 
Ab binds to the epitopes 133-157 in the structured C-terminal globular domain. In the 




O.D. values of PrP detections in the uninfected samples with and without denaturation, 
compared to the PrP-KO analyte (Figures 3-16.A and B). However, all detected PrP 
levels were not very different among tested GdnHCL doses. These results indicated that 
denaturation did not influence the octarepeat peptide region of the PrPC structure, 
because the N-terminal was a liner domain where POM2 mAb bound to its epitopes. In 
contrast, the D-5 ELISA results indicated that both uninfected and infected samples 
decreased PrPC detections in a comparison of non-denatured and 0M-denatured 
samples at 37°C incubation and/or 50mM Tris (a dilution buffer of GdnHCL) (Figure 3-
16.A). Since the D18 Fab Ab binds to the globular structure domain, these procedures 
could influence the PrP structure or its conformational stability. Hence, this observation 
suggested that denatured PrPC molecules might require longer renaturation times to 
fold native structures. These renaturation times might be longer than the process of 
sample coatings, immediately after the denaturation and subsequent ten-fold dilution in 
the sample preparation. Overall, GdnHCL is a proper denaturant applying to the sample 
preparation in the D-5 ELISA protocol. At least 4M concentration is necessary to 





































































Figure 3-16. GdnHCL-dose dependent responses in RML-infected murine  
BH samples. (A) the D-5 ELISA method, compared to (B) POM2 mAb as  
a capture antibody with the detecting antibody PRC5 mAb. (n=3, each sample 









Renaturation times of denatured PrP molecules  
 Presumably, the renaturing process of a denatured PrP molecule should initiate 
immediately after the ten-time dilution step. Nevertheless, its completion times might 
influence binding chances of the capture antibodies to the targeted molecules in ELISA 
plate wells. To determine potential influences of PrP renaturation times, the D-5 ELISA 
and 7-5 ELISA methods examined the time-point evaluations of sample coatings into 
wells on prepared plates. Testing BH samples included a RML-inoculated FVB/n 
mouse, an uninfected FVB/n mouse, and a PrP-KO mouse (n=1 for each). These 
samples were denatured with 5M GdnHCL, and then diluted by PBS with a 1% BSA and 
protease inhibitor to be the 200µg/ml protein concentration. Subsequently, 100µl of 
each prepared sample was coated into wells (triplicate: total protein 20µg per well) on 
prepared ELISA plates with pre-coated D18 or PRC7. The sample coating was done at 
the following times after the sample dilution: 0 (immediately after the dilution), 5, 10, 20, 
30, 40, 50, and 60 minutes as post-denaturation periods. Both D-5 ELISA and 7-5 
ELISA experiments showed the highest O.D. values of PrP detections in the infected 
material at the 0 minute time points (Figure 3-17.A and B). In contrast, longer waiting 
times for the sample coating reduced the PrP detection, especially in the 7-5 ELISA 
method. Possibly, the reduced PrP detection was related to re-aggregations or 
clusterizations of renatured PrPSc molecules in the infected material through the delay of 
sample coatings. Furthermore, PrP degradations were also possible occasions, 
because the under-glycosylated PrP forms that PRC7 recognized should be unstable 
protein structures. Overall, these results suggested a quick procedure for sample 



























Figure 3-17. Evaluations of renaturation times for denatured PrP molecules in 
RML-infected murine BH samples. Tested times of sample coatings after  
the 10-time dilution: 0 (immediately after the dilution), 5, 10, 20, 30, 40, 50, and 
60 minutes as post-denaturation periods. (A) the D-5 ELISA method, and (B)  
the 7-5 ELISA method(n=3 per a time point with each sample, 20µg total protein 
per well) 







































Comparisons of multiple capture antibodies in the Sandwich ELISA approach  
 The 7-5 ELISA and D-5 ELISA protocols have innovated molecular diagnostic 
applications for PrP detections in TSEs. To evaluate these analytical specificities, other 
anti-PrP antibodies were compared as capture antibodies under the same protocols: 
6H4 (Prionics, Schlieren, Switzerland), POM2 (Prionatis AG, Alpnach Dorf, 
Switzerland), SAF-32 (Cayman Chemical, Michigan, USA16), and mAb132 (kindly 
provided by Dr. Motohiro Horiuchi, Hokkaido University, Japan17,18). According to the 
company product information and/or related publications, the following amino acid 
positions in the PrP structure are binding epitopes of these antibodies: 
• PRC7 (IgG1) = discontinuous epitopes 154-185 in structured globular domain of 
C terminus (mouse PrP numbering) 
• D18 (Fab) = discontinuous epitopes 133-157 in structured globular domain of                                  
C terminus (mouse PrP numbering) 
• 6H4 (IgG1) = linear epitopes 144-152 in structured globular domain of C terminus 
(human PrP numbering) 
• POM2 (IgG1) = linear epitopes 58-64, 66-72, 74-80, 82-88 as four alternative 
non-competing epitopes in the octarepeat region of unstructured flexible domain 
at N terminus (mouse PrP numbering) 
• SAF-32 (IgG2b) = linear epitopes 59-89 in the octarepeat region of unstructured 
flexible domain at N terminus (mouse PrP numbering) 
• mAb 132 (IgG1) = linear epitopes 119-127 in hydrophobic core region adjacent to 
the cleavage of unstructured and structured domains between N and C termini 




 A concentration and amount for coating each capture antibody are listed below, 
based on the ELISA protocols in this dissertation, or the recommended application from 
each company and related publication mentioned above. 
• PRC7: 100µl of 20µg/ml Ab per well = 2µg/well 
• D18: 100µl of 20µg/ml Ab per well = 2µg/well 
• 6H4: 100µl of 1µg/ml Ab per well = 0.1µg/well 
• POM2: 100µl of 0.5µg/ml Ab per well = 0.05µg/well 
• SAF-32: 100µl of 0.5µg/ml Ab per well = 0.05µg/well 
• mAb132: 100µl of 0.5µg/ml Ab per well = 0.05µg/well 
 
 A detecting antibody was PRC5 mAb (1mg/ml concentration in a stock). PRC5 
mAb was used at a dilution of 1:5,000 ratio with PBS containing 1% BSA and protease 
inhibitor. 100µl of the diluted PRC5 mAb solution was added into each well (1:5,000 = 
0.2µg/ml; 100µl of 0.2µg/ml Ab per well = 0.02µg/well).  
• PRC5 (IgG2a) = discontinuous epitopes 132-158 in structured globular domain of 
C terminus (mouse PrP numbering) 
 
 For the Sandwich ELISA approach using multiple capture antibodies, testing BH 
samples included a RML-inoculated FVB/n mouse, an uninfected FVB/n mouse, and a 
PrP-KO mouse (n=1 for each). All sample preparations were performed under the 
optimized 7-5 ELISA protocol (including the D-5 ELISA method) for both denatured and 
non-denatured conditions. These BH samples for denaturation were initially treated with 




incubation with 5M GdnHCL at 37°C with an agitation of 1,000 rpm for 15 minutes. 
Subsequently, all denatured samples were diluted ten folds with PBS containing 1% 
BSA and protease inhibitor to be 200µg/ml protein concentration. For the non-denatured 
sample experiment, the BH samples were only diluted with PBS containing 1% BSA and 
protease inhibitor to be 200µg/ml protein concentration. To evaluate protein-dose 
dependences, these diluted BH samples from both denatured and non-denatured 
conditions were additionally diluted to prepare lower protein concentrations with the 
PBS buffer above, and another prepared PBS diluent with GdnHCL to be 0.5M in each 
sample: 10µg/ml, 5µg/ml, 2.5µg/ml, 1.25µg/ml, 0.625µg/ml, 0.3125µg/ml, and 
0.15625µg/ml. Following these diluting procedures, 100µl of each sample was added 
into wells (quadruplicate: total protein 20µg per well) on an ELISA plate pre-coated with 
each capture antibody. After an overnight incubation of these ELISA plates at 4°C, all 
necessary procedures were completed under the optimized 7-5 ELISA protocol.  
 1) Denatured BH samples: The 7-5 ELISA method showed high O.D. value of 
PrP detections in denatured BH samples from the RML-inoculated FVB/n mouse, but 
not for uninfected and PrP-KO mice (Figure 3-18.A). As described in the study with the 
Figure 3-12 (Figure 3-12.A) above, the D-5 ELISA method was equivalent to the 6-5 
ELISA approach for PrP detections in the TSE-infected sample (Figure 3-18.B and C). 
Both ELISA approaches also detected some PrPC amounts in the uninfected FVB/n 
mouse even with denaturation. These observations might have indicated that 
denaturations in the optimized protocol were not enough to eliminate PrPC molecules, 




results were also observed in the study of the Figure 3-16 for the GdnHCL-dose 
dependent study of the D-5 ELISA method (Figure 3-16.A).  
 Interestingly, the POM2-PRC5 ELISA application showed unique data that the 
uninfected BH sample exhibited much a higher O.D. value of the PrP detection, 
compared to the 7-5 ELISA, D-5 ELISA and 6-5 ELISA results (Figure 3-18.D). In 
addition, the detected PrP level of the infected sample was only 1.5-2 times higher than 
the level in the uninfected sample. This observation could be associated with the 
epitope sites of the POM2 mAb in the octarepeat region at the N terminal of the PrP 
structure. Since the N terminal is the unstructured flexible domain, denaturation might 
be less influential for the PrPC conformation or its stability. Possibly, the flexible PrP 
domain is not very different between normal and abnormal PrP isoforms.  
 Similar to the POM2 mAb, the epitope site of the SAF-32 mAb also localizes in 
the octarepeat region at the N terminal. In the SAF-32-PRC5 ELISA approach, it is 
interesting that the SAF-32 mAb showed a lower PrP detection in the infected sample, 
compared to the POM2-PRC5 ELISA experiment (Figure 3-18.E). As described above, 
the POM2 mAb has four different bindings epitopes in the octarepeat region, which 
might provide much higher binding chances of POM2 mAb to PrP molecules, compared 
to the SAF-32 mAb with only one binding epitope. 
 Unexpectedly, the mAb 132 antibody did not measure PrP levels in all tested BH 
samples (Figure 3-18.F). This result might be related to sample preparations under the 
applied protocols, which might not be suitable for this antibody. In fact, a previous study 
reported that the mAb 132 antibody detected PrPSc agents in Indirect ELISA methods, 




However, the denaturation in this comparative experiment was processed with 5M 
GdnHCL for 15 minutes. According to another article from Dr. Horiuchi’s laboratory, 5M 
GdnSCN was applied for the experiments with the mAb 132 antibody and TSE-infected 
cell cultures.18 In the Prion 2015 conference at CSU, Fort Collins, Colorado, his group 
presented the poster about a cell-base ELISA method using the mAb 132 antibody.30 
Further publications reported the optimized protocols of the mAb 132 application for 
PrPSc detections.31-33 The sample preparations in the mAb 132 protocols were different 
from the 7-5 and D-5 ELISA methods. 
 2) Non-denatured BH samples: The 7-5 ELISA method could not detect PrP 
levels in all tested analyte under non-denatured condition, because the PRC7 mAb 
required denaturation and renaturation of PrPSc isoforms to fold native PrPC structures 
or these equivalent conformations (Figure 3-18.G). In general, the abundance of normal 
PrPC isoforms in healthy individuals and animals are diglycosyl forms that the PRC7 
mAb cannot react. In contrast, the D-5 ELISA and 6-5 ELISA approaches detected 
higher PrPC levels in the uninfected sample, compared to the infected sample (Figures 
3-18.H and I). These measurements indicated that the RML infection and disease 
development decreased PrPC levels in the inoculated mouse brain. Nevertheless, the 
POM2-PRC5 ELISA approach with the non-denaturation presented limited differences 
of PrP detections between infected and uninfected samples (Figure 3-18.J). These 
results suggested that the RML infection and disease progression might have affected 
the structured globular domain with which D18 and 6H4 mAbs bound. The unstructured 





 Furthermore, the SAF-32 and mAb132 mAbs were not applicable to determine 
PrP levels in tested samples under the non-denatured condition (Figures 3-18.K and L). 
In fact, the mAb 132 was reported as a PrPSc-specific antibody.18 Thus, this anti-PrP 
mAb has to be less reactive to PrPC isoforms. Even with denaturation, PrPC molecules 
did not expose the binding epitopes of the mAb 132 in uninfected cells.18 Possibly, 
immediately after a denaturing process, refolded PrPC structures may prevent the 
interaction with this antibody. These observations should be associated with different 
experimental preparations and conditions. Hence, sample preparations and 
experimental conditions are influential factors for the protein conformation and 
renaturation, which affect binding epitopes of testing antibodies on targeting molecules. 
 Overall, the PrP detection is dependent on the conformation and its modification 
between PrPC and PrPSc isoforms, influenced by the binding epitopes of applied anti-
PrP antibodies. Based on the outcomes in this study section, the selection and 
combination of capture and detecting antibodies are key applications in Sandwich 
ELISA approaches. In this method, the combination of anti-PrP antibodies that bind 
epitopes in the structured globular domain could be better selections to measure higher 
PrP detections in TSE-infected materials. Therefore, the 7-5 ELISA and D-5 ELISA 
approaches have practical utilities to identify PrPSc isoforms in TSE diagnoses, and also 
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Figure 3-18. Comparisons of multiple capture antibodies in protein-dose dependent 
responses under the Sandwich ELISA approach. Using a RML-infected murine BH 
analyte and its control samples, six different anti-PrP antibodies were tested as 
capture antibodies with the detecting antibody PRC5 mAb.   
For denatured BH materials, capture antibodies were (A) PRC7 mAb, (B) D18 Ab,  
(C) 6H4 mAb, (D) POM2 mAb, (E) SAF-32 mAb, and (F) the mAb 132.  
for non-denatured BH materials, capture antibodies were (G) PRC7 mAb, (H) D18 
Ab, (I) 6H4 mAb, (J) POM2 mAb, (K) SAF-32 mAb, and (L) the mAb 132. 




Comparisons of the 7-5 ELISA and D-5 ELISA methods for PrP detections in TSE- 
mouse models expressing different PrP species  
 In this dissertation, four Sandwich ELISA systems were established for PrP 
detections. First, the 7-5 ELISA method detects PrP levels in TSE-infected mouse BH 
samples with 5M GdnHCL denaturation. Specifically, this method can measure 
unglycosyl and mono-1 glycosyl PrP forms that are predominantly generated in TSE-
infected animals, but not in healthy or non-TSE-infected hosts. Thus, the 7-5 ELISA 
method is capable of analyzing TSE infections by glycosylation states. Second, the D-5 
ELISA method detects PrPSc molecules (or total PrP levels) in denatured BH samples 
from TSE-infected mice. This analytical feature is based on the D18 property that 
requires a sample denaturation for PrPSc detection. This method has a competent ability 
to analyze TSE infections by detectable PrP levels in denatured BH samples. Third, the 
D-5 ELISA method without denaturation only recognizes PrPC levels in BH samples. In 
TSE-mouse models, uninfected BH samples exhibit higher PrPC levels than TSE-
infected BH samples. These results indicate the decreases of PrPC molecules during 
the TSE disease development and progression in infected hosts. Thus, modifications of 
PrP C levels could be implicated with the TSE pathogenesis. Additionally, the 7-5 ELISA 
method without denaturation might be applicable to evaluate the generation of 
unglycosyl and mono-1 glycosyl PrPC forms in testing BH samples, as the fourth system. 
The detection of under-glycosylated PrP forms might indicate an impairment of the PrP 
glycosylation, leading to unstable PrP structures and conformational alterations.  
 To compare the analytical properties of these four Sandwich ELISA systems, 




with different PrP species. These comparison studies included the following TSE-
infected mouse models: 1) RML-inoculation in FVB/n mouse, 2) CWD (elk CWD brain 
sample Bala05-0308)-inoculation in Tg1536 (DeerPrP) mouse, 3) CWD (Bala05-0308)-
inoculation in Tg5037 (ElkPrP) mouse, 4) CWD (elk CWD brain sample 99W12389)-
inoculated gene-targeted (GTE) M2elk mouse expressing Elk PrP, 5) Sheep scrapie 
(Colorado Scrapie)–inoculation in Tg3533 (OvineARQ PrP) mouse, and 6) TME 
(941031)-inoculation in TgF431 (MinkPrP) mouse. Controls were BH samples from a 
PrP-KO mouse, an uninfected wild-type mouse, and a transgenic or gene-targeted 
mouse matching to each TSE-inoculated mouse model.  
 Samples preparations for the 7-5 ELISA and D-5 ELISA methods were described 
above. For the denatured preparation, these BH samples were initially treated with 1% 
TX100 for one hour at 37°C with 1,000rpm agitation, and then denatured with 5M 
GdnHCL for 15 minutes at 37°C with 1,000rpm agitation. After that, the denatured 
samples were 10 times diluted with 1% BSA-containing PBS. The final protein 
concentration of these diluted BH samples was 200µg/ml (= total protein 20µg in 100µl). 
For protein-dose dependent studies, the samples were further diluted to be 100, 50, 25, 
12.5, 6.25, 3.125 and 1.5625 µg/ml concentrations (= total protein 10, 5, 2.5, 1.25, 
0.625, 0.3125, and 0.15625 µg in 100µl respectively). Subsequently, 100µl of each 
prepared sample was added into wells for each category on ELISA plates with pre-
coated capture antibodies, either PRC7 or D18. Furthermore, the non-denatured 
preparation did not include any treatment with TX100, GdnHCL, and heat incubation, 
prior to coating the samples on the prepared ELISA plates. Hence, BH samples were 




protein concentration 200µg/ml. These prepared samples were additionally diluted to 
the lower protein concentrations above. Lastly, 100µl of each diluted sample was added 
into wells for each category on the ELISA plates. After the ELISA plates with samples 
were incubated at 4°C overnight, the subsequent processes were performed under the 
optimized 7-5 ELISA and D-5 ELISA protocols. 
 1) RML-inoculated FVB/n Group: The tested RML-infected material was a BH 
sample derived from a mouse with a terminal disease condition in the inoculation study 
SK-01. For the denatured BH samples, the 7-5 ELISA and D-5 ELISA methods detected 
higher O.D. values of PrP levels in the RML-inoculated mouse, compared to uninfected 
FVB/n and PrP-KO mice (Figures 3-19.A and B). In addition, the D-5 method showed 
higher PrP level in this infected sample than the 7-5 ELISA method. This finding could 
be associated with the different features of the capture antibodies on these two ELISA 
approaches: the PRC7 mAb only recognizes unglycosyl and mono-1 glycosyl PrP forms, 
whereas the D18 Fab Ab reacts to all four varieties of glycosyl PrP forms. For screening 
the existence of abnormal PrP agents, the D-5 ELISA method has a practical utility in 
diagnostic purposes. The D-5 ELISA method also presented PrP detections in 
uninfected samples with denaturation. This detected O.D. value should be PrPC 
molecules that the denatured process did not eliminate, or denatured molecules 
refolded to native PrP conformations. Furthermore, the 7-5 ELISA method did not detect 
PrP levels in non-denatured BH samples, because PRC7 requires denaturation and 
renaturation of a PrPSc agent to be a PrPC or its equivalent conformation (Figure 3-19.C). 
In contrast, the D-5 ELISA method detected PrP levels in both uninfected and RML-




showed approximately a two-fold higher O.D. value of the PrPC level than the infected 
BH sample. This observation suggested the decrease of the PrPC amount or 
generation/synthesis in the infected mouse during disease development and 
progression of the RML mouse-adapted scrapie prion strain. Moreover, the lower PrPC 
detection in the RML-infected mouse might imply structural modifications in the binding 
epitopes or these regions of D18 and/or PRC5 antibodies on the PrPC conformation, 
which antibodies lose binding activities to targeted molecules.  
 2) CWD-inoculated Tg1536 (DeerPrP) group: The group of CWD (elk CWD 
brain isolate Bala05-0308)-infected transgenic mouse with deer PrP expressions (the 
inoculation study CLC-005) exhibited the similar patterns of PrP detections. Both the 7-5 
ELISA and D-5 ELISA methods measured the elevated PrP levels in the CWD-infected 
BH sample under the denatured condition (Figures 3-19.E and F). Also, the D-5 ELISA 
method showed a higher O.D. value of PrP detection in the infected sample than the 7-5 
ELISA results. Under the non-denatured condition, the 7-5 ELISA method did not show 
clear differences of PrP detections between uninfected and CWD-infected materials 
(Figure 3-19.G). However, the 7-5 EILSA method measured subtle PrP levels in the 
uninfected Tg1536 mouse BH sample, in comparison to the infected Tg1536 and PrP-
KO mice. Statistically, the difference of O.D. values between the uninfected and infected 
samples was p < 0.02-0.0001 from total proteins 2.5µg to 20µg, as a technical 
replication (well number = 4 for each mouse and total protein amount). At this point, it is 
not clarified if the 7-5 ELISA method detected under-glycosylated PrP forms in the 
uninfected Tg1536 BH sample. However, this detection might indicate that transgenic 




Furthermore, the D-5 ELISA method measured almost a two-fold higher PrPC level in 
the uninfected Tg1536 mouse BH sample than the infected material under the non-
denatured condition (Figure 3-19.H). These results are the same outcomes in the RML-
infected mouse group described above. 
 3) CWD-inoculated Tg5037 (ElkPrP) group: The CWD (elk CWD brain isolate 
Bala05-0308)-inoculated transgenic mouse with elk PrP expressions (the inoculation 
study CLC-004) showed similar outcomes to the RML-FVB/n and CWD-Tg1536 
(DeerPrP) groups above (Figures 3-19.I to L). The 7-5 ELISA method detected 
differences of PrP levels between uninfected and CWD-infected mouse BH samples 
under the non-denatured condition (Figure 3-19.K). The O.D. value of the uninfected 
Tg5037 mouse was higher than the infected mouse and PrP-KO mouse. Based on a 
technical replication (well numbers = 4 for each individual), p values were p < 0.02-
0.0001 from total protein 1.25µg to 20µg for the uninfected vs. infected material, 
statistically. Thus, these observations indicated that transgenic mouse breed lines with 
cervid PrP overexpressions naturally generated unglycosyl and/or mono-1 glycosyl PrP 
forms in healthy condition or non-TSE infected status. Intriguingly, the 7-5 ELISA 
method also measured the decreased level of under-glycosylated PrPC forms in the 
CWD-infected material, compared to the uninfected and PrP-KO mouse analyte. Hence, 
these PrPC molecules might have altered to denaturation-resistant agents, such as 
abnormal PrPSc isoforms during the CWD infection and its PrPSc replication. As 
hypothesized, this PrP analytical approach suggested the implication of under-




exceptional sensitivity of the 7-5 ELISA method to detect the two under-glycosylated 
PrP forms at low amounts of total protein in tested samples. 
 4) CWD-inoculated GTE M2elk (ElkPrP) group: Previously, this inoculation 
study JC-10 applied gene-targeted (GT) mice with elk PrP expressions for a bioassay of 
a CWD isolate (elk CWD brain 99W12380). Transgenic mice with cervid PrP 
expressions, such as Tg1536 (DeerPrP) and Tg5037 (ElkPrP) mouse breed lines, 
predominantly overexpress these proteins in the nervous system, compared to wild-type 
mice. In contrast, this newly developed GT mouse breed line exhibits elk PrP 
expressions throughout the body including peripheral sites. Also, elk PrP expressions in 
this mouse are equivalent levels to a wild-type mouse. For the PrP measurement, both 
7-5 ELISA and D-5 ELISA experiments detected the elevated PrP level in the denatured 
BH sample of a CWD-inoculated GT mouse (Figures 3-19.M and N). Also, the D-5 
ELISA method showed higher O.D. values than the 7-5 ELISA method. These results 
were similar observations to those from the CWD (Bala05-0308) inoculation in 
transgenic mice with cervid PrP expressions above. In contrast, the 7-5 ELISA method 
did not measure PrPC levels in the non-denatured BH samples from the infected and 
uninfected GT mice, compared to the PrP-KO mouse analyte (Figure 3-19.O). This 
observation was similar to the RML-inoculated FVB/n mouse group (a wild-type mouse 
breed line), but different from the studies of CWD-inoculated transgenic mice with cervid 
PrP expressions above. Therefore, the PrPC detections by the 7-5 ELISA method could 
be specific phenomena in non-denatured BH samples from transgenic mice with PrP 




detection in the non-denatured BH sample from the CWD-infected GT mouse, as equal 
to the outcomes of other tested groups above (Figure 3-19.P).  
 5) Sheep scrapie-inoculated Tg3533 (OvineARQPrP) group: In a past 
bioassay (the JB-66 study), a sheep scrapie brain isolate Colorado Scrapie was 
inoculated into Tg3533 (OvineARQ PrP) mice whose brains were collected and stored 
after disease developments. Under the denatured condition, the 7-5 ELISA and D-5 
ELISA method detected the elevated O.D. values of PrP levels in the Scrapie-inoculated 
BH sample (Figures 3-19.Q and R). The reason that the D-5 ELISA method could 
measure higher PrP levels than another method should link to the property of the D18 
Fab Ab for binding to all four glycosyl PrP forms. In contrast, the PRC7 mAb only reacts 
to two of these forms. However, the PrP measurements by the 7-5 ELISA method 
revealed the prominent generations of unglycosyl and/or mono-1 glycosyl PrP forms in 
TSE-infected animals. Since the majority of PrPC molecules hold diglycosyl forms, the 
loss of glycan(s) could be a specific observation in the TSE disease development and 
progression. As hypothesized, therefore, the expressional pattern of the PrP 
glycosylation could be a potential candidate as a biomarker to diagnose and monitor 
individuals and animals for the infection, disease development, progression, and 
prognosis of these fatal neurodegenerative disorders. In addition, the 7-5 ELISA method 
detected small PrPC levels in the non-denatured BH samples from the uninfected and 
infected Tg3533 mice, compared to the PrP-KO mouse (Figure 3-19.S). These similar 
detections were also recognized in the transgenic mouse studies above. However, the 
detected PrPC levels of the uninfected and infected Tg3533 mice exhibited similar O.D. 




higher generations of under-glycosyled PrP forms could be possible in their normal and 
healthy conditions, but non-existent or rare in wild-type and gene-targeted mouse breed 
lines. Lastly, the D-5 ELISA method detected a lower PrPC level in the non-denatured 
BH sample from the Scrapie-infected mouse (Figure 3-19.T). This PrPC reduction was a 
common observation in TSE-infected animals by the D-5 ELISA method above. 
Therefore, the loss of PrPC molecules should be related to the TSE disease state. 
 6) TME-inoculated TgF431 (MinkPrP) group: In the study of the Figure 3-6 
above, the 7-5 ELISA experiments analyzed BH samples of the three different mink 
TME isolates and from these inoculated TgF431 mice: inoculation studies VK-11, VK-
18, and VK-20. The 7-5 ELISA method detected higher PrP levels in denatured BH 
samples from three mice (biological replication n= 3; well number= 3 for each mouse) of 
each TME-inoculation study (Figures 3-6.A to D). However, the O.D. values of all tested 
TME-infected mice were around 1.0 or lower (total 9 mice: 3 for each study). Thus, 
these observations indicated that TME pathogens replicated less in the TgF341 mice 
but caused the disease progression in the hosts to terminal stages. As described above, 
however, the 7-5 ELISA method is only capable of detecting unglycosyl and mono-1 
glycosyl PrP forms after denaturation and renaturation. Therefore, it was possible that 
these TME-infected TgF431 mice generated more diglycosyl and/or mono-2 glycosyl 
PrP forms. To evaluate this possibility, the D-5 ELISA method would be useful for 
obtaining further information and understanding the TME pathobiology.  
 The inoculation study VK-18 was a bioassay of the TME-affected mink brain 
isolate (TME 941031) into Tg431 transgenic mice with mink PrPC expressions. PrP 




section of the protein-dose dependent ELISA experiment, both the 7-5 ELISA and D-5 
ELISA methods measured PrP levels in the denatured BH sample from the TME-
infected material (VK-18), but this O.D. value was lower than 1.0 (Figures 3-19.U and 
V). These results were similar to the data in the study with the Figure 3-6 above. 
Therefore, the TME mink brain isolate 941031 should have limited the replication and 
generation of unglycosyl and mono-1 glycosyl PrPSc forms in the infected TgF431 
(MinkPrP) mice, whereas this inoculum exhibited approximately 2.0 of the O.D. value in 
the 7-5 ELISA method (Figure 3-6.A). Unexpectedly, non-denatured BH samples of the 
uninfected and TME-infected TgF431 mice showed much higher O.D. values than the 
PrP-KO mouse (Figures 3-19.W and X). Intriguingly, both the 7-5 ELISA and D-5 ELISA 
results showed that these non-denatured BH samples had almost the same O.D. values 
of PrP levels between the uninfected and infected mice at all tested total proteins.  
 In comparison to these TME results, the 7-5 ELISA method in this study section 
showed only small PrPC detections in non-denatured BH samples from uninfected and 
infected conditions of other transgenic mice expressing different PrP species (Figures 3-
19.G to S). Also, these experiments indicated the decreased PrPC detection in TSE-
infected analyte. Hence, the TgF431 mink-PrP expressing mice might have developed 
different responses in the TME infection and pathogenesis, compared to transgenic 
mouse groups with other TSE inoculations. However, it is still possible that TME-
infected TgF431 mice reduced diglycosyl PrPC forms but generated under-glycosylated 
PrPC forms during the TME disease development. These PrPC modifications might 
impair functions of this normal protein, leading to pathological developments during the 




 To understand these observations in TgF431 mice and TME inoculations, the 7-5 
experiment re-analyzed the same tested BH samples above and a new uninfected 
normal mink brain (kindly provided by Dr. Jason Bartz, Creighton University, Omaha, 
Nebraska, USA). Under the denatured condition, this re-evaluation revealed no PrP 
detection in the normal mink brain as equivalent to the PrP-KO mouse (Figure 3-19.Y). 
In contrast, the 7-5 ELISA method detected a higher PrP level in the denatured BH 
sample of the uninfected TgF431 mouse, compared to the PrP-KO mouse and the 
uninfected mink. Although the PrP expressional level of this transgenic mouse breed 
line is equivalent to a wild-type mouse FVB/n, the Tg431 mouse generated under-
glycosylated PrP forms like other transgenic mice with PrP overexpressions (Figures 3-
6.A to D, 3-19.Y). Hence, the tested transgenic mouse breed lines in this dissertation 
should be predisposed naturally to generate under-glycosylated PrP forms. 
 Overall, the 7-5 ELISA and D-5 ELISA methods are useful applications to detect 
various species of PrP expressions in TSE-mouse models. In the TSE disease 
development, the infected mice decreased PrPC detections at their terminal stages. In 
addition, the tested transgenic mouse breed lines above might generate some PrPC 
forms with partial resistances to GdnHCL, and possibly other denaturants too. These 
PrP forms might not have native PrPC conformations but equivalent to these structures 
with which the PRC7 mAb can react after denaturation and renaturation. However, it is 
not clear yet how much this potential PrPC conformer is an influential factor for the TSE 



































































































































































































































































































































































































































































































































































































































































































































































































Figure 3-19. Protein-dose dependent responses for PrP detections in BH samples 
from TSE-inoculated mouse models under different sample preparations. 
RML-inoculated FVB/n BH analyte and its control samples:  
(A) the 7-5 ELISA method with denaturation, (B) the D-5 ELISA method with 
denaturation, (C) the 7-5 ELISA method with non-denaturation, and (D)  
the D-5 ELISA method with non-denaturation.  
CWD-inoculated Tg1536(DeerPrP) BH analyte and its control samples:  
(E) the 7-5 ELISA method with denaturation, (F) the D-5 ELISA method with 
denaturation, (G) the 7-5 ELISA method with non-denaturation, and (H)  
the D-5 ELISA method with non-denaturation.  
CWD-inoculated Tg5037(ElkPrP) BH analyte and its control samples: 
(I) the 7-5 ELISA method with denaturation, (J) the D-5 ELISA method with 
denaturation, (K) the 7-5 ELISA method with non-denaturation, and (L)  
the D-5 ELISA method with non-denaturation.  
CWD-inoculated GT(ElkPrP) BH analyte and its control samples:  
(M) the 7-5 ELISA method with denaturation, (N) the D-5 ELISA method with 
denaturation, (O) the 7-5 ELISA method with non-denaturation, and (P)  
the D-5 ELISA method with non-denaturation.  
Scrapie-inoculated Tg3533(OvineARQ PrP) BH analyte and its control 
samples: (Q) the 7-5 ELISA method with denaturation, (R) the D-5 ELISA method 
with denaturation, (S) the 7-5 ELISA method with non-denaturation, and (T)  
the D-5 ELISA method with non-denaturation.  
TME-inoculated TgF431(MinkPrP) BH analyte and its control samples:  
(U) the 7-5 ELISA method with denaturation, (V) the D-5 ELISA method with 
denaturation, (W) the 7-5 ELISA method with non-denaturation, (X) the D-5  
ELISA method with non-denaturation, and (Y) the 7-5 ELISA method with 
denaturation including uninfected mink BH sample. (n=3 per total protein  








Proteinase K-dose dependent responses for PrP detections in the 7-5 ELISA and 
D-5 ELISA methods 
 Under the non-denatured condition, the D-5 ELISA method detected the 
decrease of PrPC levels in infected materials from TSE-mouse models, compared to 
those uninfected mouse controls. In addition, the D-5 ELISA method measured small 
levels of PrP detections in uninfected materials even under 5M GdnHCL denaturation. 
However, it was not confirmed if the D-5 ELISA method detected only PrPC molecules 
under non-denaturation and what PrP molecules the uninfected transgenic mice 
exhibited in their denatured BH samples. According to a common theory of prion 
propagation, abnormal PrPSc proteins behave as templates for converting normal PrPC 
proteins into the misfolded isoform by changing their conformations. The templates 
guide the misfolding of more normal proteins into the pathologic PrP conformation. 
These newly formed PrP molecules can then go on to convert more proteins as new 
templates. These consequences trigger a chain reaction that produces large amounts of 
the PrPSc isoform. In addition, PrP molecules with conformational alterations acquire 
resistances to protease, denaturation by chemical and physical agents, radiation, and 
others. Thus, the decreased PrPC levels in TSE-infected animals could be associated 
with the structural conversions of normal PrPC to misfolded PrPSc forms. These 
conversions would reduce total amounts of PrPC molecules, compared to uninfected 
mice. In addition, the D-5 ELISA method might indicate that the detected PrP level in 
the denatured BH samples from uninfected transgenic mice reflects the tolerance of the 
PrP structure against 5M GdnHCL. Possibly, detected PrPC molecules have alternative 




 To understand the existing PrP molecules that the D-5 ELISA method measured 
in the denatured BH samples from uninfected transgenic mice, the D-5 ELISA method 
was applied to test both denatured and non-denatured BH samples of a hemizygous 
Tg4112 mouse breed line with murine PrPC overexpressions: 2-4 folds higher than a 
wild-type FVB/n mouse. The PrP levels that the 7-5 ELISA and D-5 ELISA methods 
detected in the non-denatured BH samples could be the same types of the existing PrP 
molecules in the denatured samples the D-5 detected above. Other testing BH samples 
included PrP-KO, uninfected FVB/n and RML-inoculated FVB/n mice. The final amount 
of total protein was 20µg per well (n=3 as technical replication) for each mouse. Prior to 
these D-5 ELISA experiments, a working prediction was that the uninfected Tg4112 
mouse BH sample with the same species of PrP expressions would not exhibit 
detectable PrP levels under denatured and non-denatured conditions, as similar to the 
observations in uninfected wild-type mice. However, the Tg4112 mouse BH sample 
showed much higher detections of PrP levels in both denatured and non-denatured 
procedures (Figures 3-20.A and B). Under the denatured condition, the O.D. value of 
the uninfected Tg4112 mouse was closely high to that of the RML-infected murine 
material. Hence, this result indicated that the Tg4112 mouse naturally generated 
resistant PrP molecules to the high concentration of GdnHCL denaturation. In contrast, 
both uninfected FVB/n and Tg4112 mice showed higher PrP levels than the infected 
mouse under the non-denaturation procedure; the Tg4112 mouse exhibited an elevated 
O.D. value in comparison to the uninfected FVB/n mouse. Thus, these unpredicted 




generate both native and unknown PrPC molecules because of the tolerance to 
denaturation.  
 Uninfected transgenic mouse breed lines with PrP overexpressions 
spontaneously presented developments and progressions of clinical neurological signs 
and neuromuscular degenerations.34 In fact, the laboratory database has records of 
some spontaneous disease cases in the in-house uninfected transgenic mouse breed 
lines (i.e. Tg4112). These evidences suggested that PrP or PrPC overexpressions are 
irregular conditions that might trigger dysfunctions in the nervous system. Thus, the PrP 
overproduction and/or accumulation must be pathologic or toxic conditions to mice, but 
not dependent on either PrPC or PrPSc isoform to cause functional impairments. 
Furthermore, intermediate conformers between PrPC and PrPSc isoforms have been 
found in uninfected brains and cultured cells.35-38 These newly PrP conformers were 
spontaneously generated with the PrPSc-like characteristics of insoluble aggregation 
and resistance to proteolysis, which the N-linked glycosylation status of the PrP 
conformation could be involved in these unusual PrP generations. Therefore, the 
GdnHCL-resistant PrP conformers in the uninfected Tg4112 mouse might result from 
irregularly alterations in protein foldings or syntheses during PrP overproductions in 
natural conditions.  
 For further analyses for the generation of non-native PrP conformers in 
uninfected Tg4112 mice, proteinase K (PK) was applied to sample preparations for 
ELISA experiments. This approach would evaluate the presence of PK-resistant PrP 
molecules in uninfected Tg4112 mice. For this experimental aim, the D-5 ELISA and 7-5 




FVB/n, uninfected Tg4112, and RML-infected FVB/n mice) under both denatured and 
non-denatured conditions with or without the PK digestion. Since the established 
Sandwich ELISA protocol did not include the PK treatment, the following sample 
preparations were applied. 
 1) Low dose of PK treatment: 
 Denaturation: BH samples were treated with 2.5µg/ml PK concentration in PBS 
with 1% TX100 and 0.1% Sarkosyl (denoted as PK+), whereas PBS with only 1% 
TX100 was added into non-PK treating samples (denoted as PK-). These samples were 
incubated at 37°C for one hour with 1,000rpm agitation, followed by an addition of 
PMSF (2mM) for PK+ samples and PBS for PK- samples. After the incubation on ice for 
10 minutes, all samples were denatured with 5M GdnHCL, and then 10 times diluted by 
PBS with 1% BSA and protease inhibitor to be final protein concentration 200µg/ml 
under the optimized ELISA protocol.  
 Non-denaturation: PK+ BH samples were treated as the processes above until 
the PMSF step. Subsequently, the PK+ samples were diluted by PBS with 1% BSA and 
protease inhibitor to be final protein concentration 200µg/ml. PK- samples were 
prepared under the optimized protocol, and diluted by the PBS solution to be 200µg/ml. 
100µl of each prepared sample from these procedures was coated onto respective wells 
(n=3 as a technical replication: each well contained total protein 20µg of a prepared 
sample.) on ELISA plates pre-coated with either D18 or PRC7 capture antibody. All of 
following procedures were completed under the optimized ELISA protocol.  
 For the lower PK dose experiment, the D-5 ELISA and 7-5 ELISA methods 




samples under the denatured and non-denatured conditions, compared to the non-PK 
treated results (Figures 15-C to 15-J). In addition, the 7-5 ELISA method detected high 
PrP levels of uninfected Tg4112 BH samples under denatured and non-denatured 
conditions with and without the PK treatment (Figure 15-G to 15-J). These results 
indicated that Tg4112 mice generated under-glycosylated PrP forms with some 
resistances to high GdnHCL and low PK concentrations. Therefore, the detected PrPC 
molecule might have the PK tolerance to 2.5µg/ml concentration that was not effective 
for protein digestions. Hence, these consequences suggested that the generation of 
under-glycosylated PrP forms concurrently occurred with the production of non-native 
PrP conformers in the Tg4112 mouse. Since the loss of glycans is involved in causing 
fatal diseases (i.e. congenital defect of glycan) and sensitizing cells to apoptosis, the 
overproduction and accumulation of under-glycosylated PrP forms can be factors        
affecting health conditions, especially for maintaining normal functions in nervous 
systems that contain abundances of PrPC levels.  
 2) Higher dose of PK treatment: 
 Denaturation: Instead of the 2.5µg/ml PK and 0.1% Sodium-lauroyl sarkosinate 
(Sarkosyl) concentrations above, PBS with 50µg/ml PK concentration in 2% Sarkosyl 
was applied to PK+ BH samples. Sarkosyl is a detergent commonly used in the TSE 
research for purifying protease-resistant PrP molecules from TSE-infected materials.39 
In the WB protocol of this dissertation, 2% of this detergent was used in sample 
preparations with the PK reagent. However, Sarkosyl inhibits interactions of PrPC and 
PrPSc isoforms by polymerizing synthetic peptide fragments of PrP molecules.40 In 




sample incubation for one hour with 1,000rpm agitation at 37°C, PMSF (2mM) was 
added into PK+ samples, whereas only PBS was applied for PK- samples. Following 
sample incubation on ice for 10 minutes, denaturation with 5M GdnHCL was performed 
for these samples. Denatured samples were ten-times diluted by PBS with 1% BSA and 
protease inhibitor to be a final protein concentration of 200µg/ml under the optimized 
ELISA protocol.  
 Non-denaturation: PK and PMSF treatments were performed for PK+ samples, 
which were then diluted with PBS containing 1% BSA and protease inhibitor to be 
200µg/ml. PK- samples were diluted with the same PBS solution to be the 200µg/ml 
final protein concentration. 
 As described in the lower PK treatment above, sample coating and subsequent 
procedures were performed under the optimized ELISA protocol. For the denatured 
sample condition in the D-5 ELISA experiment, the higher PK concentration eliminated 
PrP detections in uninfected FVB/n and Tg4112 mouse BH samples, whereas the RML-
infected FVB/n BH sample was resistant to this PK dose (Figures 3-20.K and L). Thus, 
the detected PrP molecules in these uninfected mice were possibly neither PrPSc nor 
the intermediate PrP conformers mentioned above, but still tolerant to 5M GdnHCL. For 
the non-denatured condition, in contrast, the D-5 ELISA method could not detect any 
PrP levels in all tested BH samples with the PK treatment (Figures 3-20.M and N). 
Hence, the D-5 ELISA method detected PK-sensitive PrP molecules under the non-
denaturation, which must be only PrPC isoforms, especially for the uninfected samples. 
Possibly, the limited response of the lower PK dose was associated with the structural 




Intriguingly, the 7-5 ELISA method showed the reduction of an O.D. value in the 
denatured BH sample of RML-infected FVB/n mouse with the high PK dose (Figures 3-
20.O and P). This decreased O.D. value indicated the instability of under-glycosylated 
PrPSc forms during the PK treatment. These PrPSc forms might be less resistant to the 
PK digestion, compared to diglycosyl PrPSc agents. In fact, the denatured RML-infected 
BH sample did not affect PrP detections with the PK treatment by the D-5 ELISA 
method that detected all four glycosyl PrP forms (Figures 3-20.K and L). Therefore, the 
difference of PK-treated PrP levels between these two ELISA methods indicated the 
existence of PK-sensitive PrPSc agents, known as equivalently infectious to PK-resistant 
PrPSc agents in the same TSE strain.41-43   
 In addition, the 7-5 ELISA method detected the under-glycosylated PrP forms 
with GdnHCL tolerance in the Tg4112 BH sample without PK treatment, but the higher 
PK dose eliminated the PrP detection (Figures 3-20.O to R). These outcomes 
suggested that under-glycosylated PrP forms could be predisposed to lose these 
conformational stabilities against the increasing PK doses. In addition, the Tg4112 
mouse generated large amounts of under-glycosylated PrP forms with GdnHCL 
tolerance, which exhibited a similar O.D. value to the TSE-infected material (Figure 3-
20.O). Thus, these PrP forms might have generated the PrP oligomerization or 
aggregation for maintaining these conformational stabilities or tolerances to influential 
factors. It is curious that transgenic mouse breed lines with PrP overexpressions have 
this phenomenon, rather than misfolding of the PrPC structure. These protein-complex 
formations might preserve PrP molecules from direct exposures to denaturants or other 




preserved PrP molecules in the formations. In addition, uninfected wild-type mouse 
breed lines (FVB/n and C57BL6: Figures 3-19.A and C) and several uninfected 
transgenic mice exhibited GdnHCL-tolerant PrPC molecules. If these murine PrPC 
molecules have some conformational modifications from the native PrPC structures, 
these altered agents could have acquired some resistance to denaturation, similar to 
PrPSc isoforms. Thus, the denaturation-tolerant PrPC forms might interact with the PrPSc 
templates for pathogen replications and propagations. Eventually, these interactions 
would develop more tolerance to exposures from local and systemic environments, 
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Figure 3-20. PrP detections in BH samples from a hemizygous Tg4112 mouse  
with murine PrPC overexpressions. The D-5 ELISA method, testing with  
(A) denatured and (B) non-denatured mouse BH samples.  
The D-5 ELISA method, evaluating the BH samples with (C) non-PK but 
denaturation, (D) low PK with denaturation, (E) non-PK and non-denaturation,  
and (F) low PK with non-denaturation. The 7-5 ELISA method, testing with  
(G) non-PK but denaturation, (H) low PK with denaturation, (I) non-PK and  
non-denaturation, and (J) low PK with non-denaturation.  
The D-5 ELISA method, testing with (K) non-PK but denaturation, (L) high PK 
with denaturation, (M) non-PK and non-denaturation, and (N) high PK with  
non-denaturation. The 7-5 ELISA method, evaluating (O) non-PK but 
denaturation, (P) high PK with denaturation, (Q) non-PK and non-denaturation, 







PK digestions for sub-clinical cases in TSE-mouse models 
 According to the laboratory database, the endpoint experiment of the elk CWD 
brain isolate Bala05-0308 infection was determined in Tg5037 (ElkPrP) mice for the 
estimation of prion titer. For this purpose, the CWD isolate was prepared from 10-1 to 10-
10 dilutions in 10-fold increments. These prepared inocula were injected intracerebrally 
into a Tg5037 mouse group (n=8) at each dilution point.  In this inoculation study, the 
endpoint of the TSE infection was examined as the dilution point, which half of the 
inoculated mice in a group developed clinical signs of the disease in relation to the 
inoculum. The RA-150 study was one of these endpoint experiments where the 10-4 
diluted CWD isolate was inoculated into Tg5037 (ElkPrP) mice. As an outcome, three 
mice developed clinical signs but other three mice did not show (2 of the 8 mice were 
dead). Tissues from these disease mice (animal numbers b581, b582, b586) with 
clinical signs were collected at terminal disease stages. The 7-5 ELISA method 
examined these brains as a biological replication (n=3) in the study section with the 
Figure 3-2 (Figure 3-2.B). Three other mice without clinical signs were euthanized at 16 
months following the inoculations. To determine if modifications of PrPC and PrPSc 
levels were involved in the disease development, the D-5 ELISA and 7-5 ELISA 
methods evaluated these mouse brains with subclinical conditions. In addition, an 
efficacy of PK digestions was determined in these CWD-inoculated Tg5037 mouse BH 
samples by these Sandwich ELISA methods, followed by the same sample preparations 
and experimental procedures from the higher PK-dose study as described above. The 
application of PK digestions would identify the existence of PK-resistant PrP agents in 




two (animal numbers b583 and b584) of these subclinical mice were tested with and 
without denaturation and PK digestion. Also, this experiment included mouse BH 
samples from PrP-KO, uninfected Tg5037, and the CWD-inoculated Tg5037 at 
terminally disease condition in RA-150 study (animal number b582). The D-5 ELISA and 
7-5 ELISA methods analyzed these prepared samples under the optimized protocol: 
respective wells for each sample contains 20µg of total protein per well on ELISA plates 
as described above. 
 Under the denaturation without PK digestions, the D-5 ELISA and 7-5 ELISA 
methods detected a high PrP level in the BH sample from the CWD-infected mouse with 
the disease condition (Figures 3-20.A and C). Using the PK reagent, these ELISA 
approaches only detected a PK-resistant PrP level in the denatured BH sample from the 
terminal-stage mouse (Figures 3-20.B and D). In contrast, O.D. values of the sub-
clinical mice were similar to the uninfected Tg5037 mice with and without the PK 
treatment (Figures 3-20.A and D). These results indicated that the subclinical mice did 
not have prion replication even inoculated with the CWD isolate. 
 In contrast, the subclinical mice exhibited increased PrPC levels in their BH 
samples under the non-denatured condition (no addition of Tris buffer or incubation with 
heating) in comparison to the uninfected sample, while the CWD-positive sample 
decreased (Figures 3-20.E and G). With the PK treatment, all tested samples lost PrP 
detections under the non-denatured condition (Figures 3-20.E to H). Therefore, these 
ELISA results suggested that the modification of PrPC levels were involved in the 
disease development in TSE-affected animals. However, it is unknown if the increase of 




TSE-inoculated mice, which eventually maintained subclinical conditions. Since one of 
PrPC functions is neuroprotection, the increased PrPC levels could participate in 
preservative mechanisms for brains in the CWD inoculated sub-clinical mice against the 
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Figure 3-21. PrP detections in BH samples from CWD-inoculated Tg5037(ElkPrP) 
mice with subclinical conditions.  
The D-5 ELISA method with (A) non-PK but denaturation, (B) high PK with 
denaturation, (C) non-PK and non-denaturation, and (D) high PK with  
non-denaturation. The 7-5 ELISA method with (E) non-PK but denaturation,  
(F) high PK with denaturation, (G) non-PK and non-denaturation, and  






Range of PK-dose dependent responses  
 To confirm capacities of the PrPC tolerance and the PrPSc resistance against PK 
digestions, the D-5 ELISA and 7-5 ELISA methods evaluated different doses of PK 
responses. Since the tested mouse BH samples from the RML bioassays above were 
limited, this ELISA experiment replaced those analyte to test another TSE-infected BH 
sample from the inoculation study TS-06 (RML-inoculations into FVB/n mice; animal 
number c280). Using BH samples from PrP-KO, uninfected FVB/n and RML-inoculated 
FVB/n mice (n=1 for each mouse type), various PK concentrations (0, 0.5, 1, 5, 10, 20, 
50 and 100 µg/ml) were incubated at 37°C for one hour, followed by 2mM PMSF 
incubation on ice for 10 minutes. As described in the higher PK treatment study, the 
same procedures and preparations were performed in these ELISA experiments. Note: 
Sarkosyl was included for sample preparations in the study section with the Figure 3-15. 
Based on preliminary results, however, the tested PK concentrations showed different 
PrP detections under 0.1% or 2% Sarkosyl. To evaluate a PK efficacy properly, the 
following ELISA experiment excluded Sarkosyl in the sample preparation. Also, each 
prepared sample was coated into wells on ELISA plates pre-coated with the D18 or 
PRC7 capture antibody (well number = 4 for each as quadruplication). 
 Intriguingly, both the D-5 ELISA and 7-5 ELISA methods measured the peak of 
O.D. values at 10µg/ml PK treatment in the denatured RML-infected BH sample 
(Figures 3-22.A and B). It was unknown from this experiment how the 10µg/ml PK 
concentration enhanced PrP detections in TSE-infected material. In addition, the non-
PK treated RML-infected BH sample had equivalent PrP detections to 50µg/ml PK 




and/or between 10 and 50µg/ml PK treatment could reflect the amounts of PK-sensitive 
PrPSc agents in this infected BH sample. In contrast to the higher PK dose (50µg/ml) 
study by the 7-5 ELISA methods in the study section with the Figure 3-20 (Figure 3-
20.P), the denatured RML-infected mouse BH sample did not exhibit much reductions of 
PrP detections at 50 and 100µg/ml PK concentrations in this study section of the D-5 
ELISA and 7-5 ELISA experiments (Figures 3-22.A and B). As noticed above, this 
experiment tested a new RML-inoculated FVB/n mouse BH sample from a different 
inoculation experiment, because of limited BH amounts from RML-infected FVB/n mice 
in the RA-150 study. Thus, these outcomes possibly indicated that the under-
glycosylated PrP generation might be dependent on animals, disease conditions and 
progressions, or inoculated TSE isolates. In addition, this experiment did not include 
Sarkosyl for the reason mentioned above. Therefore, these two factors were potentials 
for higher PrP detections under the PK digestion and denaturation in this experiment.  
 For the non-denatured condition, the D-5 ELISA and 7-5 ELISA method 
measured the complete elimination of PrP detections in both uninfected and infected 
samples at 10µg/ml and higher concentrations of PK treatments. These results 
indicated that detected PrP levels under the non-denatured condition were PrPC levels 
(Figures 3-22.C to F). Moreover, the outcomes suggested that the maximum tolerant 
capacity of PrPC molecules against PK digestion could be estimated as between 5-
10µg/ml concentrations (Figure 3-22.E and F). Although the established ELISA 
protocols do not require the PK reagent for PrP detections in TSE-infected materials, 
the 10µg/ml PK treatment would enhance higher PrPSc detections in denatured BH 
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Figure 3-22. PK-dose dependences for PrP detections in the D-5 and 7-5 ELISA 
methods. Using a RML-inoculated FVB/n BH analyte and its control samples, PK 
with denaturation in (A) the D-5 ELISA method and (B) the 7-5 ELISA method; PK 
with non-denaturation in (C) the D-5 ELISA method and (D) the 7-5 ELISA method. 
Detected O.D values at lower PK concentrations in in (E) the D-5 ELISA method 

































































Supplemental application of chemicals that enhance PrP detection in Sandwich 
ELISA applications 
 Based on the finding in the study section with the Figure 3-20 that the 50µg/ml 
PK concentration reduced the PrP detection in the RML-infected mouse BH sample 
(Figure 3-20.P), the previous 7-5 ELISA experiment for its protocol optimizations was 
reviewed. For enhancing PrP detections by the 7-5 ELISA method, different reagents 
were tested to select effective detergents. Currently, Triton X-100 (TX100) is used in 
sample preparations for the 7-5 ELISA protocol. In addition, Sarkosyl is an effective 
reagent in WB for CWD-inoculated transgenic mouse BH samples. However, this 
reagent was influential for PrP detections in RML-inoculated murine BH samples in 
Sandwich ELISA methods. Therefore, the 7-5 ELISA method examined the efficacy of 
Sarkosyl with CWD-inoculated transgenic mouse BH samples. This experiment 
compared with TX100, Sarkosyl, and the mixture (TX100 and Sarkosyl) for sample 
preparations.  
 Here, it is important to note that the following ELISA procedures were slightly 
different from the current 7-5 ELISA protocol. Tested mouse BH samples included from 
PrP-KO, uninfected Tg5037 (ElkPrP), CWD (Bala05-0308 elk brain)-inoculated Tg5037 
(inoculation experiment RA-150; animal number b582), uninfected Tg1563 (DeerPrP), 
and CWD (Bala05-0308)-inoculated Tg1536 (inoculation experiment RA-154; animal 
number B694): one mouse BH sample per each category (n=1). Initially, these BH 
samples were diluted by PBS with either 0.5% TX100, 0.4% Sarcosyl, or both. After the 
incubation for 75 minutes at 37°C, these detergent-treated samples were denatured 




PBS, these diluted samples was 300µg/ml protein concentration, and then 100µl of 
each prepared sample was coated into wells (well number = 2 as duplication; total 
protein 30µg per well). Subsequent procedures were performed under the current 7-5 
ELISA protocol. Intriguingly, the use of 0.4% Sarkosyl reduced the O.D. value of the PrP 
detection in the CWD-inoculated Tg5037 (ElkPrP) mouse BH sample, compared to the 
same BH sample treated with TX100 (Figure 3-23.A).  
 This decreased PrP level was also similar O.D. values to the uninfected controls. 
These observations corresponded to the result from the RML-inoculated FVB/n mouse 
BH sample in the study section of the Figure 3-20, which was treated by PBS with 
50µg/ml PK concentration and 2% Sarkosyl (Figure 3-20.P). Nevertheless, the D-5 
ELISA and 7-5 ELISA methods for the PK-dose dependence showed significant O.D. 
values of PrP detections in the denatured RML-infected material with 50µg/ml or higher 
PK concentrations when Sarkosyl was excluded (Figures 3-22.A and B). These findings 
suggested that some TSE strains or animals might present dose-dependent sensitivities 
to Sarkosyl in Sandwich ELISA experiments. Indeed, the CWD-infected Tg5037 mouse 
BH sample reduced PrP detections with Sarkosyl treatment, compared to the infected 
Tg1536 (DeerPrP) mouse with the same inoculum (Figure 3-23.A). As described in the 
study section of the Figure 3-5, deer and elk PrP structures have one amino acid 
difference at the residue 226: deer has glutamine (abbreviated as Gln or Q), while elk 
has glutamic acid (abbreviated as Glu or E). In the globular domain of the PrPC 
structure, this amino acid residue 226 exists in α-helix 3, and consists of the β2-α2 loop. 
The interaction between the α-helix 3 and the β2-α2 loop is influential for structural 




tertiary structure have roles in the CWD prion replication and pathogenesis.22 Since the 
CWD inoculum Bala05-0308 was originally isolated from elk, its interspecies 
transmission might have altered PrPSc structures for adapting in the new host Tg1536 
(DeerPrP) mice through the interaction with deer PrP molecules and the further PrP 
replications. Therefore, this conformational compatibility might rearrange PrP structures 
between elk and deer, and possibly acquire resistance to Sarkosyl. Moreover, Sarkosyl 
can cause PrP aggregations that are not dependent on the PrPSc features, such as 
infectivity and PK resistance.39 If this phenomenon occurred in the tested BH samples 
from the TSE mouse models above, the Sarkosyl-induced PrP aggregations might 
affect denaturation effects and/or reactivities of PRC7 and PRC5 mAbs to their binding 
epitopes. 
 The 7-5 ELISA studies above indicated that this PrP analytical method is 
sensitive to certain chemicals in sample preparations and experiments. In other words, 
non-tested reagents might have potentials to enhance PrP detections in the 7-5 ELISA 
method. In the literature search for establishing a Sandwich ELISA protocol, I 
recognized that some TSE researchers, such as Dr. Stanley Prusiner and Dr. Christine 
Sigurdson at the University of California, San Francisco, and San Diego, respectively, 
used buffers with extra reagents of sodium group/series for sample preparations and 
dilutions in ELISA methods: i.e. sodium bicarbonate (NaHCO3) and sodium chloride 
(NaCl).44,45 Since buffers for the 7-5 ELISA method did not contain these sodium 
reagents, several reagents were determined with denatured mouse BH samples under 
the 7-5 ELISA protocol.  Further identifications would improve PrPSc detections in TSE 




sodium hydroxide (NaOH), 2) sodium chloride (NaCl), and 3) Monosodium phosphate 
(NaH2PO4, also named as monobasic sodium phosphate and sodium dihydrogen 
phosphate). NaOH is known to convert a PK-resistant PrPSc agent into a PK-sensitive 
form, and also decrease prion infectivity.46,47 However, 10mM NaOH did not eliminate 
PK-resistant PrPSc detections in scrapie-infected hamster BH samples under its dose-
dependent dilutions and incubation-time points by WB assay.46 Thus, an initial testing 
concentration of the three chemicals was 10mM for the evaluation if the 7-5 ELISA 
method would be able to detect PrPSc levels with 10mM NaOH. Each sodium product 
was prepared with PBS (no magnesium and calcium) for three different testing 
conditions in sample preparations under the 7-5 ELISA protocol: either 1) incubated with 
1% TX100, 2) denatured with 5M GdnHCL, or 3) performed both 1) and 2) conditions. 
For the control (1% Tx100 only), PBS was added into testing BH samples, instead of 
the same volume of each chemical. Testing BH samples included PrP-KO, uninfected 
Tg5037 (ElkPrP), and CWD (Bala05-0308)-inoculated Tg5037 (inoculation study RA-
150) mice: one sample from each category as n=1. Total protein 20µg of each prepared 
sample was applied to respective wells on a PRC7 pre-coated ELISA plate (well 
numbers = 2 as duplication).  
 Incubated with TX100 in the 1) condition, 10mM NaOH completely eliminated the 
PrP detection in the CWD-infected BH sample, equivalent to PrP-KO and uninfected 
mice (Figure 17-B). A previous article reported that the 10mM NaOH concentration did 
not eliminate the PrP detection in scrapie-inoculated hamster brains by WB assay.46 
Thus, the PrP reduction in the 7-5 ELISA method might be associated with different 




mouse with elk PrP expressions. Moreover, NaCl slightly enhanced the PrP detection in 
the infected BH sample, whereas NaH2PO4 decreased (Figure 3-23.B). These 
observations also resulted in other steps of the detergent with GdnHCL, and with both 
TX100 and GdnHCL (data not present). In addition, the 7-5 ELISA method determined 
NaCl dose-dependent responses (5, 10, 50, and 100mM) with TX100 treatment using 
the same tested BH samples above.  However, all tested NaCl concentrations did not 
enhance PrP detections in CWD-infected mouse BH samples, compared to the same 
analyte with PBS (Figure 3-23.C).  
 For finding an effective detergent, the second approach evaluated sodium 
bicarbonate (NaHCO3). Its different concentrations (5, 10, and 50mM) in 1% TX100-
containing PBS (without magnesium and calcium) were applied to the same BH 
samples above. All processes and sample preparations were performed under the 7-5 
ELISA protocol, as described in the study section of the Figure 3-16. Intriguingly, the 
supplemental addition of 50mM NaHCO3 increased 1.3 fold of the O.D. value in the 
CWD-infected BH sample, compared to the same analyte with PBS (Figure 3-23.D). 
 Furthermore, 25, 50, and 100mM of NaHCO3 were examined with the same BH 
samples. Indeed, the 25mM concentration showed an equivalent O.D. value of the PrP 
detection to 50mM and 100mM concentrations (Figure 3-23.E). These O.D. values in 
the detergent-treated BH samples from a CWD-infected mouse were approximately 
1.25 times higher than the same analyte with PBS. Therefore, the use of at least 25mM 
NaHCO3 could promote high PrP detections in CWD-infected materials. However, the 
application of this detergent might cause chemical reactions. It is known that the 




Then, H2CO3 quickly decomposes to release water (H2O) and carbon dioxide (CO2). In 
addition, heating causes the thermal decomposition to NaHCO3 that is converted to 
sodium carbonate (Na2CO3), H2O, and CO2. Even at room temperature, NaHCO3 
initiates the CO2 production in diluted solutions. Thus, NaHCO3 might cause extra 
dilutions of tested samples by the produced water, as a sequence of the reaction with 
GdnHCL and heating. 
 To avoid the potential of extra dilutions, I had an interest to test the NaHCO3-
converted product, sodium carbonate (Na2CO3), which is resistant to thermal 
decomposition even at higher temperatures. Since the temperature for the sample 
incubation was at 37°C in the ELISA protocol, Na2CO3 should be less reactive to this 
lower heating temperature during the sample preparation and subsequent processes on 
ELISA plates. Under the same procedures with sodium bicarbonate above, the 7-5 
ELISA method analyzed 25, 50, and 100mM of Na2CO3 with the same CWD-sample 
group. In contrast to the results from NaHCO3, the 25mM Na2CO3 concentration 
increased 1.4 times of the O.D. value in the CWD-infected material, compared to the 
same analyte with PBS (Figure 3-23.F). Also, the increase of Na2CO3 concentrations is 
predisposed to reduce PrP detections. This phenomenon might link to the potential 
production of NaOH in the samples, which the chemical reaction of Na2CO3 with H2O 
produces NaOH and CO2. In fact, the reduction of PrP detections was obvious under 
the low NaOH concentration (Figure 3-23.B). However, this NaOH production should 





 To identify the reduction of PrP detections as specific to sodium carbonate 
Na2CO3, a chemical product of carbonate-bicarbonate buffer-capsule (Sigma-Aldrich) 
was tested. This chemical product contained both Na2CO3 and NaHCO3 in equilibrium. 
Indeed, the aqueous solution of the chemical product has been used for coating capture 
antibodies in the 7-5 ELISA and D-5 ELISA protocols. Under the same procedure above, 
this combined chemical product of 25, 50, and 100mM was determined with the same 
CWD-sample group under the 7-5 ELISA protocol. Since this chemical contained higher 
Na2CO3 amounts from the product and the possible NaHCO3 conversation, the 
reduction of PrP detections was predictable. However, the outcomes from the 
carbonate-bicarbonate product were similar to those from the sodium bicarbonate 
treatment (Figure 3-23.E and G). Although the mechanisms of reactions between PrP 
and these sodium products were unknown in these experiments, the results showed 
that 25mM of the three chemical products enhanced PrP detections in TSE-infected 
materials. One possible assumption was that efficacies of sodium bicarbonate and 
sodium carbonate might reveal binding epitopes of anti-PrP mAbs in the 7-5 ELISA 
method.  Therefore, Na2CO3 and NaHCO3 are effective supplemental detergents for the 
7-5 ELISA protocol, especially for cases that additional enhancements of PrP detections 
would be required, such as limited amounts of testing samples for TSE diagnoses.  
 In past Sandwich ELISA experiments, PrP detections in TSE-infected materials 
were not successful when some buffers contained sodium deoxycholate (DOC: 
deoxycholic acid sodium salt) and/or sodium dodecyl sulfate (SDS). It was unknown 
how these chemicals interfered for PrP detections in the 7-5 ELISA method. DOC is one 




ELISA method measured the extracted samples of TSE-infected cells, treated by the 
lysis buffer with DOC. However, these samples did not exhibit PrP detections. Since the 
7-5 ELISA method has been developed using mouse BH samples and recombinant PrP 
molecules, this protocol might be not applicable to cellular materials. In addition, SDS is 
one of the chemical materials in the application of PNGaseF that enzymatically removes 
N- and O-glycans from proteins (protein deglycosilation). The PNGaseF application was 
success for the WB assay to detect PrP levels in TSE-infected cellular extract 
samples.20 The successful use of PNGaseF will promote more PrP detections by the 
PRC7 mAb, because all PNGaseF-treated PrP molecules would be unglycosyl forms. 
According to the results in this study section, doses of each chemical influenced PrP 
detections in the 7-5 ELISA method. Therefore, the following concentrations of DOC 
and SDS were evaluated under the same procedures and preparations with the CWD-
sample group above with the 1% TX100: DOC = 0.1, 0.25, and 0.5%; and SDS = 0.1, 
0.5, and 1%. In the 7-5 ELISA results, all DOC concentrations reduced O.D. values of 
PrP detections in the CWD-infected material (Figure 17-H). However, 0.1% SDS 
treatment enhanced PrP detections in the infected materials, while the increased 
concentrations reduced PrP detections (Figure 3-23.I). Thus, these outcomes 
suggested 1) no use of DOC for PrP detections in cellular extracts under the 7-5 ELISA 
protocol, and 2) minimal use of SDS at lower than 0.5% if needed.  
  Overall, the 7-5 ELISA approach must be sensitive to certain chemicals and 
concentrations that affect PrP detections. It is important to make sure what chemical 
components the testing sample and other materials contain, prior to the 7-5 ELISA 




the other hand, sodium bicarbonate and sodium carbonate are effective chemicals for 
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Figure 3-23. Evalutions of supplemental reagents with TX100 for enhancing  
PrP detections in BH samples from CWD-mouse models. (A) Comparisons of 
TX100 and Sarkosyl in the 7-5 ELISA method with denatured analyte,  
(B) Comparisons of NaOH, NaCl, and NaH2PO4 with TX100 in the 7-5 ELISA 
method with denatured analyte, (C) NaCl-dose dependent responses in  
the 7-5 ELISA method, (D) sodium carbonate (NaHCO3)-dose dependent 
responses in the 7-5 ELISA method with denatured analyte, (E) PrP detections 
with lower NaHCO3 concentrations in the 7-5 ELISA method with denatured 
analyte, (F) PrP detections with sodium carbonate (Na2CO3) in the 7-5 ELISA 
method with denatured analyte, (G) PrP detections with sodium carbonate-
bicarbonate reagent in the 7-5 ELISA method with denatured analyte,  
(H) PrP detections with sodium deoxycholate (DOC/SDS) in the 7-5 ELISA 
method with denatured analyte, and (I) applications of lower DOC concentrations. 







PK-sensitive PrPSc detections in mouse models of human inherited prion disease  
 Gerstmann-Sträussler-Scheinker syndrome (GSS) is an autosomal-dominant 
inherited TSE disease in humans, caused by mutation at the codon 102 on 
choromosome 20 of Prnp gene from Proline (P) to Leucine (L), referred to as P102L. 
Transgenic (Tg) mouse breed lines of GSS models have been established.48-54 In this 
study section, experimental studies examined BH samples from a transgenic mouse 
breed line expressing the mutation P101L in the murine PrP gene, here denoted as 
Tg(GSS), corresponding to the human P102L GSS mutation.19 These Tg(GSS) mice 
spontaneously developed the CNS dysfunction and reproduced the neuropathological 
features of GSS. Moreover, these Tg(GSS) mice generate PK-sensitive PrP forms.19 In 
fact, GSS patients also exhibit abundant portions of PK-sensitive PrPSc agents in their 
brains.55  Thus, the Tg(GSS) mice present GSS features clinically and molecularly. 
According to the laboratory database, hemizygous Tg464 mice of Tg(GSS) mouse 
breed lines overexpress murine PrP molecules with the mutation of the GSS-
corresponding residue P101L, which are twelve times higher than the PrPC expression 
in uninfected wild-type mice. Clinically, the Tg464 mice spontaneously exhibited onsets 
of neurological signs and disease developments. Moreover, the inoculation of brain 
materials from a spontaneously sick Tg464 mouse into immature host Tg464 mice at 
non-sick stages caused earlier disease progressions, compared to the scrapie sick day 
of the spontaneous GSS development in these mice.  
 Prior to the 7-5 ELISA experiment, WB with the PK reagent were performed with 
Tg464 mouse BH samples to confirm the non-existence of PK-resistant PrPSc 




inoculation study KN-35, as well as negative and positive controls: PrP-KO, uninfected 
FVB/n, uninfected Tg4112 (MousePrP overexpression), and RML-inoculated FVB/m 
mice. The WB results indicated that PK-treated BH samples of all GSS mice lost PrP 
detections, similar to outcomes in uninfected wild-type FVB/n and Tg4112 mice. In 
contrast, the RML-infected BH sample exhibited PK-resistant PrP agents (Figure 3-
24.A). Therefore, the Tg464 mouse breed line only expressed PK-sensitive PrP 
molecules in the disease condition, but not PK-resistant PrPSc forms. 
 1) GdnHCL-dose dependent responses of Tg(GSS) mouse BH samples by 
the 7-5 ELISA method: The dose dependence of GdnHCL denaturation was 
determined with Tg464 mice, if the spontaneous GSS mouse model would show the 
same outcomes from the 7-5 ELISA method above using other TSE strains and 
transgenic mice with different PrP species. Testing BH mouse samples included the 
three Tg464 mice (n=3), and controls of PrP-KO, uninfected FVB/n, and RML-inoculated 
FVB/n mice (n=1). Under the optimized 7-5 ELISA protocol, three different doses of 
GdnHCL (0M, 2.5M and 5M) were examined with these BH samples for denaturation. 
The final protein concentration of these prepared samples was 200µg/ml, and then 
100µl of each sample was coated into wells (total protein per well = 20µg; well numbers 
for each sample = 3 as technical triplication). In the coated samples, the residual 
amounts of GdnHCL were 0, 0.25, and 0.5M for each denaturation category, 
respectively.  In the results, 0M GdnHCL (only addition of 50mM Tris) denaturation did 
not enhance PrP detections in the RML-infected and the Tg(GSS) BH samples (Figure 
3-24.B). However, the Tg464 mice showed low O.D. values of PrP detections that could 




experiments above. In contrast, the increased GdnHCL doses enhanced higher PrP 
detections in these disease mouse BH samples, especially at 5M GdnHCL (Figures 3-
24.C and D). Thus, the optimized protocol maintained the 5M GdnHCL denaturation in 
Sandwich ELISA experiments with the Tg464 mice BH samples below. Based on these 
results, PrP molecules in the GSS mouse models should form abnormal PrPSc or PrPSc-
like structures at their terminal stages, because the PRC7 mAb requires denaturation 
and renaturation of the PrPSc isoforms for these detections. Also, the tested Tg(GSS) 
transgenic mice generated unglycosyl and/or mono-1 glycosyl PrP forms that the PRC7 
mAb can react with. Hence, under-glycosylated PrPSc forms could be PK-sensitive PrP 
agents in TSE-disease mice.  
 In the TSE pathogenesis, PK-sensitive PrPSc agents exhibit an equivalent 
infectivity and neurotoxicity to PK-resistant PrPSc agents in the same TSE strain.41-43 
These PK-sensitive PrPSc agents are also known as forming smaller oligomeric 
aggregates that induce neurotoxicity and neurodegeneration.56-57 In fact, the small 
aggregate is a causal molecule of the protein misfolding and disease initiation, because 
smaller aggregates possess a higher seeding potency in the conformational conversion 
and replicative process, under a template-associated progression of the protein-only 
hypothesis.58  Since the 7-5 ELISA protocol does not require the PK reagent, the 
established approaches should be capable of detecting small aggregates of PK-
sensitive PrPSc forms in TSE-infected materials. According to the results, the 7-5 ELISA 
application presented a successful utility to evaluate PK-sensitive PrPSc agents in 
Tg464 mice. Indeed, this ELISA method highly detected these PrPSc agents in BH 




Therefore, the 7-5 ELISA method will be ultimately beneficial for detecting PK-sensitive 
PrPSc agents in TSE diagnostic investigations and understanding the TSE pathogenesis 
in research.  
 2) Different tissue-collecting time points from Tg(GSS) mice and the 7-5 
ELISA approach: According to the laboratory database, many collected tissues from 
previous GSS mouse model studies were already used, and thus amounts of stored 
samples from Tg(GSS) mice were very limited. However, some brains from non-sick 
conditions of homozygous Tg464 mice were available for this ELISA experiment. This 
pilot study included five BH samples from non-sick Tg464 mice: 2 brains at 61 days, 1 
brain at 81 days, and 2 brains at 142 days from their births, in addition to the three 
GSS-developed Tg464 mice above. Notably, these GSS mice were originated from the 
inoculation study KN-35: the inoculation of 1% crude brain homogenate from a 
spontaneously GSS-developed Tg464 mouse into young Tg464 mice at 40 days old 
(non-clinical sign). Their scrapie sick days were Mean ± SEM = 105.38 ± 2.03 days, 
whereas those in homozygous Tg464 mice with spontaneous disease developments 
were an average of 160 days. All BH samples from these non-sick and disease mice 
were prepared by the same procedures, including denaturation with 5M GdnHCL under 
the 7-5 ELISA protocol. Intriguingly, Tg464 mice with non-clinical signs exhibited higher 
PrP levels even from 61 days of birth. (Figure 3-24.E). Compared to the non-disease 
conditions, the 7-5 ELISA method measured the increased O.D. value in the disease 
conditions of Tg464 mice. These results indicated that the GSS mouse model highly 
generated under-glycosylated PrPSc forms from early lifetime after the birth.  However, it 




the feature of PrP-overexpressing transgenic mouse breed lines, such as Tg4112 
mouse with mouse PrP overexpressions.  
 3) Different tissue-collecting time points from Tg(GSS) mice and                      
the D-5 ELISA approach: To evaluate modifications of PrPC and PrPSc levels in 
disease progressions, the D-5 ELISA methods examined one BH sample from each 
tissue-collecting time point, under the denatured and non-denatured sample 
preparations: non-sick 61, 81, and 142 days after the birth, and a GSS-disease 
developed Tg464 mouse that the 7-5 ELISA method already tested. As described 
above, the D18 Fab Ab has unique characteristics for ELISA applications. This antibody 
requires denaturation to detect PrPSc levels in TSE-infected materials. In contrast, this 
antibody recognizes only PrPC levels in uninfected and infected murine BH samples. 
Also, the D18 Fab Ab is capable of reacting with all four glycosyl PrP forms.  
 In this D-5 ELISA experiment, all procedures were performed by the optimized 
ELISA protocol.  Each well on an ELISA plate contained total protein 20µg of each 
prepared sample (well number = 3 as technical replication). Intriguingly, the D-5 ELISA 
method detected an inverse proportion of PrPC and PrPSc modifications in the GSS 
development, which PrPC levels decreased, but PrPSc levels increased through their 
lifetimes (Figure 3-24.F). Compared to the 61 days at a non-sick state, the GSS 
condition increased approximately 1.3% of denatured PrPSc detections. In the non-
denatured preparation, the GSS mouse decreased almost 1.3% of PrPC detections in 
comparison to the 61 days BH sample. Thus, this PrPC decrease might indicate 
conformational changing amounts or rates of the PrPC molecule to the abnormal PrPSc 




interacts with the normal PrP molecule. In another aspect, the PrPC decrease in the 
disease condition might reflect damages in the affected brain.  The death of many 
affected cells should reduce total amounts of PrPC detections in the tested brain 
sample. In contrast, the 7-5 ELISA method showed low O.D. values of PrP detections at 
all time points of Tg464 mouse BH samples (Figure 3-24.G). This observation indicated 
that tested Tg(GSS) mice generated less amounts of unglycosyl and/or mono-1 glycosyl 
PrP forms through disease developments. However, both denatured and non-denatured 
PrP detections in these analyte increased O.D. values from the 81 days after birth. 
Thus, this increase should be proof of under-glycosylated PrP generations in the TSE 
pathogenesis. 
 Based on the features of D18 and PRC7 antibodies, Tg464 mice generate both 
PrPC and PrPSc isoforms with the GSS genetic background. In the D-5 ELISA method, 
the detected PrP level must be the PrPC structure under the non-denaturation, whereas 
the denatured PrP levels indicate PrPSc conformations. Thus, PrPC molecules with the 
P101L mutation in Tg464 mice initially formed α-helical structures, but subsequently 
misfolded to β-sheet rich structures in TSE conditions. Hence, the reduction of PrPC 
detections reflects not only the PrP conformational change from the normal to abnormal 
isoform, but also the disease development and progression.  At this point, however, it is 
unknown what factors trigger the conformational changes from PrPC and PrPSc 
conformers in this spontaneous Tg(GSS) mouse model.  
 Supplementarily, the D-5 ELISA method determined PrPC modulations in drug-
induced mouse models of Parkinson’s disease (PD), one of the major 




Department of Environmental and Radiological Health Sciences at Colorado State 
University; data not present). Under the non-denatured sample preparation, the D-5 
ELISA method revealed the reduction of PrPC levels in BH samples from the PD mouse 
models at the onset of clinical signs, compared to pre-treated mice. Moreover, these PD 
mouse BH samples were determined by Sandwich ELISA approaches using other 
capture antibodies PRC7 and POM2 mAbs. With the detecting antibody PRC5 mAb, a 
POM2-base ELISA approach showed similar reductions of PrPC levels in the disease-
developed PD mice. However, the 7-5 ELISA method did not measure PrPC levels. 
These results suggested that the abundance of PrPC molecules were a diglycosyl state 
in normal and PD conditions. Hence, the generation of under-glycosylated PrP forms 
should be a specific phenomenon in the TSE pathogenesis.                               
 As the 7-5 ELISA method detected in Tg464 mice of the GSS model above 
(Figure 3-24.G), the modulation of PrP glycosylations might link to the conformational 
change from PrPC and PrPSc structures, or the generation of abnormal PrP conformers 
in the GSS pathogenesis. Because the loss of glycans causes the instability of protein 
conformations, PrP molecules with glycosidic deficits might allow more replications of 
PrPSc isoforms via the interaction of these molecules and abnormal templates. To 
evaluate this potential implication, the 7-5 and D-5 ELISA approaches would be capable 
of analyzing modulations of the PrPSc glycosylation state and the PrPC and PrPSc 
detection in longitudinal studies of the GSS disease development and progression in 
Tg464 mice. 
 For further identifications, these ELISA experiments should be applied for 




adapted scrapie strain (i.e. RML and 22L) into a wild-type mouse breed line (i.e. FVB/n 
and C57BL6 mice). This experimental plan will reduce potential influences from 
unknown generations of under-glycosylated PrP forms that the 7-5 ELISA method 
detected in uninfected transgenic mouse breed lines. However, these longitudinal 
studies of TSE-mouse models would have technical limitations for monitoring PrP 
modulations. Brain biopsies must be difficult to repeat at different time points in a same 
animal, even collecting partial brain tissue samples. Because of mouse body size, this 
procedure is risky for maintaining mouse health conditions and lives for completing the 
studies. Therefore, timed-specimen collections should be a practical plan for this aim. 
For each specific time point of tissue collections, the same numbers of mice should be 
prepared at the beginning of the studies. Then, tissues would be collected at each time 
point for analyzing the disease progression and the correlative PrPC-PrPSc modulation. 
As described above, the 7-5 ELISA and D-5 ELISA approaches are very sensitive to 
detect PrP quantities in testing samples, even subtle differences. Also, these Sandwich 
ELISA protocols are especially capable of measuring both PK-sensitive and resistant 
PrPSc isoforms in TSE-infected materials. Consequently, these approaches would be 
indispensable innovations for identifying the underlying mechanisms of the PrPSc 

































































































































































































































Figure 3-24. PK-sensitive PrPSc molecules in GSS-mouse models.  
(A) Western blot (WB) analyses of PrP detections in BH samples from  
three Tg464 (GSS) mice with terminal stages. These mice did not exhibit  
PK-resistant PrP detections, compared to the RML-inoculated FVB/n BH analyte.   
6H4 mAb for the upper analysis and PRC7 mAb for the lower analysis.  
(B) 0M GdnHCL, (C) 2.5M GdnHCL, and (D) 5M GdnHCL denaturations for  
BH samples of the disease Tg464 (GSS) mice without PK treatments for  
PrP detections by the 7-5 ELISA method. (E) the 7-5 ELISA method detected  
PrP levels in denatured BH samples from Tg464 (GSS) mice, at different ages with 
non-clinical conditions or GSS development, without PK treatments.  
Brains from non-sick mice were collected at 61, 81, and 142 days of ages.  
Brains from the diseased mice were collected at terminal stages. 
In both non-denatured and denatured BH samples, (F) the D-5 ELISA method 
measured all forms of the PrP glycosylation, and (G) the 7-5 ELISA method detected 
unglycosyl and mono-1 glycosyl PrP forms. Modulations of PrP levels  
in BH samples from Tg464 (GSS) mice at different-time points of  
tissue collections. Ages at 61, 81, and 142 days were no clinical signs.  
Brains from the diseased mice as GSS were collected at terminal stages. 









 The 7-5 ELISA method is an exceptionally sensitive approach for detecting PrPSc 
isoforms in a RML mouse scrapie-infected brain homogenate (BH) sample (Figures 3-
1.A and B). The O.D. value differences between TSE-infected and uninfected or PrP-
KO mouse are statistically significant (n=3 for technical repeats; p<0.0001). Biological 
replicates (n=3) of three mouse groups (TSE-infected, uninfected, and PrP-KO) showed 
specificities of the 7-5 ELISA method for the PrP detection in BH samples from RML-
inoculated FVB/n, CWD-inoculated Tg5037 and CWD-inoculated Tg1536 mice (Figures 
3-2.A, B and C). At the 20µg amount of total protein, the differences of O.D. values 
between TSE-infected and uninfected BH samples are statistically significant (p<0.01-
0.0001). These differences arose from the PRC7 mAb feature that only reacts with 
unglycosyl and mono-1 glycosyl PrP forms. Hence, the 7-5 ELISA results indicate that 
under-glycosylated PrP forms are highly generated in TSE-infected animals during the 
disease development, but not in uninfected animals because PrPC molecules normally 
preserve the diglycosyl form. Therefore, the PrP glycosidic state could be implicated 
with mechanisms of the TSE pathogenesis.  
 Furthermore, the 7-5 ELISA method is capable of detecting PrP levels in BH 
samples from TSE-infected mouse models with different PrP species backgrounds, 
such as mice, elk, deer, sheep, or mink (Figures 3-3.A to E). According to the protein 
dose-dependent approach, tested TSE-infected BH samples obviously exhibited the 
increased PrP detection at higher amounts of total protein, while uninfected controls did 
not show any or subtle change (Figures 3-3.A to E). Indeed, these outcomes were 




scrapie, and TME. Based on high PrP detections in TSE-infected mouse BH samples, 
the 7-5 ELISA method revealed that these disease animals preferentially generated 
under-glycosylated PrP forms in their brains. At the same tested total protein, the 7-5 
ELISA method intriguingly detected different PrP levels of mouse BH samples among 
the five mouse-adapted scrapie strains (Figures 3-4.A to E). Although all strains 
exhibited significantly higher PrP detections than controls, these O.D values showed 
strain differences in inoculated mice. Hence, these results suggested that the 
generation and quantity of under-glycosylated PrP forms might be dependent on distinct 
PrPSc strains in infected hosts. In addition, each strain presented different responses to 
concentrations of the denaturant, guanidine hydrochloride (GdnHCL), under the 7-5 
ELISA method analyses at the 20µg of total protein per BH sample. Thus, this ELISA 
application additionally evaluated different denaturants and reagents with various prion 
isolates and strains. Possibly, these responses for chemicals reflect differences of 
conformational stabilities among prion isolates and strains. In diagnostic and analytical 
aspects, the 3-5M range of GdnHCL should be applicable for denaturation to detect 
higher amounts of PrP molecules in TSE-infected materials (Figures 3-4.A to E). 
 In CWD mouse models, the 7-5 ELISA method found that structure 
rearrangements of PrPSc agents between different species were dependent on the 
origin of CWD isolates and the conformational compatibility of PrP molecules. The 
inoculation of moose-CWD isolate (08W-11,741) into Tg1536 (DeerPrP expression) 
mice enhanced the detection of under-glycosylated PrP forms in these BH samples, 
compared to the PrP level of the moose-CWD BH inoculum at the same amount of total 




not increase PrP detections. These observations could be associated with identical 
primary PrP structures in deer (Odocoileus species) and Shira’s moose (Alces alces 
shirasi). However, the PrP structure of elk is different from deer and moose at the amino 
acid residue 226 in the globular domain, which is considerably essential for the CWD 
prion propagation and disease development.22 The experimental results suggested that 
the conformational compatibility was a critical factor for PrPSc transmissions between 
different species, as well as its structure rearrangement and propagation in infected 
hosts. In fact, the inoculation of a CWD isolate from elk (99W12389) did not enhance 
the generation of under-glycosylated PrP forms in Tg1536 (DeerPrP) mice (Figure 3-
5.D). However, the 7-5 ELISA method showed higher detections of under-glycosylated 
PrP forms in Tg1536 (DeerPrP) mice with inoculations of the murine-brain isolate, 
originated from the elk CWD 99W12389-infected Tg5037 (ElkPrP) mouse (Figure 3-
5.E). Moreover, the inoculation of another elk CWD isolate (Bala04) also exhibited the 
same observation in these transgenic mice (Figures 3-5.F and G). These outcomes 
indicated that the passage of cervid CWD inocula into differing transgenic mice with 
cervid PrP expressions enhanced the adaptation and propagation of infected PrPSc 
agents in new murine hosts, even though their PrP structures were different. Hence, the 
predominant adaptation and selection of the infected PrPSc structure reflect the 
interspecies transmission of TSEs in new hosts. Thus, the 7-5 ELISA results revealed 
that some factors in CWD-infected murine hosts could be involved in the mechanism of 
the PrPSc adaptation and propagation, which should be dependent on the structural 





 Furthermore, the 7-5 ELISA method measured the non-enhanced PrP level in 
transgenic mice with mink PrP expressions (TgF431) that were inoculated with the three 
different TME isolates from mink (#58 NBP, 10-5 cloned TME 941031 and 10-5 cloned 
TME 941201), compared to analyte of these mink TME brain inocula at the same 
amount of total protein (Figure 3-6.B, C and D). These results might suggest that the 
structural arrangement of mink TME PrP agents was not well promoted in murine hosts 
to generate and propagate this abnormal PrPSc agent, because of the conformational 
incompatibility between these two different PrP species backgrounds. Possibly, some 
other factors in hosts implicated the compatibility for propagations of the heterogeneous 
PrPSc agent. In fact, experimental transmissions of TME isolates are not successful into 
several wild-type mouse breed lines because of possible biological reasons, while 
Syrian golden hamsters have been used in TME transmissible studies.3,59 Moreover, 
black ferret, a close mustelid to mink, was less susceptible to the TME infection and 
disease development, compared to mink.60 As described above in deer and elk, mink 
and ferret have differences in amino acid sequences of the PrP genes at two codons: 
phenylalanine (Phe or F) vs. lysine (Lys or L) at 179, and arginine (Arg or R) vs. 
glutamine (Glu or Q) at 224, respectively (mink vs. ferret). Therefore, the amino acid 
differences (cervid at 224 and mustelid at 226) in the globular domain of the PrP 
structure could be important factors in the conformational compatibility for the 
adaptation, structure rearrangement and propagation of infected PrPSc agents in new 
hosts, especially interspecies transmissions of TSEs. After the adaption of infected 
PrPSc conformers, these hosts predominantly would generate these pathogenic agents 




disease developments of the TSE strain phenotype, such as drowsy (DY) and hyper 
(HY) observations of TME isolates.3,61  
 In comparison to the cervid prion cell assay (CPCA), the 7-5 ELISA approach 
demonstrated its potential utility to estimate the prion infectivity and titration (Figures 3-
7.A to D, and 3-8). This pilot application provided a new scope of the 7-5 ELISA method 
in the TSE research for further investigations. In addition, the CPCA results with the 
PRC7 mAb indicated that SMB-PS cells expressed similar levels of under-glycosylated 
PrP forms to those of SMB cells under the non- PK treatment (Figures 3-9.A to F). 
These SMB cells are a scrapie-infected clonal cell line, originally derived from the 
mouse brain with the inoculation of the mouse-adapted scrapie strain Chandler.13 In 
contrast, SMB-PS cells are the permanently cured SMB cells with the treatment of 
pentosan sulphate (PS) that do not express PK-resistant PrP molecules even after 50 
passages.14 Moreover non-infected RK13 cells with murine PrP expressions (RKM7) did 
not exhibit the PrP detection. Although an abundance of normal PrPC molecules states 
the diglycosyl form, the PRC7 mAb only reacts with unglycosyl and mono-1 glycosyl 
PrP forms. These SMB results indicated that RKM7 cells did not generate under-
glycosylated PrP forms under the non-TSE infection condition. Hence, TSE-infected 
cells would continue to generate under-glycosylated PrP forms even after a cure from 
the PrPSc-producing condition. Based on these outcomes, SMB-PS cells might have 
dysfunctions in the process of protein glycosylations, even though this cell line does not 
express PK-resistant PrP molecules.  
 In this dissertation, the central hypothesis proposed that the detection of under-




progression. In fact, the 7-5 ELISA method highly detected the mono-1 glycosyl and/or 
unglycosyl PrP forms in BH samples from TSE-infected animals, whereas non-infected 
materials did not present or only expressed subtle levels of PrP detections. Therefore, 
the loss of full glycosylation on the PrP structure could be one of the pathological 
mechanisms in the TSE etiology. Thus, the 7-5 ELISA method should be applicable for 
monitoring and profiling modulations of under-glycosylated PrP forms through the TSE 
disease development and progression. 
 In addition to the establishment of the 7-5 ELISA method, another Sandwich 
ELISA protocol was innovated for measuring only PrPC or total PrPSc levels. The D-5 
ELISA method is a unique application of the D18 Fab Ab and PRC5 mAb as capture 
and detecting antibodies, respectively. Notably, this Fab Ab requires denaturation to 
detect PrP27-30 rod isolated from a scrapie prion, which is the protease-resistant core 
of an infectious PrPSc isoform and important for its infectivity and pathogenesis.15,27,28 
Without the sample denaturation process, the D18 Fab Ab was not able to measure the 
PrP27-30 rod by ELISA methods.15 Since this antibody can detect all four glycosylated 
PrP forms (unglycosyl, mono-1 glycosyl, mono-2 glycosyl, and diglycosyl), the use of 
D18 Fab Ab can measure total amounts of PrPSc agents in testing samples. In contrast, 
the 7-5 ELISA method specifically detects unglycosyl and mono-1 glycosyl PrP forms 
with which the PRC7 mAb only reacts (but PRC5 mAb can bind to all four glycosylated 
PrP forms). Importantly, the D18 Fab Ab reactivity to normal PrPC molecules was 
applied for a therapeutic strategy, which this antibody could interfere with the interaction 
of PrPC and PrPSc isoforms.29 Since this study was performed without the sample 




normal PrPC isoforms in non-denatured samples. Based on these characteristic features 
of the D18 Fab Ab, the D-5 ELISA protocol analyzes PrPSc or PrPC levels in testing 
samples with or without denaturation, respectively. 
 For GdnHCL-denatured murine BH samples, the D-5 ELISA method detected 
higher O.D. values of PrP levels in TSE-inoculated mice, compared to the control BH 
samples (Figure 3-13.A). These findings resulted in two different inocula (RML and 22L) 
of mouse-adapted scrapie prions in FVB and C57BL6 wild-type mice, respectively. 
Furthermore, this new Sandwich ELISA approach revealed the decrease of PrPC levels 
in the infected BH samples without denaturation (Figure 3-13.B). Therefore, these pilot 
studies suggested that the D-5 ELISA approach would be capable of analyzing the 
modulation of normal PrPC and abnormal PrPSc levels in the TSE disease state by 
different sample preparations. Possibly, the loss of PrPC levels causes functional 
abnormalities in the infected animals through the TSE disease development.  
 To find an optimized concentration of the D18 Fab Ab as a capture antibody in a 
Sandwich ELISA method, different concentrations of this Ab were examined with the 
RML-infected mouse BH sample and its controls (PrP KO and uninfected FVB mice). 
For both denatured and non-denatured sample conditions, the 20 µg/ml D18-coating 
concentration showed the highest O.D. values of PrP detections in the RML-infected 
sample (Figures 3-14.A to D). Also, the 5µg/ml concentration could be a minimum 
amount for coating the D18 Fab Ab, which exhibited a higher PrP detection, similar to 
the 20 µg/ml concentration. Intriguingly, the D-5 ELISA method determined that 
GdnHCL was effective for the sample denaturation to detect higher PrP levels in the 




dependent study, at least 4M concentration of GdnHCL was necessary to measure 
higher O.D. values in BH samples by the D-5 ELISA method (Figure 3-16.B). In the 
Chapter 2, the 7-5 ELISA method also showed similar outcomes that 4-5M GdnHCL 
enhanced higher PrP detections in TSE-infected BH samples (Figure 2-16.A to C, 
Chapter 2). Thus, higher GdnHCL concentrations are essential for enhancing higher 
detections of PrPSc levels in denatured TSE-infected materials by Sandwich ELISA 
methods. However, PrP levels in TSE-infected materials decreased with prolonged 
coating times on ELISA plates, pre-coated with capture antibodies for the D-5 and 7-5 
ELISA methods (Figures 3-17.A and B). In these experiments, prepared samples 
exhibited aggregated clusters around the 20-minute time point during waiting times for 
coating on the plates. This aggregation was increasingly observed according to the time 
course, but a reason or cause of this cluster aggregation was unclear. These 
observations suggested that testing samples must be coated on the prepared ELISA 
plates immediately after processes of sample denaturation and dilution. 
 Using the RML-inoculated BH sample and its controls, multiple capture 
antibodies were compared in the Sandwich ELISA approach with the detecting antibody 
PRC5 mAb under the 7-5 and D-5 ELISA protocols (Figures 3-18.A to L). This study 
evaluated specificities of these two Sandwich ELISA methods for the PrP detection in 
TSE-infected materials. The six capture antibodies were categorized into the three 
groups, based on binding epitopes of these antibodies on domains of the PrP structure: 
1) structured globular domain of C terminus (PRC7, D18, 6H4); 2) unstructured flexible 
domain at N terminus (POM2, SAF-32); and 3) hydrophobic core region adjacent to the 




Except for the mAb 132, other capture antibodies were able to detect higher PrP levels 
in the denatured RML-infected BH sample, compared to its control, using the detecting 
antibody PRC5 mAb for Sandwich ELISA methods (Figures 3-18.A to F). Specifically, 
the capture antibodies binding to the C terminus of the PrP structure (the Group 1) 
showed significantly higher PrP detections in the infected materials than other antibody 
groups (Figure 3-18.A to C). Intriguingly, the POM2 mAb detected high PrP levels in the 
denatured uninfected FVB/n BH sample (Figure 3-18.D). In contrast, PRC7, D18, and 
6H4 mAbs measured no or subtle amounts, compared with a PrP-KO mouse BH 
sample (Figure 3-18.A to C). These results indicated that the POM2 mAb exhibited high 
binding probabilities to PrP conformers, because of its four different binding epitopes at 
the N-terminus. In addition, denaturation was not influential to the unstructured flexible 
domain of the N-terminus in the PrP structure.  
 Moreover, PRC7, SAF-32, and mAb132 mAbs were not capable of measuring 
PrP levels in tested samples under the non-denatured condition. D18 and 6H4 mAbs 
measured higher PrPC levels in the uninfected BH sample, compared to the RML-
infected material. However, the POM2 capture antibody showed similar values of the 
PrP detections in both infected and uninfected BH samples. Therefore, these 
observations suggested the following possibilities about PrPC detections in TSE-infected 
animals: 1) decreased PrPC levels reflect the reduced amount of PrP productions in 
TSE-infected cells or the loss of PrPC-expressing cells (cell death); and 2) the PrPC 
molecule might have the conformational modification on its structured globular domain 
of the C-terminus, because the PrP detection targeting to the N-terminus did not show 




PrP conformation from a predominantly α-helix PrPC structure to a β-sheet rich PrPSc 
structure, targeting the structured globular domain of the C-terminus could be an 
appropriate approach to evaluate PrP levels between TSE-infected and uninfected 
samples. Thus, the D-5 ELISA approaches can be useful to analyze PrP conformational 
modulations in TSE-infected samples with or without denaturation. 
 To determine modulations of PrP levels observed above, both the 7-5 ELISA and 
D-5 ELISA methods evaluated BH samples from various murine models of different TSE 
inocula with and without GdnHCL denaturation: RML mouse-adapted scrapie, CWD 
(Bala05-0308), CWD (99W12389), sheep scrapie, and TME 941031 (Figures 3-19.A to 
Y). Testing BH samples included all TSE-infected mice and their controls with different 
PrP species background. With denaturation, the 7-5 ELISA method specifically 
measured high PrP levels in all infected samples (Figures 3-19.A, E, I, M, Q, U, and Y). 
This finding indicated preferential generations of unglycosyl and mono-1 glycosyl PrP 
forms during the disease development and terminal stage. Also, the D-5 ELISA method 
detected increases of total PrP levels in these TSE-infected mice with denaturation 
(Figures 3-19.B, F, J, N, R, and V). Since the D18 Fab Ab requires denaturation to 
detect PrPSc agents, the majority of the detected PrP molecules must be the 
pathological conformers. According to the D-5 ELISA results without denaturation, the 
infected mice decreased PrPC levels at terminal stages of the TSE progression. Since 
these mice increased total PrP (PrPSc) amounts, modulations of PrPC and PrPSc levels 
could implicate with pathological developments and progressions of various TSEs in 




 In addition, these PrP modulations might affect PrPC-mediated functions. 
Intriguingly, the 7-5 ELISA and D-5 ELISA methods did not measure abnormal PrPC-
PrPSc modulations in sub-clinical conditions of Tg5037 mice with CWD inoculations 
(Figures 3-21.A to H). In fact, these sub-clinical animals exhibited similar PrP levels to 
uninfected Tg5037 mice. However, uninfected transgenic mice with PrP 
overexpressions spontaneously developed neurological dysfunctions and 
progressions.34 In the laboratory database, some records indicated spontaneous 
disease developments in uninfected transgenic mice with PrP overexpressions. 
Therefore, excessive PrP generations could be toxic to mice and could induce 
pathological conditions in the nervous system.  
 Based on the outcome from the uninfected transgenic mice, the D-5 ELISA 
method detected GdnHCL-resistant PrPC molecules (Figures 3-19.E to Y). Also, the 7-5 
ELISA method measured the generation of under-glycosylated PrP forms under the 
non-TSE condition both with and without denaturation. A transgenic mouse breed line 
with murine PrP expressions (Tg4112) exhibited these PrP detections in BH samples. 
Their PrP molecules, including under-glycosylated forms, were resistant to a lower dose 
of proteinase K (PK) (Figures 3-20.C and J). These observations suggested that under-
glycosylated PrP forms generated in transgenic mice might have different 
conformations, compared to the normal PrPC structure that is PK-sensitive and the 
diglycosyl form. In addition to detectable amounts of total PrP levels, the glycosylation 
state could be essential in maintaining healthy conditions and developing pathological 
abnormalities. As an example, congenital disorder of glycosylation is known as causing 




glycosylations.62,63 Therefore, the ELISA approaches could evaluate the PrP detection 
and glycosylation states as possible underlying mechanisms of the PrP abnormality, 
converting from normal to pathological/toxic conformers in the condition with PrP 
overexpressions or excessive generations.  
 In a transgenic mouse model of Gerstmann-Sträussler-Scheinker syndrome 
(GSS), the pilot study evaluated the PrP modulations through the disease course. The 
7-5 and D-5 ELISA methods were capable of measuring PK-sensitive PrP molecules in 
the GSS mouse model. Similar to animal TSEs described above, higher doses of 
GdnHCL denaturation were necessary to detect and enhance PrP levels in BH samples 
from spontaneously disease-developed Tg464 mice (GSS-developed mice) using the 7-
5 ELISA method (Figures 3-24.B to D). Compared to the younger ages of the 
hemizygous Tg464 mice without any clinical signs, the 7-5 ELISA method increased 
detections of under-glycosylated PrP forms in the GSS-developed mice (Figure 3-24.E). 
Intriguingly, the D-5 ELISA method identified the time-dependent (longitudinal) 
modulation of PrPC and PrPSc detections in BH samples from Tg464 mice at pre- and 
post- onset of GSS clinical signs (Figure 3-24.F). As described above, the D-5 ELISA 
method is capable of detecting only PrPC molecules without denaturation, or PrPSc 
agents with denaturation, based on the feature of the D18 Fab Ab reactivity. Under the 
D-5 ELISA approach, PrPSc levels did not change in the GdnHCL-treated BH samples of 
Tg464 mice at three different time points, prior to the onset of clinical signs. Also, these 
PrPSc levels are lower O.D. values than PrPC levels (detected without denaturation) in 
the same animals. The Tg464 mouse with GSS clinical signs exhibited a higher PrPSc 




PrPC levels toward to the GSS disease onset. These observations indicated that these 
Tg464 mice exhibited clinical signs when the PrPSc level exceeded the PrPC level. 
Moreover, these PrP modulations might affect physiological functions in which PrPC 
isoforms mediate. Eventually, GSS-developed mice would present clinical signs and 
neurological deficits. Notably, these D-5 ELISA results identified that Tg464 mice with 
the P101L mutation generated both PrPC isoforms and PrPSc conformers. Hence, some 
factors or mechanisms initiated the conformational conversion from mutated PrPC 
molecules to pathological structures. In this aspect, the 7-5 ELISA results indicated one 
possibility for this misfolding mechanism (Figure 3-24.G). At the second earliest time 
point (81 days) in Tg464 mice, the detectable level of under-glycosylated PrP forms 
increased. In contrast, PrPC levels decreased from 81 days to the GSS onset (Figure 3-
24.F). These observations suggested that the generation of under-glycosylated PrP 
forms could be pathological evidence at early stages of the TSE disease progression. 
Possibly, under-glycosylated PrP forms were immature states of the PrPC generation in 
Tg464 mice. Or, the TSE development might defect or impair the glycosidic process 
through the PrPC synthesis in affected cells. 
 As proposed, the loss of full glycosylation implicates with the TSE pathogenesis. 
Since glycosylation is important to preserve the protein structure and stability, the 
glycosidic modulation can initiate unstable conditions for maintaining proper PrPC 
conformations. Consequently, these unstable states might be prone to alter PrPC 
structures abnormally. These aberrant formations would impair functions of normal prion 
protein during the disease development. Therefore, the generation of under-




disease progression. Obviously, the 7-5 ELISA and D-5 ELISA methods are capable of 
analyzing PrP modulations in the TSE disease development. For future directions, these 
established analytical methods would be applicable for longitudinal and kinetic studies 
of the PrP modulation (both PrPC and PrPSc levels) in TSE mouse models. In addition to 
histological and other standard PrP analyses, electrodiagnoses (i.e. EEG, EMG) and 
biomechanical gait analyses would be useful tools for evaluating neurological functions 
and abnormalities. In the diagnostic advantages for detecting PK-sensitive PrP 
molecules, the 7-5 and D-5 ELISA approaches will provide more accurate PrPSc 
analyses in the TSE research and public health, including human and veterinary 
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EVALUATION OF THE UTILITY OF THE 7-5 ELISA METHOD  






 This dissertation hypothesizes that the generation of under-glycosylated PrP 
forms is a key hallmark of diagnostic biomarkers for the TSE-infection state and disease 
progression. In this chapter, the 7-5 ELISA method evaluated cervid tissue samples to 
address this hypothesis in chronic wasting disease (CWD). Successfully, the 7-5 ELISA 
method detected under-glycosylated PrP forms in CWD-infected BH samples from elk, 
deer and moose, but not in the CWD-negative control. Importantly, the ELISA result 
corresponded to WB in tested deer brain samples. Moreover, the 7-5 ELISA method 
could detect PrP levels in CWD-infected analyte that WB could not identify. Hence, the 
analytical sensitivity of the 7-5 ELISA method could overcome a threshold limitation of 
WB for the PrP detection. In addition, the 7-5 ELISA method detected higher PrP levels 
in non-nervous tissues from CWD-positive cervid, compared to the uninfected control. 
These observations indicated that CWD-positive animals prominently generated under-
glycosylated PrP forms in both nervous and non-nervous tissues and organs. Therefore, 
the 7-5 ELISA method is a useful tool to determine under-glycosylated PrP forms, which 









 CWD is the first TSE, identified in free-ranging (wild) animal populations. This 
infectious disease occurs only in the family Cervidae (cervid ruminants), such as mule 
deer, white-tailed deer, black-tailed deer, elk, moose, and reindeer.1 CWD-affected 
cervid has also been found in the captivity nature. After the first identification in 1967 
(later published as the TSE pathology in 1980), CWD incidences have pandemically 
expanded throughout the US, Canada, South Korea, and Norway.2-6 In North America, 
CWD has annually spread its incidences throughout geographical ranges. However, 
causative factors for geographic distributions of the CWD prevalence are not confirmed 
yet.7   
 CWD agents transmit through horizontal (animals to animals) and vertical 
(maternal) pathways.8-13 Dependent on herds and living areas, the CWD morbidity 
varies from 1% to over 90% rates.2,8,14-17 In fact, cervid animals that are born and/or live 
in endemic CWD areas suffer from higher rates of the disease occurrence and 
prevalence. For instance, elk in the Rocky Mountain area exhibited 80% rate of the 
mother-to-offspring transmissions in CWD-infected dams.12   
 In public health, the CWD transmission is not evident from cervids to humans via 
the consumption of venison or related products. However, a recent study revealed that 
CWD agents converted recombinant human PrPC molecules, and also formed amyloid 
aggregations.18 Since antler velvets and skeletal muscles of CWD-infected animals 
contain infectious PrPSc isoforms, the longitudinal consumption of these products could 
be a source of CWD transmissions to humans, which ingested CWD agents might 




to develop a new variant of food-borne diseases as zoonotic TSE in humans. Therefore, 
CWD surveillance and research are still important subjects in public health. To prevent 
potential CWD transmissions, sensitive analytical methods are critically important for 
detecting PrPSc agents and TSE infection states.  
 For this aim, PrP glycosylations are distinctive targets that influence PrPSc 
isoforms for crossing the species barriers and forming PK-resistances with 
conformational stabilities.25-27 Although CWD-infected brain samples abundantly exhibit 
diglycosyl forms, these samples also highly express under-glycosylated forms.1,28 Thus, 
monitoring the PrP-glycosidic patterns and PrP-expressional modifications would be 
enable to evaluate the TSE infection state and the transmissive efficiency between 
different species. Therefore, targeting abnormalities of the PrP glycosylation will be 
essential approaches to eradicate future TSE epidemics, resulting in preventive 
managements for human populations from potential CWD exposures. In this chapter, 
the 7-5 ELISA method will demonstrate its analytical feature and utility in the CWD 
diagnosis using cervid tissue analyte. 
 
 
Materials and Methods 
 
The 7-5 ELISA method for Cervid Tissues 
 At first, the PRC7 mAb, a capture antibody of the 7-5 ELISA method, was diluted 
with a coating buffer (0.05M Carbonate-Bicarbonate in distilled water) to be 20µg/ml 
concentration. Subsequently, 100µl of the diluted PRC7 solution was added per well on 
a 96-well ELISA plate (Nunc MaxiSorp® flat-bottom 96-well plate, Thermo Fisher 




4°C. After removing all solutions from the ELISA plate, 200µl of a blocking buffer, which 
contained 3% of bovine serum albumin (BSA: Sigma-Aldrich Co. LLC, St. Louis, 
Missouri, USA) into 1X phosphate buffered saline (PBS: no calcium and magnesium, 
HyClone Laboratories, Inc. GE Healthcare Life Sciences, Logan, Utah, USA), was 
added into each well to minimize non-specific binding sites on well surfaces. The plate 
was incubated at 37°C for one hour. During this incubation time, testing brain/tissue 
homogenate samples were prepared for coating into wells on the plate. In this Chapter 
4, all testing homogenate samples were analyzed with 200µg/ml of each sample as the 
final protein concentration. For planning a technical triplicate (testing three wells per 
sample) with coating 100µl of the processed sample (200µg/ml) per well (total protein 
20µg in each well), 400µl of the final volume was prepared for each analyte. As the first 
step (sample dilution), testing homogenate samples were diluted with 1X PBS (no 
calcium and magnesium) to be 5.87mg/ml. Second (detergent), 10% Triton X-100 
(TX100) was added into each homogenate sample to be 1% concentration: 1.5µl of 
10% TX100 in 1X PBS was added into 13.5µl of the diluted homogenate sample 
(5.87mg/ml) (= total 15µl volume of 5.33mg/ml protein concentration with 1% TX100 at 
this point). This mixed analyte was incubated for one hour at 37°C with 1000rpm 
agitation. Third (denaturation), the incubated sample (15µl) was mixed with 25µl of 8M 
guanidine hydrochloride (GdnHCL: G3272, Sigma-Aldrich Co. LLC, St. Louis, Missouri, 
USA) in 1X TBS-Tween buffer (TBST: 50mM Tris, 150mM NaCl, 0.05% Tween-20 in 
distilled water, pH 7.6). In this denaturation step, a final concentration of GdnHCL was 
5M in 40µl of the sample volume that contained 2mg/ml concentration of a testing 




agitation. Fourth (10-time dilution), immediately after the incubation, 360µl of a dilution 
buffer (1% BSA-containing PBS: no calcium and magnesium) was added into each 
denatured sample, and then mixed together. At this final step of the sample preparation, 
the total sample volume was 400µl (200µg/ml concentration of a testing homogenate 
sample) with 0.5M GdnHCL. Once the incubation of the blocking process was 
completed, all blocking solutions were removed from the ELISA plate. Subsequently, 
the plate was washed three times with 1X TBST by a plate washer (the FinstrumentsTM 
Microplate Washer, MTX Lab Systems, Inc. Vienna, Virginia, USA). Thereafter, 100µl of 
each prepared homogenate sample (200µg/ml) was transferred into each designated 
well (total protein 20µg per well; well number = 3 as a technical triplicate) on the 
processed ELISA plate. This sample-coated plate was incubated overnight at 4°C. 
Followed by this incubation, the plate was emptied and washed three times with 1X 
TBST by the plate washer. The detecting antibody PRC5 mAb was diluted as 1:5,000 
ratio in a dilution buffer (1% BSA-containing PBS without calcium and magnesium). 
After adding 100µl of the diluted PRC5 solution per well for all testing wells, the ELISA 
plate was incubated for one hour at 37°C. After that, the plate was evacuated and 
washed three times with 1X TBST by the plate washer. At the same time, a horseradish 
peroxidase (HRP)-conjugated secondary antibody (Goat Anti-Mouse IgG2a HRP 
conjugate, 1mg/ml, Alpha Diagnostic Intl. Inc. Texas, USA) was prepared to be 1:5,000 
ratio in a dilution buffer. Once all solutions were cleared from the plate, 100µl of the 
diluted secondary antibody solution was added into each well for all testing wells on the 
plate. Following one hour incubation of the plate at 37°C, all solutions were removed 




ABTS® Peroxidase Substrate (KPL, Inc. Maryland, USA) was applied to the plate for 
evaluating an enzymatic reaction and color development under the manufacturer’s 
protocol. The absorbency of each well on the ELISA plate was analyzed by an 
ultramicroplate reader (ELx808 Absorbance Reader, BioTek Instruments, Inc, Winooski, 
Vermont, USA) at a wavelength of 405nm. 
 
Tested tissue homogenate samples 
 Brain and non-brain tissue samples derived from cervid (deer, elk, and moose) 
were homogenated to 10% in cold 1X PBS by an automatic tissue homogenizer 
(FastPrep®-24 Instrument, MP Biomedicals LLC, Solon. Ohio, USA) under the 
manufacturer’s protocol, and then repeatedly extracted using different sizes of syringe 
needles. A protein concentration of each homogenate sample was measured by an 
ultramicroplate reader (ELx808 Absorbance Reader, BioTek Instruments, Inc, Winooski, 
Vermont, USA), using the BCA Protein Assay Kit (Pierce™ BCA Protein Assay Kit) 
under the manufacturer’s protocol. All prepared samples were evaluated by the 7-5 
ELISA method, under the protocol above, in the following three different sections for 
each experimental purpose.  
 1) Pilot applications of cervid tissue samples with the 7-5 ELISA method: 
The utility of the 7-5 ELISA method was evaluated specifically for PrPSc detections in 
infected materials with chronic wasting disease (CWD). The following brain homogenate 
(BH) samples were derived from CWD negative and positive cervid (Table 4). This 
experiment also included PrP-KO mouse BH samples. As noted below, there are three 




(M = Methionine; L = Leucine).29 In addition, three pairs of brain and lymph node tissue 
samples from the same three animals (one elk, one whitetail deer and one red deer) 
were provided by Ms. Carla Calvi, a former research coordinator in the CSU Prion 
Research Center, who initially obtained the samples from Dr. Mark Zabel’s laboratory in 
the Department of Microbiology, Immunology and Pathology at Colorado State 
University (Table 5). The 7-5 ELISA method analyzed these paired tissue samples with 
the controls (PrP-KO mouse and CWD-negative elk BH samples). 
 2) Testing non-brain tissue samples from cervids by the 7-5 ELISA method: 
Multiple types of tissue samples isolated from one CWD-negative (#502) and two CWD-
positive deer (#782 and #785, experimentally inoculated) were kindly provided by Dr. 
Edward Hoover’s laboratory. In addition to the brain samples (obex) from these three 
deer, the 7-5 ELISA method examined six other non-brain tissue samples: parotid 
lymph node, tonsil, vagus nerve, third eyelid, muscle and rectum (Table 6). BH samples 
from PrP-KO, uninfected FVB/n, and RML (Rocky Mountain Laboratories strain)-
inoculated FVB/n mice were included as the negative and positive controls of the 7-5 












Table 4. Tested brain samples by the 7-5 ELISA method for  
detecting CWD prion 
 
Sample Species Tissue CWD 
PrP-KO A Mouse Brain Negative 
PrP-KO B Mouse Brain Negative 
PrP-KO C Mouse Brain Negative 
FR56.98 Deer Brain Negative 
AK03008 Elk (ML)* Brain Negative 
AK03024 Elk (LL)* Brain Negative 
Db99 Deer Brain Positive 
99W12389 Elk (MM)* Brain Positive 
03-3297 Elk (ML)* Brain Positive 
03-3355 Elk (LL)* Brain Positive 
08W-11,741 Moose  Brain Positive 


































Table 5. Paired tissue samples derived from CWD-positive cervid 
 
Species CWD Brain Lymph node 
Elk Positive Tested Tested 
Whitetail deer Positive Tested Tested 
Red deer Positive Tested Tested 
  Note: The 6 control BH samples in Table 1 (PrP-KO A B C, FR56.98, AK03008 and   





Table 6. Deer tissue samples from Dr. Edward Hoover’s Laboratory 
 
Deer CWD Obex PLD* Tonsil VN** TE*** Muscle RM**** 
#502 Negative Tested Tested Tested Tested Tested Tested Tested 
#782 Positive Tested Tested Tested Tested Tested Tested Tested 
#785 Positive Tested Tested Tested Tested Tested Tested Tested 












 3) Sensitivity of the 7-5 ELISA method for subtle PrP levels in CWD-affected 
elk brain samples: 
 Elk brain samples from two different herds. Dr. Tracy Nichols, the USDA 
National Wildlife Research Center (NWRC), in Fort Collins, Colorado, kindly provided 
eleven CWD-positive elk brain samples, which Dr. Jeffrey Christiansen, a postdoctoral 
fellow in the Prion Research Center at CSU, initially obtained. Based on the sample 
background information from Dr. Nichols, these elk showed clinical signs of CWD 
disease developments. The elk brain samples were originated from two herd groups: 
Syb and NWRC. The Syb group of elk herd was settled into the highly CWD-affected 
research site in Wyoming for CWD exposures. Seven Syb elk died in short terms after 
their settlement. The NWRC group of elk with “T” numbers was herded in the low CWD-
contaminated area near Fort Collins, Colorado. Four NWRC animals showed clinical 
signs terminally, and the CWD infection state was confirmed with immunohistochemistry 
(IHC) for these four brains. However, western blot (WB) analyses using proteinase K 
(PK) could not detect PK-resistant PrP agents (=PrPSc) in the 6 brain samples (3 Syb 
and 3 NWRC elk) among the 11 elk (7 Syb and 4 NWRC elk), which Dr. Christiansen 
tested with the PRC5 mAb that can react with all four states of PrP glycosylated forms 
(Figure 3-A).  To evaluate the threshold limitation to detect subtle amounts of PrPSc 
agents and the existences of PK-sensitive PrPSc forms in these CWD-infected elk, the 
7-5 ELISA method was applied to all elk brain samples above. This experiment also 
determined a sensitivity of this ELISA approach for CWD detections. In addition, two BH 
samples from CWD-negative elk were analyzed: AK03008 and AK03024 were isolated 




experiment included murine BH samples from PrP-KO, uninfected wild-type FVB/n, 
RML-inoculated FVB/n, uninfected Tg5037 (ElkPrP), and CWD (Bala05 strain)-
inoculated Tg5037 mice.  
 
Table 7. Elk brain samples from two herd groups and control samples 
Species TSE state Numbers Animals 
Elk Syb CWD (Wyoming) 7 Syb 7, Syb 13, Syb 21, Syb 27,                          
Syb 35, Syb J19, Syb J27 
Elk NWRC CWD (Colorado) 4 T45-7353, T56-1821,                                       
T56-4100, T90-3137 
Elk Alaska Negative 2 AK03008 (Elk-1 CWD-),                         
AK03024 (Elk-2 CWD-) 
Mouse Negative 1 PrP-KO 
Mouse Negative 1 FVB/n 
Mouse Negative 1 Tg5037 (ElkPrP) 
Mouse RML 1 FVB/n 
Mouse CWD  
(Bala05, Canada) 
1 Tg5037 (ElkPrP) 
 
 
 Multiple CWD-positive cervid brain samples. The CWD infection states of 
multiple cervid brain samples isolated were previously confirmed.30 Among these CWD-
positive brain samples that were stored at -80°C, Dr. Jeffrey Christiansen re-examined 
18 samples by WB analyses with the PRC5 mAb. However, seven of the 18 CWD-
positive brain samples did not show clear observations of PK-resistant PrP existences 
(Figure 3-D to 3-F). Therefore, the 7-5 ELISA method was applied to determine existing 




sensitive to PK reagents. All testing samples were listed below, including controls 
(Table 8).  
 As described in the 7-5 ELISA method protocol above, tested tissue samples in 
this Chapter were examined at the final total protein 20µg per well (well number = 3 as 
technical replication for each individual) on ELISA plates. 
 
 
Table 8. List of testing CWD-positive cervid brains and controls 
Species TSE state Numbers  BH samples of Animals 
Mouse Negative 1 PrP-KO (whole brain) 
Deer Negative 3 FPS 6.98 (brain cerebral cortex),                                          
#694 (midbrain), #695 (midbrain) 
Elk Negative 2 AK03008 (elk ML: obex), AK03024 (elk LL: obex) 
Deer CWD 7 Dp99, 978-24384, D10, 001-39697,                                          
989-09147, HP2, CSU-135 
Elk CWD 11 99W12389 (elk MM), Bala 1A (01-0306),                         
Bala 2A (02-0306), Bala 3A (03-0306),                             
Bala 4A (04-0306), 03W3297 (elk ML), 03-03355 (elk LL), 
012-09442, 012-22012,  14-005 NPS, 001-44720 
Moose CWD 2 08W-11,741, Bala 13 Moose TSE 
 
 
Western blot analyses for cervid tissues 
 All results and images of WB analyses were provided by courtesy of Dr. Jeffrey 




references, the protocol was described as following. Each BH sample was digested with 
100µg/ml PK in cold lysis buffer for one hour at 37°C. After this incubation, PMSF (2µM 
at a final concentration in each digested sample) terminated this enzymatic digestion, 
and then the prepared samples were boiled for 10 minutes. Proteins were resolved by 
SDS-PAGE and transferred to Immobilon-FL PVDF (Polyvinylidene Difluoride) 
membranes (Millipore, Billerica, USA). These membranes were probed with primary 
mAbs followed by the HRP–conjugated anti-mouse secondary antibody (GE Healthcare, 
Little Chalfont, UK). Protein was visualized by chemiluminescence using ECL Plus (GE 
Healthcare, Piscataway, USA) and an FLA-5000 scanner (Fujifilm Life Science, 



















Pilot results of the 7-5 ELISA method with cervid tissue samples 
 Based on the optimized Sandwich ELISA protocol, the 7-5 ELISA method 
analyzed the following BH samples in three ca    tegories: three PrP-KO mice, three 
CWD negative cervids (one deer and two elk), and five CWD-infected cervids (three elk, 
one deer, and one moose). At the total protein amount 20µg per well for each sample 
(well number = 3 as technical triplicate), the 7-5 ELISA method detected high PrP levels 
in the three CWD-infected materials (99W12389, Db99, and 08W-11,741), originally 
derived from different species (elk, deer, and moose, respectively) (Figure 4-1.A). In 
contrast, PrP detections in all CWD negative samples were equivalent O.D. values to 
the PrP-KO mice. However, the two CWD positive elk BH samples (03-3297 and 03-
3355) showed lower O.D. values. Notably, these two samples have been stored in -
80°C freezers for many years. In the results from the study section with the Figure 2-19 
in Chapter 2, similar low PrP detections were observed in the BH samples from TSE-
infected mouse models, which were also stored long term at -80°C (Figure 2-19). Thus, 
storage conditions and terms of testing samples could be influential factors for the 7-5 
ELISA method to detect PrP levels in TSE-infected materials. However, the causal 
mechanisms of longer storage and ultralow temperature are not clarified for the PrP 
detection in the 7-5 ELISA method at this point. In another aspect, these results 
reflected a technical limitation to collect small tissue pieces with rich PrPSc amounts 
from large organs for diagnostic analyses.  Indeed, PrPSc distributions in brains and 




samples have various ranges of PrPSc amounts possibly, even if isolated from the same 
animal. 
 In addition, the 7-5 ELISA method evaluated the paired homogenate samples of 
brain and lymph nodes from the same cervid: one elk, one whitetail deer, and one red 
deer. Under the same procedures above, total protein 20µg of each prepared sample 
was coated per well on an ELISA plate (well numbers = 3). The 7-5 ELISA method 
detected equivalent O.D values of PrP levels in lymph nodes and brains from these 
infected animals (Figure 2-1.B). WB analyses also presented the same observations, 
performed by Ms. Calvi (data not present). These outcomes suggested that under-
glycosylated PrP forms were generated and/or propagated in lymph nodes through the 
CWD infection and disease development. Consequently, the 7-5 ELISA method is 
exceptionally capable of detecting PrPSc levels in non-nervous tissues, possibly 
corresponding to PrPSc levels in brains for CWD diagnosis. To determine expressions 
and distributions of under-glycosylated PrP forms throughout the body of a CWD-
affected cervid, the 7-5 ELISA method should examine more peripheral nervous tissues 




































Natural BH CWD 7-5 ELISA










Deer (FR56.98) CWD Negative
Elk ML(AK03008) CWD Negative
Elk LL(AK03024) CWD Negative
CWD Positive Elk (99W12389)
CWD Positive Deer (Db99)
CWD Positive Moose(08W-11,741)
CWDD Positive Elk (03-3297)

















Deer (FR56.98) CWD Negative Brain
Elk ML(AK03008) CWD Negative Brain
Elk LL(AK03024) CWD Negative Brain
CWD Positive Elk Brain
CWD Positive White-Tail Deer Brain
CWD Positive RedDeer Brain
CWD Positive Elk Lymph Node
CWD Positive White-Tail Deer Lymph Node
CWD Positive RedDeer Lymph Node
Figure 4-1. PrP detections in cervid tissues with CWD infections by the 7-5 ELISA 
method. (A) evaluations of CWD infectious states with detectable PrP levels, and 
(B) comparisons of PrP detections in brains and lymph nodes from same animals. 
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Deer (FR56.98) CWD Negative
Elk ML(AK03008) CWD Negative
Elk LL(AK03024) CWD Negative
CWD Positive Elk (99W12389)
CWD Positive Deer ( b99)
CWD Positive Moose(08W-11,741)
CWDD Positive Elk (03-3297)

















Deer (FR56.98) CWD Negative Brain
Elk ML(AK03008) CWD Negative Brain
Elk LL(AK03024) CWD Negative Brain
CWD Positive Elk Brain
CW  Positive White-Tail Deer Brain
CWD Positive RedDeer Brain
CWD Positive Elk Lymph Node
CWD Positive White-Tail Deer Lymph Node






Testing non-brain tissue samples from cervids by the 7-5 ELISA method 
 From Dr. Edward Hoover’s laboratory, multiple tissue samples isolated from one 
CWD-negative (#502) and two CWD-positive deer (#782 and #785, experimentally 
inoculated) were kindly provided for testing with the 7-5 ELISA method. According to the 
information from Ms. Amy Nalls in Dr. Hoover’s laboratory, the CWD infection state of 
these samples was previously examined by WB analyses and real-time quaking-
induced conversion (RT-QuIC). In addition to brain samples (obex) from the three deer, 
the 7-5 ELISA method also examined the following six tissue samples: parotid lymph 
node, tonsil, vagus nerve, third eyelid, muscle, and rectum. The controls for this ELISA 
method included BH samples from PrP-KO, uninfected FVB and RML-inoculated FVB 
mice. In the sample preparation, all samples were prepared with 1% TX100 and 5M 
GdnHCL under the current 7-5 ELISA protocol. The final total protein coating on ELISA 
plates was 20µg per well (well number = 3 as technical replication) for each sample. 
The 7-5 ELISA results for PrP detections in these deer tissue samples are following:  
 1) Obex:  Both #782 and 785 CWD-positive deer showed higher O.D. values of 
PrP levels, compared to the CWD-negative deer (#502) (Figure 4-2.A). Remarkably, 
#785 sample exhibited almost a four-times higher PrP level than #782 value. The O.D. 
value of #785 sample exhibited a high PrP detection, similarly to RML-infected FVB. In 
contrast, the O.D value of #782 sample accounted for the range of average PrP levels 
in CWD-inoculated Tg1563 (deerPrP) mice, based on the 7-5 ELISA data in Chapter 3. 
These results indicated that under-glycosylated PrP forms were highly generated in the 




 2) Parotid lymph node and tonsil: Corresponding to the obex results, these 
lymphoid tissues from the CWD-positive deer showed different PrP detections that #785 
presented a higher O.D. value than #782 (Figures 4-2.B and C). Although the PrP levels 
in the CWD-positive lymphoid samples were small amounts, p-values between infected 
and uninfected samples were p<0.001 as technical replications. Intriguingly, these 
results indicated that under-glycosylated PrP forms were generated in lymphoid tissues 
in the CWD infection state. These PrP detections in lymph nodes might be utilized to 
estimate the generated amounts of these PrP forms in brains from same animals. 
 3) Vagus nerve, third eyelid, muscle, and rectum: In contrast to the results 
from brains and lymphoid tissues, O.D. values in these four samples between the two 
CWD-positive deer showed almost no difference (Figure 4-2.D to G). The PrP levels in 
the infected samples were small quantities, compared to the uninfected samples. 
However, p-values between infected and uninfected samples were p<0.01-0.0001 as 
technical replications. Therefore, the 7-5 ELISA method is extremely sensitive to detect 
subtle levels of PrPSc agents in non-nervous tissue and/or peripheral tissues in CWD-
infected deer.  
 Overall, the 7-5 ELISA method could detect higher O.D. values of PrP levels in 
all seven different tissue samples from CWD-infected deer at the total protein amount 
20µg, compared to uninfected deer tissues. Since non-nervous tissue and peripheral 
tissues have lower PrPC expressions than brain, this analysis might decrease the 
chance of PrPSc detections in these tissues from TSE-infected individuals. However, the 
7-5 ELISA method is capable of determining the existence of under-glycosylated PrPSc 




under-glycosylated PrP forms (unglycosyl and mono-1 glycosyl forms by PRC7 mAb) 
can be generated or accumulated in these tissues during CWD infection and disease 
development. For further studies, the increase of testing total protein would enhance 






























































# 502 Parotid Lymph Node
# 782 Parotid Lymph Node























































































# 502 Vagus Nerve
# 782 Vagus Nerve

















# 502 3rd Eyelid
# 782 3rd Eyelid











































Figure 4-2. PrP detections in analyte from CWD-positive deer by the 7-5 ELISA 
method. (A) obex, (B) parotid lymph node, (C) tonsil, (D) vagus nerve, (E) third 






Sensitivity of the 7-5 ELISA method for subtle PrP levels in CWD-infected brain 
samples 
 1) Elk brain samples from two different herds: Corresponding to the WB 
results (Figure 4-3.A), the 7-5 ELISA method measured low O.D. values in the six 
samples that did not present PK-resistant PrP levels in WB analyses. Other CWD-
positive samples showed higher PrP levels over 1.0 O.D value at least (Figure 4-3.B). 
Also, the control samples for this ELISA method supported that this analysis worked 
properly. Focusing on the six materials with non PK-resistant PrP agents, the ELISA 
method detected higher O.D. values (at least 0.2 difference) in all non-PK resistant 
CWD-infected samples, compared to CWD-negative elk samples (Figure 4-3.C). In 
technical replication, p-values between each CWD sample and uninfected sample were 
p<0.0001. Therefore, these results suggested that the 7-5 ELISA method is 
exceptionally sensitive to detect subtle PrPSc amounts in CWD-infected materials that 
WB assay using PRC5 mAb and PK could not measure.  Possibly, these PrP levels 
detected by the 7-5 ELISA method might be PK-sensitive PrPSc agents with under-
glycosylated forms through CWD infection and disease progression. 
 2) Multiple CWD-positive cervid brain samples: Instead of the past 
confirmation for the CWD infection states, the WB results showed no or little detection 
of PK-resistant PrP agents in seven brain samples (001-44720, 03-03355, 012-22012, 
3A(Bala 3A), 03W3297, 7138, and Bala 13 Moose) among the 18 CWD-positive cervids 
(Figures 4-3.D to F). To evaluate the existence of PrPSc agents in these samples, the       
7-5 ELISA method analyzed PrP detections in the 17 CWD-positive (not including the 




Additionally, two CWD-positive brain samples and one negative deer brain sample were 
included. All sample information below was based on records in the laboratory database. 
 
List of the cervid brain samples  
CWD-negative state 
• Deer (3 brain samples): FPS 6.98 (brain cerebral cortex), #694 (midbrain),                
#695 (midbrain) 
• Elk (2 brain samples): AK03008 (elk ML: obex), AK03024 (elk LL: obex) 
CWD-positive state 
• Deer (7 brain samples from mule deer): Dp99, 978-24384, D10, 001-39697,              
989-09147, HP2, CSU-135 
• Elk (11 brain samples): 99W12389 (elk MM), 03W3297 (elk ML), 03-03355       
(elk LL), Bala 1A (01-0306), Bala 2A (02-0306), Bala 3A (03-0306), Bala 4A      
(04-0306), 012-09442, 012-22012, 14-005 NPS, 001-44720  
• Moore (2 brain samples): 08W-11,741, Bala 13 Moose TSE 
 
 Under the same 7-5 ELISA procedures in this study section, all cervid brain 
samples listed above were prepared for coating on ELISA plates. The final total protein 
of each prepared sample was 20µg per well for triplicates. In addition, one PrP-KO 
mouse BH sample was examined as a negative control for the PrP detection in the 7-5 
ELISA method. Intriguingly, PrP-KO mouse BH sample showed a slightly higher O.D. 
value than all CWD-negative brain samples (Figures 4-3.G to J). Possibly, the anti-




method) caused this increased O.D. value in the mouse sample. This antibody can 
react with any murine IgG2a even in the PrP-KO mouse sample, whereas cervid tissues 
do not have murine IgG2a. 
 Unexpectedly, the 7-5 ELISA method showed similar O.D. values between all 
CWD negative controls and the six CWD-positive brain samples (001-44720, 03-03355, 
012-22012, Bala 3A, 03W3297, 7138, and Bala 13 Moose), and WB analyses could not 
measure clear detections of PK-resistant PrP agents (Figures 4-3.G to J). This ELISA 
observation corresponded to the WB result. Hence, WB analyses and the 7-5 ELISA 
method indicated no detectable amount of PrPSc agents in these six CWD-positive brain 
samples. In the study section with the Figure 4-1 of this Chapter 4, however, the 7-5 
ELISA method also measured two (03W3297 and 03-03355) of the six samples for the 
PrPSc detection (Figure 4-1.A). In that past experiment (Year 2013), the 7-5 ELISA 
application detected small amounts of PrP levels in these CWD-positive brain samples. 
In contrast, the analytical assay in this study (Year 2015) could not measure these PrP 
levels in the same tested samples after a two-year storage from brain homogenizations. 
Indeed, the 7-5 ELISA method also determined similar observations in other CWD-
positive elk brain samples. These infection states were previously confirmed by PMCA 
in Dr. Mark Zabel’s laboratory, and the samples have been stored over 3-7 years in -
80°C freezers (data not present here). Thus, the cold temperature might have caused 
denaturation (cold denaturation) for PrPSc conformers in the six CWD-positive brain 
samples during -80°C storage for couple years.   
 If a denatured protein could not renature to its structured form, the two 




react with unfolding or partially unfolded PrP structures. In addition, PrPSc conformers 
after longer storage at the ultralow temperature might decrease these tolerances to 
detergents, denaturants and other factors for protein renaturations or stabilities. 
Especially, the PrP structure that the 7-5 ELISA method can detect are unglycosyl and 
mono-1 glycosyl forms. These glycosidic PrP forms must be less stable conformations 
than a diglycosyl PrP form. Since the other tested 14 CWD-positive samples showed 
clearly high O.D. values of PrP levels by the 7-5 ELISA method, the capacity of 
temperature resistance could be dependent on glycosylation states and possibly TSE 
strain differences.   
 Overall, the 7-5 ELISA method is capable of detecting PrP molecules in CWD-
infected materials isolated from elk, deer and moose, but not in CWD-negative cervid 
samples. However, this analytical assay is only available to measure existing amounts 
of conformational PrP structures after denaturation and renaturation. Because of large 
brain sizes in cervid, higher total proteins of testing samples should enhance the PrPSc 
detection by the 7-5 ELISA method.  Moreover, other additional reagents should be 
applicable to improve PrPSc detections in TSE-infected materials, such as the use of PK 
10µg for enzymatic digestions that increased O.D. values for RML-inoculated FVB 
































mAb = PRC5 (5C6) 






















































































































































































































































































































































































































































Bala 1A Elk CWD(+)
Bala 2A Elk CWD(+)
Bala 3A Elk CWD(+)
Bala 4A Elk CWD(+)


























































































































































































































































Figure 4-3. Sensitive PrP detections by the 7-5 ELISA method for CWD-infected 
BH samples. (A) PK-resistant PrP levels in diseased elk BH samples from  
CWD-epidemic areas by WB analysis with PRC5 mAb. (B) The 7-5 ELISA 
application for all tested elk BH samples in WB, and (C) the detection of  
subtle PrP levels in the CWD-positive BH samples that WB did not measure. 
(n=3, each sample with 20µg total protein amount)  
(D), (E), and (F) PK-resistant PrP levels in BH samples from CWD-positive  
elk by a WB analyses with PRC5 mAb. Highlighted samples in Red exhibit  
no to little measurements of PK-resistant PrP materials, whereas these samples 
were previously confirmed as the CWD positive.  
(G), (H), (I), and (J) The 7-5 ELISA application for all tested elk BH samples  







 In the previous chapters, the 7-5 ELISA method detected high levels of under-
glycosylated PrP forms in brain homogenate (BH) samples from mouse models of 
several transmissible spongiform encephalopathies (TSEs), but not in uninfected mice. 
As proposed, the loss of full glycosylation is implicated in pathological mechanisms of 
TSEs. Because of the unstable conformation, under-glycosylated PrP forms might 
promote conformational alterations of the normal PrP structure to the pathologic 
isoform. Eventually, this conformational modulation would impair the PrP physiology 
and induce the TSE disease progression. Therefore, this dissertation hypothesized that 
the generation of under-glycosylated PrP forms is a key hallmark of diagnostic 
biomarkers for the TSE-infection state and disease progression. In this chapter, the 7-5 
ELISA method evaluated cervid tissue samples to address this hypothesis in chronic 
wasting disease (CWD). 
 The 7-5 ELISA method successfully demonstrated the existence of under-
glycosylated PrP forms in CWD-infected BH samples from three different cervid species 
(deer, elk, and moose) (Figure 4-1.A). In contrast, BH samples from CWD-negative deer 
and elk showed similar O.D. values to PrP-KO mice. In addition, this analytical 
approach was capable of detecting lower amounts of these PrP forms in CWD-positive 
elk BH samples (Figure 4-1.A). Intriguingly, the 7-5 ELISA method detected under-
glycosylated PrP forms in other types of tissue samples from CWD-positive deer and 
elk, such as lymph nodes and muscles, compared to the uninfected deer  (Figures 4-
1.B, 4-2.B to G). Although these PrP detections showed lower O.D. values, the 7-5 




forms in CWD-positive tissue samples, compared to the controls. These results 
indicated the utility of the 7-5 ELISA method for testing non-nervous tissues from cervid 
in CWD diagnostic examinations. In clinical and diagnostic situations, tissue sample 
collections from the body surface of animals are convenient and quick approaches with 
the uses of disposable tools, such as a needle and blade. In general, brain biopsy and 
neurosurgical procedures (e.g. craniotomy) for tissue collections require special 
instruments and handling techniques, as well as longer procedure times. Without proper 
sterilizations to inactivate TSE pathogens, the reuse of medical instruments with 
potential PrPSc contaminations would be a causal source of iatrogenic transmissions in 
TSEs.34 The 7-5 ELISA results demonstrated its ability to evaluate the TSE infection 
state in tissue samples, easily collected in the clinic and the field. For a future direction, 
the 7-5 ELISA method should be applied for more additional samples of brain and other 
tissues to establish a diagnostic standard scale. These outcomes would also determine 
distributions or ranges of under-glycosylated PrP levels in CWD-positive and negative 
animals.  
 In addition, sensitive PrPSc detections are critical to develop a new analytical 
system in the TSE diagnosis and research. Dr. Hoover’s laboratory, the provider of 
tissue samples from deer with oral inoculations of CWD-positive brain materials, 
detected very high amounts of PK-resistant PrP agents in the deer brain by WB 
analyses. The 7-5 ELISA method also measured similar results in the same sample 
(Figure 4-2.A). Hence, the ELISA application and result corresponded to the WB 
analysis in tested deer brain samples. In addition, the 7-5 ELISA method determined 




same protein amount (total protein 20µg per each well on an ELISA plate). These 
outcomes indicated that the 7-5 ELISA method would be applicable for quantitative 
analyses of under-glycosylated PrP forms in TSE-infected animals. In further 
longitudinal or kinetic studies, a quantitative application of the 7-5 ELISA method would 
evaluate outcomes with background information of each tested animal, including the 
TSE-incubation time and clinical signs.  
 Moreover, the 7-5 ELISA method demonstrated its exceptional sensitivity for the 
PrP detection in CWD-infected animals that WB analyses with the PRC5 mAb and PK 
digestion could not identify (Figures 4-3.A to C). Tested elk brain samples were 
collected from two different herds in CWD-contaminated locations. Prior to this 
dissertation experiment, the sample providers evaluated clinical signs and CWD-
infection states of these elk herds. Among BH samples from the eleven CWD-positive 
elk, WB analyses could not detect PK-resistant PrP agents in six animals. However, the 
7-5 ELISA method detected higher PrP levels in these six BH samples, compared to the 
CWD-negative elk and uninfected mice (PrP-KO, FVB and Tg5037). The other five 
CWD-positive BH samples exhibited high PrP levels in this ELISA method (Figure 4-
3.B). These observations indicated that CWD-positive animals prominently generated 
under-glycosylated PrP forms. Although several factors might affect PrP detections, 
such as tissues, animals, disease stages, sampling and storage conditions, the 7-5 
ELISA method could overcome a threshold limitation of WB analyses (with PRC5 mAb 
and PK digestion) for the PrP detection. Potentially, the PrP levels that the 7-5 ELISA 




 For further analyses, the 7-5 ELISA method examined additional BH samples 
from CWD-positive cervid that were previously confirmed for infection states (based on 
the laboratory database). Initially, WB analyses with the PRC5 mAb examined 
existences of PK-resistant PrP agents in BH samples of 18 CWD-positive cervid. 
However, the samples from seven animals (001-44720, 03-03355, 012-22012, 3A(Bala 
3A), 03W3297, 7138, and Bala 13 Moose) showed no or little amounts of PK-resistant 
PrP agents (Figures 4-3.D to F). Previously, the four CWD isolates (001-44720, 012-
22012, 03W3297, and 7138) exhibited high detections of PK-resistant PrP agents, in 
addition to these transmissions to Tg1536 mice.30 Thus, these CWD isolates might have 
lost detectable amounts of PrPSc agents in brains during the -80°C storage. In fact, the 
7-5 ELISA method measured low O.D. values in six CWD-positive BH samples 
(03W3297, 03-03355, Bala 3A, Bala 13 Moose, 012-22012, and 001-44720), similar to 
detected PrP levels in all CWD negative controls (Figures 4-3.G to J). PrPSc amounts in 
these CWD-positive brain samples might be undetectable quantities by this assay. 
Furthermore, the 7-5 ELISA method previously detected small amounts of PrP levels 
(PrPSc detections) in 03W3297 and 03-03355 CWD isolates (Figures 4-1.A, Chapter 4). 
In contrast, this later ELISA experiment could not measure these PrP levels after two 
years, possibly due to long-term storages of the same brain samples and these 
defrostings. Moreover, the 7-5 ELISA method showed similar observations in other 
CWD-positive elk brain samples, stored over 3-7 years in -80°C freezers (data not 
present). Previously, Protein Misfolding Cyclic Amplification (PMCA) confirmed these 
infection states in Dr. Mark Zabel’s laboratory. Since the binding epitopes of PRC7 and 




conformation-dependent anti-PrP mAbs require renaturation of denatured PrPSc agents 
for these detections. Otherwise, these two mAbs would not be able to react with 
unfolded or partially unfolded PrP molecules. Therefore, PrPSc conformers in these 
samples might lose structural stabilities or conformations during the storage term, 
caused by cold temperature-mediated denaturation. 
 As examined in the Chapter 2, the 7-5 ELISA method could not measure the PrP 
level in the RML-inoculated FVB mouse BH sample when treated with β-
mercaptoethanol (βME), compared with PrP-KO and uninfected FVB mice (Figure  2-
12.A, Chapter 2). Since this reagent cleaves disulfide bonds in structured globular 
domains of proteins and also disrupts protein conformational structure, both PRC7 and 
PRC5 mAb cannot recognize PrP molecules with non-conformational conditions. In 
addition, PrPSc conformers after longer storages at the ultralow temperature might 
decrease tolerances to detergents, denaturants and other factors for the protein 
renaturation or stability. Thus, unglycosyl and mono-1 glycosyl PrP forms with which the 
PRC7 mAb reacts might reduce conformational stabilities, compared to a diglycosyl PrP 
form. Also, these tolerances could be dependent on isolates or strains (Figures 4-3.G to 
J). Therefore, the 7-5 ELISA method might have a potential utility to determine the 
capacity of temperature resistance and conformational stability, based on PrP 
glycosylation states  
 To evaluate these possibilities described above and enhance PrP detections, 
PMCA can be applied to amplify PrPSc isoforms in the BH samples from CWD-positive 
animals, in which the 7-5 ELISA method and/or WB analysis did not detect PrPSc 




useful method for this purpose.38 These amplified products should consist of 
conformational PrP structures. Subsequently, PRC7 and PRC5 mAbs in the 7-5 ELISA 
method and WB analysis will be capable of determining the existence of pathologic PrP 
isoforms in amplified products of each brain sample. In addition, tissues from TSE 
isolates should be examined by the 7-5 ELISA method, prior to infections of these 
inocula into cell cultures and mice. Quantities of under-glycosylated PrPSc forms in the 
inocula might influence prion infectivity, replication, propagation, and incubation time for 
in vitro and in vivo studies. This approach will provide quality controls of stored tissue 
samples and TSE-infection/inoculation experiments. Otherwise, unexpected outcomes 
or failures of experiments would delay planned research projects if amounts of under-
glycosylated PrPSc forms were limited in each testing sample. Therefore, the ELISA 
application will be useful for the quality management of these experiments. 
 Overall, the 7-5 ELISA method is capable of detecting PrP molecules in CWD-
infected materials isolated from elk, deer and moose, but not in CWD-negative cervid 
tissue samples. However, this analytical assay is only available to measure existing 
amounts of conformational PrP structures in testing samples after denaturation and 
renaturation. Based on protein-dose dependent studies, it is clear that increases of total 
proteins enhance the PrPSc detection in TSE-infected tissue samples by the 7-5 ELISA 
method. Unlike mice, large volumes of tissue samples are available to collect easily 
from cervid because of their large body size. Thus, CWD diagnostic examinations 
should examine higher total proteins of testing samples, rather than the 20µg we tested 
in this Chapter 4. Furthermore, other additional reagents might be capable of increasing 




digestions that increased O.D. values for the RML-inoculated FVB mouse brain sample 
(Figure 3-15, Chapter 3). As hypothesized, the 7-5 ELISA method prominently detected 
under-glycosylated PrP forms in CWD-positive tissue samples. These results indicate 
that the generation of under-glycosylated PrP forms is a key hallmark of diagnostic 
biomarkers for the TSE-infection state and disease progression. Therefore, the 7-5 
ELISA method will be available to utilize as a novel sensitive analytical assay for TSE 
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 TSEs are fatal neurodegenerative disorders that transmit horizontally and 
environmentally in humans and animals. Currently, CWD outbreaks have emerged in 
not only North America, but also Asia and Europe. Although various analytical methods 
have been applied to the TSE diagnoses, each method has both advantages and 
limitations, such as technical processes.1,2 Because of the existence of PK-sensitive 
PrPSc pathogens that implicate with neurotoxicity and lethal outcomes, the application of 
PK reagents might result in false negative detections in the traditional TSE diagnostic 
methods.3-5 However, early detections and preventions of TSEs are critically important 
to eradicate further epidemic incidences throughout the world. In this dissertation, the 
overreaching goal set aims to establish new analytical systems for the TSE diagnoses 
without the use of PK reagents. 
 For these purposes, the first part of this dissertation investigated new Sandwich 
ELISA protocols that could overcome some limitations of the current TSE diagnoses.       
In order to evaluate capabilities of the in-house anti-PrP mAbs, PRC7 and PRC5, the 
Indirect ELISA method was beneficial as an initial approach. Using recombinant prion 
protein (RecPrP) of elk and mouse species, these two mAbs demonstrated detectable 
abilities of PrP particles for the Indirect ELISA application. In addition, each mAb 
presented similar O.D. values for denatured and non-denatured RecPrP samples 




antibodies, these results indicated that the denatured PrP particles refolded (renatured) 
to these native conformations. Furthermore, the Sandwich ELISA method proved 
specificities of these mAbs for the PrP detection. In fact, the combination of the capture 
PRC7 antibody with the detecting PRC5 antibody (the 7-5 ELISA method) showed 
increased PrP detections under the RecPrP-dose dependence for both elk and mouse 
species. Corresponding to the Indirect ELISA results, the 7-5 ELISA method also 
showed similar O.D. values in detections of denatured and non-denatured RecPrP 
samples (Figure 2-2, Chapter 2). At a certain dose of guanidine hydrochloride 
(GdnHCL), some PrP particles might not have renatured to the native folding structures. 
As a result, the 7-5 ELISA method reduced the detection of denatured RecPrP particles. 
Hence, these observations indicated that PRC5 and/or PRC7 could not bind to unfolded 
conditions of PrP particles. Thus, the 7-5 ELISA method demonstrated the property of 
the conformational-dependent recognition, because of only detecting the structured PrP 
particles.  
 Conversely, this detectable specificity was a potential concern for applying to 
brain samples from TSE-affected animals. Since the RecPrP conformations were non-
glycosylated forms, the PRC7 mAb could bind to these particles without glycosidic 
restrictions, such as mono-2 glycosyl and diglycosyl forms. In contrast to this concern, 
the 7-5 ELISA method was particularly capable of detecting GdnHCL-resistant PrP 
agents in brain homogenates (BH) from TSE-inoculated mice. This analytical ability 
indicated that the detected particles were unglycosyl and/or mono-1 glycosyl PrPSc 
forms because the PRC7 mAb only bound to those two forms. Thus, the 7-5 ELISA 




development. These evidences supported this dissertation hypothesis that an under-
glycosylated PrP form would be the hallmark as an essential diagnostic biomarker to 
evaluate the TSE-infection state and disease progression. Therefore, the 7-5 ELISA 
method proved a potential utility as a new analytical system for the TSE diagnosis. 
Followed by optimizing a procedure protocol, the 7-5 ELISA method increased its 
detectability of PrPSc agents in BH samples from TSE-infected mice. To confirm the 
conformation-dependent feature of this analytical method, β-mercaptoethanol (βME) 
was applied to cleave disulfide bonds of the structural globular domain in the PrP 
structure. In fact, βME-treated BH samples lost protein folding and stability, resulting in 
no PrP detection by the 7-5 ELISA method (Figure 2-12, Chapter 2). These outcomes 
indicated that the 7-5 ELISA method has the characteristic feature of the conformation-
dependent PrP detection.  
 In the second part of this dissertation, the 7-5 ELISA method showed an 
exceptional sensitivity for the PrPSc detection in BH samples from various transgenic-
mouse models of different TSE diseases (Figure 3-1, 3-2, and 3-3, Chapter 3). The 
capability of this analytical assay indicated the abundant existences of under-
glycosylated PrPSc forms at the terminal stage of the disease progression in mice. 
Hence, TSE-affected brains generated under-glycosylated PrPSc forms throughout 
different species and with various PrPSc strains. Notably, strain differences exhibited 
variances in generations, quantities, and conformational stabilities among the detected 
PrPSc agents in inoculated hosts (Figures 3-4, Chapter 3). Thus, the 7-5 ELISA method 
distinguished strain differences, based on the detections of under-glycosylated PrPSc 




prion infectivity and titration, in comparison to CPCA results with the PRC7 mAb 
(Figures 3-7, 3-8, 3-9, 3-10, and 3-11, Chapter 3). These outcomes indicated the 
implication of under-glycosylated PrPSc forms in the TSE infection. The glycosidic deficit 
on the PrP conformation should be associated with the TSE pathogenesis. The unstable 
structures of under-glycosylated PrP forms might link to conformational alterations of 
the normal PrPC structure to the pathologic isoform. Therefore, the 7-5 ELISA method 
can be applied to evaluate the kinematic modulations of under-glycosylated PrP agents 
during the TSE disease progression. 
 In the third part of the dissertation, the 7-5 ELISA method detected the existence 
and implication of under-glycosylated PrP forms in tissue samples (brains, peripheral 
nerves, lymph nodes, muscles, skins) from different cervid species with CWD infections 
(Figure 4-1 and 4-2, Chapter 4). This analytical approach was capable of detecting 
subtle amounts of the PrPSc agents in CWD-positive samples, which western blot 
analyses did not detect (Figures 4-3, Chapter 4). These results indicated the utility of 
the 7-5 ELISA method for testing non-nervous tissues from cervid for CWD diagnostic 
examinations. In clinical and diagnostic situations, this sensitivity for PrPSc detections in 
non-CNS tissues could be essential to diagnose TSE states conveniently and quickly, 
rather than brain collections. Using disposable tools, these easier procedures would be 
beneficial for avoiding a potential risk of the iatrogenic TSE transmission. As 
hypothesized, the 7-5 ELISA method measured significant levels of under-glycosylated 
PrP forms, predominantly generated in various TSE diseases. Therefore, the detection 
of under-glycosylated PrP forms is a key hallmark of diagnostic biomarkers for TSE-




its utility as a new sensitive analytical assay for TSE diagnosis and PrPSc analysis, 
resulting in beneficial impacts for the fields of veterinary medicine and public health. 
 Furthermore, the D-5 ELISA method also demonstrated a unique feature of PrPSc 
and PrPC detections. Since D18 Fab Ab and PRC5 mAb can bind to all four glycosyl PrP 
forms, the D-5 ELISA method is capable of detecting PrP molecules with any 
glycosylated states. With or without the denaturation process, this assay could measure 
total PrPSc or PrPC levels in testing BH samples, respectively. For GdnHCL-denatured 
murine BH samples, the D-5 ELISA method measured higher O.D. values of PrP 
detections in TSE-inoculated individuals, compared to the control BH samples (Figure 
4-9.A, Chapter 4). In contrast, this new approach revealed the decrease of PrPC levels 
in these infected BH samples without denaturation (Figure 4-9.B, Chapter 4). These 
results proved that the D-5 ELISA approach could analyze modulations of normal PrPC 
and abnormal PrPSc levels in TSE disease states by a single change in sample 
preparations. Therefore, the loss of PrPC isoforms should correlate with the cause of the 
functional abnormality in TSE-infected animals through disease progressions. Based on 
the comparison study of capture antibodies (Figures 4-13, Chapter 4), the PrPC decline 
might reflect the following possibilities: 1) the reduced generation of PrPC isoforms; 2) 
the death of PrPC-expressing cells; and 3) the conformational modification of the 
structured globular domain on PrPC isoforms. Thus, the D-5 ELISA approaches would 
be capable of monitoring the PrPC deficiency, the PrP conformational modulation, and 
the PrPSc propagation through longitudinal periods of the TSE disease course. 
Modulations of PrPC and PrPSc levels could be involved in the pathological development 




instance, the D-5 ELISA approaches detected the increased PrPSc levels and the 
decreased PrPC levels in BH samples from the diseased mice (terminal stages) of 
different TSE models (Figures 4-14, Chapter 4). Interestingly, these PrP modulations 
did not present clear differences between uninfected control mice and CWD-inoculated 
mice with asymptomatic conditions (Figures 4-15, Chapter 4). The pilot study of the 
GSS mouse models also proved phenomena of these PrP variances from asymptomatic 
states to clinical disease onsets (Figures 4-17, Chapter 4). Remarkably, these D-5 
ELISA results identified that the GSS mice with the corresponding gene mutation 
exhibited both PrPC isoforms and PrPSc conformers. This finding is essential to 
determine how mutated PrPC molecules misfold to pathological structures and what 
influential factors initiate the PrP transformations. In addition, these PrP modulations 
should affect physiological functions of PrPC isoforms. Therefore, these impairments 
would develop neurological abnormalities and deficits in affected mice. 
 Overall, the 7-5 ELISA and the D-5 ELISA methods indicated three possible 
aspects of the TSE pathogenesis. As proposed, the loss of full glycosylation should 
correlate with pathological alterations of the PrP structure in the TSE disease 
development. Since glycosylation is an important factor to preserve protein structure, its 
modulation can initiate unstable conditions for maintaining the proper PrP conformation. 
Consequently, this unstable state could alter the PrP structure pathologically. 
Eventually, these aberrant formations could lead to the impairment of the PrPC functions 
in physiology. Possibly, PrPSc conformers can interact with other molecules that the 
normal PrPC structure does not bind to. Or, this opposite phenomenon might occur 




under-glycosylated PrPSc forms. This mAb cannot bind to the abundance of native PrPC 
structures with two glycans. Therefore, the loss of glycans might escalate or interfere 
with molecular interactions abnormally, resulting in the impairment of PrPC functions. 
Subsequently, the toxic gain or functional loss of these interactions could trigger 
pathogenic alterations in cellular biology and physiology. These pathogenic 
mechanisms are common in other neurodegenerative diseases, such as AD, PD, ALS, 
HD, and frontotemporal dementia.6 Declines of PrPC productions and expressions affect 
these normal functions and cause pathogenic alterations. In conclusion, the monitor of 
PrPC-PrPSc variances is a valuable analysis to understand disease stages and 
prognoses. The generation of under-glycosylated PrP forms must be a characteristic 
feature of TSEs as a diagnostic biomarker for disease infection and progression. Based 
on all findings in this dissertation, the 7-5 ELISA and D-5 ELISA methods have 
exceptional capabilities of analyzing PrP modulations in the TSE disease development.  
 
Future Directions 
 Unfolded protein responses are the central role of pathological mechanisms for 
disturbing protein conformations in neurodegenerative diseases including TSEs.7,8 The 
predominance of partially unfolded PrP forms appears in the process of conformational 
conversions to misfolded structures.9 These immature or intermediate conformations 
should be under-glycosylated forms of PrP molecules, in an alteration from PrPC to 
PrPSc structures and/or during new PrPSc replication and generation. Thus, I propose 
that the PrPSc conformers in under-glycosylated or immature/intermediate states are 




method could not detect PrPSc levels (under-glycosylated forms) without denaturation. 
These observations indicated that denaturation might induce a renaturation process for 
unfolding PrPSc forms to PrPC or its equivalent structure that PRC7 could bind to. 
 As a future direction, I hypothesize that the PrP glycosylation state changes 
during different stages of the TSE pathogenesis, especially for under-glycosylated PrP 
forms. For this aim, the 7-5 ELISA method would be applicable to determine the 
modulation of glycosylated PrP formations at different time points, through the disease 
course of asymptomatic, symptomatic, and progressive conditions in TSE-mouse 
models. This experimental project can investigate the under-glycosylated PrP formation 
and variance during the PrPSc replication and generation. This longitudinal approach will 
identify the kinetic changes of the PrP glycosidic state as involved in the disease 
development. Furthermore, the D-5 ELISA methods would investigate PrP modulations 
(both PrPC and PrPSc) in longitudinal and kinetic studies using TSE mouse models. 
Besides histological analyses and other standard PrP analyses, electrodiagnoses (i.e. 
EEG) and biomechanical gait analyses will be supportive approaches if applicable. In 
the diagnostic application for the CWD infectious state, the two Sandwich ELISA 
approaches would establish the scale ranges of PrP levels in normal/uninfected, 
asymptomatic, and early to terminal stages of disease courses via large sample studies 
of cervid tissues and live animals. For kinetic and longitudinal analyses, fluids (i.e. 
blood, saliva, urine) and cutaneous/subcutaneous tissues will be practical samples to 
monitor the modulation of PrPC-PrPSc variances as well as the PrPSc appearance. Based 
on the diagnostic advantages of these ELISA methods, the detectable property of PK-




in TSE research, veterinary medicine, and public health. For human medicine, the 7-5 
and D-5 ELISA methods might have a beneficial impact applying to major disorders 
including DM and cancer.10-15 Recent studies have revealed the interaction or 
implication of PrPC isoforms with disease-related molecules in non-TSE 
neurodegenerative pathologies, such as AD, PD, HD, and ALS.16-36 Theoretically, these 
Sandwich ELISA protocols can be utilized for these neurological diseases by only a 
single modification.   
 In further expansions, the 7-5 and D-5 ELISA utilities can be applicable to 
traumatic brain injury (TBI). Recently, TBI has had serious attention through the world, 
because of prominent causes for mortality and morbidity.37,38 The TBI severity has a 
classification with three grades: mild, moderate, and severe. Acute TBI causes short-
term complications, such as subdural hematoma and catastrophic brain injury, which a 
severe TBI grade might result in death. In contrast, the low severity of TBI, such as mild 
TBI and concussion, causes functional impairments and axonal injuries in brains, rather 
than gross structural damages. Military professionals and contact-sports athletes who 
have histories of TBI, such as concussions or head trauma, are prone to exhibit a 
typical brain lesion, called chronic traumatic encephalopathy (CTE).39,40 Over the past 
decades, trauma-mediated degenerations in brains are commonly recognized in boxers 
who have had repetitive impacts to their brains.41 At present, CTE induces severe 
issues in sports and recreational activities.42 In the US, the annual incidence of 
concussions is estimated as 3.8 million people. These issues mostly occur in 
competitive sports events and recreational activities.43 Possibly, 50% of the concussion 




with frequent physical contacts have higher incidences, such as American football, 
soccer, basketball, hockey (field and ice), and rugby. Currently, the US public 
perception has increased the awareness of CTE in contact-sports athletes, particularly 
in National Football League (NFL) players.44 Both media and scientific fields have 
investigated the connections of repetitive mild TBI with CTE in American football 
players, leading to other neurodegenerative developments and deaths. Over 3,000 
former NFL players and their families have argued that the NFL failed to acknowledge 
and address the risks of repetitive TBI as leading to developments of neurodegenerative 
disorders such as CTE, AD and PD. The damaged brains would induce neurological 
impairments and psychiatric abnormalities. Thus, the medical and legal investigations of 
CTE in the NFL are indispensable from a forensic psychiatry perspective. Now, this 
attention is more focused on high school football players and their parents for the risks 
of silent CTE developments and future clinical onsets. Thus, it is critical how children in 
contact sports can prevent potential risks of neurological impairments, which would 
influence their educational abilities and long-term lives with good health.  
 In the CTE progression, affected people show various clinical symptoms, such as 
cognitive impairment, mood change, and behavioral abnormality.39,40 Their brains 
exhibit aberrant depositions of hyper phosphorylated tau proteins, which are 
characteristic features of the CTE diagnosis at postmortem autopsies. A recent study 
found the correlation that increased levels of phosphorylated tau proteins were 
implicated with PrPC expression levels in the brain and blood, following severe TBI.45 
This correlation linked to observations of clinical dysfunctions, such as cognitive 




related pathogenesis. Nevertheless, the tau deposition is a detectable feature with other 
factors, such as genetic mutations, drugs, toxins, aging, environmental factors, and 
postmortem brain processing. Possibly, athletes with these backgrounds might have 
greater susceptibilities for developing CTE and other neurodegenerative diseases, as 
resulted from TBI and its delayed complications. Intriguingly, athletes who had sport-
related concussions exhibited a significant increase of PrPC levels in their plasma.46 
Thus, the measurement of plasma PrPC levels can be a reliable diagnostic biomarker 
for the assessments of the TBI severity and prognosis. However, the implication of PrPC 
isoforms is not well understood in TBI and CTE yet. 
 Furthermore, numbers of media reports have reinforced the implications of 
mental health problems and CTE in former professional athletes (contact sports) and 
military veterans who had repetitive TBI.47,48 CTE could implicate to their underlying 
suicidality, resulting from posttraumatic stress disorder (PTSD) and depression. 
Possibly, proteinopathy in the CTE development might be a causative factor in these 
clinical features, similar to other neurodegenerative diseases. Thus, additional 
researches are necessary to identify mediators or moderators of mental health 
problems and suicidality in neuropathology of TBI and CTE, especially for pathogenic 
and molecular mechanisms. An experimental study reported that TBI impaired 
expression levels of GABA-receptor subunits in brains, which affect these associated 
pathways of signaling transductions.49 Since GABAergic synaptic systems inhibit 
excitable neuronal circuits in the brain, reductions of GABA receptors influence 




 In addition, PrPC defects diminish fast inhibitions of post-synaptic potential via 
GABA receptors. Thus, PrPC alterations impair the receptor activities in neuronal 
circuits, leading to aberrant changes in neurophysiology.52 These abnormalities disrupt 
Ca2+ homeostasis and cause depolarizations in the brains, which provoke clinical 
onsets in individuals with brain lesions.51 Moreover, synaptic PrPC depositions progress 
neuronal degenerations in brains.53,54 These pathologic progressions link to the loss of 
inhibitory GABA receptors in the brain. The synaptic degenerations exacerbate axonal 
transports and PrPC activities, eventually causing apoptotic cell death and pathogenic 
development in the brain.55 Hence, PrPC expressions are relative factors in TBI-
mediated changes in brains. In mouse models, blast-induced TBI increases PrPC levels 
in plasma after the injury.56 This PrPC increase indicates that blast waves disrupt brains 
and dislodge extracellular-localized PrPC molecules, leading to elevated PrPC 
concentrations through the systemic circulation. In fact, the plasma PrPC level is 
correlated to increasing the blast intensity. Therefore, the PrPC level should be a 
valuable biomarker to detect and evaluate TBI, its severity and delayed complications. 
To investigate the PrPC implication in TBI and CTE pathogeneses, I assume that the 
established methods in this dissertation, especially the D-5 ELISA without denaturation, 
would be capable of understanding the PrPC modulation in the disease progression and 
prognosis. Ultimately, PrPC isoforms might be the targeting molecules for novel 
therapeutic innovations in brain damages, not only for TBI and CTE, but also stroke and 
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